NCT#,phase,condition,sponsor,start_date,mesh_list,criterion
NCT00000172,Phase 3,Alzheimer Disease,"Janssen, LP",unknown,Alzheimer Disease;Galantamine, Conditions that could confound diagnosis
NCT00000172,Phase 3,Alzheimer Disease,"Janssen, LP",unknown,Alzheimer Disease;Galantamine, Neurodegenerative disorders
NCT00000172,Phase 3,Alzheimer Disease,"Janssen, LP",unknown,Alzheimer Disease;Galantamine, Acute cerebral trauma
NCT00000172,Phase 3,Alzheimer Disease,"Janssen, LP",unknown,Alzheimer Disease;Galantamine, Psychiatric disease
NCT00000172,Phase 3,Alzheimer Disease,"Janssen, LP",unknown,Alzheimer Disease;Galantamine, More than one infarct on CT/MRI scans
NCT00000172,Phase 3,Alzheimer Disease,"Janssen, LP",unknown,Alzheimer Disease;Galantamine, History of alcohol or drug abuse
NCT00000172,Phase 3,Alzheimer Disease,"Janssen, LP",unknown,Alzheimer Disease;Galantamine, Contradictions for a cholinominetic agent: seizures; ulcers; pulmonary conditions (including severe asthma); unstable angina; Afib; bradycardia less than 50; and AV block.
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," Any significant neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, Major depression or another major psychiatric disorder as described in DSM IV within the past 2 years.
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," Psychotic features, agitation or behavioral problems within the last 3 months which could lead to difficulty complying with the protocol."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria).
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, History of schizophrenia (DSM IV criteria).
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol including: a) History of systemic cancer within the last 5 years (non-metastatic skin cancers are acceptable). b) History of myocardial infarction within the past year or unstable or severe cardiovascular disease including angina or CHF with symptoms at rest. c) Clinically significant obstructive pulmonary disease or asthma. d) Clinically significant and unstable gastrointestinal disorder such as ulcer disease or a history of active or occult gastrointestinal bleeding within two years. e) Clinically significant laboratory test abnormalities on the battery of screening tests (hematology, prothrombin time, chemistry, urinalysis, ECG). f) Insulin-requiring diabetes or uncontrolled diabetes mellitus. g) Uncontrolled hypertension (systolic BP greater than 170 or diastolic greater than 100). h) History of clinically significant liver disease, coagulopathy, or vitamin K deficiency within the past 2 years."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," Medications a) Use of centrally active beta-blockers, narcotics, methyldopa and clonidine within 4 weeks prior to screening. b) Use of anti-Parkinsonian medications (e.g. Sinemet, amantadine, bromocriptine, pergolide and selegiline) within 2 months prior to screening. c) Use of neuroleptics or narcotic analgesics within 4 weeks prior to screening. d) Use of long-acting benzodiazepines or barbituates within 4 weeks prior to screening. e) Use of short-acting anxiolytics or sedative hypnotics more frequently than 2 times per week within 4 weeks prior to screening (note: sedative agents should not be used within 72 hours of screening)."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," f) Initiation or change in dose of an antidepressant lacking significant cholinergic side effects within the 4 weeks prior to screening (use of stable doses of antidepressants for at least 4 weeks prior to screening is acceptable). g) Use of systemic corticosteroids within 3 months prior to screening. h) Medications with significant cholinergic or anticholinergic side effects (e.g. pyridostigmine, tricyclic antidepressants, meclizine, and oxybutynin) within 4 weeks prior to screening. i) Use of anti-convulsants (e.g. Phenytoin, Phenobarbital, Carbamazepine) within 2 months prior to screening. j) Use of warfarin (Coumadin) within 4 weeks prior to screening."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil, Vitamin Supplements a) Use of vitamin supplements other than standard multivitamin included as part of the treatment intervention used in this protocol within 2 weeks prior to screening.
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," Any prior use of any FDA approved medications for the treatment of Alzheimer's disease (e.g. tacrine, donepezil, or other newly approved medications)."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening."
NCT00000173,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Mar-99,Alzheimer Disease;Cognitive Dysfunction;Vitamin E;Donepezil," Subjects who, in the investigator's opinion, will not comply with study procedures."
NCT00000177,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),Oct-95,Alzheimer Disease;Estrogens," Patients with an uncontrolled health problem, such as untreated high blood pressure or thyroid disease."
NCT00000178,Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Prednisone, Patients with diabetes or severe osteoporosis
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Hypersensitivity to aspirin or NSAID
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Active peptic ulcer disease within 5 years
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Renal insufficiency with creatinine greater than 1.5
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Clinically significant liver disease
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Poorly controlled hypertension
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Congestive heart failure
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Bleeding ulcer
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib, Active neoplastic disease (skin tumors other than melanoma are not exclusionary; patients with stable prostate cancer may be included at the discretion of the project director)
NCT00004845,Phase 2/Phase 3,Alzheimer Disease,National Institute on Aging (NIA),unknown,Alzheimer Disease;Naproxen;Rofecoxib," Inflammatory diseases (including crystal arthropathy, rheumatoid arthritis, systemic lupus, erythematosus, Sjogren's syndrome, inflammatory bowel disease)"
NCT00006187,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Patient is living in a nursing home or skilled nursing facility
NCT00006187,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Women will be ineligible if not postmenopausal or surgically sterilized
NCT00006187,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Site physician or Sponsor may exclude patients with serious medical problems such as cancer, cardiovascular disease, major neurological or psychiatric illness, thyroid disease, or major head trauma"
NCT00006399,Phase 2,Alzheimer Disease,National Center for Research Resources (NCRR),Sep-99,Alzheimer Disease;Donepezil;Progesterone;Estrogens, Women who are currently taking estrogen therapy.
NCT00006399,Phase 2,Alzheimer Disease,National Center for Research Resources (NCRR),Sep-99,Alzheimer Disease;Donepezil;Progesterone;Estrogens, Women who are smokers.
NCT00006399,Phase 2,Alzheimer Disease,National Center for Research Resources (NCRR),Sep-99,Alzheimer Disease;Donepezil;Progesterone;Estrogens, Women who have had breast cancer.
NCT00007189,Phase 3,Alzheimer Disease,Seattle Institute for Biomedical and Clinical Research,Jan-01,Alzheimer Disease;Celecoxib;Naproxen, History of peptic ulcer disease with bleeding or obstruction.
NCT00007189,Phase 3,Alzheimer Disease,Seattle Institute for Biomedical and Clinical Research,Jan-01,Alzheimer Disease;Celecoxib;Naproxen, Clinically significant liver or kidney disease.
NCT00007189,Phase 3,Alzheimer Disease,Seattle Institute for Biomedical and Clinical Research,Jan-01,Alzheimer Disease;Celecoxib;Naproxen," History of hypersensitivity to aspirin, ibuprofen, celecoxib, naproxen, or other NSAIDs."
NCT00007189,Phase 3,Alzheimer Disease,Seattle Institute for Biomedical and Clinical Research,Jan-01,Alzheimer Disease;Celecoxib;Naproxen, Use of anti-coagulant medication.
NCT00007189,Phase 3,Alzheimer Disease,Seattle Institute for Biomedical and Clinical Research,Jan-01,Alzheimer Disease;Celecoxib;Naproxen, Cognitive impairment or dementia.
NCT00007189,Phase 3,Alzheimer Disease,Seattle Institute for Biomedical and Clinical Research,Jan-01,Alzheimer Disease;Celecoxib;Naproxen, Current alcohol abuse or dependence
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease, Currently on anticoagulant therapy
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease, Cancer diagnosed and treated within the past two years (except for skin cancer)
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease, Participant with class III - IV congestive heart failure
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease, Currently being treated with psychopharmacological drugs for depression
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease, Hospitalized for depression within the last year
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease, Taking Aricept (or similar agents) for cognitive problems or dementia
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease, Baseline blood creatinine greater than 2
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease, Baseline SGGT is a marker of liver function (3 x normalgreater than or=90 IU)
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease, Baseline hematocritless than 30
NCT00010803,Phase 3,Alzheimer's Disease,National Center for Complementary and Integrative Health (NCCIH),Oct-00,Alzheimer Disease," Baseline white blood countgreater than or=15,000"
NCT00031018,Phase 2,Alzheimer's Disease,National Center for Research Resources (NCRR),unknown,Alzheimer Disease;Memory Disorders;Cognitive Dysfunction;Interferon alpha-2;Donepezil," Absence of a reliable caregiver. Clinical or radiological evidence for other neurological disorders such as Parkinson's disease, normal pressure hydrocephalus, multi-infarct dementia, idiopathic seizure disorder, CNS infectious disease."
NCT00031018,Phase 2,Alzheimer's Disease,National Center for Research Resources (NCRR),unknown,Alzheimer Disease;Memory Disorders;Cognitive Dysfunction;Interferon alpha-2;Donepezil, History of major psychiatric disorders; schizophrenia and unipolar or bipolar depression.
NCT00031018,Phase 2,Alzheimer's Disease,National Center for Research Resources (NCRR),unknown,Alzheimer Disease;Memory Disorders;Cognitive Dysfunction;Interferon alpha-2;Donepezil," Presence of any significant medical disorder which might cause or contribute to dementia such as B12 or folic acid deficiency, untreated hypothyroidism, history of significant alcohol abuse (within the past 10 years)."
NCT00031018,Phase 2,Alzheimer's Disease,National Center for Research Resources (NCRR),unknown,Alzheimer Disease;Memory Disorders;Cognitive Dysfunction;Interferon alpha-2;Donepezil, Patients with recent (less than  2 years) hematologic/oncologic disorders (other than basal or squamous cell carcinoma of the skin.
NCT00031018,Phase 2,Alzheimer's Disease,National Center for Research Resources (NCRR),unknown,Alzheimer Disease;Memory Disorders;Cognitive Dysfunction;Interferon alpha-2;Donepezil," Patients with recent (less than  3 months) myocardial infarction, poorly controlled CHF, surgery for peripheral vascular disease, or coronary artery bypass surgery."
NCT00031018,Phase 2,Alzheimer's Disease,National Center for Research Resources (NCRR),unknown,Alzheimer Disease;Memory Disorders;Cognitive Dysfunction;Interferon alpha-2;Donepezil," Evidence of clinically significant or unstable active GI, hepatic or pulmonary disease."
NCT00031018,Phase 2,Alzheimer's Disease,National Center for Research Resources (NCRR),unknown,Alzheimer Disease;Memory Disorders;Cognitive Dysfunction;Interferon alpha-2;Donepezil," History of documented stroke or more than one confirmed TIA. Any condition which would make the patient or caregiver, in the opinion of the principal investigator unsuitable for the study."
NCT00031018,Phase 2,Alzheimer's Disease,National Center for Research Resources (NCRR),unknown,Alzheimer Disease;Memory Disorders;Cognitive Dysfunction;Interferon alpha-2;Donepezil, Patients with known hypersensitivity to Donezepil HCL or other piperidine containing drugs.
NCT00051909,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Nov-02,Alzheimer Disease, Has serious health problems other than Alzheimer's Disease
NCT00051909,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Nov-02,Alzheimer Disease, Cannot swallow whole pills
NCT00051909,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Nov-02,Alzheimer Disease, Has had a menstrual period in the last two years
NCT00051909,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Nov-02,Alzheimer Disease, Takes insulin for diabetes
NCT00051909,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Nov-02,Alzheimer Disease," Has taken Aricept, Reminyl, or Exelon in the last 5 weeks"
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, B12 or folate deficiency
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, Renal insufficiency (serum creatinine greater than =2.0)
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, Active neoplastic disease (skin tumors other than melanoma are not exclusionary; patients with stable prostate cancer may be included at the discretion of the project director)
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, Use of another investigational agent within 2 months
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex, History of clinically significant stroke
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex," Current evidence or history in the past 2 years of epilepsy, focal brain lesion, head injury with loss of consciousness and/or immediate confusion after the injury, or DSM-IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse"
NCT00056225,Phase 3,Alzheimer's Disease,National Institute on Aging (NIA),Jan-03,Alzheimer Disease;Vitamins;Vitamin B 12;Vitamin B 6;Pyridoxal;Pyridoxine;Vitamin B Complex," Blindness, deafness, language difficulties or any other disability which may prevent the subject from participating or cooperating in the protocol"
NCT00056329,Phase 3,Alzheimer Disease,New York State Institute for Basic Research,Apr-02,Alzheimer Disease;Down Syndrome;Syndrome;Vitamin E;Tocopherols, Medical/neurological condition (other than Alzheimer's disease) associated with dementia.
NCT00056329,Phase 3,Alzheimer Disease,New York State Institute for Basic Research,Apr-02,Alzheimer Disease;Down Syndrome;Syndrome;Vitamin E;Tocopherols, Brief Praxis Test score less than 20.
NCT00056329,Phase 3,Alzheimer Disease,New York State Institute for Basic Research,Apr-02,Alzheimer Disease;Down Syndrome;Syndrome;Vitamin E;Tocopherols, Modified Hachinski score greater than 4.
NCT00056329,Phase 3,Alzheimer Disease,New York State Institute for Basic Research,Apr-02,Alzheimer Disease;Down Syndrome;Syndrome;Vitamin E;Tocopherols, Major depression within 3 months.
NCT00056329,Phase 3,Alzheimer Disease,New York State Institute for Basic Research,Apr-02,Alzheimer Disease;Down Syndrome;Syndrome;Vitamin E;Tocopherols, History of any disorder of blood coagulation (inherited or acquired).
NCT00056329,Phase 3,Alzheimer Disease,New York State Institute for Basic Research,Apr-02,Alzheimer Disease;Down Syndrome;Syndrome;Vitamin E;Tocopherols, Current use of anti-coagulants.
NCT00056329,Phase 3,Alzheimer Disease,New York State Institute for Basic Research,Apr-02,Alzheimer Disease;Down Syndrome;Syndrome;Vitamin E;Tocopherols, Use of experimental medications within 3 months.
NCT00056329,Phase 3,Alzheimer Disease,New York State Institute for Basic Research,Apr-02,Alzheimer Disease;Down Syndrome;Syndrome;Vitamin E;Tocopherols, Regular use of vitamin E greater than 50 units per day during the previous 6 months.
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, Patients with any of the exclusion criteria listed below will be ineligible for entry into the study. Patients will be declared ineligible if:
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They are male;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They are younger than 65 years of age;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," They have significant neurological disease affecting the brain or psychiatric disease other than AD, such as major depression, schizophrenia, epilepsy, Parkinson's disease, or stroke;"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They have current significant systemic illness or symptoms of organ failure;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, The screening ECG shows evidence of a serious and/or unstable condition or a recent (within 6 months) myocardial infarction;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," They have a history of cancer within the last 5 years, except for basal cell or squamous cell cancer, or cervical carcinoma in situ;"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," They are taking a cholinesterase inhibitor (tacrine, donepezil, rivastigmine, or galantamine) for less than 90 days prior to baseline; or, in the opinion of the Investigator, they are likely to either require a change in dose or discontinuation of the drug"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They have never received cholinesterase inhibitor treatment and are likely to initiate it;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," They started or changed within 60 days prior to the screening visit the dosage of any drug (including an over the counter drug) that affects cognitive function, such as neuroleptics, antidepressants, anxiolytics, sedatives, hypnotics, anti-convulsants, centrally acting antihypertensive agents such as clonidine and Aldomet; or other medications that have been shown to have possible effects on cognition such as Vitamin E, non steroidal anti-inflammatory drugs, statins, and hormone replacement therapy, or if, in the Investigator's opinion, the dosage of such medication is likely to be changed during the course of this trial. Any changes in the dosage of any of these drugs during the course of the trial and the reason for the change must be fully recorded in the concomitant medication page of the patient's case report form (CRF). If a drug that affects cognition is given on a PRN basis, such treatment should be interrupted for 12 hours before a visit, it at all possible;"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They are receiving coumadin or anti-Parkinsonian medications;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," They have received other investigational drugs within 30 days or 5 half-lives prior to randomization, whichever is longer;"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," They are taking other medications known to affect serum gonadotropin (Gn) concentrations, such as goserelin or danazol, except for estrogen and/or progesterone;"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They have a history of bone fracture possibly secondary to low bone mass density;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide," They have a history of osteoporosis not associated with bone fracture unless they are receiving therapy for osteoporosis for at least 3 weeks, and the treatment regimen is expected to stay stable their DEXA measures were abnormally low (i.e., T-score less than -2.0) and they were not receiving treatment for osteoporosis for at least 3 weeks;"
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They have a screening HamD score of 15 or higher;
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, Their abuse or dependence on alcohol or other substances satisfy criteria for DSM-IV categories 303.9 or 305; or
NCT00063310,Phase 2,Alzheimer Disease,Voyager Pharmaceutical Corporation,Mar-03,Alzheimer Disease;Leuprolide, They have donated blood within 30 days of baseline or are likely to do so during the course of the trial.
NCT00065767,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Raloxifene Hydrochloride, History of deep vein thrombosis or blot clots
NCT00065767,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Raloxifene Hydrochloride, Diabetes
NCT00065767,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Raloxifene Hydrochloride, Active heart disease or stroke
NCT00065767,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Raloxifene Hydrochloride, Liver problems including hepatitis
NCT00065767,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Raloxifene Hydrochloride, Severe vision or hearing problems
NCT00065767,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Raloxifene Hydrochloride, Tobacco use
NCT00066157,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Medroxyprogesterone Acetate;Estradiol 17 beta-cypionate;Estradiol 3-benzoate;Medroxyprogesterone;Estradiol;Polyestradiol phosphate;Estrogens;Progesterone, History of cancer of reproductive tissues
NCT00066157,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Medroxyprogesterone Acetate;Estradiol 17 beta-cypionate;Estradiol 3-benzoate;Medroxyprogesterone;Estradiol;Polyestradiol phosphate;Estrogens;Progesterone, History of deep vein thrombosis or blot clots
NCT00066157,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Medroxyprogesterone Acetate;Estradiol 17 beta-cypionate;Estradiol 3-benzoate;Medroxyprogesterone;Estradiol;Polyestradiol phosphate;Estrogens;Progesterone, Diabetes
NCT00066157,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Medroxyprogesterone Acetate;Estradiol 17 beta-cypionate;Estradiol 3-benzoate;Medroxyprogesterone;Estradiol;Polyestradiol phosphate;Estrogens;Progesterone, Heart disease or stroke
NCT00066157,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Medroxyprogesterone Acetate;Estradiol 17 beta-cypionate;Estradiol 3-benzoate;Medroxyprogesterone;Estradiol;Polyestradiol phosphate;Estrogens;Progesterone, Liver problems including hepatitis
NCT00066157,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Medroxyprogesterone Acetate;Estradiol 17 beta-cypionate;Estradiol 3-benzoate;Medroxyprogesterone;Estradiol;Polyestradiol phosphate;Estrogens;Progesterone, Severe vision or hearing problems
NCT00066157,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Medroxyprogesterone Acetate;Estradiol 17 beta-cypionate;Estradiol 3-benzoate;Medroxyprogesterone;Estradiol;Polyestradiol phosphate;Estrogens;Progesterone, Tobacco use
NCT00066157,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Medroxyprogesterone Acetate;Estradiol 17 beta-cypionate;Estradiol 3-benzoate;Medroxyprogesterone;Estradiol;Polyestradiol phosphate;Estrogens;Progesterone, Lack of an adequate caregiver
NCT00066157,Phase 2/Phase 3,Alzheimer Disease,"University of Wisconsin, Madison",Sep-01,Alzheimer Disease;Medroxyprogesterone Acetate;Estradiol 17 beta-cypionate;Estradiol 3-benzoate;Medroxyprogesterone;Estradiol;Polyestradiol phosphate;Estrogens;Progesterone, inability to perform psychometric testing
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Exceptions to these criteria may be considered on a case-by-case basis at the discretion of the Project Director:
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Non-AD dementia.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Females of child-bearing potential.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Residence in a long-term care facility or equivalent at Baseline.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Presence or previous history of agitation or psychosis requiring active psychotropic medication since the illness began.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, History of clinically significant stroke.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid," Current evidence or history in past two years of: focal brain lesion, head injury with loss of consciousness or Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse."
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Sensory impairment that would prevent subject from participating in or cooperating with the protocol.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Medical contraindications to study participation.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Use of another investigational agent within two months prior to Screening.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid," Evidence of any significant clinical disorder or laboratory finding that renders the subject unsuitable for receiving an investigational new drug including clinically significant or unstable hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, metabolic, renal, or other systemic disease or laboratory abnormality."
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid," Clinical contraindication to the use of valproate (e.g., known hypersensitivity or allergic reactions, severe neutropenia, severe hepatic disease, or urea cycle disorder. A urea cycle disorder should be considered in patients with history of unexplained encephalopathy following protein meals, or family history of urea cycle disorder)."
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, History of seizure within past 5 years prior to Screening.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid," Platelet count less than  100,000/mm^3."
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, International Normalized Ratio (INR) greater than  1.2 or partial thromboplastin time (PTT) greater than  40 seconds.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Active neoplastic disease. Exceptions: skin tumors other than melanoma are not excluded; patients with stable prostate cancer may be included at the discretion of the Project Director; women who have been treated for breast cancer and have no metastases and whose survival is expected to exceed 2 years may be considered for inclusion on a case-by-case basis in consultation with the Project Director; patients with purely localized bladder wall cancers may be included at the discretion of the Project Director.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Excluded Medications:
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid," Use of psychotropics for treatment of agitation or psychosis. Antidepressants used in stable doses for 3 months prior to Screening to treat depression or anxiety, but not agitation, will be permitted. Low dose sedatives for sleep, but not agitation, will be permitted. Cholinesterase inhibitors used in stable doses for at least 3 months prior to Screening are permitted."
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Regular use of narcotic analgesics within 3 months of Screening.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid," Anti-parkinsonian medications (e.g. levodopa, selegiline, pergolide, bromocriptine, pramipexole) within 2 months of Screening."
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid," Use of drugs with significant central anticholinergic or antihistaminic effects (eg, benztropine, trihexyphenidyl, dicyclomine, diphenhydramine, cyproheptadine, diphenoxylate, hydroxyzine, meclizine, prochlorperazine, promethazine) within 2 months of Screening."
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Use of other investigational drug studies within two months prior to Screening.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Use of other anticonvulsants within 5 years prior to Screening.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Use of zidovudine at any time.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Use of tricyclic antidepressants within 1 month prior to Screening.
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid," Regular use of high doses of salicylates at Screening (greater than  1,300 mg/d)."
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid," Vitamin E greater than  2,100 IU/d within 1 month prior to Screening."
NCT00071721,Phase 3,Alzheimer Disease,Alzheimer's Disease Cooperative Study (ADCS),Oct-03,Alzheimer Disease;Valproic Acid, Warfarin use is permitted when approved by the Project Director and INR and PTT criteria are met.
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Neurodegenerative disorders
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine," One of the following conditions possibly resulting in cognitive impairment: Acute cerebral trauma or injuries secondary to chronic trauma (such as boxing), hypoxic cerebral damage, whether or not due to acute or chronic cerebral hypoperfusion"
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine," Vitamin deficiency states, such as folate, vitamin B12 or other B complex deficiencies"
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine," Neurosyphilis or other infections resulting in cerebral abscesses, meningitis, or encephalitides such as AIDS"
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Primary or metastatic cerebral neoplasia
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine," Significant endocrine or metabolic disease e.g., untreated or uncontrolled thyroid, parathyroid or pituitary disease, Cushing's syndrome, severe renal failure or uncontrolled diabetes mellitus"
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Mental retardation or oligophrenia
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine," Multi-infarct dementia or clinically active cerebrovascular disease as evidenced by: a history of a significant cerebrovascular event yielding a physical or neurologic deficit likely to confound the assessment of the subject's intellectual function, multiple focal signs on neurological examination indicative of multiple ischemic attacks, significant findings on an available CT or MRI scan taken within the last 12 months"
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Subjects with the following co-existing medical conditions: Any history of epilepsy or convulsions except for febrile convulsions during childhood
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine," Current clinically significant psychiatric disease, in particular current major depression, schizophrenia, bipolar disorder, moderate to severe or uncontrolled behavioral disturbances"
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine," Peptic ulcer disease: if the ulcer is considered to be still active, or if treatment is not successful (symptoms present)"
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine," Clinically significant hepatic, renal, pulmonary, metabolic or endocrine disturbances"
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Clinically significant urinary outflow obstruction
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine," Current, clinically significant cardiovascular disease that would be expected to limit the subject's ability to participate in and complete a 12-Week trial. The following would usually be considered clinically significant cardiovascular diseases: cardiac surgery or myocardial infarction within the past 6 months, angina or coronary artery disease that required a change in anti-angina medication within the last 3 months, decompensated congestive heart failure, cardiac disease potentially resulting in syncope, near syncope or other alterations of mental status, atrial fibrillation, bradycardia less than  50/min., atrio-ventricular block greater than  first degree"
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Severe mitral or aortic valvular disease
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Uncontrolled high blood pressure (systolic blood pressure greater than  170 mmHg or diastolic blood pressure greater than  110 mmHg) or sustained hypotension
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine," Any agent being used for the treatment of dementia (approved, experimental or over the counter agents"
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine," Subjects who have previously received Cognex, Aricept, metrifonate, Exelon, Reminyl, or Namenda for treatment of Alzheimer's disease, no matter if approved or experimental can be included in this trial provided that during the 30 days prior to baseline they were not taking these agents"
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, O History of drug or alcohol abuse within the last year or prior prolonged history of the same
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Female subjects of childbearing potential
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Subjects who in the opinion of the investigator are otherwise unsuitable for a trial of this type
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine," History of severe drug allergy or hypersensitivity, including recorded hypersensitivity to cholinesterase inhibitors, choline agonists or identical agents, or bromide"
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Subjects who have previously been enrolled in other galantamine trials
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Subjects who have received an investigational medication within the last 30 days
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Conditions that could interfere with the absorption of the compound or with the evaluation of the disease
NCT00082602,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-04,Alzheimer Disease;Galantamine, Employees of the investigator
NCT00083421,Phase 2,Alzheimer's Disease,Ono Pharma USA Inc,Jun-04,Alzheimer Disease, Serious systemic disease that may preclude survival to study completion
NCT00083421,Phase 2,Alzheimer's Disease,Ono Pharma USA Inc,Jun-04,Alzheimer Disease, Other illnesses that may include dementive features
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, History of active peptic ulcer disease within 1 year of screening.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Clinically significant cardiac arrhythmia.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Resting pulse less than 50.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Active neoplastic (cancer) disease (skin tumors other than melanoma are not excluded; participants with stable prostate cancer may be included at the discretion of the Project Director).
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Use of another investigational agent within 2 months of screening.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, History of clinically significant stroke.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A," Current evidence or history in the past 2 years of epilepsy, focal brain lesion, head injury with loss of consciousness and/or immediate confusion after the injury, or DSM-IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse."
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A," Blindness, deafness, language difficulties or any other disability which may prevent the participant from participating or cooperating in the protocol."
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Residence in a skilled nursing facility; but patients in an assisted living facility are acceptable.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Excluded Medications:
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A," Use of cholinesterase inhibitors (galantamine, rivastigmine, donepezil, and tacrine) within 2 months of screening."
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Regular use of narcotic analgesics (greater than 2 doses per week) within 4 weeks of screening.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A," Use of medications with significant central nervous system anticholinergic activity within 2 months of screening (e.g. tricyclic antidepressants, diphenhydramine)."
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A," Use of anti-Parkinsonian medications (including Sinemet, amantadine, bromocriptine, pergolide, selegiline) within 2 months of screening."
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Participation in any other investigational drug study within 2 months of screening (individuals may not participate in any other drug study while participating in this protocol).
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Use of estrogen is allowed if the dose has been stable for 3 months prior to screening.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Use of vitamin E is allowed if the dose has been stable for 3 months prior to screening.
NCT00083590,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Apr-04,Alzheimer Disease;Huperzine A, Use of memantine is allowed if the dose has been stable for 3 months prior to screening.
NCT00087724,Phase 2,Alzheimer's Disease,Astellas Pharma Inc,Jul-04,Alzheimer Disease, Subject has history or evidence of significant neurologic disease other than AD
NCT00087724,Phase 2,Alzheimer's Disease,Astellas Pharma Inc,Jul-04,Alzheimer Disease, Subject has a history of stroke
NCT00087724,Phase 2,Alzheimer's Disease,Astellas Pharma Inc,Jul-04,Alzheimer Disease, Subject has been treated for schizophrenia or recurrent mood disorder within the previous three years
NCT00087724,Phase 2,Alzheimer's Disease,Astellas Pharma Inc,Jul-04,Alzheimer Disease, Subject has a hematologic or solid malignancy diagnosed within five years prior to study entry
NCT00087724,Phase 2,Alzheimer's Disease,Astellas Pharma Inc,Jul-04,Alzheimer Disease, Subject has medically unstable COPD or asthma
NCT00087724,Phase 2,Alzheimer's Disease,Astellas Pharma Inc,Jul-04,Alzheimer Disease, Subject has end stage CHF (NYHA Class III or IV) or unstable angina
NCT00087724,Phase 2,Alzheimer's Disease,Astellas Pharma Inc,Jul-04,Alzheimer Disease, Subject has evidence of significant renal insufficiency
NCT00087724,Phase 2,Alzheimer's Disease,Astellas Pharma Inc,Jul-04,Alzheimer Disease, Subject has insulin-dependent diabetes mellitus or HbA1Cgreater than 8.5% at screening
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Patients will not be eligible to participate in the study if they meet any of the following criteria:
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Potential participant with any other cause of dementia.
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Life expectancy less than 2 years.
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Potential participant with a clinically significant and/or uncontrolled condition or other significant medical disease.
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Use of an investigational drug within 30 days prior to the screening visit or during the entire study.
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Previous use of 3APS.
NCT00088673,Phase 3,Alzheimer Disease,Bellus Health Inc,Jun-04,Alzheimer Disease, Patient recruitment is done by participating centers.
NCT00090116,Phase 3,Alzheimer's Disease,Forest Laboratories,Mar-03,Alzheimer Disease, folate deficiency;
NCT00090116,Phase 3,Alzheimer's Disease,Forest Laboratories,Mar-03,Alzheimer Disease, clinically significant central nervous system disease other than Alzheimer's disease;
NCT00090116,Phase 3,Alzheimer's Disease,Forest Laboratories,Mar-03,Alzheimer Disease," clinically significant pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular disease"
NCT00093951,Phase 2,Alzheimer's Disease,Saegis Pharmaceuticals,Apr-04,Alzheimer Disease;(3-aminopropyl)(n-butyl)phosphinic acid, Call 1-877-MY-MEMORY and ask to be referred to a study center located near you for entry criteria information.
NCT00093951,Phase 2,Alzheimer's Disease,Saegis Pharmaceuticals,Apr-04,Alzheimer Disease;(3-aminopropyl)(n-butyl)phosphinic acid, Prohibited Meds:
NCT00093951,Phase 2,Alzheimer's Disease,Saegis Pharmaceuticals,Apr-04,Alzheimer Disease;(3-aminopropyl)(n-butyl)phosphinic acid," Alzheimer's medications (Aricept, Exelon, Remydl, Nemenda)"
NCT00095719,Phase 3,Alzheimer's Disease,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Dec-03,Alzheimer Disease;Dementia;Aripiprazole," Current DSM-IV Axis 1 diagnosis other than Alzheimer's, vascular or mixed Dementia."
NCT00097916,Phase 3,Alzheimer's Disease,Forest Laboratories,Sep-04,Alzheimer Disease;Memantine, Other evidence of psychiatric disorders
NCT00097916,Phase 3,Alzheimer's Disease,Forest Laboratories,Sep-04,Alzheimer Disease;Memantine, Oncologic diagnosis
NCT00097916,Phase 3,Alzheimer's Disease,Forest Laboratories,Sep-04,Alzheimer Disease;Memantine," Clinically significant gastrointestinal, renal, hepatic, endocrine or cardiovascular disease"
NCT00099242,Phase 3,"Dementia, Alzheimer Type",Novartis Pharmaceuticals,Nov-03,Alzheimer Disease;Dementia;Rivastigmine, Any condition (other than Alzheimer's) that could explain patient's dementia
NCT00099242,Phase 3,"Dementia, Alzheimer Type",Novartis Pharmaceuticals,Nov-03,Alzheimer Disease;Dementia;Rivastigmine," An advanced, severe or unstable disease that may put the patient at special risk"
NCT00099242,Phase 3,"Dementia, Alzheimer Type",Novartis Pharmaceuticals,Nov-03,Alzheimer Disease;Dementia;Rivastigmine," Current diagnosis of active, uncontrolled seizure disorder or unstable cardiovascular disease"
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease," Subject has participated in a clinical trial of another investigational drug or device, or has taken any experimental drug within 30 days prior to admission to the Phase 1 unit. (Subjects previously enrolled in 1019-03-01 may be enrolled in 1019-04-01, only after a wash-out period of 45 days.)"
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease, Subject has a history compatible with vascular dementia as evidenced by a score of 5 or greater on the modified Hachinski Ischemia Scale.
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease," Subject has evidence of clinically significant unstable cardiovascular, renal, hepatic, gastrointestinal, neurological, or metabolic disease within the past 6 months (as determined by medical history, ECG results, chest x-ray, or physical examination)."
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease, Subject performance status is greater than  3 on items 1 through 5 and greater than  2 on item 6 from the Degree of Disability Section of the  Rapid Disability Scale-2. 
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease, Subject has diabetes that requires oral antidiabetic therapy or insulin.
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease," Subject has a systolic blood pressure (sitting) of greater than 160 mmHg, a diastolic (sitting) greater than 95 mmHg, a decrease in systolic blood pressure of more than 30 mmHg upon standing for 2 minutes from a sitting or supine position, a pulse (sitting or supine) less than 50 or greater than 85."
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease," Subject has any visual, hearing, or communication disabilities impairing his/her ability to participate in the study."
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease, Subject is being treated with anticholinergics and/or clinically relevant cytochrome P450 3A4 inducers/inhibitors. The use of other concomitant medications for stable medical conditions is acceptable provided drug and dosage are stable for at least 4 weeks prior to dosing.
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease," Subject is currently taking herbal supplements which interfere with drug metabolism, e.g. St. John's wort, ginkgo biloba."
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease," Subject has tested positive for drugs of abuse (amphetamines, barbiturates, cocaine, phencyclidine, or cannabinoids) on screening or Day -1"
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease, Subject has a current or past medical history of alcohol abuse.
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease," Subject has any elevations (greater than  1.2 x ULN) on screening or Day -1 for ALT, AST, bilirubin, creatinine, blood urea nitrogen, or alkaline phosphatase."
NCT00100334,Phase 1/Phase 2,Alzheimer's Disease,PRAECIS Pharmaceuticals Inc.,Dec-04,Alzheimer Disease, Subject has any other screening or Day -1 laboratory values outside the normal ranges that are deemed clinically significant by the investigator.
NCT00103649,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Potential participant with any other cause of dementia.
NCT00103649,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Potential participant with serious health problems other than Alzheimer's disease
NCT00103649,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Use of an investigational drug within two months prior to randomization or during this study
NCT00104013,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Potential participant with any other cause of dementia.
NCT00104013,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Potential participant with serious health problems other than Alzheimer's disease
NCT00104013,Phase 3,Alzheimer Disease,Sanofi,Nov-03,Alzheimer Disease;Dementia;Xaliproden, Use of an investigational drug within two months prior to randomization or during this study
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Patients taking (a) Aricept doses other than 10 mg daily (or 10 mg for less than  8 weeks); (b) other medications for Alzheimer's Disease except for stable, prescribed doses of 20 mg daily memantine for at least 4 weeks (preceded by titration to 20 mg daily)."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,No reliable caregiver.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Neurological disorders affecting cognition or the ability to assess it that are not associated with Alzheimer's Disease, such as Parkinson's disease, multi-infarct dementia, dementia due to cerebrovascular disease, Huntington's disease, Pick's disease, Creutzfeld-Jacob disease, Lewy Body disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, or multiple sclerosis, as well as patients with human immunodeficiency virus (HIV) disease, neurosyphilis, or a history of significant head trauma followed by persistent neurological deficits or known structural brain abnormalities."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Psychiatric disorders affecting the ability to assess cognition such as schizophrenia, bipolar or unipolar depression, and sleep disorders."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Dementia complicated by other organic disease or Alzheimer's Disease with delusions (DSM 290.20 or 290.12), delirium (DSM 290.30 or 290.11), or depression (DSM 290.21 or 290.13)."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Drug or alcohol abuse or dependence in less than = 5 years by DSM IV criteria.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Any active or clinically significant conditions affecting absorption, distribution, or metabolism of the study medication (e.g., inflammatory bowel disease, gastric or duodenal ulcers, hepatic disease, or severe lactose intolerance)."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Uncontrolled hypertension (sitting systolic greater than = 160 mmHg and/or diastolic greater than = 95 mmHg) as assessed by the Investigator regardless of whether or not the patient is taking antihypertensive medications.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Insulin-dependent diabetes or diabetes not stabilized by diet and/or oral hypoglycemic agents as demonstrated by an Hb A1c of greater than  8.0% or a random serum glucose value of greater than  170 mg/dL.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Evidence of clinically significant, active gastrointestinal, renal, hepatic, respiratory, endocrine, or cardiovascular system disease. Patients with right bundle branch block (complete or partial) may be included in the study, but patients with left bundle branch block are excluded."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"History of malignant neoplasms (does not include basal or squamous cell carcinoma of the skin) treated within 5 years prior to study entry, current evidence of malignant neoplasm, recurrent, metastatic disease, or major risk factors for malignant melanoma (xeroderma pigmentosum, personal history of melanoma, more than 100 moles, and puva or other radiotherapy."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Donation of blood or blood products during 30 days prior to Screening or plans to donate blood while participating in the study or within 30 days after completion of the study.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Women who are pregnant or breast-feeding.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Patients and/or caregivers who are unwilling or unable to fulfill the requirements of the study.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Known hypersensitivity to cholinesterase inhibitors or MAO or MAO-B inhibitors.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Use of any unapproved prior or concomitant medications, including:"
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline, Recent (less than = 12 weeks) or concomitant use of other MAO inhibitors.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline," Recent (less than = 6 weeks) or concomitant use of SSRIs. (SSRIs and tricyclic and tetracyclic antidepressants in low doses are permissible, as follows: citalopram less than = 20 mg daily, escitalopram less than = 10 mg daily, and sertraline 25-100 mg daily)."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline, Recent (less than = 1 week) or concomitant use of sympathomimetics (including ephedra supplements).
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline, Recent (less than = 1 week) or concomitant use of meperidine.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline, Recent (less than = 1 week) or concomitant use of dextromethorphan.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline, Recent (less than = 1 week) or concomitant use of gentamicin.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Any condition that would make the patient or the caregiver, in the opinion of the Investigator, unsuitable for the study."
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,Involvement in any other investigational trial in the preceding 3 months or likely involvement in any other investigational trial during the course of this study.
NCT00104273,Phase 2,Alzheimer's Disease,"Teva Branded Pharmaceutical Products R&amp;D, Inc.",Aug-04,Alzheimer Disease;Dementia;Rasagiline,"Contraindications to MRI scanning, including CNS aneurysm clips, implanted neural stimulators, implanted cardiac pacemakers or defibrillators, cochlear implants, metallic ocular foreign body, insulin pump, or metal shrapnel or bullet."
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, Women with an intact uterus
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," A clinically significant medical condition, including lab abnormality, which in the opinion of the investigator would place the patient at undue risk, or would impair the patient's ability to participate in the study. These include but are not limited to: history of cerebral vascular accident (CVA), adrenal insufficiency, porphyrias, autoimmune disorders, type I diabetes, chronic obstructive pulmonary disease (COPD), hematologic or oncologic disorders in the previous 2 years, vitamin B12 or folate deficiency"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," A clinically significant active gastrointestinal, renal, hepatic, endocrine, or cardiovascular system disease that is not well controlled by diet, pharmacological treatment, or other therapeutic intervention"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," History of psychotic episodes or bipolar disorder, or additional diagnosis of delusions, delerium, or depression"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," Evidence of other psychiatric or neurologic disorders (e.g., stroke, schizophrenia, or Parkinson disease)"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, Hachinski ischemia score of 5 or more
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, Known hypersensitivity to cholinesterase inhibitors
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," Use of systemic or pulmonary inhaled corticosteroids within the 30 days prior to randomization, or require use of these medications during the study"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," Use of memantine (Namenda) within the 30 days prior to randomization, or require use of this medication during the study"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," Currently taking medications known to significantly induce or inhibit the metabolism of CYP 3A4, or have taken these medications 7 days prior to randomization (see list below under prohibited medications)"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," Use of anticholinergic compounds within the 30 days prior to randomization, or require use of this medication during the study"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, History of electroconvulsive therapy (ECT); patients may not undergo ECT during the course of the trial
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," Positive urine drug screen for any non-prescribed drug of abuse (including but not limited to amphetamines, cannabinoids, barbiturates, cocaine, opiates, benzodiazepines)"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, History of illicit drugs usage or a history of drug or alcohol dependence
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," Known to have another form of dementia that may also explain the patient's deficits including reversible dementias, Binswanger's, Parkinson's dementia complex, Korsakoff's, mental retardation or vascular dementia. Patients who meet clinical criteria for AD but who have deep white matter lesions on MRI or CT scan will be accepted."
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, Currently taking prescription anticoagulants such as warfarin (Coumadin)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," Planned surgical procedures during the study period, including the 4 week off drug period between weeks 16 and 20"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," Participation in a clinical investigation of any drug, or other biological or investigational therapy within 30 days prior to dosing"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," Previous participation in a trial using mifepristone, or known sensitivity or allergy to C-1073 (mifepristone) or its constituents"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, Body Mass Index (BMI) over 35
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, Prohibited Medications:
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," Medications known to significantly induce or inhibit the metabolism of CYP 3A4, specifically:"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, carbamazepine (Carbatrol Tegretol)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, modafinil (Provigil)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, nefazodone (Serzone)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, droperidol
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, erythromycin
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, fluconazole (Diflucan)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, itraconazole (Sporanox)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, ketoconazole (Nizoral)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, simvastatin (Zocor)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, lovastatin (Mevacor)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, vinblastine
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, vincristine
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, paclitaxel (Taxol)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, tamoxifen (Nolvadex)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," cyclosporine (Neoral, Sandimmune)"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, tacrolimus (Gengraf)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, sirolimus (Rapamune)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, midazolam (Versed)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, nicardipine (Cardene)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," nifedipine (Adalat, Procardia)"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone," felodipine (Lexxel, Plendil)"
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, thioridizine
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, pimozide (Orap)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, quinidine
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, Patient may also not take St. John's Wort during the study or within 7 days prior to study entry
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, the use of grapefruit juice will be excluded during the course of the study.
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, use of anticholinergic compounds over the past 30 days prior to randomization
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, warfarin (Coumadin)
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, all systemic and inhaled pulmonary corticosteroids
NCT00105105,Phase 2,Alzheimer's Disease,Corcept Therapeutics,Apr-03,Alzheimer Disease;Mifepristone, memantine (Namenda)
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, Significant neurological disease other than AD
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, Major psychiatric disorder
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, Significant systemic illness
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, History of stroke or seizure
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, Weight greater than 120 kg (264 lbs.)
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, History of autoimmune disease
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, Smoking more than 20 cigarettes per day
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease," Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications"
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease, Prior treatment with experimental immunotherapeutics or vaccines for AD
NCT00112073,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Apr-05,Alzheimer Disease," Presence of pacemakers or foreign metal objects in the eyes, skin, or body"
NCT00130429,Phase 2,Alzheimer's Disease,Phytopharm,Jan-04,Alzheimer Disease, Recent history or clinical evidence of significant neurological disease other than dementia due to Alzheimer's disease
NCT00130429,Phase 2,Alzheimer's Disease,Phytopharm,Jan-04,Alzheimer Disease, Known to have another condition that is associated with dementia
NCT00130429,Phase 2,Alzheimer's Disease,Phytopharm,Jan-04,Alzheimer Disease," Use of psychotropic medication within the previous 4 weeks (excluding cholinesterase inhibitors, selective serotonin reuptake inhibitors and venlafaxine)"
NCT00130429,Phase 2,Alzheimer's Disease,Phytopharm,Jan-04,Alzheimer Disease, Hormone replacement therapy started or changed within the previous 6 months
NCT00130429,Phase 2,Alzheimer's Disease,Phytopharm,Jan-04,Alzheimer Disease, Received any investigational drugs within the previous 12 weeks
NCT00141661,Phase 2,Alzheimer Disease,Pfizer,Oct-05,Alzheimer Disease, Current evidence of a neurological or psychiatric illness that could contribute to dementia.
NCT00141661,Phase 2,Alzheimer Disease,Pfizer,Oct-05,Alzheimer Disease, Living alone.
NCT00141661,Phase 2,Alzheimer Disease,Pfizer,Oct-05,Alzheimer Disease, Poorly controlled high blood pressure.
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease," Any condition that would, in the opinion of the Principal Investigator, render the patient or the caregiver unsuitable for the study, or place them at substantial risk of adverse outcome"
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Unwillingness or inability of the patient and/or caregiver to fulfill the requirements of the study
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Resident in a skilled nursing facility
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease," Any significant neurological disease other than probable AD (e.g. Parkinson's disease, Huntington's disease, brain tumor, normal pressure hydrocephalus, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of stroke, or history of head injury requiring hospitalization)"
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, An alternate cause for dementia other than AD as determined by a required CT or MRI scan within 24 months prior to screening
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Current history of major psychiatric disorder
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Major depression as determined by a Cornell Scale for Depression in Dementia
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Clinically significant hypothyroidism
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Clinically significant B12 deficiency
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Unstable or clinically significant cardiovascular disease
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Diabetes of any type
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, History of tertiary syphilis
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease," Cancer within 3 years prior to baseline, with the exception of squamous and basal cell carcinoma"
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Vital sign abnormalities
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Clinically significant renal disease or insufficiency
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Clinically significant hepatic disease or insufficiency
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Alcohol consumption greater than 2 oz of spirits per day or 14 oz per week (1 oz of spirits is equal to 6 oz of wine or 12 oz of beer)
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Current history of alcohol abuse or other substance abuse within 24 months prior to baseline
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Known HIV infection
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Use of any investigational compound within 30 days prior to screening
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Use of prohibited medications (contact site for details)
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Prior or current use of medium-chain triglycerides (MCTs) for medical purposes
NCT00142805,Phase 2,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Known allergies to coconut oil
NCT00151333,Phase 2,Alzheimer's Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Feb-05,Alzheimer Disease, Significant neurologic disease other than AD that may affect cognition.
NCT00151333,Phase 2,Alzheimer's Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Feb-05,Alzheimer Disease, Current clinically significant systemic illness which is likely to deteriorate or affect the subject's safety during the study.
NCT00151333,Phase 2,Alzheimer's Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Feb-05,Alzheimer Disease, Other exclusions apply
NCT00151398,Phase 2,Alzheimer Disease,Wyeth is now a wholly owned subsidiary of Pfizer,unknown,Alzheimer Disease;Donepezil, Use of medications for cognitive enhancement within 3 months of baseline.
NCT00151398,Phase 2,Alzheimer Disease,Wyeth is now a wholly owned subsidiary of Pfizer,unknown,Alzheimer Disease;Donepezil, Significant neurologic disease other than AD that may affect cognition.
NCT00151502,Phase 3,Alzheimer's Disease,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Nov-02,Alzheimer Disease;Atorvastatin, Subjects with dementia due to causes other than Alzheimer's disease.
NCT00151502,Phase 3,Alzheimer's Disease,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Nov-02,Alzheimer Disease;Atorvastatin," Any condition, which, in the investigator's judgment might increase the risk to the subject or decrease the reliability of the data required to meet the objectives of the study."
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,"Patients with history of severe systemic disease such as coronary artery disease, myocardial infarct, progressive heart failure, chronic obstructive pulmonary disease within the past 1 year;"
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,"Patients with hepatic and renal insufficiency (ALTAST 3 times above normal range; serum creatinine 2 times above normal range), diabetic patients with poor control of blood sugar (HbA1cgreater than 8.5) at study entry;"
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,"Patients with central nervous system disease other than AD such as cerebral vascular disease, Parkinson's disease, epilepsy, traumatic brain injury, central nervous system infection, and alcoholic encephalopathy;"
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,Patients with concurrent psychosis or mood disorder (Hamilton depression scale score greater than  17);
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,Patients diagnosed cancer and treated within the past two years (except for non-invasive skin cancer);
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,"Patients with general medical conditions, which may confound the results of the study, pose additional risk or preclude evaluation and assessments in this study as judged by the investigator;"
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,Patients currently treated with any prohibited medications (listed in Concomitant Treatment section) are not able to fulfill the 2 week-washout period;
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,Participation in another study within the last 30 days;
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,Females who are within two years of their menopause unless proved not pregnant (determined by urine test);
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,"Dementia caused by other etiology as indicated by clinically significant abnormal Vit B12, folic acid, or thyroid function tests."
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,Patients with neurosyphilis confirmed by CSF STS/TPHA;
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,The neuroimage CT or MRI could not be compatible with the diagnosis of probable AD as stated in the NINCDS criteria;
NCT00154635,Phase 2,"Dementia, Alzheimer Type",National Taiwan University Hospital,Sep-05,Alzheimer Disease,Patients with a Hachinski score (Appendix 5) above 3 are excluded.
NCT00160147,Phase 3,Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type,Solvay Pharmaceuticals,Dec-05,Dementia;Alzheimer Disease;Psychotic Disorders;Mental Disorders;Problem Behavior, History of seizure disorder
NCT00160147,Phase 3,Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type,Solvay Pharmaceuticals,Dec-05,Dementia;Alzheimer Disease;Psychotic Disorders;Mental Disorders;Problem Behavior, Clinically significant electrocardiogram (ECG)
NCT00160147,Phase 3,Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type,Solvay Pharmaceuticals,Dec-05,Dementia;Alzheimer Disease;Psychotic Disorders;Mental Disorders;Problem Behavior," Clinical or radiological evidence of stroke, vascular dementia or dementia due to substance abuse, or head trauma"
NCT00164749,Phase 1/Phase 2,Alzheimer's Disease,Chinese University of Hong Kong,Oct-04,Alzheimer Disease;Curcumin, Anticoagulant or antiplatelet treatment or bleeding risk factors
NCT00164749,Phase 1/Phase 2,Alzheimer's Disease,Chinese University of Hong Kong,Oct-04,Alzheimer Disease;Curcumin, Currently smoking
NCT00164749,Phase 1/Phase 2,Alzheimer's Disease,Chinese University of Hong Kong,Oct-04,Alzheimer Disease;Curcumin," Other severe, end-stage illness"
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients with dementia other than AD.
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil,Patient whose imaging test shows  circumscribed cerebral lesion or multiple infarcts  which is suspected to be the responsible cause of dementia (mixed-type dementia)
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil,Patients with other types of dementia
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients with a current DSM-IV diagnosis of major depressive disorder or any current serious psychiatric diagnosis othe than AD.
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients without a reliable caregiver.
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients who are expected to enter a nursing home facility within 6 months after starting study treatment (excluding a transient entry).
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil," Patients with active or clinically significant conditions affecting absorption, distribution or metabolism of study drugs (e.g., inflammatory bowel disease, gastric or duodenal ulcers, or severe lactose intolerance)."
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients with a known hypersensitivity to a component of donepezil hydrochloride preparation or piperidine derivatives.
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil," Patients complicated with a severe gastrointestinal, hepatic, renal, endocrine, or cardiovascular system disease (e.g., sick sinus syndrome, intraarterial and supraventricular conduction disorder, etc.)."
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients with a history of severe bronchial asthma or obstructive pulmonary disease.
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil," Patients with a severe extrapyramidal disease (Parkinson's disease, Parkinson's syndrome, etc.)."
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients with diabetes mellitus with uncontrolled blood glucose levels (HbAlc of 10%).
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Hypertension patients with uncontrolled blood pressure (diastolic blood pressure of 95 mmHg).
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients with uncontrolled thyroid dysfunction.
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients with a history of seizure or convulsion within the previous 3 months (obtaining informed consent).
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients with a known or suspected history of alcohoism or drug dependence within the recent 10 years.
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients with malignant tumors.
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil," Women of pregnant, possibly pregnant, or lactating."
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Patients who have participated in another clinical study within the recent 3 months (before giving consent).
NCT00165659,Phase 2,Alzheimer Disease,Eisai Limited,Nov-02,Alzheimer Disease;Donepezil, Any other patients who are judged to be ineligible for study entry by the investigator or subinvestigator.
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease, Significant neurological disease other than AD
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease, Major psychiatric disorder
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease, Significant systemic illness
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease, History of stroke or seizure
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease, Weight greater than 120kg (264 lbs.)
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease, History of autoimmune disease
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease, Smoking more than 20 cigarettes per day
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease," Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications"
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease, Prior treatment with experimental immunotherapeutics or vaccines for AD
NCT00174525,Phase 2,Alzheimer's Disease,Pharmacology Research Institute,Apr-05,Alzheimer Disease," Presence of pacemakers or foreign metal objects in the eyes, skin, or body"
NCT00190021,Phase 3,Dementia of Alzheimer Type,Beersheva Mental Health Center,unknown,Dementia;Alzheimer Disease;Donepezil, vascular demential
NCT00190021,Phase 3,Dementia of Alzheimer Type,Beersheva Mental Health Center,unknown,Dementia;Alzheimer Disease;Donepezil," concurrent Axis I DSM-IV diagnosis (delirium, schizophrenia, delusional disorder and affective disorders)"
NCT00190021,Phase 3,Dementia of Alzheimer Type,Beersheva Mental Health Center,unknown,Dementia;Alzheimer Disease;Donepezil," significant medical illness (cardiovascular, liver, renal, edocrinal, B12 or folic acid deficience and neurological illnesses)"
NCT00190021,Phase 3,Dementia of Alzheimer Type,Beersheva Mental Health Center,unknown,Dementia;Alzheimer Disease;Donepezil, drug or alcohol addiction
NCT00191009,Phase 2/Phase 3,Alzheimer Disease,Eli Lilly and Company,Oct-03,Alzheimer Disease;Atomoxetine Hydrochloride, Patients who are receiving pharmacologic treatments (other than a cholinesterase inhibitor or memantine) for Alzheimer's Disease.
NCT00191009,Phase 2/Phase 3,Alzheimer Disease,Eli Lilly and Company,Oct-03,Alzheimer Disease;Atomoxetine Hydrochloride, Patients who have a history in the past 5 years or any current evidence of major psychiatric illness.
NCT00191009,Phase 2/Phase 3,Alzheimer Disease,Eli Lilly and Company,Oct-03,Alzheimer Disease;Atomoxetine Hydrochloride, Patients who have narrow angle glaucoma.
NCT00191009,Phase 2/Phase 3,Alzheimer Disease,Eli Lilly and Company,Oct-03,Alzheimer Disease;Atomoxetine Hydrochloride, Patients who are experiencing clinically significant urinary hesitancy or retention as assessed by a physician.
NCT00205179,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jan-05,Alzheimer Disease, Current or recent use (less than 6 months) of menopausal Hormone Replacement Therapy (HRT)
NCT00205179,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jan-05,Alzheimer Disease, Current or recent use (less than 4 months) or oral antibiotic therapy
NCT00205179,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jan-05,Alzheimer Disease, Typical dietary intake of soy isoflavones greater than 5 mg/day
NCT00205179,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jan-05,Alzheimer Disease," History or significant gastro-intestinal or colon disease, or colon/intestinal resection"
NCT00205179,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jan-05,Alzheimer Disease, Irritable bowel syndrome
NCT00205179,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jan-05,Alzheimer Disease," History of breast cancer, or abnormal mammogram within 12 months"
NCT00205179,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jan-05,Alzheimer Disease," History of chronic obstructive pulmonary disease, diabetes mellitus, liver disease or unstable ischemic heart disease"
NCT00205179,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jan-05,Alzheimer Disease," Significant neurological disease other than AD that might affect cognitive function, such as stroke, Parkinson's disease, multiple sclerosis, or serious traumatic brain injury"
NCT00216593,Phase 3,Alzheimer Disease,"Janssen Pharmaceutica N.V., Belgium",Dec-03,Alzheimer Disease;Dementia;Galantamine, Dementia caused by cerebrovascular disease
NCT00216593,Phase 3,Alzheimer Disease,"Janssen Pharmaceutica N.V., Belgium",Dec-03,Alzheimer Disease;Dementia;Galantamine," disturbances of consciousness, delirium, psychosis"
NCT00216593,Phase 3,Alzheimer Disease,"Janssen Pharmaceutica N.V., Belgium",Dec-03,Alzheimer Disease;Dementia;Galantamine, severe aphasia
NCT00216593,Phase 3,Alzheimer Disease,"Janssen Pharmaceutica N.V., Belgium",Dec-03,Alzheimer Disease;Dementia;Galantamine, or major sensorimotor impairment
NCT00216593,Phase 3,Alzheimer Disease,"Janssen Pharmaceutica N.V., Belgium",Dec-03,Alzheimer Disease;Dementia;Galantamine," cognitive impairment due to acute cerebral trauma, hypoxic cerebral damage, vitamin deficiency, infections, primary of metastatic cerebral neoplasia, endocrine or metabolic disease or mental retardation, pregnant or nursing women or those without adequate contraception."
NCT00231946,Phase 3,Alzheimer's Disease,Voyager Pharmaceutical Corporation,Sep-05,Alzheimer Disease," Significant neurological disease affecting the brain or psychiatric disease other than AD, such as current untreated major depression, schizophrenia, epilepsy, Parkinson's disease, Creutzfeldt-Jakob's disease, or clinical episode of stroke"
NCT00231946,Phase 3,Alzheimer's Disease,Voyager Pharmaceutical Corporation,Sep-05,Alzheimer Disease," Laboratory or clinical signs of untreated, clinically significant abnormal thyroid function, in the Investigator's opinion"
NCT00231946,Phase 3,Alzheimer's Disease,Voyager Pharmaceutical Corporation,Sep-05,Alzheimer Disease," Received other investigational drugs within 30 days or 5 half-lives prior to baseline, whichever is longer"
NCT00231946,Phase 3,Alzheimer's Disease,Voyager Pharmaceutical Corporation,Sep-05,Alzheimer Disease," Taking other medications, with the exception of estrogen, known to affect serum gonadotropin (Gn) concentrations, including but not limited to goserelin, danazol, or leuprolide"
NCT00231946,Phase 3,Alzheimer's Disease,Voyager Pharmaceutical Corporation,Sep-05,Alzheimer Disease, Other exclusion criteria exist--eligibility can be assessed by the trial site
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,"A non-Alzheimer primary dementia (e.g., vascular dementia, Lewy body dementia, fronto-temporal dementia, vitamin B-12 deficiency, hypothyroidism)"
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,"Current major depression, delirium, alcohol or psychoactive substance abuse or dependency, schizophrenia, or delusional disorder as defined by DSM-IV"
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,Presence of any uncontrolled systemic illness that would interfere with participation in the study or a life expectancy of less than one year
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,Pregnant or intention to become pregnant
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,Enrollment in another interventional clinical trial
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,Current prescription with more than one AChE inhibitor
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,Current prescription for warfarin
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,Use of vitamin E supplements in the past 2 weeks
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,Use of memantine in the past 4 weeks or known intolerance
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,Estimated creatinine clearance less than 5ml/min (Cockcroft-Gault formula)
NCT00235716,Phase 3,Alzheimer's Disease,US Department of Veterans Affairs,Aug-07,Alzheimer Disease;Vitamins;Vitamin E;Tocopherols;Tocotrienols;alpha-Tocopherol;Memantine,Use of amantadine in the past 2 weeks
NCT00236431,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Cognitive Dysfunction;Galantamine, Neurodegenerative disorders such as Parkinson's disease
NCT00236431,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Cognitive Dysfunction;Galantamine," Cognitive impairment resulting from acute cerebral trauma, hypoxic cerebral damage, vitamin deficiency states, infections such as meningitis or AIDS, or primary or metastatic cerebral neoplasia"
NCT00236431,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Cognitive Dysfunction;Galantamine, Epilepsy
NCT00236431,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Cognitive Dysfunction;Galantamine, Significant psychiatric disease
NCT00236431,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Cognitive Dysfunction;Galantamine, Peptic ulcer disease
NCT00236431,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Cognitive Dysfunction;Galantamine," Clinically significant heart, lung, liver or kidney diseases"
NCT00236431,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Cognitive Dysfunction;Galantamine, Pregnant or nursing women or those without adequate contraception
NCT00236574,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Dementia;Cognitive Dysfunction;Galantamine," Contraindications for magnetic resonance imaging, for example, presence of pacemaker or presence of metal in high risk areas"
NCT00236574,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Dementia;Cognitive Dysfunction;Galantamine, Neurodegenerative disorders such as Parkinson's disease
NCT00236574,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Dementia;Cognitive Dysfunction;Galantamine," Cognitive impairment resulting from acute cerebral trauma, hypoxic cerebral damage, vitamin deficiency states, infections such as meningitis or AIDS, or primary of metastatic cerebral neoplasia"
NCT00236574,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Dementia;Cognitive Dysfunction;Galantamine, Significant endocrine or metabolic disease
NCT00236574,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Dementia;Cognitive Dysfunction;Galantamine, Mental retardation
NCT00236574,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",May-01,Alzheimer Disease;Dementia;Cognitive Dysfunction;Galantamine," Women who are pregnant, nursing, or lacking adequate contraception"
NCT00244322,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Oct-05,Alzheimer Disease," Cannot be currently using or require MAOI antidepressants (such as selegiline or Eldepryl(R)), antipsychotics, benzodiazepines, calcium channel blockers for heart disease, and propanolol."
NCT00244322,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Oct-05,Alzheimer Disease," Cannot have a clinically significant and/or uncontrolled condition or other significant disease, including a condition requiring treatment with warfarin or heparin; or have had or currently have a peptic ulcer, reflux disease, or gastrointestinal (GI) bleeding."
NCT00277810,Phase 2/Phase 3,Alzheimer Disease,Pfizer,Mar-06,Alzheimer Disease, Significant neurological disease other than AD
NCT00277810,Phase 2/Phase 3,Alzheimer Disease,Pfizer,Mar-06,Alzheimer Disease, Diagnosis of major depression
NCT00277810,Phase 2/Phase 3,Alzheimer Disease,Pfizer,Mar-06,Alzheimer Disease, History of stroke or other heart disease
NCT00285025,Phase 2,Alzheimer Disease,Sanofi,Mar-05,Alzheimer Disease," Any cause of dementia not due to Alzheimer's disease, Delusions, delirium, psychosis, depression, or other significant psychiatric disorder."
NCT00285025,Phase 2,Alzheimer Disease,Sanofi,Mar-05,Alzheimer Disease," Treatment with any registered or putative cognitive enhancer or disease modifier other than donepezil, rivastigmine or galantamine."
NCT00285025,Phase 2,Alzheimer Disease,Sanofi,Mar-05,Alzheimer Disease," Females who are pregnant or breast-feeding. Females of child bearing potential (premenopausal female biologically capable of becoming pregnant) must have a confirmed negative serum b-HCG pregnancy test at the screening visit, and must use an acceptable method of birth control."
NCT00285025,Phase 2,Alzheimer Disease,Sanofi,Mar-05,Alzheimer Disease," Severe or unstable cardiovascular, respiratory, renal, hematological, endocrinological, neurological or other somatic disease."
NCT00285025,Phase 2,Alzheimer Disease,Sanofi,Mar-05,Alzheimer Disease, Use of CYP3A4 strong inhibitors
NCT00285025,Phase 2,Alzheimer Disease,Sanofi,Mar-05,Alzheimer Disease," Evidence (detected by history, physical examination and / or laboratory / ECG tests) of any clinically significant or unstable medical disorder that could interfere with the subject's participation in the clinical trial; interfere with the absorption, metabolism or excretion of the study medication; or interfere with the evaluation of the study drug. Alterations of laboratory tests or ECG findings of potential clinical significance."
NCT00285077,Phase 2,Alzheimer Disease,Sanofi,Mar-04,Alzheimer Disease, Females who are pregnant or breast-feeding.
NCT00285077,Phase 2,Alzheimer Disease,Sanofi,Mar-04,Alzheimer Disease," Females of child bearing potential (premenopausal female biologically capable of becoming pregnant) must have a confirmed negative serum b-HCG pregnancy test at the screening visit,and must use an acceptable method of birth control."
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Non-Alzheimer dementia.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Active renal disease.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Abnormally high serum viscosity levels.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Immunoglobulin A (IgA) deficiency.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin","Untreated congestive heart failure, unstable angina or a history of recent myocardial infarction."
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Unstable arrhythmia.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Untreated or poorly controlled hypercholesterolemia.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Untreated or poorly controlled hypertension.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Poorly controlled diabetes.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Thrombosis (central or peripheral) in the past year.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Modified Hachinski score greater than  5.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin","Active cancer diagnosis, except basal cell carcinoma."
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Active autoimmune or neuroimmunologic disorder.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",History of IVIg treatment in past 6 months.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Untreated major depression or other major psychiatric disorders.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin","Known coagulopathy or platelet counts less than  100,000."
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin","Positive serology for Hepatitis B or C, or HIV."
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Active migraines or frequent headaches (3 or more times per week).
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Taking immunosuppressive drugs.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin","Chronic (more than thrice weekly) use of non-steroidal anti-inflammatory drugs (NSAIDs), excluding aspirin 81 milligrams daily."
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin",Received an investigational treatment for AD within 3 months of study entry.
NCT00299988,Phase 2,Alzheimer's Disease,Weill Medical College of Cornell University,Feb-06,"Alzheimer Disease;Immunoglobulins;Immunoglobulins, Intravenous;Antibodies;gamma-Globulins;Rho(D) Immune Globulin","A history of or current disorder or disease that in a physician co-investigator's judgment may impede the subject's participation in the study, pose immoderate risk to the patient or confound the results of the study"
NCT00301574,Phase 3,Alzheimer Disease,Janssen Pharmaceutical K.K.,Apr-01,Alzheimer Disease;Galantamine," Patients with neurodegenerative diseases other than Alzheimer's disease, such as Lewy bodies disease, (dementia due to tiny round structures made of proteins that develop within nerve cells in the brain), Parkinsonism, etc"
NCT00301574,Phase 3,Alzheimer Disease,Janssen Pharmaceutical K.K.,Apr-01,Alzheimer Disease;Galantamine," Patients with cognitive dysfunction due to cerebral damage resulting from a lack of oxygen, a brain injury, etc"
NCT00301574,Phase 3,Alzheimer Disease,Janssen Pharmaceutical K.K.,Apr-01,Alzheimer Disease;Galantamine, Patients with multi-infarct dementia (brought on by a series of strokes) or active cerebrovascular disease
NCT00301574,Phase 3,Alzheimer Disease,Janssen Pharmaceutical K.K.,Apr-01,Alzheimer Disease;Galantamine, Patients with clinically significant cardiovascular disease
NCT00301574,Phase 3,Alzheimer Disease,Janssen Pharmaceutical K.K.,Apr-01,Alzheimer Disease;Galantamine," Patients currently taking drugs such as a cholinesterase inhibitors, which improve cerebral circulation/metabolism"
NCT00304629,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",Mar-00,Alzheimer Disease;Galantamine," If a patient developed, during the trial GAL-INT-8, symptoms of other neurological or psychiatric diseases that might contribute to dementia, the subject cannot be enrolled. This includes subjects developing neurodegenerative disorders such as Parkinson's disease, Pick's disease or Huntington's chorea, or Creutzfeldt-Jacob disease, and subjects with cognitive impairment resulting from stroke, acute cerebral trauma, hypoxic cerebral damage, infection or primary or metastatic cerebral neoplasia"
NCT00304629,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",Mar-00,Alzheimer Disease;Galantamine," Subjects with the following co-existing medical conditions: a) Any history of epilepsy or convulsions except for febrile convulsions during childhood b) Peptic ulcer: if the ulcer is considered to be still  active , i.e., if treatment for this condition started less than 3 months ago or if treatment is not successful (symptoms still present), the subject is not eligible. c) Clinically significant hepatic, renal, pulmonary, metabolic or endocrine disturbances"
NCT00304629,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",Mar-00,Alzheimer Disease;Galantamine," Patients with current, clinically significant cardiovascular disease that would be expected to limit the subject's ability to complete a 12-month trial. The following would usually be considered clinically significant cardiovascular disease: a) Unstable angina"
NCT00304629,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",Mar-00,Alzheimer Disease;Galantamine," angina or coronary artery disease that required a change in medication (anti-angina or digitalis) within the last 3 months b) Decompensated congestive heart failure i.e. when symptoms occur in a subject on stable medication during rest or light exercise (NYHA III and IV). Note: if the only signs of decompensation are pretibial or malleolar oedema and the exercise tolerance is still reasonable (absence of dyspnoea) the subject should not be excluded c) Cardiac disease potentially resulting in syncope, near syncope or other alterations of mental status"
NCT00304629,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",Mar-00,Alzheimer Disease;Galantamine," In addition, the following conditions should lead to exclusion: atrial fibrillation without prophylactic treatment to prevent thromboembolic stroke, bradycardia less than 50 beats/min., atrioventricular block greater than  first degree. d) Severe mitral or aortic valvular disease e) Hypotension or treatment for hypotension f) Systolic blood pressure greater than 170 mmHg or diastolic blood pressure greater than 110 mmHg"
NCT00304629,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",Mar-00,Alzheimer Disease;Galantamine," Patients using any agent for the treatment of dementia (approved, experimental, including over the counter agents), including, but not limited to nootropic agents, cholinomimetic agents, choline, oestrogens taken without medical need, chronic NSAIDs (30 consecutive days), vitamin E more than 30 IU daily, and deprenyl"
NCT00304629,Phase 3,Alzheimer Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",Mar-00,Alzheimer Disease;Galantamine, Conditions that could interfere with the absorption of the compound or with the evaluation of the disease
NCT00309725,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",unknown,Alzheimer Disease;Galantamine," Disorders such as Parkinson's disease, Pick's disease, or Huntington's chorea, Down's syndrome, Creutzfeldt-Jakob disease, Cushing's syndrome, or uncontrolled diabetes"
NCT00309725,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",unknown,Alzheimer Disease;Galantamine," Cognitive impairment resulting from trauma, injury, or hypoxia"
NCT00309725,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",unknown,Alzheimer Disease;Galantamine, Infection
NCT00309725,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",unknown,Alzheimer Disease;Galantamine, Mental retardation or dementia or clinically active cerebrovascular disease
NCT00309725,Phase 3,Alzheimer's Disease,"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.",unknown,Alzheimer Disease;Galantamine," Current, clinically significant cardiovascular disease that would limit the patient's ability to complete a six-week trial."
NCT00314912,Phase 3,Alzheimer's Disease,Bellus Health Inc,May-06,Alzheimer Disease;Tramiprosate, Patients will not be eligible to participate in the study if they meet any of the following criteria:
NCT00314912,Phase 3,Alzheimer's Disease,Bellus Health Inc,May-06,Alzheimer Disease;Tramiprosate, The patient participates in another drug trial during the study.
NCT00314912,Phase 3,Alzheimer's Disease,Bellus Health Inc,May-06,Alzheimer Disease;Tramiprosate, The patient with a clinically significant and/or uncontrolled condition or other significant medical disease.
NCT00314912,Phase 3,Alzheimer's Disease,Bellus Health Inc,May-06,Alzheimer Disease;Tramiprosate, The patient is unable to swallow medication tablets.
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine, Patients with a modified Hachinski Ischemia Score greater than 4 at Screening.
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine, Patients who have taken memantine within one month of Screening (Visit 1)
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine," Patients who have a known hypersensitivity to memantine, neramexane, rimantadine, or amantadine."
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine, Patients whose AChEI therapy is likely to be interrupted or discontinued during the course of the study.
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine, Patients who are receiving therapy with more than one AChEI.
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine," Patients with computed tomography (CT) or magnetic resonance imaging (MRI) evidence of hydrocephalus, stroke, a space-occupying lesion, cerebral infection, or any clinically significant central nervous system disease other than Alzheimer's disease."
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine," Patients with a DSM-IV Axis I disorder other than Alzheimer's disease, including amnestic disorders, schizophrenia or schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, or post-traumatic stress disorder."
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine," Patients who, in the clinician's judgement, are likely to be placed in a nursing home within the next 6 months."
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine," Patients who had evidence of other neurological disorders that included, but were not limited to, stroke, Parkinson's disease, seizure disorder, or head injury with loss of consciousness within the prior 5 years"
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine, Patients who had dementia that was complicated by other organic disease
NCT00322153,Phase 3,Dementia of the Alzheimer's Type,Forest Laboratories,Jun-05,Alzheimer Disease;Dementia;Memantine, Patients who had dementia complicated by the presence of predominant delusions
NCT00329082,Phase 2,Alzheimer's Disease,Eli Lilly and Company,May-06,Alzheimer Disease," Have a history of serious infectious disease affecting the brain, head trauma, cancer, drug or alcohol abuse in the past 5 years"
NCT00329082,Phase 2,Alzheimer's Disease,Eli Lilly and Company,May-06,Alzheimer Disease, Have serious or uncontrolled health problems or laboratory tests
NCT00329082,Phase 2,Alzheimer's Disease,Eli Lilly and Company,May-06,Alzheimer Disease, Multiple or severe drug allergies
NCT00329082,Phase 2,Alzheimer's Disease,Eli Lilly and Company,May-06,Alzheimer Disease, Prior participation in an active immunization study
NCT00334568,Phase 2,Alzheimer's Disease,GlaxoSmithKline,Dec-04,Alzheimer Disease;Rosiglitazone, Has a history of or suffers from claustrophobia.
NCT00334568,Phase 2,Alzheimer's Disease,GlaxoSmithKline,Dec-04,Alzheimer Disease;Rosiglitazone," Is unable to lie comfortably on a bed inside a PET camera with their head in the field of view for at least 60 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis)."
NCT00334568,Phase 2,Alzheimer's Disease,GlaxoSmithKline,Dec-04,Alzheimer Disease;Rosiglitazone," Has a history or presence of other neurological or other medical conditions that may influence the outcome or analysis of the PET scan results. Examples of such conditions include, but are not limited to stroke, traumatic brain injury, epilepsy or space occupying lesions."
NCT00334568,Phase 2,Alzheimer's Disease,GlaxoSmithKline,Dec-04,Alzheimer Disease;Rosiglitazone, History of Type I or Type II diabetes mellitus.
NCT00334568,Phase 2,Alzheimer's Disease,GlaxoSmithKline,Dec-04,Alzheimer Disease;Rosiglitazone, Fasting plasma glucose level greater than 126 mg/dL (greater than 7.0 mmol/L) or HbA1c greater than 6.2%.
NCT00334568,Phase 2,Alzheimer's Disease,GlaxoSmithKline,Dec-04,Alzheimer Disease;Rosiglitazone, History or clinical/laboratory evidence of moderate congestive heart failure defined by the New York Heart Association criteria (class II-IV.
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, A subject will not be eligible for inclusion in this study if any of the following criteria apply:
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," Diagnosis of possible, probable, or definite vascular dementia in accordance with NINDS-AIREN criteria (Appendix 5)."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, (Note: National Institute of Neurological Disorders and Stroke (NINDS) and Association Internationale pour la Recherche et l'Enseignement en Neurosciences (AIREN).)
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," History or evidence of any other CNS disorder that could be interpreted as a cause of dementia: e.g. cerebrovascular disease (stroke, hemorrhage), structural abnormality, epilepsy, infectious or inflammatory/demyelinating CNS conditions, Parkinson's disease."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," Evidence of the following disorders: current vitamin B12 deficiency, positive syphilis serology, or active thyroid dysfunction (particularly that suggestive of hypothyroidism), including abnormally high or low serum levels of thyroid stimulating hormone (TSH), that are clinically significant in the opinion of the investigator."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, (Note: Testing is required for each parameter only when no result is available from previous 12 months.)
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, History of Type 1 diabetes mellitus or secondary diabetes mellitus.
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," Type 2 diabetes mellitus where the subject is being treated with insulin, a PPAR agonist, or an insulin secretagogue (e.g. a sulfonylurea or glitinide)."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, Any patient with an HbA1c 8.5%. (See Section 6.3.8.4 for Safety Measures for Enrolled Subjects with Type 2 Diabetes Mellitus.)
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, History or clinical/investigational evidence of congestive heart failure defined by the New York Heart Association criteria (Class I to IV cardiac status; Appendix 6).
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," History of cardiovascular event within the last 6 months (i.e. intervention, percutaneous coronary intervention, vascular surgery, acute coronary syndrome [non Q-wave myocardial infarction, Q-wave myocardial infarction, unstable angina] or significant arrhythmia; or major intervention (e.g. cardiac surgery or angiography plus stenting) scheduled)."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," History of significant psychiatric illness such as schizophrenia or bipolar affective disorder that in the opinion of the Investigator would interfere with participation in the study, major depressive disorder (according to DSM-IV) in the past year, or current active depression requiring initiation of treatment."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," (Note: If not currently treated, but active depression is suspected, the Cornell Scale for Depression in Dementia (CSDD, Appendix 7) can be used by the Investigator as a guide for deciding whether a prospective subject requires treatment. If the subject has a CSDD score greater than 7, the Investigator should decide if the subject has depression in need of prescribed medication, and a CSDD greater than 12 is considered a strong indicator that treatment is needed. Subjects will be allowed to re-screen after their depression has been adequately managed for greater than 3 months.)"
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," History or presence of gastro-intestinal, hepatic, or renal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, or any other clinically relevant abnormality, medical or psychiatric condition, which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, Clinically significant peripheral edema at the time of screening.
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," Current or recent drug or alcohol abuse or dependence (defined by DSM-IV criteria for substance-related disorders), or recent or remote history of the same if that could be a contributing factor to the dementia."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, Systolic blood pressure greater than 165 or less than 90 mmHg or diastolic blood pressure greater than 95 or less than 60 mmHg at the time of screening.
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, Clinically significant anemia (i.e. hemoglobin less than 11 g/dL for males or less than 10 g/dL for females) or presence of hemoglobinopathies which would prevent accurate assessment of HbA1c.
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, Abnormal kidney function tests (greater than 1.5 times the upper limit of normal (ULN)).
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," ALT, AST, or alkaline phosphatase values greater than 2.5 times the ULN, total bilirubin values greater than 1.5 times the ULN, or history of severe hepatobiliary disease (e.g. hepatitis B or C, or cirrhosis, Child-Pugh Class B/C)."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," (Note: For subjects with a diagnosis of Gilberts Syndrome and an isolated increase in total bilirubin greater than 1.5 ULN, fractionation should be performed. If all of the following conditions are met, the patient may enter or remain in the study, even if total bilirubin greater than 1.5 ULN:"
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, an elevated unconjugated (indirect) bilirubin;
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, the percentage of direct bilirubin less than 35%;
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," ALT, AST, and alkaline phosphatase less than 2.5 ULN if subject is in screening (less than 2.0 ULN for Canadian subjects only), or 3 ULN if subject is already randomized into the study)"
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, History of a bone marrow transplant.
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," Subject is unable (with assistance, if appropriate) to take study medication as prescribed throughout the study or is at risk of non-compliance with study medication or procedures."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," Subject is an immediate family member or employee of the participating Investigator, of any of the participating site staff, or of GSK."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," In France, a subject is neither affiliated with nor a beneficiary of a social security category."
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone, The French subject has participated in any study using an investigational drug during the previous 30 days or 5 half-lives (whichever is longer).
NCT00348140,Phase 3,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Rosiglitazone," Cognitive tasks prescribed for cognitive rehabilitation and performed under medical supervision are prohibited for 6 months prior to Screening, as well as for the duration of the study."
NCT00359944,Phase 2,Alzheimer's Disease,Sunovion,Feb-06,Alzheimer Disease, Need to drive during the study
NCT00359944,Phase 2,Alzheimer's Disease,Sunovion,Feb-06,Alzheimer Disease," Treatment with acetylcholinesterase inhibitors or NMDA antagonist, such as Aricept or Namenda, within 2 weeks of check-up and during the study"
NCT00359944,Phase 2,Alzheimer's Disease,Sunovion,Feb-06,Alzheimer Disease, Frequent Smoker
NCT00359944,Phase 2,Alzheimer's Disease,Sunovion,Feb-06,Alzheimer Disease, Frequent Consumer of Caffeine
NCT00362024,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease, Patients must not be living in nursing home or skilled nursing facility
NCT00362024,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease," Patients must not have current evidence and/or history of Crohn's disease, ulcerative colitis, proctitis, GI bleeding, mesenteric arteritis"
NCT00362024,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease," Patients must not have current evidence and/or history of poorly-controlled hypertension, clinically significant cardiac arrhythmia, angina, or CHF"
NCT00362024,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease, Patients must not have current evidence and/or history of a psychotic disorder or major untreated depressive disorder
NCT00362024,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease," Patients must not have current evidence and/or history of stroke or multiple lacunar infarcts, or neurological or neurodegenerative disorder (other than AD)"
NCT00362024,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease, Various concomitant therapy restrictions
NCT00368459,Phase 2,Alzheimer Disease,Stanford University,Aug-06,Alzheimer Disease;Raloxifene Hydrochloride,Failure to meet inclusion criteria
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,Major structural brain disease
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,Major medical illness or unstable medical condition within 6 months of screening that may interfere with the subject's ability to comply with study procedures and abide by study restrictions.
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,Residence in a nursing home or assisted care facility that provides the subject with 24-hour care and supervision.
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,"Women who are pregnant, nursing, or if of child-bearing potential not using a medically accepted, highly effective method of birth control."
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,Active alcohol dependence or drug abuse.
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,"Use of the following medications within 60 days prior to enrollment:cognition enhancing agents, narcotic analgesics, low potency neuroleptics, antihypertensive agents with frequent Central Nervous System (CNS) side effects, anti-Parkinsonian medications, medications with central anticholinergic activity, medications for epilepsy, lithium."
NCT00377715,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Sep-05,Alzheimer Disease,"Participation in an investigational drug or device study within 30 days prior to study entry, or 60 days prior to study entry if the investigational drug study involved therapy for Alzheimer's Disease."
NCT00380276,Phase 3,Alzheimer's Disease,Myrexis Inc.,Sep-06,Alzheimer Disease," History or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor."
NCT00380276,Phase 3,Alzheimer's Disease,Myrexis Inc.,Sep-06,Alzheimer Disease," Chronic or acute renal, hepatic or metabolic disorder."
NCT00380276,Phase 3,Alzheimer's Disease,Myrexis Inc.,Sep-06,Alzheimer Disease," Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening."
NCT00380302,Phase 1/Phase 2,Alzheimer Disease,Sanofi,Sep-06,Alzheimer Disease, Severe or unstable medical diseases
NCT00380302,Phase 1/Phase 2,Alzheimer Disease,Sanofi,Sep-06,Alzheimer Disease, Neurological disorder other than Alzheimer's disease
NCT00380302,Phase 1/Phase 2,Alzheimer Disease,Sanofi,Sep-06,Alzheimer Disease, Depression that is not well controlled
NCT00380302,Phase 1/Phase 2,Alzheimer Disease,Sanofi,Sep-06,Alzheimer Disease, Treatment with memantine
NCT00380302,Phase 1/Phase 2,Alzheimer Disease,Sanofi,Sep-06,Alzheimer Disease, Inpatient in a total care facility (e.g.: Nursing home)
NCT00380302,Phase 1/Phase 2,Alzheimer Disease,Sanofi,Sep-06,Alzheimer Disease, Lack of reliable caregiver
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease," Any other medical condition which, in the opinion of the Investigator, would jeopardize your safety, impact the validity of the study results, or interfere with your ability to complete the study according to the protocol."
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, Intolerance to Aricept.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, Dementia other than Alzheimer's type.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, Parkinson's Disease.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, History of seizure or epilepsy.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, History of stroke.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, Participation in another research study within last 30 days.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, Enrollment in any previous research study testing PRX-03140.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, Use of prescription cognitive enhancing medications (except Aricept) or MAO inhibitors within last 4 weeks.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, Use of tobacco products within last 4 weeks.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, Positive blood screen for Hepatitis B surface antigen or Hepatitis C antibody.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, Positive urine screen for alcohol or drugs of abuse or history of drug or alcohol abuse within last 6 months.
NCT00384423,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",Oct-06,Alzheimer Disease, Major surgery within last 4 weeks.
NCT00414622,Phase 2,Alzheimer Disease,CoMentis,Nov-06,Alzheimer Disease, others
NCT00420420,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease, Patients cannot be living in a skilled nursing facility
NCT00420420,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease, Patients cannot have poorly-controlled hypertension
NCT00420420,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease," Patients cannot have the following conditions within 6 months of screening: significant cardiovascular disorders, active major depressive disorder, gastroesophageal reflux disease (GERD), or clinically significant sleep disorder"
NCT00420420,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,Nov-06,Alzheimer Disease, Various concomitant therapy restrictions
NCT00423085,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jan-07,Alzheimer Disease;Rivastigmine, A current DSM-IV diagnosis of major depression
NCT00423085,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jan-07,Alzheimer Disease;Rivastigmine, Taken rivastigmine in the past
NCT00423085,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jan-07,Alzheimer Disease;Rivastigmine, A score of greater than  5 on the Modified Hachinski Ischemic Scale (MHIS) Other protocol-defined inclusion/exclusion criteria may apply
NCT00423085,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jan-07,Alzheimer Disease;Rivastigmine, Other protocol-defined inclusion/exclusion criteria may apply
NCT00423085,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jan-07,Alzheimer Disease;Rivastigmine, Extension Phase Eligibility Criteria
NCT00423085,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jan-07,Alzheimer Disease;Rivastigmine, Patients who have any important protocol deviations until the completion of the Double-blind Treatment Phase
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine," Have an advanced, severe, progressive, or unstable disease of any type that may interfere with efficacy and safety assessments or put the patient at special risk;"
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine," Have a history of malignancy of any organ system, treated or untreated, within the past 5 years;"
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine, Have a history within the past year or current diagnosis of cerebrovascular disease;
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine, Have a current diagnosis of severe or unstable cardiovascular disease; Have a history of myocardial infarction (MI) in the last six months;
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine," Severe or unstable respiratory conditions (e.g., severe asthma , severe pulmonary (lung) disease);"
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine, Digestive problems related to peptic ulcer;
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine, Urinary obstruction or current severe urinary tract infection;
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine, Abnormal thyroid function tests;
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine, Low folate or Vitamin B12;
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine, Have a disability that may prevent the patient from completing all study requirements;
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine, Have a current diagnosis of an active skin lesion/disorder that would prevent adhesion of a patch;
NCT00428389,Phase 3,Alzheimer's Disease,Novartis,Jan-07,Alzheimer Disease;Rivastigmine, Other protocol-defined inclusion/exclusion criteria may apply
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin, The patient satisfies the NINDS-AIREN criteria for probable vascular dementia.
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin, A known exaggerated pharmacological sensitivity or allergy to NSAID's.
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin," History of peptic ulceration, gastric surgery or gastrointestinal bleeding."
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin, Current diagnosis of active peptic ulceration.
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin, Current diagnosis of severe and unstable cardiovascular disease.
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin, Current diagnosis of renal failure.
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin," Advanced, severe and unstable disease of any type, other than Alzheimer's disease, that may interfere with primary and secondary variable evaluations, including a medical condition which should be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical or mental status of the patient to a significant degree or put the patient at special risk."
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin," Intake of any of the following concomitant medications: salicylates, coumarin derivatives, ACE-inhibitors, loop diuretics."
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin," Intake of any of the following concomitant medications more than two months immediately prior or during the study: NSAID's, systemic corticosteroids."
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin," Intake of any of the following concomitant medications with a possible effect on cognition: estrogen, deprenyl, vitamin E, neuroleptics, anticholinergics. Patients using stable doses of cholinesterase inhibitors were eligible, with the provision that the dose should not be changed during the study. Cholinesterase inhibitors could not be initiated during the study."
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin, Excessive use of alcohol (more than 5 units per day)
NCT00432081,Phase 3,Alzheimer Disease,Radboud University Medical Center,May-00,Alzheimer Disease;Indomethacin," The patient is, either alone or with the aid of a caregiver, not able to reliably take the medication."
NCT00438568,Phase 2,Alzheimer's Disease,University of Washington,Jun-06,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Chronic sinus problems/allergies with chronic use of nasal decongestants or antihistamines
NCT00438568,Phase 2,Alzheimer's Disease,University of Washington,Jun-06,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc"," Significant neurologic disease that might affect cognition (other than AD), such as stroke, Parkinson's disease, multiple sclerosis, severe head injury with loss of consciousness for more than 30 minutes or with permanent neurologic symptoms"
NCT00438568,Phase 2,Alzheimer's Disease,University of Washington,Jun-06,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc"," Significant medical illness or organ failure, such as uncontrolled hypertension or cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or kidney disease"
NCT00438568,Phase 2,Alzheimer's Disease,University of Washington,Jun-06,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Preexisting diabetes or current or previous use of hypoglycemic agents or insulin; participants will be excluded if they have a fasting blood sugar greater than 165 on baseline OGTT
NCT00438568,Phase 2,Alzheimer's Disease,University of Washington,Jun-06,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc"," Clinically significant elevations in liver function tests, cholesterol, or triglycerides"
NCT00438568,Phase 2,Alzheimer's Disease,University of Washington,Jun-06,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc"," Major psychiatric disorders (e.g., untreated major depression and schizophrenia)"
NCT00438568,Phase 2,Alzheimer's Disease,University of Washington,Jun-06,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc"," Chronic use of the following types of medications: anti-psychotic, anxiolytic, and opiates"
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin, Other neurodegenerative diseases such as Lewy body or Parkinson's
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin," Cognitive impairment due to: acute trauma, subdural hematoma, hypoxic cerebral damage, B12 deficiency, infections such as AIDS or meningitis, cerebral neoplasia, endocrine deficiencies, mental retardation"
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin, Significant cerebrovascular disease or multi-infarct dementia
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin, Intra-cranial pathology such as tumour
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin," Co-existing medical conditions such as epilepsy, major psychiatric conditions, depression (Cornell Depression in Dementia Scale score of 12 or more), significant liver, kidney, lung, metabolic or endocrine diseases"
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin, Clinically significant cardiac disease such as uncontrolled angina or hypertension
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin," Anti-dementia treatments other than donepezil, galantamine, rivastigmine, memantine"
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin, Enrollment in trials with other investigational drugs
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin, Antibiotic use more than one month in the last six months
NCT00439166,Phase 3,Alzheimer's Disease,Hamilton Health Sciences Corporation,Feb-07,Alzheimer Disease;Doxycycline;Rifampin, Allergy to doxycycline or rifampicin
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Non-AD dementia
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Residence in a long-term care facility at baseline
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, History of clinically significant stroke
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Modified Hachinski Ischemia score  4
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease," Current evidence or history in past two years of epilepsy, seizure, focal brain lesion, head injury with loss of consciousness or DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse"
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Sensory impairment which would prevent subject from participating in or cooperating with the protocol
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Use of another investigational agent within two months
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease," Evidence of any significant clinical disorder or laboratory finding that renders the participant unsuitable for receiving an investigational new drug including clinically significant or unstable hematologic, hepatic, cardiovascular (including history of ventricular fibrillation or ventricular tachycardia), pulmonary, gastrointestinal, endocrine, metabolic, renal, or other systemic disease or laboratory abnormality"
NCT00440050,Phase 3,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),Feb-07,Alzheimer Disease, Active neoplastic disease (skin tumors other than melanoma may be included; participants with stable prostate cancer may be included at the discretion of the Project Director)
NCT00443417,Phase 2,Alzheimer's Disease,"SK Chemicals Co., Ltd.",Apr-07,Alzheimer Disease, Patient in mild cognitive impairment (MCI; CDR-SB less than 2.5)
NCT00443417,Phase 2,Alzheimer's Disease,"SK Chemicals Co., Ltd.",Apr-07,Alzheimer Disease, Other central nervous disease
NCT00443417,Phase 2,Alzheimer's Disease,"SK Chemicals Co., Ltd.",Apr-07,Alzheimer Disease," hypothyroidism, Vitamin B12/ Folic acid deficiency, hypercalcemia, neurosyphilis, AIDS"
NCT00443417,Phase 2,Alzheimer's Disease,"SK Chemicals Co., Ltd.",Apr-07,Alzheimer Disease, T.I.A or Major infarction within the last 12 months
NCT00443417,Phase 2,Alzheimer's Disease,"SK Chemicals Co., Ltd.",Apr-07,Alzheimer Disease, Any serious disorder that could limit the ability of the patient to participate in the study
NCT00443417,Phase 2,Alzheimer's Disease,"SK Chemicals Co., Ltd.",Apr-07,Alzheimer Disease, COPD or asthma
NCT00443417,Phase 2,Alzheimer's Disease,"SK Chemicals Co., Ltd.",Apr-07,Alzheimer Disease," Any condition which would make the patient or the caregiver, in the opinion of the investigator, unsuitable for the study"
NCT00454870,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Feb-07,Alzheimer Disease, Head trauma associated with cognitive impairment
NCT00454870,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Feb-07,Alzheimer Disease," Evidence of significant neurological disease other than AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, CNS tumor, progressive supranuclear palsy, seizure disorder, etc."
NCT00454870,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Feb-07,Alzheimer Disease," Received AChE inhibitor therapy (e.g., rivastigmine, tacrine or galantamine) or NDMA-receptor antagonist, memantine, within 30 days or donepezil within 40 days of randomization"
NCT00454870,Phase 2,Alzheimer's Disease,Memory Pharmaceuticals,Feb-07,Alzheimer Disease, Received any investigational drug within 2 months of randomization or treatment with other nicotinic receptor agonists within 3 months of screening
NCT00471211,Phase 2,Alzheimer's Disease,Prana Biotechnology Limited,Dec-06,Alzheimer Disease, unstable and significant medical conditions
NCT00471211,Phase 2,Alzheimer's Disease,Prana Biotechnology Limited,Dec-06,Alzheimer Disease, recurrent major psychiatric disorder
NCT00471211,Phase 2,Alzheimer's Disease,Prana Biotechnology Limited,Dec-06,Alzheimer Disease, treatment with memantine
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Patients are excluded if they are taking (a) no medication for Alzheimer's disease, (b) Aricept or bioequivalent generic donepezil at doses other than 10 mg daily, or 10 mg for less than 3 months before Screening; (c) other medications for Alzheimer's disease, except that memantine, Vitamin E, fish oil, and/or gingko biloba are allowed if doses have been stable for at least 3 months prior to the Screening visit. Patients undergoing any alternative medical techniques, such as acupuncture or acupressure, specifically for the treatment of AD are not eligible"
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,No caregiver available to meet the inclusion criteria for caregivers.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Patients who have no measurable blood levels of donepezil in blood samples collected at Screening.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Patients with neurological disorders that affect cognition or the ability to assess cognition but are distinguishable from Alzheimer's disease. These include, but are not limited to, Parkinson's disease, multi-infarct dementia, and dementia due to cerebrovascular disease."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Patients with psychiatric disorders affecting the ability to assess cognition such as schizophrenia, bipolar or unipolar depression. Patients with clinically significant sleep disorders will also be excluded unless these are controlled by treatment and clinically stable for greater than  3 months prior to screening."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Patients with dementia complicated by other organic disease or Alzheimer's disease with delirium.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Patients with drug or alcohol abuse or dependence within the past 5 years according to DSM IV criteria.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Patients with any conditions affecting absorption, distribution, or metabolism of the study medication (e.g., inflammatory bowel disease, gastric or duodenal ulcers, hepatic disease, or severe lactose intolerance)."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Patients with evidence of clinically significant, active gastrointestinal, renal, hepatic, respiratory, endocrine, or cardiovascular system disease (including history of life-threatening arrhythmias)."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Patients with a history of cancer (does not include basal or squamous cell carcinoma of the skin) treated within 5 years prior to study entry, or current evidence of malignant neoplasm, recurrent, metastatic disease. Males with localized prostate cancer requiring no treatment would not be excluded."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Known plan for elective surgery during the treatment period that would require general anesthesia and administration of neuromuscular blocking agents.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Donation of blood or blood products during 30 days prior to Screening or plans to donate blood while participating in the study or within 30 days after completion of the study.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Patients who are unwilling or unable to fulfill the requirements of the study.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Known hypersensitivity to acetylcholinesterase inhibitors or memantine.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Use of any prohibited prior or concomitant medications) Any condition that would make the patient, in the opinion of the investigator, unsuitable for the study."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Involvement in any other investigational drug clinical trial during the preceding 3 months, or likely involvement in any other such trial during the course of this study."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Patients taking concomitant antidepressant medication known to have significant anticholinergic effects, such as tricyclic antidepressants prescribed at doses recommended for the treatment of major depression."
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Patients who cannot swallow or who have difficult swallowing whole tablets.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Patients with fecal and/or urinary incontinence who are unable to cooperate with routine specimen collection.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Caregivers who are unwilling or unable to give informed consent or otherwise to fulfill the requirements of the study.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,Caregivers who do not meet certain psychometric test criteria.
NCT00478205,Phase 3,Alzheimer's Disease,Eisai Inc.,Jun-07,Alzheimer Disease;Donepezil,"Any condition that would make the caregiver, in the opinion of the Investigator, unsuitable for the study."
NCT00479557,Phase 2,Alzheimer Disease,Pfizer,May-07,Alzheimer Disease;Saponin QA-21V1, Significant Neurological Disease other than Alzheimer's disease
NCT00479557,Phase 2,Alzheimer Disease,Pfizer,May-07,Alzheimer Disease;Saponin QA-21V1, Major psychiatric disorder
NCT00479557,Phase 2,Alzheimer Disease,Pfizer,May-07,Alzheimer Disease;Saponin QA-21V1, Contraindication to undergo brain MRI
NCT00479557,Phase 2,Alzheimer Disease,Pfizer,May-07,Alzheimer Disease;Saponin QA-21V1, Clinically significant systemic illness
NCT00479557,Phase 2,Alzheimer Disease,Pfizer,May-07,Alzheimer Disease;Saponin QA-21V1, Other exclusion criteria apply
NCT00481520,Phase 2,Alzheimer Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Jun-07,Alzheimer Disease,"Significant neurological disease other than Alzheimer's disease, which may affect cognition (eg, epilepsy, Parkinson disease)."
NCT00481520,Phase 2,Alzheimer Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Jun-07,Alzheimer Disease,"Current diagnosis of a major depressive disorder or other major psychiatric symptom according to the criteria of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Version (DSM-IV-TR)."
NCT00481520,Phase 2,Alzheimer Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Jun-07,Alzheimer Disease,"Current clinically significant systemic illness, which is likely to deteriorate or affect the subject's safety, influence cognitive assessment or ability to complete the study."
NCT00481520,Phase 2,Alzheimer Disease,Wyeth is now a wholly owned subsidiary of Pfizer,Jun-07,Alzheimer Disease,"Any clinically important deviation from normal limits in physical and neurological examination, vital signs, on electrocardiogram (ECG) or clinical laboratory test results that could compromise the study or be detrimental to the subject."
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, Current use of cholesterol-lowering medication
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, Active liver disease
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, History of adverse reaction to statins
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, Contraindication to lumbar puncture
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, Elevated lab values (creatine kinase and creatinine)
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, Use of medications known to interact with statins
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, History of dementia
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, Currently pregnant or planning to become pregnant
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, Use of large quantities of grapefruit juice (more than 1 quart per day)
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, Current involvement in another investigational drug study
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, Contraindications to MRI (for MRI sub-study)
NCT00486044,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",Feb-05,Alzheimer Disease;Simvastatin, Ethical contraindication to placebo (persons with high vascular risk)
NCT00500500,Phase 2,Alzheimer Disease,Ipsen,Jul-05,Alzheimer Disease, patient already treated by medicines which could interfere with the study
NCT00500500,Phase 2,Alzheimer Disease,Ipsen,Jul-05,Alzheimer Disease, low level of vitamin B12 and folate which are considered as clinically relevant
NCT00500500,Phase 2,Alzheimer Disease,Ipsen,Jul-05,Alzheimer Disease," clinically relevant pathologies (eg: pulmonary illness, cardiovascular illness; evolutive cancer, neurological illness, blood illness.)"
NCT00501111,Phase 2,Alzheimer Disease,AstraZeneca,Jul-07,Alzheimer Disease;Donepezil, Significant neurologic disease or dementia other than Alzheimer's disease
NCT00501111,Phase 2,Alzheimer Disease,AstraZeneca,Jul-07,Alzheimer Disease;Donepezil," Major depressive disorder, other major psychiatric disorder"
NCT00501111,Phase 2,Alzheimer Disease,AstraZeneca,Jul-07,Alzheimer Disease;Donepezil, Use of acetylcholinesterase inhibitor or memantine for treatment of Alzheimer's disease within 8 weeks prior to enrollment
NCT00501111,Phase 2,Alzheimer Disease,AstraZeneca,Jul-07,Alzheimer Disease;Donepezil, Impaired vision and/or hearing making cognitive testing difficult
NCT00506415,Phase 3,Alzheimer Disease,Novartis Pharmaceuticals,Jun-07,Alzheimer Disease;Cognitive Dysfunction;Rivastigmine," Presence of an advanced, severe, progressive, or unstable disease of any type that could interfere with efficacy and safety assessments or put the patient at particular risk,"
NCT00506415,Phase 3,Alzheimer Disease,Novartis Pharmaceuticals,Jun-07,Alzheimer Disease;Cognitive Dysfunction;Rivastigmine," Any medical or neurological condition other than Alzheimers Disease that could explain the patient's dementia,"
NCT00506415,Phase 3,Alzheimer Disease,Novartis Pharmaceuticals,Jun-07,Alzheimer Disease;Cognitive Dysfunction;Rivastigmine," A diagnosis of probable or possible vascular dementia,"
NCT00506415,Phase 3,Alzheimer Disease,Novartis Pharmaceuticals,Jun-07,Alzheimer Disease;Cognitive Dysfunction;Rivastigmine," A current diagnosis of unsuccessfully-treated depression, or any other mental disorder that may interfere with the evaluation of the patient's response to study medication,"
NCT00506415,Phase 3,Alzheimer Disease,Novartis Pharmaceuticals,Jun-07,Alzheimer Disease;Cognitive Dysfunction;Rivastigmine," A history or current diagnosis of cerebrovascular disease (e.g. stroke),"
NCT00506415,Phase 3,Alzheimer Disease,Novartis Pharmaceuticals,Jun-07,Alzheimer Disease;Cognitive Dysfunction;Rivastigmine, A current diagnosis of severe or unstable cardiovascular disease (e.g. unstable coronary artery disease).
NCT00506415,Phase 3,Alzheimer Disease,Novartis Pharmaceuticals,Jun-07,Alzheimer Disease;Cognitive Dysfunction;Rivastigmine, Other protocol-defined inclusion/exclusion criteria may apply.
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease," Patient has a known sensitivity to TRx0014, similar agents or any of the excipients used."
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease, Screening blood sample shows that the patient has glucose-6-phosphate dehydrogenase deficiency.
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease," Patient has known hereditary methaemoglobinaemia, has been known to have suffered an attack of acquired methaemoglobinaemia or has a blood level of methaemoglobin at screening which is above the upper limit of normal for age and laboratory."
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease," Patient has significant impairment of renal, hepatic or haematological function for the age of the patient."
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease," Patient is currently taking other anti-dementia drugs (e.g. memantine, cholinesterase inhibitors) or has taken these within the previous six weeks."
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease, It is anticipated that there will be a definite indication for the commencement of other licensed anti-dementia drug treatment within the 24 week treatment period of the trial.
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease," Patient has started taking other medication known to have an effect on mood or cognition (e.g. anticholinergics, hypnotics, sedatives, anxiolytics, neuroleptics, antidepressants, antiepileptics) within the previous six weeks; or has changed their dose of these medications within the previous six weeks."
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease," Patient has started taking 'alternative therapy' for AD e.g. vitamin E, folic acid, hormone replacement therapy (HRT), ginkgo biloba within the previous six weeks; or has changed their dose of these treatments within the previous six weeks."
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease," Patient is receiving warfarin or digitalis or any other medication that has a narrow margin between effective dose and toxic dose or between effective dose and ineffective dose, where the subject would be at risk if the levels were elevated or fell due to interaction with TRx0014."
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease, Patients who are unlikely to comply with trial visit schedule or with trial medication.
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease, Significant intercurrent illness which may compromise safety of the patient/validity of the data.
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease, Females with the potential of childbearing and are not using adequate contraception or females who are breastfeeding.
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease," Patients with a history of alcohol and/or drug abuse, defined as meeting DSM-IV criteria for substance dependence. This applies to alcohol and/or any illicit drug, including cannabis within the last six months."
NCT00515333,Phase 2,"Dementia, Alzheimer Type",TauRx Therapeutics Ltd,Aug-04,Dementia;Alzheimer Disease, Patient has participated in a clinical investigation of a medication or device within the previous three months.
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Prior history of prostate cancer or prostate specific antigen level greater than 4.0ng/ml
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Peripheral or vascular disease
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate," Significant history of alcohol abuse, current alcohol abuse (more than 2 drinks per day), or other substance abuse"
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, History of severe head injury (with loss of consciousness greater than 30 minutes)
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate," Significant neurological illness, such as Parkinson's disease, seizure disorder, multiple sclerosis, major stoke"
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Smokes cigarettes
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate," Major psychiatric illness, such as schizophrenia or bipolar disorder"
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Prohibited Medications:
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Anti-convulsants
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Anti-psychotics
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Sedating antihistamines
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Sedative/hypnotics
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Benzodiazepines
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Hormone or testosterone regimens
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Gonadotropin-releasing hormone (GNRH) antagonists
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate, Flutamide
NCT00539305,Phase 3,Alzheimer's Disease,University of Washington,Jul-09,Alzheimer Disease;Cognitive Dysfunction;Methyltestosterone;Testosterone;Testosterone undecanoate;Testosterone enanthate;Testosterone 17 beta-cypionate," Anti-depressants and/or anti-cholinesterase inhibitors, but acceptable if on stable dose for 3 months or more"
NCT00555204,Phase 2,Alzheimer's Disease,Abbott,Nov-07,Alzheimer Disease, Patient is living in a nursing home
NCT00555204,Phase 2,Alzheimer's Disease,Abbott,Nov-07,Alzheimer Disease, Patient has a history of any significant neurologic disease other than Alzheimer's disease
NCT00555204,Phase 2,Alzheimer's Disease,Abbott,Nov-07,Alzheimer Disease, Patient has any uncontrolled medical illness
NCT00555204,Phase 2,Alzheimer's Disease,Abbott,Nov-07,Alzheimer Disease, Patient uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence
NCT00566397,Phase 2,Alzheimer's Disease,Pfizer,Dec-07,Alzheimer Disease," Current evidence or history of neurological, psychiatric and any other illness that could contribute to non-Alzheimer's dementia."
NCT00566397,Phase 2,Alzheimer's Disease,Pfizer,Dec-07,Alzheimer Disease, Known history of familial AD or any evidence for early onset AD known or possibly associated with genetic mutations.
NCT00566397,Phase 2,Alzheimer's Disease,Pfizer,Dec-07,Alzheimer Disease, Evidence or history of diabetes mellitus Type 1 or Type 2.
NCT00566397,Phase 2,Alzheimer's Disease,Pfizer,Dec-07,Alzheimer Disease, History or symptoms of autoimmune disorders.
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,No caregiver available to meet the inclusion criteria for caregivers.
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,"Participants with any active or clinically-significant conditions affecting absorption, distribution, or metabolism of the study medication (example, inflammatory bowel disease, gastric or duodenal ulcers, hepatic disease, or severe lactose intolerance)."
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,"Known plan for elective surgery during the study period that would require general anesthesia and administration of neuromuscular blocking agents, such as succinylcholine, to induce paralysis/muscle relaxation. Minor surgery, such as colonoscopy or cataract surgery, will be permitted as long as it does not require the use of these paralytic agents."
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,Participants who are unwilling or unable to fulfill the requirements of the study.
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,Use of any prohibited prior or concomitant medications.
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,"Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study."
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,"Participant taking concomitant antidepressant medication known to have significant anticholinergic effects, such as tricyclic antidepressants prescribed at doses recommended for the treatment of major depression."
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,Participants who cannot swallow or who have difficulty swallowing whole tablets.
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,Participants taking any alternative medication such as vitamins and/or herbal products or alternative medical techniques such as acupuncture or acupressure specifically for the treatment of Alzheimer's disease.
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,Caregivers who are unwilling or unable to give informed consent or otherwise to fulfill the requirements of the study.
NCT00566501,Phase 3,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease;Donepezil,"Any condition that would make the caregiver, in the opinion of the investigator, unsuitable for the study."
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol, Significant neurological disease other than AD
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol, Major psychiatric disorder
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol, Significant medical illness
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol, History of stroke or seizure
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol, History of a heart attack within the last 2 years
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol, Prior treatment with certain experimental medicines
NCT00568776,Phase 2,Alzheimer Disease,"OPKO Health, Inc.",Dec-07,Alzheimer Disease;Inositol," Presence of pacemakers or foreign metal objects in the eyes, skin, or body that would prevent patient from having MRI scan"
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Significant neurological disease other than AD
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Major psychiatric disorder
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Significant systemic illness
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease," History of stroke or seizure, autoimmune disease, myocardial infarction within the last 2 years"
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Smoking greater than 20 cigarettes per day
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease," Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications"
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Prior treatment experimental immunotherapeutics or vaccines for AD
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Women of childbearing potential
NCT00574132,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease," Presence of pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body"
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Significant neurological disease other than AD
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Major psychiatric disorder
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Significant systemic illness
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease," History of stroke or seizure, autoimmune disease, myocardial infarction within the last 2 years"
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Smoking greater than 20 cigarettes per day
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease," Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications"
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Prior treatment experimental immunotherapeutics or vaccines for AD
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease, Women of childbearing potential
NCT00575055,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-07,Alzheimer Disease," Presence of pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body"
NCT00580931,Phase 1/Phase 2,Alzheimer's Disease,"University of California, Irvine",unknown,Alzheimer Disease;Niacinamide;Niacin;Nicotinic Acids, Dementia due to another cause
NCT00580931,Phase 1/Phase 2,Alzheimer's Disease,"University of California, Irvine",unknown,Alzheimer Disease;Niacinamide;Niacin;Nicotinic Acids, Other neurological or psychiatric diseases
NCT00580931,Phase 1/Phase 2,Alzheimer's Disease,"University of California, Irvine",unknown,Alzheimer Disease;Niacinamide;Niacin;Nicotinic Acids, Pseudodementia
NCT00580931,Phase 1/Phase 2,Alzheimer's Disease,"University of California, Irvine",unknown,Alzheimer Disease;Niacinamide;Niacin;Nicotinic Acids, Unstable medical condition
NCT00580931,Phase 1/Phase 2,Alzheimer's Disease,"University of California, Irvine",unknown,Alzheimer Disease;Niacinamide;Niacin;Nicotinic Acids," Initial treatment within 30 days of screening with a ChEI, memantine or any investigational drug"
NCT00580931,Phase 1/Phase 2,Alzheimer's Disease,"University of California, Irvine",unknown,Alzheimer Disease;Niacinamide;Niacin;Nicotinic Acids," History of alcoholism, drug abuse, liver disease, peptic ulcer disease"
NCT00580931,Phase 1/Phase 2,Alzheimer's Disease,"University of California, Irvine",unknown,Alzheimer Disease;Niacinamide;Niacin;Nicotinic Acids," Pregnancy, or the potential to become pregnant."
NCT00581867,Phase 1/Phase 2,Alzheimer's Disease,"Jeff Burns, MD",Oct-07,"Alzheimer Disease;Insulin;Insulin, Globin Zinc;Insulin Aspart", Patients with Late Alzheimer's disease
NCT00594568,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Mar-08,Alzheimer Disease, Is not capable of swallowing whole oral medication
NCT00594568,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Mar-08,Alzheimer Disease, Has serious or unstable illnesses
NCT00594568,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Mar-08,Alzheimer Disease, Does not have a reliable caregiver
NCT00594568,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Mar-08,Alzheimer Disease, Chronic alcohol or drug abuse within the past 5 years
NCT00594568,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Mar-08,Alzheimer Disease, Has ever had active vaccination for AD
NCT00602680,Phase 2,Alzheimer's Disease,Sanofi,Jan-08,Alzheimer Disease;Donepezil, Concomitant or previous treatment by acetylcholinesterase inhibitors and/or memantine
NCT00602680,Phase 2,Alzheimer's Disease,Sanofi,Jan-08,Alzheimer Disease;Donepezil, Medical condition which may interfere with the study
NCT00602680,Phase 2,Alzheimer's Disease,Sanofi,Jan-08,Alzheimer Disease;Donepezil, History of epileptic seizures
NCT00602680,Phase 2,Alzheimer's Disease,Sanofi,Jan-08,Alzheimer Disease;Donepezil, Lens opacity
NCT00602680,Phase 2,Alzheimer's Disease,Sanofi,Jan-08,Alzheimer Disease;Donepezil, Lack of reliable caregiver
NCT00602680,Phase 2,Alzheimer's Disease,Sanofi,Jan-08,Alzheimer Disease;Donepezil, The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1," Dementia due to any condition other than AD, including vascular dementia (modified Hachinski Ischemic Scale  5; positive NINDS-AIREN criteria)"
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1," Evidence of clinically significant unstable cardiovascular, renal, hepatic, gastrointestinal, neurological, or metabolic disease within the past 6 months (as determined by medical history, ECG results, chest x-ray, or physical examination)"
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Use of any drug within 14 days prior to randomization unless the dose of the drug  and  the condition being treated have been stable for at least 30 days  and  are expected to remain stable during the study  and  neither the drug nor the condition being treated is expected to interfere with the study endpoints
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Any medical or psychiatric condition that may require medication or surgical treatment during the study
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Life expectancy less than 6 months
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Any other screening laboratory values outside the normal ranges that are deemed clinically significant by the investigator
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Use of an investigational drug within 30 days prior to the screening visit or during the entire study
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1," Significant neurological disease other than AD, including cerebral tumor, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus,  and  other entities"
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Major depression according to DSM-IV
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1," Psychotic episodes requiring hospitalization or antipsychotic therapy for more than 2 weeks within the past 10 yrs, not linked to AD"
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Agitation sufficient to preclude participation in this trial
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Alcohol or drug dependence diagnosed within the past 10 yrs
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Epilepsy or anti-epileptic drug therapy
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1," Abnormal laboratory tests that might point to another etiology for dementia: serum B12, folate, thyroid functions, electrolytes, syphilis serology"
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Musculoskeletal diseases that could interfere with assessment
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1," Acute or poorly controlled medical illness: blood pressuregreater than  180 mmHg systolic or 100 mmHg diastolic; myocardial infarction within 6 months; uncompensated congestive heart failure (NYHA Class III or IV), severe renal, hepatic or gastrointestinal disease that could alter drug pharmacokinetics; blood glucose greater than  180 mg/dl on repeated testing at entry into study or need for insulin therapy"
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Previous randomization in this trial or participation in another investigational trial less than  2 months prior to randomization
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1," Likelihood, according to clinical judgment, of being transferred to a nursing home within 6 months"
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Change in dosage of any concomitant antidepressant within 30 days prior to randomization
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Lack of caregiver
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Pregnant or lactating females
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedures outlined in this protocol
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, HIV positive
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Hepatitis B or C positive
NCT00606164,Phase 2,Alzheimer's Disease,Blanchette Rockefeller Neurosciences Insitute,Apr-08,Alzheimer Disease;Bryostatin 1, Concomitant use of medications other than AD or antidepressant medications for which the dose regimens are stabilized for at least 30 days prior to enrollment in study
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease, ANY one of the following will exclude a subject from being enrolled into the study:
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,Significant neurological disease other than AD that may affect cognition.
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"Screening visit brain MRI scan (ie, Study 201 Visit 21 (Week 71), or for Study 102, the Study 251 Screening Visit) indicative of any other significant abnormality including but not limited to multiple microhemorrhages or evidence of a single prior hemorrhage greater than 1 cm3, multiple lacunar infarcts or evidence of a single prior infarct greater than 1 cm3, evidence of a cerebral contusion, encephalomalacia, arachnoid cysts, or brain tumors (eg, meningioma) unless approved by the medical monitor."
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"Current presence of a clinically significant major psychiatric disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV) or any clinically significant symptom that could affect the subject's ability to participate in the study."
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,Current clinically significant systemic illness that is likely to result in deterioration of the subject's condition or affect the subject's safety during the study.
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,History of clinically evident stroke or history of clinically significant carotid or vertebrobasilar stenosis or plaque.
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"History of seizures, excluding febrile seizures in childhood."
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,Weight greater than 120 kg (264 lbs).
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,History or evidence of any clinically significant autoimmune disease or disorder of the immune system.
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"Clinically significant infection within the last 30 days (eg, chronic persistent or acute infection)."
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"Treatment with immunosuppressive medications (eg, systemic corticosteroids) within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last three years."
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,Myocardial infarction within the last two years.
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"History of cancer within the last five years, with the exception of basal cell carcinoma, and nonmetastatic squamous cell carcinoma of the skin."
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"Other clinically significant abnormality on screening (ie, Study 201 Visit 22 [Week 78], or Study 102 Visit 11 [Week 16]) physical, neurological, laboratory, or ECG examination (eg, atrial fibrillation) that could compromise the study or be detrimental to the subject."
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"Hemoglobin less than 11 g/dL at screening (ie, Study 201 Visit 22 [Week 78], or Study 102 Visit 11 [Week16])."
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,Smoking more than 20 cigarettes per day.
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,History of alcohol or drug dependence or abuse within the last two years.
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"Current use of anticonvulsant for seizures, anti-Parkinson's, anticoagulant (excluding the use of aspirin 325 mg/day or less), or narcotic medications."
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,Any prior experimental treatment with AN1792 or other experimental immunotherapeutic or vaccine for AD (other than bapineuzumab).
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,Any known hypersensitivity to any of the excipients contained in the study drug formulation.
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,Women of childbearing potential.
NCT00606476,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-06,Alzheimer Disease,"Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, cerebrospinal fluid (CSF) shunts, metal fragments or foreign objects in the eyes, skin, or body that would contraindicate a brain MRI scan (unless otherwise approved by the Sponsor and/or its designees)."
NCT00624026,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Nov-07,Alzheimer Disease;Memantine," Any type of evident aphasia, which may interfere with patient's communication difficulties caused by Alzheimer's disease"
NCT00624026,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Nov-07,Alzheimer Disease;Memantine," History of severe drug allergy, or hypersensitivity, or patients with known hypersensitivity to amantadine, lactose."
NCT00624026,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Nov-07,Alzheimer Disease;Memantine, Evidence (including CT/MRI results) of any clinically significant central nervous system disease other than Alzheimer's disease.
NCT00624026,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Nov-07,Alzheimer Disease;Memantine, Modified Hachinski Ischemia score greater than 4 at screening.
NCT00624026,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Nov-07,Alzheimer Disease;Memantine, Current evidence of clinically significant systemic disease
NCT00624026,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Nov-07,Alzheimer Disease;Memantine, Known or suspected history of alcoholism or drug abuse within the past 10 years.
NCT00624026,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Nov-07,Alzheimer Disease;Memantine, Previous treatment with memantine or participation in an investigational study with memantine.
NCT00630851,Phase 3,Alzheimer Disease,Pfizer,Oct-02,Alzheimer Disease;Donepezil, Other types of dementia or psychiatric or neurologic disorders
NCT00630851,Phase 3,Alzheimer Disease,Pfizer,Oct-02,Alzheimer Disease;Donepezil, Musculoskeletal disease
NCT00645190,Phase 3,Alzheimer Disease,Xian-Janssen Pharmaceutical Ltd.,Mar-04,Alzheimer Disease;Galantamine, Patients with neurodegenerative disorders such as Parkinson's disease
NCT00645190,Phase 3,Alzheimer Disease,Xian-Janssen Pharmaceutical Ltd.,Mar-04,Alzheimer Disease;Galantamine," Patients with some conditions possibly resulting in cognitive impairment, e.g. acute cerebral trauma, infection"
NCT00645190,Phase 3,Alzheimer Disease,Xian-Janssen Pharmaceutical Ltd.,Mar-04,Alzheimer Disease;Galantamine, Has evidence of multi-infarct dementia or clinically active cerebrovascular disease.
NCT00663026,Phase 2,Alzheimer Disease,Pfizer,Nov-08,Alzheimer Disease, Magnetic Resonance Imaging (MRI) showing other brain abnormalities
NCT00663026,Phase 2,Alzheimer Disease,Pfizer,Nov-08,Alzheimer Disease, Other diagnosed neurological or psychiatric disorders
NCT00663936,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Apr-08,Alzheimer Disease,"Patients with clinically significant cardiac, hepatic or renal impairment"
NCT00663936,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Apr-08,Alzheimer Disease,Patient have a dementia not of the Alzheimer's type etc (According to the protocol)
NCT00663936,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Apr-08,Alzheimer Disease,"Patients who are taking any drug other than donepezil for Alzheimer's disease, including rivastigmine (Exelon), galantamine (Razadyne), memantine (Namenda) or tacrine (Cognex) taken within twelve (12) weeks of the Baseline Visit (Visit 2)."
NCT00667810,Phase 3,Alzheimer Disease,Pfizer,Jun-08,Alzheimer Disease, Significant neurological disease other than AD
NCT00667810,Phase 3,Alzheimer Disease,Pfizer,Jun-08,Alzheimer Disease, Major psychiatric disorder
NCT00667810,Phase 3,Alzheimer Disease,Pfizer,Jun-08,Alzheimer Disease," Contraindication to undergo brain MRI [e.g., pacemaker, cerebrospinal fluid (CSF) shunt, or foreign metal objects in the body]"
NCT00667810,Phase 3,Alzheimer Disease,Pfizer,Jun-08,Alzheimer Disease, Women of childbearing potential
NCT00675623,Phase 3,Alzheimer's Disease,"Medivation, Inc.",May-08,Alzheimer Disease, Anti-dementia drugs including cholinesterase-inhibitors or N-methyl-D-aspartate receptor (NMDA) receptor antagonists within 90 days
NCT00675623,Phase 3,Alzheimer's Disease,"Medivation, Inc.",May-08,Alzheimer Disease, Other causes of dementia
NCT00675623,Phase 3,Alzheimer's Disease,"Medivation, Inc.",May-08,Alzheimer Disease, Other primary psychiatric or neurological disorders
NCT00675623,Phase 3,Alzheimer's Disease,"Medivation, Inc.",May-08,Alzheimer Disease, Unstable medical illnesses or significant hepatic or renal disease
NCT00676143,Phase 3,Alzheimer Disease,Pfizer,Jan-08,Alzheimer Disease," Significant neurological disease other than AD, or a major psychiatric disorder"
NCT00676143,Phase 3,Alzheimer Disease,Pfizer,Jan-08,Alzheimer Disease," Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)"
NCT00676143,Phase 3,Alzheimer Disease,Pfizer,Jan-08,Alzheimer Disease, Woman of childbearing potential
NCT00679627,Phase 3,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Jun-08,Alzheimer Disease;Galantamine," Neurodegenerative disorders other than AD, such as Parkinson's Disease, Frontotemporal Dementia or Huntington's disease"
NCT00679627,Phase 3,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Jun-08,Alzheimer Disease;Galantamine, Any of specified conditions which may contribute to dementia
NCT00679627,Phase 3,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Jun-08,Alzheimer Disease;Galantamine," any of specified coexisting diseases, including significant cardiovascular disease."
NCT00684944,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease, There are no exclusion criteria. All patients taking medication at the termination of study TRx-014-001 and who wish to participate are eligible for recruitment.
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, No history of drug or alcohol abuse
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, No clinically significant laboratory abnormalities or medical history
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, No investigational drug within 30 days of Randomization
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, Intolerance or allergy to cholinesterase inhibitors
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, Cannot have been on cholinesterase inhibitors for AD for greater than  2 years
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil," If have been on cholinesterase inhibitors for less than  2 years, must have been discontinued greater than = 2 months prior to randomization"
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, Cannot have received memantine within 2 months
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, No clinically significant ECG abnormalities prior to randomization
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, No history of uncontrolled seizure disorder within 12 months
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil," Cannot be taking MAO inhibitors, bupropion,fluoxetine, paroxetine, quinidine"
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, No history of malignancy within 3 years of randomization
NCT00693004,Phase 2,Alzheimer's Disease,"Epix Pharmaceuticals, Inc.",May-08,Alzheimer Disease;Donepezil, Women cannot be pregnant or breastfeeding
NCT00704782,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Apr-08,Alzheimer Disease, Unstable medical illnesses or significant hepatic or renal disease
NCT00704782,Phase 2,Alzheimer's Disease,"Medivation, Inc.",Apr-08,Alzheimer Disease, Other primary psychiatric or neurological disorders
NCT00710684,Phase 2,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Donepezil," Subjects with a diagnosis of possible, probable or definite vascular dementia may not participate."
NCT00710684,Phase 2,Alzheimer's Disease,GlaxoSmithKline,unknown,Alzheimer Disease;Donepezil," Subjects with known hypersensitivity to sunlight or a history of seizures, previous exposure to SB-742457, taking agents for which there is a theoretical risk of interaction with SB-742457, or taking medication for Alzheimer's disease or centrally acting agents which might impact study outcomes may not participate."
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, Contraindication to lumbar puncture
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, DARAD exclusion criteria as follows:
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, dementia due to other neurodegenerative diseases
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin," cognitive impairment due to head trauma, etc."
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, stroke or significant cerebrovascular disease
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin," clinically significant cardiac disease such as recent MI, uncontrolled hypertension"
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, taking other anti-dementia treatments or investigational drugs
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, allergy to doxycycline or rifampin
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, significant psychiatric conditions like depression
NCT00715858,Phase 3,Alzheimer's Disease,McMaster University,May-08,Alzheimer Disease;Doxycycline;Rifampin, cancer
NCT00722046,Phase 2,Alzheimer's Disease,Pfizer,Dec-08,Alzheimer Disease, Diagnosis or history of other demential or neurodegenerative disorders
NCT00722046,Phase 2,Alzheimer's Disease,Pfizer,Dec-08,Alzheimer Disease, Diagnosis or history of clinically significant cerebrovascular disease
NCT00722046,Phase 2,Alzheimer's Disease,Pfizer,Dec-08,Alzheimer Disease," Specific findings on magnetic resonance imaging (MRI); cortical infarct, micro hemorrhage, multiple white matter lacunes, extensive white matter abnormalities"
NCT00722046,Phase 2,Alzheimer's Disease,Pfizer,Dec-08,Alzheimer Disease, History of autoimmune disorders
NCT00722046,Phase 2,Alzheimer's Disease,Pfizer,Dec-08,Alzheimer Disease, History of allergic or anaphylactic reactions
NCT00744978,Phase 2,Alzheimer's Disease,Pfizer,Jul-09,Alzheimer Disease;Varenicline, Diagnosis or history of other dementia or neurodegenerative disorders
NCT00744978,Phase 2,Alzheimer's Disease,Pfizer,Jul-09,Alzheimer Disease;Varenicline, Diagnosis or history of clinically significant cerebrovascular or cardiovascular disease
NCT00744978,Phase 2,Alzheimer's Disease,Pfizer,Jul-09,Alzheimer Disease;Varenicline, Subjects with pulmonary disease or evidence of clinically significant pulmonary symptoms
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease," Patients who don't have a reliable caregiver who is in frequent contact with the patient, who will accompany the patient to the office and/or be available by telephone at designated times, and will monitor administration of prescribed medications."
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Patients who have an MRI or CT scan since the onset of symptoms of AD that is inconsistent with a diagnosis of AD.
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease," Patients who have received acetylcholinesterase inhibitors (AChEIs) or memantine for less than 4 months, or have less than 2 months of stable therapy on these treatments."
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease," Patients who have current serious or unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator or subinvestigator(s)'s opinion, could interfere with the analyses of safety and efficacy in this study."
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease," Patients who have a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in protracted loss of consciousness within the last 5 years, or multiple episodes of head trauma."
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease," Patients who have a history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal PSA post-resection."
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Patients who have allergies to humanized monoclonal antibodies.
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease," Patients who have a history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal PSA post-resection."
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease," Patients who have ECG abnormalities obtained that, in the opinion of the investigator, are clinically significant with regard to the subject's participation in the study, including QTc prolongation (Bazett's corrected QTc interval, QTcB; males greater than 435 msec or females greater than 455 msec) or abnormally wide QRS complexes (resulting from bundle-branch blocks, interventricular conduction delays, or pacemakers)."
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease," Patients who have a current, required use or expected use of excluded drugs through the duration(These drugs include typical neuroleptics (antipsychotics). In addition, typical neuroleptics may not be taken within 4 weeks."
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease," Patients who are currently taking chronic medications that affect central nervous system (CNS) function, and are not dose-stabilized for at least 4 weeks."
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Patients who have a ventriculoperitoneal shunt or gamma globulin (IgG) therapy within the last year.
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Patients who have previously completed or withdrawn from this study or previous participation in any other study investigating active immunization against A.
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease," Patients who have any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or cardiac pacemaker."
NCT00749216,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Patients who weigh less than 40 kg.
NCT00751907,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jun-06,Alzheimer Disease;Atorvastatin, Current use of cholesterol lowering medication
NCT00751907,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jun-06,Alzheimer Disease;Atorvastatin, History of liver disease
NCT00751907,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jun-06,Alzheimer Disease;Atorvastatin, History of adverse reaction to statin medications
NCT00751907,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jun-06,Alzheimer Disease;Atorvastatin, Elevated lab values (CK and creatinine)
NCT00751907,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jun-06,Alzheimer Disease;Atorvastatin, Use of medications that counteract with atorvastatin
NCT00751907,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jun-06,Alzheimer Disease;Atorvastatin, History of dementia
NCT00751907,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jun-06,Alzheimer Disease;Atorvastatin, Currently pregnant
NCT00751907,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jun-06,Alzheimer Disease;Atorvastatin, Use of large quantities of grapefruit juice (more than 1 quart/day)
NCT00751907,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jun-06,Alzheimer Disease;Atorvastatin, Current involvement in another investigational drug study
NCT00751907,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",Jun-06,Alzheimer Disease;Atorvastatin, Contraindications to MRI
NCT00762411,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Is not capable of swallowing whole oral medication
NCT00762411,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Has serious or unstable illnesses
NCT00762411,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Does not have a reliable caregiver
NCT00762411,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Chronic alcohol and/or drug abuse within the past 5 years
NCT00762411,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Sep-08,Alzheimer Disease, Has ever had a active vaccination for AD
NCT00804271,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Dec-08,Alzheimer Disease;Memantine," Evidence of clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease."
NCT00804271,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Dec-08,Alzheimer Disease;Memantine, Intake of any medication that is contra-indicated in combination with memantine.
NCT00804271,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Dec-08,Alzheimer Disease;Memantine," History of severe drug allergy, or hypersensitivity, or patients with known hypersensitivity to ingredients of memantine or lactose."
NCT00804271,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Dec-08,Alzheimer Disease;Memantine, Known or suspected history of alcoholism or drug abuse within the past 2 years.
NCT00804271,Phase 3,Alzheimer's Disease,Merz Pharmaceuticals GmbH,Dec-08,Alzheimer Disease;Memantine, Current or previous treatment with memantine or participation in an investigational study with memantine.
NCT00809510,Phase 2,Alzheimer's Disease,Abbott,Jan-09,Alzheimer Disease," The subject is currently, or plans to participate in another experimental study during the course of this trial."
NCT00809510,Phase 2,Alzheimer's Disease,Abbott,Jan-09,Alzheimer Disease, The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Premenopausal women
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Dementia due to other causes than Alzheimer's disease
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, History of stroke
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Immunocompromised
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease," Active peptic ulcer, GI bleed, chronic inflammatory bowel disease, chronic diarrhea or past GI surgery that would impact drug absorption"
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Unstable Vitamin B-12 deficiency
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Hematologic or solid malignancy within 5 years
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Geriatric Depression Scale greater than = 6
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Unstable medical condition
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Alcohol or drug abuse history with 12-months of study entry
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Significant drug allergy
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Alzheimer's disease modification experimental therapy with 12 months of study entry
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease," Prisoners, compulsory psychiatric patients, or residents of nursing home or skilled nursing facility at entry"
NCT00810147,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,Feb-09,Alzheimer Disease, Any other experimental therapy with 30-days of study entry
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," Other causes of dementia (eg, vascular dementia, Lewy-body dementia, fronto-temporal dementia, Creutzfeldt-Jacob disease, Huntington's disease, Parkinson's disease)."
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," History of or present significant other diseases of the central nervous system (eg, brain tumor, normal pressure hydrocephalus, Parkinson's Disease, stroke, severe brain trauma, brain surgery, epilepsy, encephalitis)."
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Geriatric depression scale score greater than  7 (short form with scale from 0 to 15).
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," Present significant psychiatric disorder (eg, major depression)."
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", History of psychosis or hallucinations.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Mental retardation.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Unstable medical disease in the opinion of the investigator.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Insulin dependent diabetes mellitus.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Acute infectious disease.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Vitamin B12 deficiency unless on stable replacement therapy for at least 3 months is acceptable.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Unstable thyroid dysfunction.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Uncontrolled hypertension.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Severe liver or kidney disease.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Major surgery within 3 months prior to screening.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," Prohibited medications: Antiepileptic drugs, antipsychotics (but allowed for treatment of acute episodes), antiparkinson agents, anticholinergic drugs, selegiline, monoamine oxidase inhibitors (MAOI), tricyclics, immunosuppressive medications, anti-histamines (unless on a stable dose for at least 3 months or used for treatment of acute episodes), benzodiazepines (but allowed for treatment of acute episodes), and lithium."
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," Antidepressants are permitted, if on a stable dose for at least 3 months and without significant anticholinergic side-effects."
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Peripheral venous conditions which impair establishing regular venous access for infusions.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," Potential reasons that patient may become non-evaluable during the study (eg, planned moving into a nursing home, but assisted living is acceptable)."
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," Peripheral venous conditions, which impair establishing regular venous access for infusions."
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Known IgA deficiency with antibodies to IgA.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," History of hypersensitivity to blood or plasma derived products, or any component of octagam 10%, such as maltose."
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," Medical conditions which interfere with protein catabolism (eg, nephrotic syndrome)."
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Known blood hyperviscosity or other hypercoagulable states.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Deep vein thrombosis within preceding 4 years.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Symptomatic stroke.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Transient ischemic attack (TIA) within preceding 2 years.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Participation in another drug trial within the previous 3 months before screening.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Participation in immunological treatment studies of AD other than with intravenous immunoglobulin (IGIV) within the previous 6 months before screening.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", IGIV use in the previous 6 months.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Live viral vaccination within the last month before study entry.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," Not eligible for lumbar puncture (anticoagulant therapy, coagulation disorders, severe spinal alterations)."
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin", Patients with a past or present history of drug abuse or alcohol abuse within the preceding 5 years.
NCT00812565,Phase 2,Alzheimer's Disease,Octapharma,Feb-09,"Alzheimer Disease;gamma-Globulins;Immunoglobulins, Intravenous;Rho(D) Immune Globulin"," Patients with any condition that would make the patient, in the opinion of the Investigator, unsuitable for the study."
NCT00814801,Phase 3,Alzheimer's Disease,Janssen Pharmaceutical K.K.,Feb-07,Alzheimer Disease;Galantamine," Patients with neurodegenerative diseases other than Alzheimer's disease, such as Lewy bodies disease, (dementia due to tiny round structures made of proteins that develop within nerve cells in the brain), Parkinsonism, etc"
NCT00814801,Phase 3,Alzheimer's Disease,Janssen Pharmaceutical K.K.,Feb-07,Alzheimer Disease;Galantamine," Patients with cognitive dysfunction due to cerebral damage resulting from a lack of oxygen, a brain injury, etc"
NCT00814801,Phase 3,Alzheimer's Disease,Janssen Pharmaceutical K.K.,Feb-07,Alzheimer Disease;Galantamine, Patients with multi-infarct dementia (brought on by a series of strokes) or active cerebrovascular disease
NCT00814801,Phase 3,Alzheimer's Disease,Janssen Pharmaceutical K.K.,Feb-07,Alzheimer Disease;Galantamine, Patients with clinically significant cardiovascular disease
NCT00814801,Phase 3,Alzheimer's Disease,Janssen Pharmaceutical K.K.,Feb-07,Alzheimer Disease;Galantamine," Patients currently taking drugs such as a cholinesterase inhibitors, which improve cerebral circulation/metabolism"
NCT00829374,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Mar-09,Alzheimer Disease, Other causes of dementia
NCT00829374,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Mar-09,Alzheimer Disease, Major structural brain disease
NCT00829374,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Mar-09,Alzheimer Disease, Unstable medical condition or significant hepatic or renal disease
NCT00838110,Phase 3,Alzheimer's Disease,Pfizer,Feb-09,Alzheimer Disease," Have major structural brain disease (e.g., ischemic infarcts, subdural hematoma, hemorrhage, hydrocephalus, brain tumors, multiple subcortical ischemic lesions, or a single lesion in a critical region [e.g., thalamus, hippocampus])."
NCT00838110,Phase 3,Alzheimer's Disease,Pfizer,Feb-09,Alzheimer Disease, Have any major medical illness or unstable medical condition within six months of screening that may interfere with the patient's ability to comply with study procedures and abide by study restrictions.
NCT00838110,Phase 3,Alzheimer's Disease,Pfizer,Feb-09,Alzheimer Disease, Have not been on a stable dose of anti-dementia therapy for at least 60 days prior to dosing or intend to start anti-dementia therapy during the double blind portion of the study.
NCT00838110,Phase 3,Alzheimer's Disease,Pfizer,Feb-09,Alzheimer Disease, Reside in a nursing home or assisted care facility with need for 24-hour care and supervision.
NCT00842673,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Subjects who reside in a skilled nursing facility.
NCT00842673,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Subjects with B12 or folate deficiency.
NCT00842673,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Subjects with chronic hepatic disease.
NCT00842673,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Subjects with a recent history of hematologic/oncologic disorders.
NCT00842673,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Subjects who have experienced a myocardial infarction with the past year.
NCT00842673,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Dementia caused or complicated by other organic disease
NCT00842816,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Subjects who reside in a skilled nursing facility.
NCT00842816,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Subjects with B12 or folate deficiency.
NCT00842816,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Subjects with chronic hepatic disease.
NCT00842816,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Subjects with a recent history of hematologic/oncologic disorders.
NCT00842816,Phase 2,Alzheimer's Disease,"Sonexa Therapeutics, Inc.",Feb-09,Alzheimer Disease, Subjects who have experienced a myocardial infarction with the past year.
NCT00843518,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Feb-09,Alzheimer Disease;Psychomotor Agitation;Aggression, Meet DSM-IV-TR or Delirium Rating Scale-Revised-98 criteria for delirium.
NCT00843518,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Feb-09,Alzheimer Disease;Psychomotor Agitation;Aggression, Does not score 4 on the Modified Hachinski Ischemia Scale for vascular dementia.
NCT00843518,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Feb-09,Alzheimer Disease;Psychomotor Agitation;Aggression, Have a magnetic resonance imaging (MRI) or computer tomography (CT) scan on file since the onset of symptoms of AD and performed within the past 24 months that is inconsistent with a diagnosis of AD.
NCT00843518,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Feb-09,Alzheimer Disease;Psychomotor Agitation;Aggression," Have a current, required use, or expected use of psychoactive drugs or other medications not allowed in this trial."
NCT00843518,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Feb-09,Alzheimer Disease;Psychomotor Agitation;Aggression," Have currently active significant medical, neurological, or psychiatric problems that are not allowed in this trial or other brain disorders."
NCT00843518,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Feb-09,Alzheimer Disease;Psychomotor Agitation;Aggression," Have received acetylcholinesterase inhibitor (AChEIs) or memantine for less than 4 months, or have less than 2 months of stable therapy on these treatments by Visit 2."
NCT00855868,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-09,Alzheimer Disease, other neurological disease
NCT00855868,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-09,Alzheimer Disease, evidence of MRI abnormality
NCT00855868,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-09,Alzheimer Disease, psychiatric disorder
NCT00855868,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-09,Alzheimer Disease, alcohol abuse
NCT00855868,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-09,Alzheimer Disease, clinically significant lab abnormalities
NCT00855868,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-09,Alzheimer Disease, residence in nursing facility
NCT00855868,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Mar-09,Alzheimer Disease, participation in clinical trial with experimental medication in past 1 month
NCT00857233,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Jun-04,Alzheimer Disease;Memantine," Diseases/medication which judged by the investigator could interfere with the assessments of safety, tolerability or efficacy."
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis," Have primary brain tumor, known metastases to the brain, central nervous system (CNS) lymphoma;"
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis," Have any major, focal structural loss of brain matter;"
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis, Are aggressively being treated with life sustaining measures (e.g. currently on respirator; receiving high dose chemotherapy);
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis," Have a clinically significant infectious disease, including Acquired Immune Deficiency Syndrome (AIDS), Human Immunodeficiency Virus (HIV) infection, previous positive test for hepatitis or HIV or Creutzfeldt-Jakob disease (CJD);"
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis," Are receiving any investigational medications, or have participated in a trial with investigational medications within the last 30 days;"
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis," Have ever participated in an experimental study with an amyloid targeting agent (e.g. anti-amyloid immunotherapy, secretase inhibitor);"
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis, Have had a radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session; or
NCT00857415,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Dec-08,Alzheimer Disease;Amyloidosis, Are females of childbearing potential who are pregnant or not using adequate contraception.
NCT00857649,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Dec-03,Alzheimer Disease;Memantine," Evidence of clinically significant active disease, evidence of other neurological disorders, and previous treatment with memantine"
NCT00876863,Phase 2,Alzheimer's Disease,Sangamo Therapeutics,unknown,Alzheimer Disease, Significant neurological disease other than Alzheimer's disease
NCT00876863,Phase 2,Alzheimer's Disease,Sangamo Therapeutics,unknown,Alzheimer Disease, Significant depression or other psychiatric disorder
NCT00876863,Phase 2,Alzheimer's Disease,Sangamo Therapeutics,unknown,Alzheimer Disease, Unstable medical conditions
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," Diagnosis of vascular dementia according to NINDS-AIREN criteria, or other non-AD dementia, or CNS pathology (including but not limited to brain injury, brain tumour, stroke, normal pressure hydrocephalus, Parkinson's disease, epilepsy,multiple sclerosis,) that may be responsible for dementia."
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," Clinically significant pathology and/or uncontrolled condition, including but not limited to cancer, infectious (like AIDS), gastro-intestinal, hepatic, renal, respiratory, endocrine(like diabetes mellitus, thyroiditis) pathology."
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," History or current clinically significant psychiatric pathology (including but not limited to psychotic disorders, bipolar disorder, personality disorders) that may interfere with study assessments."
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," Current major depressive disorder, either treated or not, associated with clinically significant symptoms."
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," Low blood level of vitamin B12, TSH levels out of normal range at screening."
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate, Current forbidden medication intake or intake within 2 weeks prior to screening.
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," Recent history (within the past year prior to inclusion) or current cardiovascular pathology and/or symptoms considered as clinically significant, including but not limited to angina pectoris, uncontrolled arrhythmia, significant ECG abnormalities. Lifetime history of heart failure, myocardial infarction, severe and/or uncontrolled angina pectoris,and/or ventricular arrhythmia disqualifies the patient."
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate, History or presence of clinically conditions that may interfere with product metabolism or with study assessments.
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate, Systolic blood pressure  160 mmHg and/or diastolic blood pressure  90 mmHg at screening and/or randomisation.
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate, QTc interval (Bazett's correction)  430 msec for male and  450 msec for female at screening.
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," Laboratory values (biochemistry, haematology, urinalysis) considered as clinically significant and/or that may interfere with study assessments, according to the investigator."
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," ALAT, ASAT, ALP greater than  2.5 times the upper normal limit (UNL), total bilirubin greater than  1.5 UNL or history of significant liver pathology including hepatitis caused by drugs, HBV, HCV."
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate," BUN, creatinin greater than  1.5 UNL."
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate, Current or recent history of drug or alcohol abuse or dependence.
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate, Patient not registered at  Scurit Sociale .
NCT00880412,Phase 2,Alzheimer's Disease,Exonhit,Apr-08,Alzheimer Disease;Etazolate, Participation in another study within 1 month prior to screening and during the whole duration of the study.
NCT00884507,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,May-09,Alzheimer Disease, dementia due to condition other than Alzheimer's disease;
NCT00884507,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,May-09,Alzheimer Disease, other significant neurological disorder;
NCT00884507,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,May-09,Alzheimer Disease, untreated/non-stabilized major depressive disorder;
NCT00884507,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,May-09,Alzheimer Disease," bipolar disorder, schizophrenia, or any other serious psychiatric condition."
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Premenopausal women
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, DSM-IV diagnosis of Dementia History of stroke
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Immunocompromised
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease," Active peptic ulcer, GI bleed, chronic inflammatory bowel disease, chronic diarrhea or past GI surgery that would impact drug absorption"
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Unstable Vitamin B-12 deficiency
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Hematologic or solid malignancy within 5 years
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Geriatric Depression Scale  6
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Unstable medical condition
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Alcohol or drug abuse history with 12-months of study entry
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Significant drug allergy
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease," Prisoners, compulsory psychiatric patients, or residents of nursing home or skilled nursing facility at entry"
NCT00890890,Phase 2,Alzheimer's Disease,Bristol-Myers Squibb,May-09,Alzheimer Disease, Any other experimental therapy with 30-days of study entry
NCT00895895,Phase 2,Alzheimer Disease,Pfizer,May-09,Alzheimer Disease;Donepezil, Relevant neurologic disease other than Alzheimer Disease that may affect cognition or ability to complete the study.
NCT00895895,Phase 2,Alzheimer Disease,Pfizer,May-09,Alzheimer Disease;Donepezil, Current major depressive disorder or other current major psychiatric disorder.
NCT00895895,Phase 2,Alzheimer Disease,Pfizer,May-09,Alzheimer Disease;Donepezil, History of clinically evident stroke or clinically important carotid or vertebrobasilar stenosis or plaque.
NCT00895895,Phase 2,Alzheimer Disease,Pfizer,May-09,Alzheimer Disease;Donepezil," Use of prescription or nonprescription medications for cognitive enhancement (including memantine, ginkgo biloba, huperzine A, and cholinesterase inhibitors) within 3 months before the baseline visit."
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Has serious or unstable illness(es)
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Does not have a reliable caregiver who is in frequent contact with patient (at least 10 hours per week)
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Meets National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) criteria for vascular dementia
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease," Does not have good venous access, such that intravenous (IV) drug delivery would be difficult"
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Has had multiple episodes of head trauma or history within the last 5 years of a serious infectious disease affecting the brain
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Has allergies to humanized monoclonal antibodies
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Chronic alcohol and/or drug abuse within the past 5 years
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Has any contraindications for MRI studies
NCT00904683,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Requires treatment with another monoclonal antibody
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Has serious or unstable illness(es)
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Does not have a reliable caregiver who is in frequent contact with patient (at least 10 hours per week)
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Meets National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) criteria for vascular dementia
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease," Does not have good venous access, such that intravenous (IV) drug delivery would be difficult"
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Has had multiple episodes of head trauma or history within the last 5 years of a serious infectious disease affecting the brain
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Has allergies to humanized monoclonal antibodies
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Chronic alcohol and/or drug abuse within the past 5 years
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Has any contraindications for MRI studies
NCT00905372,Phase 3,Alzheimer's Disease,Eli Lilly and Company,May-09,Alzheimer Disease, Requires treatment with another monoclonal antibody
NCT00912288,Phase 3,Alzheimer Disease,Pfizer,Sep-09,Alzheimer Disease," Have taken medicines for Alzheimers disease other than memantine (e.g., donepezil, rivastigmine, galantamine, tacrine) within 2 months prior to this study."
NCT00912288,Phase 3,Alzheimer Disease,Pfizer,Sep-09,Alzheimer Disease, Dementia other than Alzheimers disease.
NCT00912288,Phase 3,Alzheimer Disease,Pfizer,Sep-09,Alzheimer Disease," Any medical condition or reason that interferes with the ability of the patient to participate in or complete the trial or places the patient at undue risk, as judged by the study doctor."
NCT00916617,Phase 2,Alzheimer Disease,Pfizer,Jun-09,Alzheimer Disease, Significant brain MRI abnormalities
NCT00916617,Phase 2,Alzheimer Disease,Pfizer,Jun-09,Alzheimer Disease, Clinically important psychiatric symptoms
NCT00916617,Phase 2,Alzheimer Disease,Pfizer,Jun-09,Alzheimer Disease, History of stroke
NCT00930059,Phase 2,Alzheimer's Disease,Pfizer,unknown,Alzheimer Disease," Use of acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine) or memantine within 12 weeks of the start of the study"
NCT00930059,Phase 2,Alzheimer's Disease,Pfizer,unknown,Alzheimer Disease, Significant cardiovascular disease in the past 6 months
NCT00930059,Phase 2,Alzheimer's Disease,Pfizer,unknown,Alzheimer Disease, Illness other than Alzheimer's disease that could contribute to cognitive impairment
NCT00930059,Phase 2,Alzheimer's Disease,Pfizer,unknown,Alzheimer Disease, History of stroke or seizure disorder
NCT00934050,Phase 2,Alzheimer's Disease,"OPKO Health, Inc.",Jun-09,Alzheimer Disease;Inositol, Subject has no new medical contraindications to continued participation in the study.
NCT00937352,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Jul-09,Alzheimer Disease," Any new medical contraindication or clinically significant abnormality on physical, neurological, laboratory, vital signs or ECG examination (eg, atrial fibrillation) that precludes continued or initiation of treatment with bapineuzumab or participation in the study"
NCT00937352,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Jul-09,Alzheimer Disease, Screening visit brain MRI scan (MRI from Study 301 or 302 Visit 14/Week 71) indicative of any significant abnormality not approved by the medical monitor prior to enrollment
NCT00937352,Phase 3,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Jul-09,Alzheimer Disease," Current use of experimental medications for AD (other than bapineuzumab) and all other experimental medications, herbal preparations containing Ginko biloba, and anticoagulants (except the use of aspirin 325mg/day or less, Plavix, and Persantine but not for stroke)"
NCT00939783,Phase 3,Alzheimer's Disease,Pfizer,Sep-09,Alzheimer Disease," Have any severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study."
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, Active liver disease
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, History of adverse reaction to statins
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, Contraindication to lumbar puncture
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, Elevated creatine kinase and creatinine lab values
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, Use of medications known to interact with statins
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, History of dementia or mild cognitive impairment
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, Currently pregnant or planning to become pregnant
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, Use of large quantities of grapefruit juice (more than 1 quart per day)
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, Contraindications to MRI (for MRI sub-study)
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, Currently on cholesterol-lowering medication or use in past 4 months
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin," History of heart attack, heart problems, stroke and/or diabetes"
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, Drinking more than a quart of grapefruit juice per day
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin," Metal implants, or metal debris in body (MRI)"
NCT00939822,Phase 2,Alzheimer's Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease;Simvastatin, List of medications that interact with simvastatin
NCT00945672,Phase 2,Alzheimer's Disease,Pfizer,Aug-09,Alzheimer Disease, Diagnosis or history of other demential or neurodegenerative disorders.
NCT00945672,Phase 2,Alzheimer's Disease,Pfizer,Aug-09,Alzheimer Disease, Diagnosis or history of clinically significant cerebrovascular disease.
NCT00945672,Phase 2,Alzheimer's Disease,Pfizer,Aug-09,Alzheimer Disease," Specific findings on magnetic resonance imaging (MRI); cortical infarct, micro hemorrhage, multiple white matter lacunes, extensive white matter abnormalities."
NCT00945672,Phase 2,Alzheimer's Disease,Pfizer,Aug-09,Alzheimer Disease, History of autoimmune disorders.
NCT00945672,Phase 2,Alzheimer's Disease,Pfizer,Aug-09,Alzheimer Disease, History of allergic or anaphylactic reactions.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Failure to perform screening or baseline examinations.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Hospitalization or change of chronic concomitant medication within 1 month prior to screening period.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,"Clinical, laboratory or neuroimaging findings consistent with:"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," other primary degenerative dementia, (dementia with Lewy bodies, frontotemporal dementia, Huntington's disease, Jacob-Creutzfeld Disease, Down's syndrome, etc)"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," other neurodegenerative condition (Parkinson's disease, amyotrophic lateral sclerosis, etc.)"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," cerebrovascular disease (major infarct, one strategic or multiple lacunar infarcts, extensive white matter lesions)"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," other central nervous system diseases (severe head trauma, tumors, subdural haematoma or other space occupying processes, etc.)"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, seizure disorder
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," other infectious, metabolic or systemic diseases affecting central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, serum electrolytes out of normal range, juvenile onset diabetes mellitus, etc.)"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,"A current DSM-IV diagnosis of active major depression, schizophrenia or bipolar disorder."
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,"Clinically significant, advanced or unstable disease that may interfere with evaluations that may bias the assessment of the clinical or mental status of the patient or put the patient at special risk, such as:"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," chronic liver disease, liver function test (LFT) abnormalities or other signs of hepatic insufficiency"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, respiratory insufficiency
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, renal insufficiency (serum creatinine greater than 2mg/dl and creatinine clearance  60 mL/min according to Cockgroft-Gault formula).
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," heart disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy within 6 months before screening)"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, bradycardia (heart beat less than 50/min.) or tachycardia (heart beat greater than 95/min.)
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, hypertension or hypotension if not well controlled or unstable for greater than  2 months prior to baseline.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," AV block (type II / Mobitz II and type III), congenital long QT syndrome, sinus node dysfunction or prolonged QTcB-interval (males greater than 450 and females greater than 470 msec)"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, uncontrolled diabetes
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, malignant tumors within the last 5 years except skin malignancies (other than melanoma) or indolent prostate cancer
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, metastases
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,"Disability that may prevent the subject from completing all study requirements (e.g., blindness, deafness, severe language difficulty, etc.)"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Women who are fertile and of child bearing potential.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Anticoagulant treatment with heparin i.v.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Chronic drug intake of:
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," drugs metabolized by the CYP3A4 with narrow therapeutic window (i.e. warfarin, digitoxin, )."
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," antidepressants, benzodiazepines, neuroleptics or sedatives except those defined as allowed in the inclusion criterion number 12"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, proton-pump inhibitors
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, antiepileptics
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, anticholinergics
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, nootropics
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," centrally active anti-hypertensive drugs (clonidine, alpha-methyl dopa, guanidine, guanfacine, )"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease, opioid containing analgesics
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," non-steroid anti-inflammatory agents (except taken as concomitant medication per request as defined in the inclusion criterion number 12), cortico-steroids or immunosuppressants"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease," memantine, lithium or other inhibitor of GSK3 enzyme"
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Suspected or known drug or alcohol abuse.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Suspected or known allergy to any components of the study treatments.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Enrolment in another investigational study or intake of investigational drug within the previous 3 months.
NCT00948259,Phase 1/Phase 2,Alzheimers Disease,Noscira SA,Dec-08,Alzheimer Disease,Any condition which in the opinion of the investigator makes the patient unsuitable for inclusion.
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil, The subject is currently taking or has taken a medication for the treatment of Alzheimer's disease or dementia within 60 days prior to Screening Visit 1
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil, The subject has a history of any significant neurologic disease other than AD.
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil," In the opinion of the investigator, the subject has any clinically significant uncontrolled medical or psychiatric illness."
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil, The subject has reported history of discontinuation of donepezil due to lack of efficacy.
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil, The subject has a history of intolerance or adverse reaction to donepezil that led to discontinuation.
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil," The subject has a known hypersensitivity to donepezil, piperidine derivatives, or any of the excipients in either donepezil hydrochloride or ABT-126 formulations."
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil, Patient uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence.
NCT00948909,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Oct-09,Alzheimer Disease;Donepezil, Subjects with AST and ALT values at Screening Visit 1 that are greater than or equal to 1.5-fold the upper limit of normal (ULN).
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate," co-medication with NSAIDs (longterm medication) (ASS is not an exclusion criteria), Gingko- or other natural extracts, other anti-dementiva except of Donepezil"
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, familial autosomal-dominant inherited AD
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, instable medical condition
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, other primary psychiatric/neurologic disorders
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, missing informed consent
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, no readiness to save and refer pseudonym personal data
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, hospitalisation due to juridical or legal regulation
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, any condition disturbing or making MRI and other measures impossible
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, clinically relevant GI-disorders at screening and 1 year before
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate," clinically relevant lung, infectious, heart or other CNS disorders, clinical or paraclinical suspicion of TBC, history of vascular CNS-disorders at screening and 1 year before"
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, clinically relevant liver disorders at screening and 1 year before
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate," clinically relevant functional disorders of liver, kidney or bone marrow defined by following lab values at screening:"
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, Marrow dysfunction:
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate," HB less than  8,5 g/dl"
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate," WBC less than  2,5/nl"
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, Thrombocytes less than  125/nl
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, Kidney dysfunction:
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate," Creatinin-Clearance according to Cockcroft-Gault-Formula: Cl less than  110ml/min (male) resp. Cl less than  95ml/min (female), from the age of 30 decline of 10ml/min per decade"
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, Liver dysfunction:
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, ASAT/ALAT greater than  3.5 x higher than the upper reference value
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, Bilirubin greater than  2.0 mg/dl
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, known allergy of elements of Sunphenon EGCg or additives of Sunphenon EGCg resp. placebo
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, long-term hepatotoxic medication
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate," current intake of cytochrom P450 3A4-inhibitors or -inductors, such as antimycotics of the azol-type or macrolide-antibiotics"
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, clinical-anamnestic or paraclinical manifestations suggesting an alcohol or drug abuse
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, participation in any clinical trial less than  3 months prior to screening or ongoing
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate," any medical, psychiatric or other condition which might constrain the ability of the patient to understand the informed consent, to give consent, to adhere to the protocol or to accomplish the study"
NCT00951834,Phase 2/Phase 3,Alzheimer's Disease,"Charite University, Berlin, Germany",Oct-09,Alzheimer Disease;Epigallocatechin gallate, massive and extended sun exposure
NCT00954590,Phase 3,Moderate to Severe Alzheimer,"Medivation, Inc.",Oct-09,Alzheimer Disease, Other causes of dementia
NCT00954590,Phase 3,Moderate to Severe Alzheimer,"Medivation, Inc.",Oct-09,Alzheimer Disease, Major structural brain disease
NCT00954590,Phase 3,Moderate to Severe Alzheimer,"Medivation, Inc.",Oct-09,Alzheimer Disease, Unstable medical condition or significant hepatic or renal disease
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,Any cause of dementia not due to Alzheimer's disease :
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease," other central nervous conditions causing progressive deficits in memory and cognition, e.g. cerebrovascular disease, Parkinson's disease, Huntington's disease, brain tumor"
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease," systemic conditions known to cause dementia, e.g., hypothyroidism, untreated vitamin B12 or folic acid deficiency, niacin deficiency, neurosyphilis, HIV infection"
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease, substance-induced conditions
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,Alzheimer disease with delusions or delirium
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,"Treatment with any registered or putative cognitive enhancer or disease modifier other than donepezil, galantamine, rivastigmine or memantine"
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,Uncontrolled depression at screening
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,"Evidence of psychosis and/or use of antipsychotic drugs at screening, or history of significant psychotic disorder or hospitalization for psychiatric disorders"
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,"Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection."
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,History of infection requiring hospitalization or treatment with antibiotics within 2 weeks of screening
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,"Inadequate organ function, defined as follows : total bilirubin  1.5 x ULN, SGOT and SGPT  2.5 x UNL, creatinine clearance calculated by Crocroft method less than  35 ml/mn, ANC  2500, platelets  100 000 at baseline"
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,"Treatment with any investigational agent within 4 weeks of screening,"
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,Men and their partner refusing to use 2 methods of medically acceptable forms of contraception during the study.
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,"History of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent"
NCT00976118,Phase 2,Alzheimer's Disease,AB Science,Feb-06,Alzheimer Disease,"Any condition that, in the investigator's opinion, could be detrimental to subjects participating in this study as life expectancy less than  1 year, or any clinically important deviations from normal clinical laboratory values or concurrent medical events."
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone, Absence of a reliable caregiver who is willing to participate and comply with protocol responsibilities
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone, Diabetes mellitus requiring medical therapy (diet-controlled diabetes is acceptable)
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone," Acute or chronic liver failure, hepatitis within the last two years, or history of drug-induced liver transaminase elevations"
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone," Heart failure meeting New York Heart Association Grade III or IV criteria (i.e., functionally disabling)"
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone," Evidence of active gastrointestinal, renal, pulmonary, endocrine or cardiovascular system disease sufficient to cause cognitive impairment or interfere with past levels of daily function; participants with controlled hypertension (supine diastolic BP less than  95mmHg), right bundle branch block (complete or partial) and pacemakers may be included in the study; participants with thyroid disease also may be included in the study, provided they are euthyroid on treatment"
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone, Active treatment for cancer or history of cancer within 3 years of screening (basal cell and squamous cells skin cancers are acceptable; incidental finding of carcinoma cells at transurethral prostate resection without subsequent medical or surgical therapy is acceptable)
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone," Evidence of other psychiatric/neurologic disorders sufficient to be the primary source of cognitive impairment (i.e., stroke, idiopathic Parkinson's disease, schizophrenia, bipolar or unipolar depression, seizure disorder, head injury with loss of consciousness within the past year) or a modified Hachinski's ischemia score of 5 or greater; delusions, hallucinations or depression not successfully treated or not on stable medical therapy for these conditions 30 days prior to enrollment; known or suspected history (within the past 10 years) of alcoholism or drug misuse"
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone, Participants and/or caregivers who are unwilling or unable to fulfill the requirements of the study
NCT00982202,Phase 2,Alzheimer Disease,National Institute on Aging (NIA),Jan-02,Alzheimer Disease;Pioglitazone," Any condition which would make the participant or the caregiver, in the opinion of the investigator, unsuitable for the study"
NCT00991419,Phase 2,Alzheimer's Disease,AstraZeneca,Feb-10,Alzheimer Disease, Significant recent (within 6 months) history of neurological (including stroke) or psychiatric disorder or substance abuse
NCT00991419,Phase 2,Alzheimer's Disease,AstraZeneca,Feb-10,Alzheimer Disease, Participated in a PET study within the last 12 months
NCT00991419,Phase 2,Alzheimer's Disease,AstraZeneca,Feb-10,Alzheimer Disease, Pregnancy or lactation
NCT00996918,Phase 3,Alzheimer Disease,Pfizer,Dec-09,Alzheimer Disease," Any medical or psychiatric contraindication or clinically significant abnormality that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response."
NCT00996918,Phase 3,Alzheimer Disease,Pfizer,Dec-09,Alzheimer Disease, Any significant brain MRI abnormality.
NCT00996918,Phase 3,Alzheimer Disease,Pfizer,Dec-09,Alzheimer Disease," Use of any investigational drugs or devices, other than bapineuzumab within the last 60 days prior to screening"
NCT00998764,Phase 3,Alzheimer Disease,Pfizer,Dec-09,Alzheimer Disease," Any medical or psychiatric contraindication or clinically significant abnormality that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response."
NCT00998764,Phase 3,Alzheimer Disease,Pfizer,Dec-09,Alzheimer Disease, Any significant brain MRI abnormality.
NCT00998764,Phase 3,Alzheimer Disease,Pfizer,Dec-09,Alzheimer Disease," Use of any investigational drugs or devices, other than bapineuzumab within the last 60 days prior to screening"
NCT01018875,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Dec-09,Alzheimer Disease;Donepezil," treatment of AD or dementia with 60 days of Screening visit, or is participating in cognitive therapy for the treatment of AD or dementia. 2. Subject uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence. 3. Subject has a history of any significant neurologic disease other than AD. 4. Subject has a history of intolerance or adverse reaction to donepezil that led to discontinuation. 5. Subject has received any investigation product within 6 weeks prior to study drug administration."
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease," The patient has evidence of any clinically significant neurodegenerative disease or other serious neurological disorders other than AD including but not limited to Lewy body dementia, fronto-temporal dementia, Parkinson's disease, Huntington's disease, major cortical stroke, major head trauma and, primary or secondary cerebral neoplasia."
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease," The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) Axis I disorder other than AD including amnestic disorders, major depressive disorder, delirium, schizophrenia or schizoaffective disorder, bipolar disorder, psychosis, panic, post traumatic stress disorder or/and cognitive disorder not otherwise specified."
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease, The patient has clinical and radiological findings that fulfil the standards of the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherch et l'Enseignement en Neurosciences (NINDS-AIREN) criteria for vascular dementia.
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease," The patient has CT or MRI evidence of hydrocephalus, stroke, a space-occupying lesion, cerebral infection or any clinically significant central nervous system disease other than AD."
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease, The patient has clinically significant abnormal vital signs.
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease," The patient has one or more laboratory values outside the normal range, based on the blood or urine samples, which are, in the investigator's judgement, considered to be clinically significant."
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease, The patient has a clinically significant abnormal ECG.
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease," The patient has an oncological diagnosis (haematological or solid tumour) that is currently being treated, or for which there has been treatment within 5 years preceding screening, or for which there is still evidence of active disease (patients with local dermatological tumours such as basal or squamous cell carcinoma may be included)."
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease, The patient's donepezil therapy is likely to be interrupted or discontinued during the study.
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease," The patient has a disease or takes medication that, in the investigator's judgement, could interfere with the assessments of safety, tolerability, or efficacy."
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease," The patient is, in the investigator's judgement, unlikely to comply with the clinical study protocol or is unsuitable for any reason."
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease, The patient is a member of the site personnel or their immediate families.
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease," The patient is treated against his/her will (for example, by court order)."
NCT01019421,Phase 2,Alzheimer's Disease,H. Lundbeck A/S,Dec-09,Alzheimer Disease, The patient or patient caregiver is unwilling or unable to abide by the visit schedule and other requirements of the study.
NCT01020838,Phase 3,Alzheimer Disease,Life Molecular Imaging SA,Nov-09,Alzheimer Disease," Has severe cerebral macrovascular (ie, multi-stroke) disease or brain tumor (metastasis/brain cancer) as verified by MRI"
NCT01020838,Phase 3,Alzheimer Disease,Life Molecular Imaging SA,Nov-09,Alzheimer Disease," Has any contraindication to magnetic resonance imaging (MRI) examination, eg, metal implants or phobia as determined by the onsite radiologist performing the scan"
NCT01020838,Phase 3,Alzheimer Disease,Life Molecular Imaging SA,Nov-09,Alzheimer Disease, Has been previously enrolled in this study or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening and/or was administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study
NCT01020838,Phase 3,Alzheimer Disease,Life Molecular Imaging SA,Nov-09,Alzheimer Disease, Has severe cardio-vascular instability requiring intensive care surveillance and/or therapeutic intervention (i.e. catecholamine infusion)
NCT01028053,Phase 3,Alzheimer's Disease,GE Healthcare,Dec-09,Alzheimer Disease;Cognitive Dysfunction;Flutemetamol," The subject has any significant neurologic disease other than suspected aMCI; such as Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities."
NCT01028053,Phase 3,Alzheimer's Disease,GE Healthcare,Dec-09,Alzheimer Disease;Cognitive Dysfunction;Flutemetamol," The subject has one or more aneurysm clips, artificial heart valves, metal implants, embedded metal fragments or pacemakers that would pose a risk during an MRI."
NCT01028053,Phase 3,Alzheimer's Disease,GE Healthcare,Dec-09,Alzheimer Disease;Cognitive Dysfunction;Flutemetamol," The subject has major depression, bipolar disorder, as described in the DSM-IV within the past year."
NCT01028053,Phase 3,Alzheimer's Disease,GE Healthcare,Dec-09,Alzheimer Disease;Cognitive Dysfunction;Flutemetamol, The subject has history of schizophrenia (DSM-IV criteria).
NCT01028053,Phase 3,Alzheimer's Disease,GE Healthcare,Dec-09,Alzheimer Disease;Cognitive Dysfunction;Flutemetamol," The subject has had, within the prior 3 months, psychotic features, agitation or behavioral problems that could lead to protocol compliance issues."
NCT01035138,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Dec-09,Alzheimer Disease, Meets LFAN or LFBC study discontinuation criteria at the last visit of the LFAN or LFBC study
NCT01039701,Phase 2,Mild to Moderate Alzheimer's Disease,AstraZeneca,Dec-09,Alzheimer Disease, history of allergy/hypersensitivity reactions
NCT01039701,Phase 2,Mild to Moderate Alzheimer's Disease,AstraZeneca,Dec-09,Alzheimer Disease, significant neurological disease or dementia other than Alzheimer's disease
NCT01039701,Phase 2,Mild to Moderate Alzheimer's Disease,AstraZeneca,Dec-09,Alzheimer Disease, myocardial infarction or acute coronary syndrome within the last year
NCT01055392,Phase 2,Alzheimer Disease,University of Sao Paulo,Mar-07,Alzheimer Disease;Cognitive Dysfunction;Lithium Carbonate, sensory deficiencies that might preclude the administration of cognitive tests;
NCT01055392,Phase 2,Alzheimer Disease,University of Sao Paulo,Mar-07,Alzheimer Disease;Cognitive Dysfunction;Lithium Carbonate, active major psychiatry disorder;
NCT01055392,Phase 2,Alzheimer Disease,University of Sao Paulo,Mar-07,Alzheimer Disease;Cognitive Dysfunction;Lithium Carbonate," unstable clinical conditions such as cardiac insufficiency, uncontrolled diabetes mellitus, renal failure;"
NCT01055392,Phase 2,Alzheimer Disease,University of Sao Paulo,Mar-07,Alzheimer Disease;Cognitive Dysfunction;Lithium Carbonate, previous use of lithium salts;
NCT01055392,Phase 2,Alzheimer Disease,University of Sao Paulo,Mar-07,Alzheimer Disease;Cognitive Dysfunction;Lithium Carbonate, concurrent participation in other clinical trial or intervention studies;
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,Non-AD dementia
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,Residence in nursing home facility at screening visit (residence in community assisted living and long-term care facilities in which the participant still performs majority of basic activities of daily living will not be an exclusion)
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,History of clinically significant stroke (stroke with neurologic deficits greater than  6 months after diagnosis)
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,"Health conditions such as cancer diagnosed less than  5 years prior to enrollment (prostate cancer gleason grade less than  3 and non metastatic skin cancers are acceptable), liver disease, history of ventricular fibrillation or ventricular tachycardia, major psychiatric disorder, central nervous system diseases (e.g. brain tumor, seizure disorder)"
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,Insulin dependent diabetes or uncontrolled diabetes (diabetes controlled on medications other than insulin are acceptable)
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,"Hyperlipidemic (triglycerides greater than 500 mg/dl, LDL greater than  160 mg/dl, total cholesterol greater than 240 mg/dl). LDL levels between 160 mg/dl and 165 mg/dl will be reviewed by the PI and included if judged to be safe. Patients who have a history or hyperlipidemia, but are not taking lipid-lowering medications due to potential memory impairment side effects will be reviewed on a case-by-case basis by the PI and enrolled in the study if deemed safe by PI and the patient's primary care provider."
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,Fish intake of one 6 ounce serving greater than  once a week less than 4 months prior to enrollment
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,"Omega-3 fatty acid supplement intake (e.g. fish oil capsules, cod liver oil, or flaxseed oil) less than 4 months prior to enrollment"
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,Lipoic Acid supplementation less than 1 month prior to enrollment
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,"Taking systemic corticosteroids, neuroleptics, antiparkinsonian agents, and narcotic analgesics. Certain low dose antipsychotic use will be reviewed by the principle investigator on a case-by-case basis and may be allowed if determined that dose is not strong enough to affect performance on cognitive evaluations. Low dose sinemet and dopamine agonist taken once a day for restless leg syndrome is not an exclusion."
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,"Contraindications to MRI (for subjects enrolled at Bend, Medford, and Klamath sites that decide not to undergo MRI, this will not be an exclusion)."
NCT01058941,Phase 1/Phase 2,Alzheimer's Disease,Oregon Health and Science University,Sep-10,Alzheimer Disease;Thioctic Acid,Enrollment in another study
NCT01066546,Phase 3,Alzheimer's Disease,Pfizer,Apr-10,Alzheimer Disease, Any major medical illness or unstable medical condition that may increase the risk associated with study participation or investigational product administration or may interfere with the ability to interpret study safety data
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a," Subjects with constant use in the 3 months prior study enrolment of other drugs that can modify the course of the disease (e.g. statins, nonsteroidal anti-inflammatory drugs [NSAIDs] and steroids) or symptomatic cognitive treatments (e.g. cholinesterase inhibitors)"
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a, Subjects with modified Hachinski Ischemic Score  4
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a, Subjects who are unable to undergo neuropsychological evaluation (including analphabetism)
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a," Subjects with significant liver (aspartate aminotransferase, alanine aminotransferase , alkaline phosphatase greater than  2.0 times the upper limit of normal [ULN] of the local laboratory, or total bilirubin greater than  1.5 times the ULN of the local laboratory), thyroid (according to clinical judgment) or hematological dysfunctions (e.g. leucocytes  2.0 * 109/Liter [L]; platelets  100 * 109/L; hemoglobin  12 gram/deciliter [g/dL] for women and  13 g/dL for men, serum albumin  3 g/dL)"
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a, Subjects with history (past or recurrent) of depression unresponsive to medication or past medical history of suicidal ideation
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a," Subjects with severe cardiac disease (angina, congestive heart failure class 3-4 New York Heart Association [NYHA] Functional Classification , or severe arrhythmia)"
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a, Subjects with epilepsy
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a," Subjects with concomitant use of hypnotic, anxiolytic, antidepressant, antipsychotic, anticholinergic"
NCT01075763,Phase 2,Alzheimer's Disease,"Merck KGaA, Darmstadt, Germany",Nov-04,Alzheimer Disease;Interferons;Interferon-beta;Interferon beta-1a, Subjects with known allergic reactions against IFNs or other components of the applied drug
NCT01078168,Phase 2,Alzheimer Disease,K. Lieb,Mar-10,Alzheimer Disease;Acitretin, hereditary cognitive impairment
NCT01078168,Phase 2,Alzheimer Disease,K. Lieb,Mar-10,Alzheimer Disease;Acitretin, known history of brain injuries
NCT01078168,Phase 2,Alzheimer Disease,K. Lieb,Mar-10,Alzheimer Disease;Acitretin, Insufficient German language skills
NCT01078168,Phase 2,Alzheimer Disease,K. Lieb,Mar-10,Alzheimer Disease;Acitretin, actual treatment with other potential disease modifying drugs of AD
NCT01078168,Phase 2,Alzheimer Disease,K. Lieb,Mar-10,Alzheimer Disease;Acitretin, multimorbidity or significant organ (esp. liver or renal) dysfunction
NCT01078168,Phase 2,Alzheimer Disease,K. Lieb,Mar-10,Alzheimer Disease;Acitretin, evidence of Non-AD neurodegenerative disorder (e.g. Parkinson)
NCT01078168,Phase 2,Alzheimer Disease,K. Lieb,Mar-10,Alzheimer Disease;Acitretin," contraindication to acitretin such as osteoporosis, hypoalbuminaemia"
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease, Any cause of dementia not due to Alzheimer's disease
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease, Past history of other central nervous condition or psychiatric disease
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease, Symptom of depression and drug addiction
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease, Impairment in the physical function by other factor than the Alzheimer's Disease
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease, Patients who are expected to move in to care facilities during the study period
NCT01120002,Phase 2,Alzheimer's Disease,Osaka City University,May-10,Alzheimer Disease, triglyceride greater than  400 mg/dL
NCT01125683,Phase 2,Alzheimers Disease,AstraZeneca,Jun-10,Alzheimer Disease;Donepezil, History of any clinically significant disease or dementia other than Alzheimers Disease
NCT01125683,Phase 2,Alzheimers Disease,AstraZeneca,Jun-10,Alzheimer Disease;Donepezil, Current major depressive disorder or other major psychiatric disorders
NCT01127633,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Dec-10,Alzheimer Disease," Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study"
NCT01127633,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Dec-10,Alzheimer Disease, Meets LZAM or LZAN discontinuation criteria at the end of treatment in LZAM or LZAN study
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,Subject has a known hypersensitivity or intolerance to donepezil that led to discontinuation or a known reported history of donepezil treatment failure.
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,"Subject is currently taking or has taken a medication for the treatment of AD or dementia within 60 days of Screening Visit 1, or is participating in cognitive therapy for the treatment of AD or dementia."
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,"Subject has a history of a drug or alcohol disorder (abuse/dependence), based on either DSM-IV-TR or ICD-10 criteria, excluding nicotine, within 2 years prior to Screening Visit 1."
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,"In the opinion of the investigator, the subject has any clinically significant uncontrolled medical or psychiatric illness that would affect the safety of the subject."
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,"The subject has a current thyroid disease or history of thyroid disease, and is not currently being treated with a stable dose of thyroid replacement medication."
NCT01137526,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",May-10,Alzheimer Disease;Donepezil,For any reason the investigator considers the subject to be an unsuitable candidate to receive ABT-384 or donepezil.
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone," Sleep disturbance associated with an acute illness, delirium or psychiatric disease;"
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone," Clinically significant movement disorder, such as akinesia, that would affect actigraphic differentiation of sleep and wakefulness"
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Severe agitation;
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Unstable medical condition;
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Discontinuation of psychotropic or sleep medications within 2 weeks of the screening visit;
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Patient unwilling to maintain caffeine abstinence after 2:00 PM for the duration of the protocol;
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone," Patient unwilling to comply with the maximum limit of 2 alcoholic drinks per day, and only 1 alcoholic drink after 6:00 PM for the duration of the protocol;"
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone, Prior use of trazodone for the treatment of sleep disturbances;
NCT01142258,Phase 3,Alzheimer's Disease,Brasilia University Hospital,Mar-10,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Trazodone," Caregiver deemed too unreliable to supervise the wearing of the actigraph, to administer trazodone the proper time, to maintain tbe sleep diary, or to bring the patient to the scheduled visits;"
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease, Have previously completed or withdrawn from this study or any other study investigating solanezumab
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease," Does not have good venous access, such that intravenous drug delivery or multiple blood draws would be precluded"
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease, Has allergies to humanized monoclonal antibodies
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease," Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis)"
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease, Has a history of chronic alcohol or drug abuse/dependence
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease, Is clinically judged by the investigator to be at serious risk for suicide
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease, Has a recent (within 6 months before screening) or current laboratory result (if available) indicating a clinically significant laboratory abnormality
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease," Has Electrocardiogram (ECG) abnormalities obtained at screening that, in the opinion of the investigator, are clinically significant with regard to the subject's participation in the study. Bazett's corrected QT [QTcB] interval must be evaluated and must not exceed greater than 458 msec in males or greater than 474 msec in females"
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease," At screening, has alanine transaminase (ALT/SGPT) values greater than or equal to 2 times the upper limit of normal (ULN) of the performing laboratory, aspartate transaminase (AST/SGOT) values greater than or equal to 3 times the ULN, or total bilirubin values greater than or equal to 2 times the ULN"
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease, Has had IgG therapy (sometimes called gamma globulin therapy) within the last year or previous participation in any other study investigating active immunization against A
NCT01148498,Phase 2,Alzheimer's Disease,Eli Lilly and Company,Aug-10,Alzheimer Disease, Requires treatment with other monoclonal antibodies
NCT01152216,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Apr-10,Alzheimer Disease, Other causes of dementia
NCT01152216,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Apr-10,Alzheimer Disease, Major structural brain disease
NCT01152216,Phase 3,Alzheimer's Disease,"Medivation, Inc.",Apr-10,Alzheimer Disease, Unstable medical condition or significant hepatic or renal disease
NCT01172145,Phase 3,Alzheimer's Disease,Brown University,Jul-05,Alzheimer Disease;Modafinil, diagnosis of Major Depression
NCT01172145,Phase 3,Alzheimer's Disease,Brown University,Jul-05,Alzheimer Disease;Modafinil, focal brain lesion on neuroimaging
NCT01172145,Phase 3,Alzheimer's Disease,Brown University,Jul-05,Alzheimer Disease;Modafinil, history of significant substance abuse
NCT01172145,Phase 3,Alzheimer's Disease,Brown University,Jul-05,Alzheimer Disease;Modafinil, history of significant head trauma with loss if consciousness greater than 10 minutes
NCT01183806,Phase 3,Alzheimer Disease,Federal University of Bahia,Jul-10,Alzheimer Disease;Rivastigmine, Mini-Mental State Examination (MMSE) score of less than 12
NCT01183806,Phase 3,Alzheimer Disease,Federal University of Bahia,Jul-10,Alzheimer Disease;Rivastigmine, Can't follow simple commands;
NCT01183806,Phase 3,Alzheimer Disease,Federal University of Bahia,Jul-10,Alzheimer Disease;Rivastigmine, Can't answer two or more items of Quality of life questionnaire
NCT01183806,Phase 3,Alzheimer Disease,Federal University of Bahia,Jul-10,Alzheimer Disease;Rivastigmine, Practiced regular exercise or physiotherapy/ occupational therapy in the last two months.
NCT01183806,Phase 3,Alzheimer Disease,Federal University of Bahia,Jul-10,Alzheimer Disease;Rivastigmine, Diagnosed psychiatric condition (including depression).
NCT01183806,Phase 3,Alzheimer Disease,Federal University of Bahia,Jul-10,Alzheimer Disease;Rivastigmine, Use of neuroleptic drugs
NCT01183806,Phase 3,Alzheimer Disease,Federal University of Bahia,Jul-10,Alzheimer Disease;Rivastigmine," Orthopedic, neurologic, or behavioral limitations that may preclude exercise training"
NCT01183806,Phase 3,Alzheimer Disease,Federal University of Bahia,Jul-10,Alzheimer Disease;Rivastigmine, Visual or hearing impairment that may preclude exercise training or comprehension
NCT01202994,Phase 2,Alzheimer's Disease,University of Utah,May-11,Alzheimer Disease;Flutemetamol," History of neurological disease known to affect cognition (e.g., stroke, head injury with loss of consciousness of greater than 30 minutes, seizure disorder, demyelinating disorder, mental retardation, etc.)"
NCT01202994,Phase 2,Alzheimer's Disease,University of Utah,May-11,Alzheimer Disease;Flutemetamol, Dementia based on DSM-IV criteria
NCT01202994,Phase 2,Alzheimer's Disease,University of Utah,May-11,Alzheimer Disease;Flutemetamol," Current or past major psychiatric illness (e.g., schizophrenia, bipolar affective disorder)"
NCT01202994,Phase 2,Alzheimer's Disease,University of Utah,May-11,Alzheimer Disease;Flutemetamol, 30-item Geriatric Depression Score greater than 14
NCT01202994,Phase 2,Alzheimer's Disease,University of Utah,May-11,Alzheimer Disease;Flutemetamol, Evidence of stroke or mass lesion on CT or MRI scan
NCT01202994,Phase 2,Alzheimer's Disease,University of Utah,May-11,Alzheimer Disease;Flutemetamol, History of alcoholism or other substance abuse
NCT01202994,Phase 2,Alzheimer's Disease,University of Utah,May-11,Alzheimer Disease;Flutemetamol," Current use of cholinesterase inhibitors, other cognitive enhancers, antipsychotics, or anticonvulsant medications"
NCT01202994,Phase 2,Alzheimer's Disease,University of Utah,May-11,Alzheimer Disease;Flutemetamol, History of radiation therapy to the brain
NCT01202994,Phase 2,Alzheimer's Disease,University of Utah,May-11,Alzheimer Disease;Flutemetamol," History of significant major medical illnesses, such as cancer or AIDS"
NCT01202994,Phase 2,Alzheimer's Disease,University of Utah,May-11,Alzheimer Disease;Flutemetamol, Uncontrolled diabetes or blood glucose greater than 180 mg/dl on the day of the FDG-PET scan
NCT01202994,Phase 2,Alzheimer's Disease,University of Utah,May-11,Alzheimer Disease;Flutemetamol, Currently pregnant
NCT01211782,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Presence of other CNS disorders as alternative causes of dementia
NCT01211782,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Type 1 or Type 2 diabetes
NCT01211782,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease, Significant renal/hepatic disease
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Other prior or current neurologic or medical disorder which may currently or during the course of the study impair cognition or psychiatric functioning
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, A history of stroke
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, A documented history of transient ischemic attack within the last 12 months
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," History of schizophrenia, schizoaffective or bipolar disorder"
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Currently meets criteria for major depression
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Within the last 2 years, unstable or clinical significant cardiovascular disease (myocardial infarction, angina pectoris)"
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Additional exclusion criteria for sub study:
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Inclusion in a research and/or medical protocol involving PET ligands or other radioactive agents within 12 months
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Present or planned participation in a research and/or medical protocol involving PET ligands or radioactive agents other than study WN25203
NCT01224106,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Have planned or are planning to have exposure to ionizing radiation that in combination with the planned administration with study amyloid PET ligand would result in a cumulative exposure that exceeds local recommended exposure limits
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction,Pregnant or becoming pregnant during the study (as documented by pregnancy testing at screening or at any date during the study according to the PI discretion) or current breast feeding.
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction,Modified Hachinski ischemic score of greater than 4 or those who meet the NINDS-AIREN criteria for vascular dementia.
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction,"Any subject who has a clinically significant abnormal laboratory values, and/or clinically significant or unstable medical or psychiatric illness."
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction," Clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances, especially thyroid disease;"
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction, Current clinically significant cardiovascular disease. Clinically significant cardiovascular disease usually includes one or more of the following:
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction, cardiac surgery or myocardial infarction within the last 6 months;
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction, unstable angina
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction, coronary artery disease that required a change in medication within the last 3 months
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction, decompensated congestive heart failure
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction," significant cardiac arrhythmia or conduction disturbance, particularly those resulting in atrial or ventricular fibrillation, or causing syncope, near syncope, or other alterations in mental status"
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction, severe mitral or aortic valvular disease
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction, uncontrolled high blood pressure
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction, congenital heart disease
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction," clinically significant abnormal result on ECG, including but not limited to QTcgreater than 450 msec iii. Clinically significant infectious disease, including AIDS or HIV infection or active hepatitis B, active hepatitis C, HIV-1, or HIV-2"
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction,"History of drug or alcohol abuse within the last year, or prior prolonged history of abuse."
NCT01238458,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,Nov-09,Alzheimer Disease;Cognitive Dysfunction,"Patients who have the evidence of neurodegenerative disorders other than AD, cognitive impairment resulting from trauma or brain damage, brain infarction, clinically significant psychiatric disease, epilepsy, are excluded."
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,"Subjects with psychiatric disorders other than Alzheimer's disease, such as schizophrenia, depression, bipolar disorder, etc"
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,"Subjects diagnosed or accompanied with Dementia due to other Neurodegenerative disorders (AIDS, syphilis, creutzfeldt-jacob disease, Picks Disease, Huntingtons Disease, Parkinsons disease related dementia)"
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects diagnosed with vascular dementia
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects diagnosed with stroke within last 3 months prior to screening visit
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,"Subjects who have medical history of significant hepatic disease in screening visit (2 ULNALT, AST)"
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects who have medical history of significant renal disease in screening visit (1.5mg/dlSerum creatinine)
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects who have difficult with regulating blood glucose level with anti-diabetes drug (8.0%less than HbA1c)
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects who have medical history of myocardial infarction or arrhythmia
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects who take warfarin with Atrial fibrillation
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Pregnant or nursing women
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects who p0articipated in other clinical trail within last 3 months
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects who have hypersensitivity to AchEl (acetylcholinesterase inhibitor)
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects who have unstable clinical laboratory result in screening visit
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects doubted the pulmonary disease on the chest X-ray in screening visit
NCT01245530,Phase 3,Alzheimer Type Dementia,Whanin Pharmaceutical Company,Jun-08,Dementia;Alzheimer Disease;Donepezil,Subjects considered unsuitable to participate in clinical trail by investigator
NCT01249196,Phase 3,Alzheimer's Disease,"SK Chemicals Co., Ltd.",May-10,Alzheimer Disease, Other central nervous disease
NCT01249196,Phase 3,Alzheimer's Disease,"SK Chemicals Co., Ltd.",May-10,Alzheimer Disease," Hypothyroidism, Vitamin B12/ Folic acid deficiency, Hypercalcemia, Neurosyphilis, AIDS"
NCT01249196,Phase 3,Alzheimer's Disease,"SK Chemicals Co., Ltd.",May-10,Alzheimer Disease, T.I.A or Major infarction within the last 12 months
NCT01249196,Phase 3,Alzheimer's Disease,"SK Chemicals Co., Ltd.",May-10,Alzheimer Disease, Any serious disorder that could limit the ability of the patient to participate in the study
NCT01249196,Phase 3,Alzheimer's Disease,"SK Chemicals Co., Ltd.",May-10,Alzheimer Disease, COPD or asthma
NCT01249196,Phase 3,Alzheimer's Disease,"SK Chemicals Co., Ltd.",May-10,Alzheimer Disease," Any condition which would make the patient or the caregiver, in the opinion of the investigator, unsuitable for the study"
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease, Significant neurological disease other than AD
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease, Major psychiatric disorder
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease, Significant systemic illness
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease," History of stroke or seizure, autoimmune disease, myocardial infarction within the last 2 years"
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease, Smoking greater than 20 cigarettes per day
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease," Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications"
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease, Prior treatment experimental immunotherapeutics or vaccines for AD
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease, Women of childbearing potential
NCT01254773,Phase 2,Alzheimer's Disease,"JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC",Dec-10,Alzheimer Disease," Presence of pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body"
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil, Brain image (computed tomography (CT) scan or Magnetic Resonance Imaging (MRI) done within past 12 months prior to the study) and laboratory tests to exclude secondary dementia or non-Alzheimer's dementia;
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil," Patient with significant clinically central nervous system illness other than AD (e.g. Parkinson's disease, Human Immunodeficiency Virus (HIV) induced dementia, Hachinski Ischaemic Score (HIS) greater than 4) or dementia complicated by other organic disease or delirium;"
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil," Patient with a severe or uncontrolled Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I disorder other than Alzheimer's disease, including amnestic disorders, schizophrenia or schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, or post-traumatic stress disorder;"
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil, Patient suffering from cerebral disturbances following a stroke or a cerebral trauma (if the event occurred within the last 6 months);
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil, Patient with a history of hypersensitivity to study drugs;
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil," Patient who has a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine (e.g., Addison's Disease), immune, neurologic, or hematologic disease as determined by the clinical judgment of the investigator;"
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil, Participation in any research study within the last 30 days;
NCT01255046,Phase 2,Alzheimer Disease,"Sinphar Pharmaceutical Co., Ltd",Dec-15,Alzheimer Disease;Donepezil, Patient with significant alcohol or drug abuse as judged by the investigator.
NCT01276353,Phase 2,Alzheimer's Type Dementia,Eisai Inc.,Jan-11,Dementia;Alzheimer Disease;Donepezil, Subjects with dementia other than Alzheimer's type
NCT01276353,Phase 2,Alzheimer's Type Dementia,Eisai Inc.,Jan-11,Dementia;Alzheimer Disease;Donepezil," Subjects with significant neurological or psychiatric disorders such as stroke, brain tumor, schizophrenia, epilepsy, normal pressure hydrocephalus, mental retardation, a history of head injury with loss of consciousness, or a history of brain surgery followed by persistent deficits"
NCT01276353,Phase 2,Alzheimer's Type Dementia,Eisai Inc.,Jan-11,Dementia;Alzheimer Disease;Donepezil, Subjects with allergy to donepezil hydrochloride or piperidine derivatives
NCT01276353,Phase 2,Alzheimer's Type Dementia,Eisai Inc.,Jan-11,Dementia;Alzheimer Disease;Donepezil," Subjects with a cause of Alzheimer's disease (AD) which is supported by any laboratory tests such as Vitamin B12, folate levels, triiodothyronine, free triiodothyronine, thyroxine, thyroid stimulating hormone (TSH) or serologic test for syphilis"
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,"Proven or clinically suspected other type of dementia such as vascular dementia, mechanic or chemical caused dementia, vitamin B12 deficiency, hypothyroidism etc."
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Epileptic Patient
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Severe liver or renal disease
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Resting pulse less than 50
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Mechanical intestinal obstruction patient
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,History of stroke
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,"History of angina or other severe cardiac, vascular, lung, gastrointestinal and hematopoietic system disease"
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Cognitive damage caused by alcohol or substance abuse
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Disable to participate or cooperate in the protocol
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Use of any agent for the treatment of dementia within 2 weeks of randomization
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Use of another investigational agent within 3 months of screening
NCT01282619,Phase 2/Phase 3,Alzheimer's Disease,"Shandong Luye Pharmaceutical Co., Ltd.",May-10,Alzheimer Disease;Huperzine A,Be sensitive to Huperzine A or other ACHEIs.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, Diagnosis of Alzheimer's disease according to the (DSM-IV-TR) or NINCDS-ADRDA criteria.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, Any medical condition that could explain the patients cognitive deficits.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen," CT or MRI brain imaging results obtained within 12 months prior to baseline showing evidence of infection, infarction, or focal lesions of clinical significance"
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, MRI scan at screening showing more than 4 cerebral microhemorrhages (lesions with diameter  10 mm).
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, Geriatric Depression Scale (30-point scale) score greater than  9 at screening.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, History of stroke.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, Modified Hachinski ischemic scale score greater than  4 at screening.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, Women of childbearing potential.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, Vitamin B12 or folate deficiency.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, Diagnosis of schizophrenia or recurrent mood disorder (including unipolar and bipolar disorders) within 3 years of screening.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, Current diagnosis of peptic ulcer or gastrointestinal bleeding within the last year and/or chronic inflammatory bowel disease.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, Concomitant use of donepezil at doses greater than  5 mg/day or other cholinesterase inhibitors (rivastigmine or galantamine) at any dose.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen, Concomitant use of memantine at dose greater than  20 mg/day.
NCT01303744,Phase 2,Alzheimer's Disease,CERESPIR,Mar-11,Alzheimer Disease;Flurbiprofen," Concomitant use of psychoactive drugs (sedatives, hypnotics, etc)."
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Other types of dementias
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Modified Hachinski Ischemia Score greater than  4
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease," Use of memantine, antipsychotics, anticholinergic medication and benzodiazepines (at a max of 3 nights/week) within 2 months"
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Changes in antidepressant dosing within 2 months
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Use of other psychotropic agents
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Myocardial infarction within the past 2 years
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Malignancy within the past 5 years
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease," Suicidal ideation, risk of suicide"
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, History of alcoholism or drug abuse within 5 years
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease," Clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness"
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Specific findings in brain imaging
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease," Abnormal findings in heart rate, blood pressure, ECG, laboratory tests, physical examination; orthostatic hypotension"
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Blood donation or participation in a drug study within 60 days
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Previous AD immunotherapy treatment
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Patient cannot complete the computerised cognitive training
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Patients who reside in a skilled nursing facility
NCT01324518,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease, Patients who are not able to swallow capsules
NCT01343966,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal"," Severe or unstable medical condition that, in the opinion of the investigator or Sponsor, would interfere with the patient's ability to complete the study assessments or would require the equivalent of institutional or hospital care"
NCT01343966,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal", History or presence of clinically evident vascular disease potentially affecting the brain
NCT01343966,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal"," History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system trauma"
NCT01343966,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal", Hospitalization within 4 weeks prior to screening
NCT01343966,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal", Previous treatment with MABT5102A or any other therapeutic that targets Abeta
NCT01343966,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal"," Treatment with any biologic therapy within 5 half-lives or 3 months prior to screening, whichever is longer, with the exception of routinely recommended vaccinations, which are allowed"
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,"Diagnosis of diabetes, including use of anti-diabetic medications, or fasting plasma glucose greater than 125 mg/dl or Hemoglobin A1cgreater than 6.4%."
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,"Unable to participate in FDG-PET scanning, including:"
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease, Inability to cooperate/claustrophobia (no sedation offered for this protocol).
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease, Inability to lie still on the scanner bed for 40 minutes.
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease, Total radiation dose exposure to the subject in any given year exceeds the limits of annual and total dose commitment of 50 mSv (5 REMs). The two FDG-PET scans will result in an approximate exposure of 10 mSv (1 REM).
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,"Diagnosis of significant neurological/psychiatric disease other than AD, including, but not limited to, any of the following: vascular dementia according to NINDS-AIREN criteria, space occupying cerebral lesion, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, and seizures."
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,History of heart failure (including CHF).
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,"Previous cardiovascular event (myocardial infarct, by-pass surgery, or PTCA) within the past 6 months prior to screening."
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,"Inability to undergo a clinical (1.5T) MRI of the brain without contrast and lack of a usable (less the 12 months prior to screening) MRI on record. Contraindications to undergoing an MRI of the brain include, but are not limited to, pacemakers; implantable cardioverter defibrillators; cochlear implants; cerebral aneurysm clips; implanted infusion pumps; implanted nerve stimulators; metallic splinters in the eye; and, other magnetic, electronic or mechanical implants or clinical findings that in the judgment of the investigator would pose a potential hazard in combination with MRI."
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,ALT and/or AST levels that are twice the upper limit of normal; bilirubin levels that exceed 2 mg/dL; serum creatinine greater than 1.5 mg/dL in men or greater than  1.4 mg/dL in women.
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,Current or history of severe or unstable disorder (medical or psychiatric) requiring treatment that may make the subject unlikely to complete the study.
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,Malignancy (other than non-melanoma skin cancer) within the last 5 years.
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,"Known history of HIV, hepatitis B, or hepatitis C."
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,Blood pressure greater than 160/100 mmHg. Subjects with elevated BP will be allowed at the discretion of the principal investigator. Individuals with hypertension must have been stabilized to the current treatment regimen for at least 6 weeks prior to screening and not need adjustments to their treatment regimen during the entire study period.
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,Change in other medications to treat Alzheimer's disease within 3 months prior to screening. Change in medication to treat other conditions within 6 weeks prior to screening or during the study period.
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,"Known or suspected intolerance or hypersensitivity to the study drugs, closely related compounds, or any of their stated ingredients."
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,History of alcohol or drug abuse within 6 months of screening.
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,Have participated in an investigational study or received an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to study drug administration.
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,Single 12-lead ECG demonstrating a QTcB greater than 450 msec or other clinically significant finding at screening. A single repeat ECG may be done at the investigator's discretion.
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,"Any surgical or medical condition which may significantly alter the absorption of any drug substance including, but not limited to, any of the following: history of major gastrointestinal tract surgery, currently active inflammatory bowel syndrome."
NCT01374438,Phase 2,Alzheimer's Disease,Metabolic Solutions Development Company,Jul-11,Alzheimer Disease,Evidence of clinically relevant pathology that in the investigator's opinion could interfere with the study results or put the subject's safety at risk.
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole," Significant neurological disease, other than AD, that may affect cognition"
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole, Current clinically-significant systemic illness that is likely to result in deterioration of the patient's condition or affect the patient's safety during the study.
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole, History of clinically-evident stroke
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole, Clinically-significant infection within the last 30 days
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole," Myocardial infarction or symptoms of active coronary artery disease (e.g., angina) in the last two years."
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole, Uncontrolled hypertension within the last 6 months.
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole, History of cancer within the last 5 years (except non-metastatic basal or squamous cell carcinoma)
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole, History of drug or alcohol abuse as defined by DSM-IV criteria within the last 2 years
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole, Insulin dependent diabetes mellitus
NCT01388478,Phase 2,Alzheimer's Disease,Virginia Commonwealth University,Jul-11,Alzheimer Disease;Pramipexole, Significant pain or musculoskeletal disorder that would prohibit participation in metabolic testing
NCT01397578,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal"," Severe or unstable medical condition that, in the opinion of the investigator or Sponsor, would interfere with the patient's ability to complete the study assessments or would require the equivalent of institutional or hospital care"
NCT01397578,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal"," History or presence of clinically evident vascular disease potentially affecting the brain (e.g., stroke, clinically significant carotid or vertebral stenosis or plaque, aortic aneurysm, intracranial aneurysm, cerebral hemorrhage, arteriovenous malformation)"
NCT01397578,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal"," History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system trauma (e.g., cerebral contusion)"
NCT01397578,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal", Hospitalization within 4 weeks prior to screening
NCT01397578,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal", Previous treatment with MABT5102A or any other therapeutic that targets Abeta
NCT01397578,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,"Alzheimer Disease;Antibodies, Monoclonal"," Treatment with any biologic therapy within 5 half-lives or 3 months prior to screening, whichever is longer, with the exception of routinely recommended vaccinations, which are allowed"
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil," Subjects with a known history of disorders that affect cognition or the ability to assess cognition, but are distinguishable from AD"
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil, Evidence of focal disease to account for dementia on any cranial image MRI or CT.
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil, Subjects with dementia complicated by other organic disease or AD with delirium according to DSM-IV criteria
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil," Subjects who cannot swallow or who have difficulty swallowing whole tablets, as tablets should not be broken or crushed"
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil, Illiteracy prior to AD
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil, Subjects who are unwilling or unable to fulfill the requirements of the study
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil, Treatment with another cholinesterase inhibitor and/or memantine in the 3 months prior to Screening
NCT01404169,Phase 3,Alzheimer's Type Dementia,Eisai Limited,unknown,Alzheimer Disease;Dementia;Donepezil, Subjects with a poor response (tolerability) to prior exposure to donepezil
NCT01409694,Phase 3,Alzheimer Disease,"University Hospital, Angers",Sep-11,Alzheimer Disease;Vitamin D;Ergocalciferols;Cholecalciferol;Vitamins;Memantine," The use of standard antidementia drugs (i.e., anticholinesterasics, memantine, or vasodilatators) in the past 60 days"
NCT01409694,Phase 3,Alzheimer Disease,"University Hospital, Angers",Sep-11,Alzheimer Disease;Vitamin D;Ergocalciferols;Cholecalciferol;Vitamins;Memantine, Severe hepatic or renal failure
NCT01409694,Phase 3,Alzheimer Disease,"University Hospital, Angers",Sep-11,Alzheimer Disease;Vitamin D;Ergocalciferols;Cholecalciferol;Vitamins;Memantine," Severe, unstable or poorly controlled medical conditions at the time of the inclusion"
NCT01409694,Phase 3,Alzheimer Disease,"University Hospital, Angers",Sep-11,Alzheimer Disease;Vitamin D;Ergocalciferols;Cholecalciferol;Vitamins;Memantine," Other cognitive disorders (untreated dysthyroid, deficiency in vitamin B9 or B12, chronic ongoing ethylism, history of syphilis, stroke, delirium revealed with the Confusion Assessment Method (CAM), severe depressive symptomatology (Geriatric Depression score  10/15))"
NCT01409694,Phase 3,Alzheimer Disease,"University Hospital, Angers",Sep-11,Alzheimer Disease;Vitamin D;Ergocalciferols;Cholecalciferol;Vitamins;Memantine, Contra-indications to memantine or vitamin D
NCT01409694,Phase 3,Alzheimer Disease,"University Hospital, Angers",Sep-11,Alzheimer Disease;Vitamin D;Ergocalciferols;Cholecalciferol;Vitamins;Memantine, Enrollment in another simultaneous clinical trial
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,clinically relevant arrhythmias;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,a resting pulse less than 50;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,active cancer other than non-melanoma skin cancers;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,use of another investigatory drug within 2 months of screening;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,significant stroke or head trauma by history or MRI;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,contraindication for having a MRI;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,diagnostic and Statistical Manual of Mental Disorders-IV criteria for a current major psychiatric disorder;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,sensitivity to yeast or yeast products;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,impaired kidney function as measured by a Glomerular Filtration Rate less than 60 milliliters/min;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,"preexisting fluid retention, pulmonary infiltrates, or congestive heart failure;"
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,history of moderate-to-severe lung disease;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,history of moderate-to-severe liver disease;
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,"pregnant women, or any women who feel they are likely to become pregnant during the study;"
NCT01409915,Phase 2,Alzheimer's Disease,"University of Colorado, Denver",Mar-11,Alzheimer Disease;Molgramostim;Sargramostim,prisoners.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Diagnosis of Alzheimer's disease according to the (DSM-IV-TR) or NINCDS-ADRDA criteria.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Any medical condition that could explain the patients cognitive deficits.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen," CT or MRI brain imaging results obtained within 12 months prior to baseline showing evidence of infection, infarction, or focal lesions of clinical significance"
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, MRI scan at screening showing more than 4 cerebral microhemorrhages (lesions with diameter  10 mm).
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Geriatric Depression Scale (30-point scale) score greater than  9 at screening.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, History of stroke.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Modified Hachinski ischemic scale score greater than  4 at screening.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Women of childbearing potential.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Vitamin B12 or folate deficiency.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Diagnosis of schizophrenia or recurrent mood disorder (including unipolar and bipolar disorders) within 3 years of screening.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Current diagnosis of peptic ulcer or gastrointestinal bleeding within the last year and/or chronic inflammatory bowel disease.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Concomitant use of donepezil at doses greater than  5 mg/day or other cholinesterase inhibitors (rivastigmine or galantamine) at any dose.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Concomitant use of memantine at dose greater than  20 mg/day.
NCT01421056,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,Jul-11,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen," Concomitant use of psychoactive drugs (sedatives, hypnotics, etc)."
NCT01428362,Phase 2,Alzheimer's Disease,VIVUS LLC,Aug-11,Alzheimer Disease," advanced, severe, progressive or unstable disease"
NCT01428362,Phase 2,Alzheimer's Disease,VIVUS LLC,Aug-11,Alzheimer Disease, history of cerebrovascular disease or myocardial infarction within 6 months
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"History and/or evidence of any other CNS disorder that could be interpreted as a cause of dementia: e.g. structural or developmental abnormality, epilepsy, infectious, degenerative or inflammatory/demyelinating CNS conditions such as, Parkinson's disease and frontotemporal dementia"
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,History of significant psychiatric illness such as schizophrenia or bipolar affective disorder that in the opinion of the Investigator would interfere with participation in the study; major depressive disorder (according to DSM-IV) in the past year; current active depression requiring initiation of treatment (or is believed to account for substantial degree of cognitive impairment)
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Evidence of the following disorders: current vitamin B12 deficiency, positive syphilis serology (unless neurosyphilis was ruled out) or active thyroid dysfunction (particularly suggestive of hypothyroidism), including abnormally high or low serum levels of thyroid stimulating hormone (TSH), where this is thought to be the cause of, or to contribute to the severity of the subject's dementia."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"History of alcohol or other substance abuse, according to the DSM-IV criteria, or recent or remote history of the same if that could be a contributing factor to dementia."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"History of intra cerebral haemorrhage due to any of the following causes: cerebral amyloid angiopathy, uncontrolled hypertension, cerebral arteriovenous malformation, coagulopathy, CNS vasculitis or any other condition that the investigator and/or medical monitor considers as a relevant risk factor for intracerebral haemorrhage"
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Recent (i.e.,less than 6 months from Screening Visit) cardiovascular event defined as:"
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"ST-elevation MI or non-ST-elevation MI, confirmed by cardiac enzyme elevation and ECG changes"
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft )
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,stroke of any etiology
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,resuscitated sudden death
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,prior carotid surgery or stenting procedure
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Poorly controlled hypertension despite lifestyle modifications and pharmacotherapy (either systolic blood pressure greater than 160mmHg or diastolic blood pressure greater than 110mmHg)
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,QTcB interval greater than 450 msec; or QTcB greater than  480 msec in subjects with bundle branch block based on ECG assessment at the Screening visit.
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"HbA1c greater than 12.0 at Screening, or uncontrolled diabetes in the opinion of the investigator."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"History of glaucoma or any other findings in the baseline eye exam that, in the opinion of the investigator, would exclude the subject from participation in the study."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"History of adult asthma (or reactive airway disease) manifested by bronchospasm in the past 6 months, or currently taking regular anti-asthmatic medication(s)."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Previous history of anaphylaxis, severe allergic reaction or history of hypersensitivity to any of the components of the formulation."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Significant abnormalities on clinical chemistry, haematology or urinalysis at Screening, including clinically significant anaemia."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"History of chronic viral hepatitis (including presence of B surface antigen or hepatitis C antibody), or other chronic hepatic disorders."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Abnormal Screening blood tests exceeding any of the limits defined below:
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Alanine transaminase (ALT) or aspartate transaminase (AST) greater than 1.5 x the upper limit of normal (ULN)
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Alkaline phosphatase (AP) and bilirubin greater than 1.5X ULN (isolated bilirubin greater than 1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35%).
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Calculated creatinine clearance less than  30 ml/min (per Cockcroft  and  Gault) at Screening
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Other clinically significant abnormality on physical (including neurological), laboratory or ECG examination that could be detrimental to the subject in the opinion of the Investigator or could compromise the integrity of the study."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Planned major surgery within the study period.
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Use of systemic steroids or other immunosuppressants within the last 30 days prior to screening.
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Current treatment with barbiturates, MAO inhibitors, butyrophenones, phenothiazines and other  conventional  antipsychotic within 30 days or 5 half-lives prior to Screening, whichever is longer."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Treatment with antidepressants, (other than MAO inhibitors), thyroid hormones, atypical antipsychotics (e.g. risperidone), benzodiazepines and other sedatives / hypnotics unless prescribed at a stable dose for at least 2 months prior to Screening. Note: Benzodiazepines or other sedatives/hypnotics (including antihistamines) with half-life less than 6 hours can be taken on a prn (as needed) basis but must not be taken within 5 half lives prior to cognitive testing."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Current treatment with known potent inhibitors of CYP3A4 (e.g. ketoconazole, rifampin, modafinil)."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Current treatment with known potent Pgp inhibitors (itraconazole, ketoconazole, cyclosporin, loperamide, diltiazem, verapamil, spironolactone, quinidine, bepridil, quinine, carvedilol)"
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Cognitive tasks prescribed for cognitive rehabilitation and performed under medical supervision in the 6 months prior to screening and/or during study
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Investigational medications or devices including symptomatic AD treatment during the 60 days prior to the Screening visit, or within 5 half-lives of use of the investigational drug prior to the Screening Visit, whichever is longer."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Participation in another investigational drug (with the exception of anti-amyloid monoclonal antibodies [mAbs]) or device study where subject was treated chronically (i.e. greater than  1 single dose) with a study agent intended to impact AD progression during the 12 months prior to the Screening visit.
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Subjects who participated in an investigational drug study that involved chronic dosing with a monoclonal antibody at any time in the past are excluded from this study, unless it is known that they received placebo during the previous study."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Subjects who participated in previous single-dose studies of anti-amyloid mAbs will be permitted provided the subject's dose of the mAb is at least 5 half-lives removed; the subjects did not experience any moderate adverse events classified as possibly drug-related or any serious adverse event during that study; the subject did not drop out of the previous study (i.e. completed all safety assessments)
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Subjects, who in the investigator's judgement, pose a significant suicide risk (e.g. history of suicidal behaviour in the last 6 months and/or any suicidal ideation of type 4 or 5 on the C-SSRS in the last 2 months)."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Subject or caregiver is an immediate family member or employee of the participating Investigator, any of the participating site staff or GSK staff."
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,"Any contraindication to lumbar puncture or insertion of CSF catheter, including but not limited to"
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Thrombocytopenia or other coagulation disorders (including subjects receiving coumarin-derived anti-coagulants or low-molecular-weight heparin).
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,The presence of cutaneous or soft tissue infection overlying or adjacent to the site of lumbar puncture.
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Previous spinal surgery that could complicate access to the subarachnoid space.
NCT01428453,Phase 2,Alzheimer's Disease,GlaxoSmithKline,1-Oct-11,Alzheimer Disease,Suspicion of increased intracranial pressure due to a cerebral mass.
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine," Medical history and/or clinically determined evidence of other central nervous system (CNS) disorders including brain tumor, active subdural hematoma, seizure disorder, multiple sclerosis dementia with Lewy bodies, vascular dementia, corticobasal syndrome, progressive supranuclear palsy, Parkinson's disease, multiple system atrophy, frontotemporal dementia, normal pressure hydrocephalus, Huntington's disease, or Jakob-Creutzfeldt disease presenting as dementia."
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine," Personal medical history and/or clinically determined disorders: current B12 deficiency, positive syphilis serology, chronic sinusitis or any untreated thyroid disease, significant head trauma, or history of difficulty with smell and/or taste prior to AD diagnosis."
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine," Diagnosis with any form of diabetes mellitus, actively takes insulin, or has HbA1c greater than  6.1 % at screening."
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine," Personal history of any of the following: moderate to severe pulmonary disease, congestive heart failure, significant cardiovascular and/or cerebrovascular events in previous 6 months, condition known to affect absorption, distribution, metabolism, or excretion of drugs such as any hepatic, renal or gastrointestinal disease or any other clinically relevant abnormality that inclusion would pose a safety risk to the subject as determined by Investigator."
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, Heavy smoker (defined as smoking half a pack or more per day in the last 10 years prior to entry in the study).
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine," Personal history of any psychiatric illness, except major depressive disorder (according to Diagnostic and Statistical Manual (DSM)-IV TR) currently in remission or stable with treatment for greater than  2 years, or any other psychiatric condition that inclusion would pose a safety risk to the subject as determined by Investigator. Patients with active depression (Geriatric Depression Scoregreater than 9) are excluded from the study."
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine," Currently taking any medications, herbals and food supplements that are determined by Investigator to interfere with procedural testing of cognitive function as well as ensure study safety."
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine," Recent change (less than  1 months) in prescribed acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) or memantine."
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, Current or recent drug or alcohol abuse or dependence defined by DSM-IV TR.
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, Systolic blood pressure greater than  160 or less than  90 mmHg or diastolic blood pressure greater than  100 or less than  60 mmHg at Screening.
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, Screening laboratory results that are medically relevant and which would pose a safety risk to the subject as determined by Investigator.
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, Participation in any other research study at least 3 months prior to this study.
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, Insulin allergy.
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, History of significant traumatic brain injury
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, History of acute and chronic rhinitis and/or sinusitis.
NCT01436045,Phase 2,Alzheimer's Disease,HealthPartners Institute,Sep-11,Alzheimer Disease;Insulin glulisine, Legally unable to provide informed written consent due to deterioration in cognitive abilities.
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, Patients with an Axis I (DSM IV) diagnosis of:
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, delirium
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, amnestic disorders
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, bipolar disorder
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, schizophrenia or schizoaffective disorder
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, mood disorder with psychotic features
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, Patients with reversible causes of dementia
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, Patients with psychotic symptoms continuously present since prior to the onset of the symptoms of dementia
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, Patients with psychotic symptoms that are better accounted for by another general medical condition or by direct physiological effects of a substance
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, Patients with a current major depressive episode with psychotic symptoms of hallucinations or delusions
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, Patients with a diagnosis of dementia related to infection with the human immunodeficiency virus
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, Patients with substance-induced persistent dementia
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole," Patients with dementia due to vascular causes, multi-infarct, head trauma, Pick's disease, Parkinson's disease, frontal or temporal dementia, Lewy body dementia, or any specific non-Alzheimer's type dementia"
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, Patients with seizure disorders
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole," Patients who have been refractory to neuroleptics used to treat psychotic symptoms in the past when treated for an adequate period with a therapeutic dose, unless permission is obtained from Bristol-Myers Squibb"
NCT01438060,Phase 3,"Dementia, Alzheimer Type","Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Aug-00,Dementia;Alzheimer Disease;Aripiprazole, Patients who have met DSM-IV criteria for any significant substance use disorder within the 6 months prior to the start of screening
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin, Significant Psychiatric disorder;
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin," stroke; current use of any of the test medications (e.g., statin, L-Arginine, Kuvan);"
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin, phenylketonuria (PKU) ;
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin, elevated serum phenylalanine level (greater than 10 mg/dL);
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin, allergy to any of the medications; current active malignancy;
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin, renal insufficiency (elevated creatinine above 1.3mg/dl);
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin, abnormal liver function (Alanine Aminotransferase (ALT) or Aspartate Transaminase (AST) 2x normal);
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin," other serious disease including coronary insufficiency or congestive heart failure, carotid stenosis greater than 50%, active peptic ulcer, urinary tract or other active infection, cancer (except skin cancer, or 5 years inactive breast or prostate cancer )etc.;"
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin, pregnancy; or
NCT01439555,Phase 2,Alzheimer's Disease,"University of Massachusetts, Worcester",Nov-11,Alzheimer Disease;Simvastatin," inability to come to UMass for follow-up. Subjects may continue to take anticholinesterase drugs for Alzheimer's Disease (Aricept, Exelon, Razadyne) and/or Namenda, if they have been on the drug(s) for at least 3 months. Subjects on levodopa and male subjects taking drugs for erectile dysfunction (Viagra, Cialis, Levitra) are cautioned regarding hypotension."
NCT01463384,Phase 2,Alzheimer's Disease,Huntington Medical Research Institutes,Sep-11,Alzheimer Disease;Cognitive Dysfunction;Minocycline;Tetracycline, Any person with medical devices such as cardiac pacemakers/defibrillators or neuro-implants as they are contra-indications for MRI/MRS exam.
NCT01463384,Phase 2,Alzheimer's Disease,Huntington Medical Research Institutes,Sep-11,Alzheimer Disease;Cognitive Dysfunction;Minocycline;Tetracycline," Since the effects of MRI are unknown to the fetus or unborn child, any person who is or may be pregnant will be excluded from the study."
NCT01463384,Phase 2,Alzheimer's Disease,Huntington Medical Research Institutes,Sep-11,Alzheimer Disease;Cognitive Dysfunction;Minocycline;Tetracycline, History of known allergy or intolerance to minocycline or any other tetracycline
NCT01463384,Phase 2,Alzheimer's Disease,Huntington Medical Research Institutes,Sep-11,Alzheimer Disease;Cognitive Dysfunction;Minocycline;Tetracycline," Impaired renal function (plasma Creatinine) or blood urea nitrogen (BUN) levels exceeds twice normal upper limit which can result in higher serum levels of tetracycline, azotemia, hyperphosphatemia and acidosis."
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,Diagnosis or presence of other dementing illnesses
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,"Use of mood stabilizers, antidepressants, anxiolytics, antipsychotics or hypnotics"
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,Treatment within 1 month prior to Screening using cognition-affecting agents (e.g. CNS stimulants)
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,Tobacco user within 4 months prior to Screening
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,Use of smoking cessation therapy within 4 months prior to Screening
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,History within past 6 months of alcohol abuse or illicit drug abuse
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,"Unable, even with caregiver assistance, to comply with study procedures in opinion of investigator"
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,Myocardial infarction within the 12 months prior to Screening
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,"Hypothyroidism, vitamin B12 or folic acid deficiency"
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,"Known systemic infection (HBV, HCV, HIV, TB)"
NCT01466088,Phase 2,Alzheimer's Disease,Targacept Inc.,Oct-11,Alzheimer Disease;Dementia;Donepezil,"Vascular dementia per NINDS-AIRENS criteria and as defined by a modified Hachinski ischemia score (HIS, Appendix 4) score of greater than  4 (i.e., vascular dementia is consistent with a modified HIS greater than  4)."
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, Non-AD dementia.
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, Probable AD with Down syndrome.
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, History of clinically significant stroke.
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol," Current evidence or history in past two years of epilepsy, focal brain lesion, head injury with loss of consciousness or DSM-IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse."
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, Sensory impairment that would preclude the participant from participating in or cooperating with the protocol.
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, Use of investigational agent within two months of Screening.
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol," Evidence of any significant clinical disorder or laboratory finding that renders the participant unsuitable for receiving an investigational drug including clinically significant or unstable hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, metabolic, renal or other systemic disease or laboratory abnormality."
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol," Active neoplastic disease, history of cancer five years prior to screening, including breast cancer (history or skin melanoma or stable prostate cancer are not excluded)."
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, History of seizure within past five years.
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, Pregnancy or possible pregnancy.
NCT01504854,Phase 2,Alzheimer's Disease,Alzheimer's Disease Cooperative Study (ADCS),May-12,Alzheimer Disease;Resveratrol, Use of resveratrol containing supplements.
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," current drug or alcohol dependence (excluding caffeine), based on self-report, including subjects who have been in a drug rehabilitation program"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, current smoker or a history of using tobacco products within 3 months prior to Screening
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," clinically significant abnormalities on physical examination, medical history, 12-lead ECG (i.e., QTc greater than  440 for male subjects and greater than  450 for female subjects), vital signs, or laboratory values, as judged by the investigator or designee"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," history or presence of any clinically significant illness (e.g., cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, musculoskeletal, or psychiatric) or any other condition, which in the opinion of the investigator would jeopardize the safety of the subject or the validity of the study results"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," use of a non-prescription drug within 7 days prior to the first drug administration. Subjects who have taken over-the-counter medication may still be entered into the study, if in the opinion of the investigator or designee, the medication received will not interfere with the study procedures or data integrity or compromise the safety of the subject"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," use of any prescription medications, recreational drugs, or natural health products (except vitamin or mineral supplements, acceptable forms of birth control, and hormone replacement) within 14 days prior to first drug administration or throughout the study, unless in the opinion of the investigator or designee, the product will not interfere with the study procedures or data integrity or compromise the safety of the subject"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, positive urine drug screen
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," positive breath alcohol test. If a subject presents with positive breath alcohol test, the subject may be rescheduled at the discretion of the investigator or designee"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, female subjects who are currently pregnant or lactating or who are planning to become pregnant within 60 days of last study drug administration
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," history of allergy or hypersensitivity to mastic or related drugs (e.g., mastic gum, mastic resin, Chios mastic powder, retsina wine, Mastic Gum 500, Mastic Gum Elma 50, Nutricology Mastic Gum)"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, history of allergy or hypersensitivity to cottonseed oil
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," positive for Hepatitis B, Hepatitis C, or HIV"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, current or pending legal charges or currently on probation
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, treatment with any investigational drug within 30 days prior to first drug administration in the treatment phase
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," a subject who, in the opinion of the investigator or designee, is not considered to be suitable and is unlikely to comply with the study protocol for any reason"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, For PART C (subjects with Alzheimer's Disease)
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," diagnosis or history of other dementia or neurodegenerative disorders causing cognitive impairment (e.g., Parkinson's disease, Lewy body disease, Fronto-temporal Dementia, alcohol and drug abuse, Traumatic Brain Injury)."
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," subjects receiving immunosuppressants, tricyclic anti-depressants, anticoagulants, or chemotherapeutic agents"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," hypertension not adequately controlled, per investigator's judgment"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," poorly controlled Type 1 and/or Type 2 diabetes, per investigator's judgment"
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease, women of child bearing potential who are not using an effective method of birth control
NCT01513967,Phase 1/Phase 2,Moderate to Severe Alzheimer Patients,Regenera Pharma Ltd,Jan-12,Alzheimer Disease," any other medical condition or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or that may interfere with the interpretation of study results, and that, in the judgment of the investigator, would make the subject inappropriate for entry into this study."
NCT01527916,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Feb-12,Alzheimer Disease;Donepezil," The subject is currently taking or has taken a medication for the treatment of Alzheimer's disease or dementia within 60 days prior to Screening Visit 1, or is participating in cognitive therapy for the treatment of Alzheimer's disease or dementia."
NCT01527916,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Feb-12,Alzheimer Disease;Donepezil, The subject has clinically significant abnormal laboratory values at Screening Visit 1 as determined by the investigator.
NCT01527916,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Feb-12,Alzheimer Disease;Donepezil," The subject has a history of any significant neurologic disease other than Alzheimer's disease including Parkinson's disease, multi-infarct or vascular dementia, Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy, multiple sclerosis, any seizures, mental retardation or a history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities."
NCT01527916,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Feb-12,Alzheimer Disease;Donepezil," In the opinion of the investigator, the subject has any clinically significant uncontrolled medical or psychiatric illness."
NCT01527916,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Feb-12,Alzheimer Disease;Donepezil, The subject has a known hypersensitivity or intolerance to donepezil that lead to discontinuation or a known reported history of donepezil treatment failure.
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil, Subjects with a known history of disorders that affect cognition or the ability to assess cognition but are distinguishable from AD
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil, Subjects with dementia complicated by other organic disease or AD with delirium
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil," Known hypersensitivity to donepezil or piperidine derivatives, or to any of the excipients in the study drug formulation"
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil, Patients who are expected to live in a nursing home within 24 weeks after randomization (eligible if temporary)
NCT01539031,Phase 3,Alzheimer's Type Dementia,"Eisai Co., Ltd.",Mar-12,Alzheimer Disease;Dementia;Donepezil," Use of any prohibited prior or concomitant medications. Memantine will be allowed if taken at prescribed doses that are less than or equal to 20 mg/day, provided that the dose has been stable for at least 6 months prior to Screening."
NCT01548287,Phase 2,Mild Alzheimer's Disease,AstraZeneca,Apr-12,Alzheimer Disease;Cognitive Dysfunction, Significant neurological disease or dementia other than AD or MCI.
NCT01548287,Phase 2,Mild Alzheimer's Disease,AstraZeneca,Apr-12,Alzheimer Disease;Cognitive Dysfunction, Current episode or symptoms of major depressive disorder or other major psychiatric disorder.
NCT01548287,Phase 2,Mild Alzheimer's Disease,AstraZeneca,Apr-12,Alzheimer Disease;Cognitive Dysfunction, History of self-reported sleep duration of less than 4 hours per night or less than 4 hours average total sleep time per night during Baseline PSG assessment.
NCT01548287,Phase 2,Mild Alzheimer's Disease,AstraZeneca,Apr-12,Alzheimer Disease;Cognitive Dysfunction, History or present symptoms of a sleeping disorder such as sleep apnea.
NCT01548287,Phase 2,Mild Alzheimer's Disease,AstraZeneca,Apr-12,Alzheimer Disease;Cognitive Dysfunction, History of cancer in the last 5 years.
NCT01548287,Phase 2,Mild Alzheimer's Disease,AstraZeneca,Apr-12,Alzheimer Disease;Cognitive Dysfunction," Use of anti-AD drugs (including off-label drugs and herbal medications) with the exception of donepezil, memantine, and/or rivastigmine transdermal system, as monotherapy or in combination in the following conditions: treatment with donepezil (5 mg to 10 mg daily), memantine, and/or rivastigmine transdermal system or combination regimens for at least 3 months and a stable dose(s) for the last 2 months prior to randomization is allowed."
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease, The subject has taken galantamine or memantine within 60 days prior to Screening Visit 1.
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease, The subject has received excluded concomitant medications.
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease, The subject has clinically significant abnormal laboratory values at Screening Visit 1 as determined by the investigator.
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease," The subject has a history of any significant neurologic disease other than Alzheimer's disease including Parkinson's disease, multi-infarct or vascular dementia, Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy, multiple sclerosis, any seizures, mental retardation or a history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities."
NCT01549834,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Mar-12,Alzheimer Disease," In the opinion of the investigator, the subject has any clinically significant uncontrolled medical or psychiatric illness."
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Dementia not due to probable Alzheimer's disease
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin," Pregnancy, breastfeeding. The rationale is that retinoids are teratogenic and are excreted in breast milk."
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, History of clinically significant stroke
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Modified Hachinski Ischemia score  4
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin," Current evidence or history in past two years of epilepsy, seizure, focal brain lesion, head injury with loss of consciousness or DSM IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, severe alcohol or substance abuse."
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Sensory impairment which would prevent subject from participating in or cooperating with the protocol.
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Use of another investigational agent within two months.
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin," Evidence of any significant clinical disorder or laboratory finding that renders the participant unsuitable for receiving an investigational new drug including clinically significant or unstable hematologic, hepatic, cardiovascular (including history of ventricular fibrillation or ventricular tachycardia), pulmonary, gastrointestinal, endocrine, metabolic, renal, or other systemic disease or laboratory abnormality. Abnormal liver function test, including AST, ALT, total bilirubin, or prothrombin time. The rationale is that retinoids can be hepatotoxic."
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin," Participants receiving behavioral medications (including antidepressants, antipsychotics and anxiolytics) must be on stable doses for at least 4 weeks prior to randomization."
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Active neoplastic disease and any medical conditions requiring concurrent immunosuppression.
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin," Hypertriglyceridemia greater than 500 mg/dL despite statin/fibrate therapy. The rationale is that retinoids can increase lipids, particularly triglyceride and this can lead to pancreatitis."
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin," Any medical conditions requiring concurrent use of tetracycline, minocycline, or doxycycline. The rationale is due to enhanced risk of increased intracranial pressure."
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Hypersensitivity to retinoids.
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin, Presence of psychosis or hallucinations at baseline as determined by Neuropsychiatric inventory or Geriatric Depression Scale-short form greater than or equal to five
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin," Presence of any unstable cardiovascular disease, uncontrolled diabetes, chronic inflammatory or infectious conditions. Retinoids have been associated with chest pain of unclear etiology, increased serum glucose, myelosuppression and increased risk of infection."
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin," Use of Drugs and supplements such as: Vitamin A supplements beyond 100% RDA, other immunosuppressants (corticosteroids, chemotherapeutic agents, etc.), Warfarin , Fish Oil (DHA)"
NCT01560585,Phase 1/Phase 2,Alzheimer's Disease,University Hospitals Cleveland Medical Center,unknown,Alzheimer Disease;Isotretinoin," Any other disease or medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this clinical trial."
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Participant in another drug or device study
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction," Have a history of frontotemporal dementia, Lewy body disease, vascular dementia, Huntington's disease, Parkinson's disease, progressive supranuclear palsy (PSNP), or other movement disorder"
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction," Participants are not on a stable standard of care (acetylcholinesterase inhibitors, memantine) initiated less than 2 months prior to entry or have less than 4 weeks of stable therapy. Note: Stable standard of care is allowed."
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Have had a serious infectious disease affecting the brain in the past 5 years
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Have had a serious or repeat head injury
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Have significant retinal impairment or disease
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Have had a stroke or other circulation problems that are affecting current health
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Have had a seizure
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction," Have major depressive disorder and are not on a stable dose of medication. Participants who no longer meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV) criteria for major depression may be included"
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction," History of schizophrenia, bipolar disorder, or severe mental illness"
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, History of alcohol or drug abuse
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction," Have asthma, chronic obstructive pulmonary disease (COPD), or other breathing disease that is not controlled with medicine"
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Have human immunodeficiency virus (HIV) or syphilis
NCT01561430,Phase 1/Phase 2,Alzheimer's Disease,Eli Lilly and Company,Mar-12,Alzheimer Disease;Cognitive Dysfunction, Are taking blood thinners
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,"Proven or clinically suspected other type of dementia such as vascular dementia, Lewy body dementia, Parkinson's disease, frontotemporal dementia, g - Jakob disease (spastic pseudo-sclerosis), normal pressure hydrocephalus etc."
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,"Sudden onset of early dementia or with gait disorders, seizures and behavioral changes."
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,"Clinical manifestations of focal neurological signs (hemiparesis, sensory loss, visual field defect) or early extrapyramidal tract signs."
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,History of cerebrovascular disease and stroke.
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,"Serious lack of folic acid and VitB12, syphilis antibody positive or thyroid dysfunction."
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,"Mechanical intestinal obstruction patient ,Resting pulse less than 60,Severe liver or renal disease."
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,Patients with mechanical intestinal obstruction.
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,"History of bone marrow transplantation.Mental illness, such as severe depression."
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,Cognitive damage caused by alcohol or drug abuse. Disable to correctly evaluate the cognitive function.
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,"Critical condition, disable to make the exact evaluation of the efficacy and safety of new drug."
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,Use of any agent for the treatment of dementia within 4 weeks of randomization.
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,Be sensitive to ACHEI.
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,Be sensitive to two or more foods/drugs.
NCT01569516,Phase 2,Alzheimer's Disease,"Changchun Huayang High-tech Co., Ltd",Jun-11,Alzheimer Disease,Use of another investigational agent within one months of screening.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Diagnosis of Alzheimer's disease according to the (DSM-IV-TR) or NINCDS-ADRDA criteria.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Any medical condition that could explain the patients cognitive deficits.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen," CT or MRI brain imaging results obtained within 12 months prior to baseline showing evidence of infection, infarction, or focal lesions of clinical significance"
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, MRI scan at screening showing more than 4 cerebral microhemorrhages (lesions with diameter  10 mm).
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Geriatric Depression Scale (30-point scale) score greater than  9 at screening.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, History of stroke.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Modified Hachinski ischemic scale score greater than  4 at screening.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Women of childbearing potential.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Vitamin B12 or folate deficiency.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Diagnosis of schizophrenia or recurrent mood disorder (including unipolar and bipolar disorders) within 3 years of screening.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Current diagnosis of peptic ulcer or gastrointestinal bleeding within the last year and/or chronic inflammatory bowel disease.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Concomitant use of donepezil at doses greater than  5 mg/day or other cholinesterase inhibitors (rivastigmine or galantamine) at any dose.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen, Concomitant use of memantine at dose greater than  20 mg/day.
NCT01602393,Phase 2,Alzheimer's Disease,Chiesi Farmaceutici S.p.A.,May-12,Alzheimer Disease;Cognitive Dysfunction;Flurbiprofen," Concomitant use of psychoactive drugs (sedatives, hypnotics, etc)."
NCT01607476,Phase 2,Alzheimer's Disease,Mayo Clinic,Jul-12,Alzheimer Disease;Corticosterone;Flutemetamol,Subjects unable to lie down without moving for 30 minutes.
NCT01607476,Phase 2,Alzheimer's Disease,Mayo Clinic,Jul-12,Alzheimer Disease;Corticosterone;Flutemetamol,Women who are pregnant or who cannot stop breast feeding for 24 hours.
NCT01607476,Phase 2,Alzheimer's Disease,Mayo Clinic,Jul-12,Alzheimer Disease;Corticosterone;Flutemetamol,"Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc,."
NCT01607476,Phase 2,Alzheimer's Disease,Mayo Clinic,Jul-12,Alzheimer Disease;Corticosterone;Flutemetamol,Subjects who are too claustrophobic to perform the tests.
NCT01607476,Phase 2,Alzheimer's Disease,Mayo Clinic,Jul-12,Alzheimer Disease;Corticosterone;Flutemetamol,"Subject who have had previous brain irradiation, stroke or brain tumor(s)"
NCT01614886,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jul-12,Alzheimer Disease;Rivastigmine, Any medical or neurological conditions other than AD that could explain the patient's dementia
NCT01614886,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jul-12,Alzheimer Disease;Rivastigmine, A current diagnosis of probable or possible vascular dementia
NCT01614886,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jul-12,Alzheimer Disease;Rivastigmine, A score of greater than  5 on the Modified Hachinski Ischemic Scale (MHIS)
NCT01614886,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jul-12,Alzheimer Disease;Rivastigmine, A current DSM-IV Axis 1 diagnosis that may interfere with the evaluation of the patient's response to study medication.
NCT01614886,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jul-12,Alzheimer Disease;Rivastigmine, Treated with donepezil or galantamine within last 4 weeks before the efficacy assessment at baseline.
NCT01614886,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jul-12,Alzheimer Disease;Rivastigmine, an advanced severe progressive or unstable disease of any type that may interfere with efficacy and safety assessments or put the patient's at special risk
NCT01614886,Phase 3,Alzheimer's Disease,Novartis Pharmaceuticals,Jul-12,Alzheimer Disease;Rivastigmine, Other protocol-defined inclusion/exclusion criteria may apply.
NCT01617577,Phase 1/Phase 2,Alzheimer's Disease,University of South Florida,Jun-09,Alzheimer Disease;Lenograstim, clinically significant cardiac arrhythmia
NCT01617577,Phase 1/Phase 2,Alzheimer's Disease,University of South Florida,Jun-09,Alzheimer Disease;Lenograstim, history of clinically significant stroke
NCT01617577,Phase 1/Phase 2,Alzheimer's Disease,University of South Florida,Jun-09,Alzheimer Disease;Lenograstim, use of another investigational drug within 2 months of screening
NCT01617577,Phase 1/Phase 2,Alzheimer's Disease,University of South Florida,Jun-09,Alzheimer Disease;Lenograstim," current evidence or history in the past 2 years of epilepsy, focal brain lesion, head injury with loss of consciousness or DSM-IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder alcohol or substance abuse; residence in a skilled nursing facility (but patients in assisted living facility are acceptable)"
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Significant central nervous system disorder other than Alzheimer's disease
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease," Patients in whom baseline MRI is contraindicated such as metal implants in head (except dental), pacemaker, and cochlear implant"
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Significant focal or intracranial pathology that would lead to a diagnosis other than probable Alzheimer's disease
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease," Clinical evidence or history of stroke, transient ischemic attack, significant head injury or other unexplained or recurrent loss of consciousness"
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Epilepsy
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease," Major depressive disorder, schizophrenia or other psychotic disorders, bipolar disorder, substance (including alcohol) related disorders"
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Resides in a hospital or continuous care facility
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, History of swallowing difficulties
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Pregnant or breastfeeding
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, History of significant hematological abnormality or current acute or chronic clinically significant abnormality
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Abnormal serum chemistry laboratory value at Screening deemed to be clinically relevant by the investigator
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Clinically significant cardiovascular disease or abnormal assessments
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Pre-existing or current signs or symptoms of respiratory failure
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease," Concurrent acute or chronic clinically significant immunologic, renal, hepatic, or endocrine disease (not adequately treated) and/or other unstable or major disease other than Alzheimer's disease"
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Prior intolerance to methylthioninium-containing drug or any of the excipients
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Treatment currently or within 3 months before Baseline with any of the following medications (unless otherwise noted):
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Tacrine
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease," Anxiolytics and/or sedatives/hypnotics (exceptions: sedation for MRI or occasional short-acting benzodiazepines, chloral hydrate, or zolpidem as needed at bedtime)"
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease," Antipsychotics (clozapine, chlorpromazine, thioridazine, or ziprasidone)"
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Carbamazepine
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease," Drugs associated with methaemoglobinaemia (e.g., dapsone, local anesthetics such as benzocaine used chronically, primaquine and related antimalarials, sulfonamides)"
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease, Warfarin (and other Coumadin derivates such as phenprocoumon)
NCT01626391,Phase 2,Alzheimer's Disease,TauRx Therapeutics Ltd,Sep-12,Alzheimer Disease," Current or prior participation in a clinical trial of a drug, biologic, or device in which the last dose was received within 28 days prior to Baseline"
NCT01661673,Phase 2,Alzheimer's Disease,FORUM Pharmaceuticals Inc,Nov-12,Alzheimer Disease;Cognitive Dysfunction," History of seizure disorder, symptomatic orthostatic hypotension, QTc values greater than 450 ms, positive drug screening tests"
NCT01661673,Phase 2,Alzheimer's Disease,FORUM Pharmaceuticals Inc,Nov-12,Alzheimer Disease;Cognitive Dysfunction," Pregnancy, nursing, (or if fertile female) not willing to utilize birth control measures during study"
NCT01661673,Phase 2,Alzheimer's Disease,FORUM Pharmaceuticals Inc,Nov-12,Alzheimer Disease;Cognitive Dysfunction, C-SSRS suicidal ideation score of 4 or 5
NCT01661673,Phase 2,Alzheimer's Disease,FORUM Pharmaceuticals Inc,Nov-12,Alzheimer Disease;Cognitive Dysfunction, Unwilling to abstain from vigorous exercise
NCT01661673,Phase 2,Alzheimer's Disease,FORUM Pharmaceuticals Inc,Nov-12,Alzheimer Disease;Cognitive Dysfunction, Concurrent disease other than MCI or early AD that is attributing to patient's cognitive impairment.
NCT01661673,Phase 2,Alzheimer's Disease,FORUM Pharmaceuticals Inc,Nov-12,Alzheimer Disease;Cognitive Dysfunction, Lumbar spine X-rays show anatomic contraindications to lumbar puncture
NCT01661673,Phase 2,Alzheimer's Disease,FORUM Pharmaceuticals Inc,Nov-12,Alzheimer Disease;Cognitive Dysfunction, History of spinal surgery or chronic low back pain
NCT01661673,Phase 2,Alzheimer's Disease,FORUM Pharmaceuticals Inc,Nov-12,Alzheimer Disease;Cognitive Dysfunction, History of migraine headaches
NCT01676935,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Aug-12,Alzheimer Disease," Experienced an adverse event or abnormal finding in physical examination, vital signs, laboratory profile and/or ECG measurements in Study M10-985 that indicates the subject could become medically unstable during the current study. - The subject is currently taking or is expected to be prescribed any excluded medications (including acetylcholinesterase inhibitors or memantine), without the approval of Abbott medical monitor. - The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals. - The subject is currently enrolled in, or plans to participate in, another experimental study during the course of this trial. - The subject developed any significant medical or psychiatric condition that, in the opinion of the investigator, renders the subject an unsuitable candidate to participate in this study. - For any other reason the investigator considers the subject to be an unsuitable candidate to receive ABT-126 or to participate in this study."
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Any neurological or psychiatric condition that may occur currently or during the course of the study that can impair cognition or functioning that is not associated with Alzheimer's disease
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Background of mental retardation
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Uncontrolled behavioral symptoms incompatible with compliance or evaluability
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Alcohol and/or substance abuse or dependence (DSM-IV-TR) in the past 2 years, except nicotine use which is allowed. However, smokers treated with nicotine replacement therapy or bupropion are excluded"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Unstable or poorly controlled hypertension as assessed by the investigator regardless of whether or not the participant is taking antihypertensive medications
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Unstable or clinically significant cardiovascular disease that could be expected to progress, recur, or change during study period to such an extent that it could bias the assessment of the clinical or mental status of the participant"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Inadequate hepatic, renal or thyroid function"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Poorly controlled diabetes (glycosylated hemoglobin [HbA1c] greater than or equal to [greater than /=] 9 percent at screening)
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Requiring nursing home care. Participants living in assisted living facilities are allowed if a reliable caregiver is available (see inclusion criteria)
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Current treatment for Alzheimer's disease other than those listed in inclusion criteria
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Participation at any time in an active Alzheimer's disease vaccine study
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Participation in a passive Alzheimer's disease immunization study less than 1 year before screening except for a) participants where documented medical history indicate that they were randomized to the placebo group in these studies, b) participants treated with bapineuzumab where a 6-month exclusion period applies"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Recent (less than /= 12 weeks) or concomitant use of other Monoamine oxidase inhibitors (selective or not) including selegiline or rasagiline
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Antidepressant treatments are not allowed except for citalopram up to 20 mg daily, escitalopram up to 10 mg daily, paroxetine up to 30 mg daily, sertraline up to 100 mg daily and trazodone up to 100 mg daily. If treated with one of these antidepressants, the treatment should be present for at least 6 weeks at screening. All other antidepressants including other SSRIs, tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), St. John's wort and bupropion are excluded"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Anti-psychotic use within 4 weeks before screening is not permitted except risperidone up to 1.5 mg/day, quetiapine up to 100 milligrams per day (mg/day), olanzapine up to 5 mg/day, and aripiprazole up to 10 mg daily"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Anxiolytics/ hypnotics use is not permitted except for benzodiazepines of short or intermediate half-life for anxiety/sleeping disorders. Zolpidem (up to 5 mg/day), zopiclone (up to 7.5 mg/day), eszopiclone (up to 2 mg/day), trazodone (up to 50 mg/day, at bedtime) or zaleplon (up to 5 mg/day) is permitted for insomnia"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Anti-Parkinson's agents within 2 weeks before screening are not permitted
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine, Recent (less than 4 weeks prior to screening) or concomitant use of anticonvulsants
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Anticholinergics/ antihistaminics within 2 weeks before screening are not permitted, except i) if used episodically more than 3 days before the screening cognitive measurement, ii) non-sedating antihistaminic medications (without anticholinergic effects such as cetirizine) or peripheral anticholinergics without central anticholinergic effects (such as, trospium for the treatment of hyperactive bladder), which are permitted"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Recent (less than 1 week prior to screening) or concomitant use of opioid drugs (tramadol, methadone, propoxyphene, or meperidine), cyclobenzaprine and dextromethorphan"
NCT01677754,Phase 2,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease;Memantine;Rivastigmine;Donepezil;Galantamine," Concomitant use of sympathomimetic drugs, including sympathomimetics in local anesthetics and ephedra supplements"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," has any contraindication to MRI examination, e.g., metal implants or phobia"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, is not able to lie down flat in the MRI and PET scanners
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, is scheduled for surgery and/or another invasive procedure within the time period of up to 10 days after [18F]NAV4694 application
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," is medically unstable and whose clinical course during the observation period is unpredictable, e.g., subjects within 14 days of myocardial infarction or stroke, unstable subjects with previous surgery (within 7 days), subjects with advanced heart insufficiency (NYHA stage IV), or with acute renal failure"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," has a history of exposure to any radiation greater than  30 mSv in the last year (e.g., occupational, diagnostic imaging, or radiation therapy)"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," is receiving drug therapy or other treatment that is known to lead to greatly fluctuating values of the hematological or chemical laboratory parameters or to severe side effects (e.g., chemotherapy)"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, has received anti-amyloid immunotherapy
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," has been previously enrolled in this study and received [18F]NAV4694 or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening, and/or any radiopharmaceutical within 10 radioactive half-lives prior to [18F]NAV4694 administration"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," has a brain tumor or other intracranial lesion, a disturbance of cerebrospinal fluid (CSF) circulation (e.g., normal pressure hydrocephalus) and/or a history of serious head trauma or brain surgery"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," has a history, physical, laboratory, or imaging findings indicative of a significant neurological or psychiatric illness (other than AD for the subjects with probable AD)"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease," has another untreated disease that can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function, anemia)"
NCT01680588,Phase 2,Alzheimer Disease,Navidea Biopharmaceuticals,Aug-12,Alzheimer Disease, has a history of alcohol abuse or drug dependency in the 3 years prior to study entry or is an alcoholic or drug addict as determined by the investigator
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Significant central nervous system (CNS) disorder other than Alzheimer's disease
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Significant focal or vascular intracranial pathology seen on brain MRI scan
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease," Clinical evidence or history of stroke, transient ischemic attack, significant head injury or other unexplained or recurrent loss of consciousness 15 minutes"
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Epilepsy
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease," Major depressive disorder, schizophrenia, or other psychotic disorders, bipolar disorder, substance (including alcohol) related disorders"
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease," Metal implants in the head (except dental), pacemaker, cochlear implants, or any other non-removable items that are contraindications to MRI"
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Resides in hospital or moderate to high dependency continuous care facility
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, History of swallowing difficulties
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Pregnant or breastfeeding
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Glucose-6-phosphate dehydrogenase deficiency
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, History of significant hematological abnormality or current acute or chronic clinically significant abnormality
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Abnormal serum chemistry laboratory value at Screening deemed to be clinically relevant by the investigator
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Clinically significant cardiovascular disease or abnormal assessments
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Preexisting or current signs or symptoms of respiratory failure
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease," Concurrent acute or chronic clinically significant immunologic, hepatic, or endocrine disease (not adequately treated) and/or other unstable or major disease other than Alzheimer's disease"
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Diagnosis of cancer within the past 2 years prior to Baseline (other than basal cell or squamous cell skin cancer or Stage 1 prostate cancer) unless treatment has resulted in complete freedom from disease for at least 2 years
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease," Prior intolerance or hypersensitivity to methylthioninium-containing drug, similar organic dyes, or any of the excipients"
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Treatment currently or within 3 months before Baseline with any of the following medications (unless otherwise noted):
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Tacrine
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease," Clozapine, olanzapine (and there is no intent to initiate therapy during the course of the study)"
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease," Carbamazepine, primidone"
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Drugs with a warning or precaution in the labeling of methemoglobinemia at approved doses
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Current or prior participation in a clinical trial as follows:
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease, Clinical trial of a product for cognition in which the last dose was received within 90 days prior to Screening (unless confirmed to have been randomized to placebo)
NCT01689233,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Oct-12,Alzheimer Disease," A clinical trial of a drug, biologic, device, or medical food in which the last dose/administration was received within 28 days prior to Baseline"
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Significant central nervous system (CNS) disorder other than Alzheimer's disease
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Significant focal or vascular intracranial pathology seen on brain MRI scan
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue," Clinical evidence or history of stroke, transient ischemic attack, significant head injury or other unexplained or recurrent loss of consciousness 15 minutes"
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Epilepsy
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue," Major depressive disorder, schizophrenia, or other psychotic disorders, bipolar disorder, or substance (including alcohol) related disorders"
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue," Metal implants in the head (except dental), pacemaker, cochlear implants, or any other non-removable items that are contraindications to MRI"
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Resides in hospital or moderate to high dependency continuous care facility
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, History of swallowing difficulties
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Pregnant or breastfeeding
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Glucose-6-phosphate dehydrogenase deficiency
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, History of significant hematological abnormality or current acute or chronic clinically significant abnormality
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Abnormal serum chemistry laboratory value at Screening deemed to be clinically relevant by the investigator
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Clinically significant cardiovascular disease or abnormal assessments
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Preexisting or current signs or symptoms of respiratory failure
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue," Concurrent acute or chronic clinically significant immunologic, hepatic, or endocrine disease (not adequately treated) and/or other unstable or major disease other than Alzheimer's disease"
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Diagnosis of cancer within the past 2 years prior to Baseline (other than basal cell or squamous cell skin cancer or Stage 1 prostate cancer) unless treatment has resulted in complete freedom from disease for at least 2 years
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue," Prior intolerance or hypersensitivity to methylthioninium-containing drug, similar organic dyes, or any of the excipients"
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Treatment currently or within 3 months before Baseline with any of the following medications:
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Tacrine
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue," Clozapine, olanzapine (and there is no intent to initiate therapy during the course of the study)"
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue," Carbamazepine, primidone"
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Drugs with a warning or precaution in the labeling about methemoglobinemia at approved doses
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Current or prior participation in a clinical trial as follows:
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue, Clinical trial of a product for cognition within 3 months of Screening (unless confirmed to have been randomized to placebo)
NCT01689246,Phase 3,Alzheimer's Disease,TauRx Therapeutics Ltd,Jan-13,Alzheimer Disease;Methylene Blue," A clinical trial of a drug, biologic, therapeutic device, or medical food in which the last dose/administration was received within 28 days prior to Baseline"
NCT01690195,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Sep-12,Alzheimer Disease," The subject experienced an adverse event or abnormal finding in physical examination, vital signs, laboratory profile and/or ECG measurements in Study M11-793 that indicates the subject could become medically unstable during the current study."
NCT01690195,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Sep-12,Alzheimer Disease, The subject is currently taking or is expected to be prescribed any excluded medications without the approval of Abbott medical monitor.
NCT01690195,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Sep-12,Alzheimer Disease, The subject was noncompliant with donepezil or rivastigmine during Study M11-793 or is expected to discontinue these medications prior to conclusion of this study.
NCT01690195,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Sep-12,Alzheimer Disease, The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.
NCT01690195,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Sep-12,Alzheimer Disease," The subject is currently enrolled in, or plans to participate in, another experimental study during the course of this trial."
NCT01690195,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Sep-12,Alzheimer Disease," The subject developed any significant medical or psychiatric condition that, in the opinion of the investigator, renders the subject an unsuitable candidate to participate in this study."
NCT01690195,Phase 2,Alzheimer's Disease,"AbbVie (prior sponsor, Abbott)",Sep-12,Alzheimer Disease, For any other reason the investigator considers the subject to be an unsuitable candidate to receive ABT-126 or to participate in this study.
NCT01696123,Phase 2,Alzheimer Disease,Shahid Beheshti University of Medical Sciences,Jan-11,Alzheimer Disease, uncontrolled diabetes mellitus
NCT01696123,Phase 2,Alzheimer Disease,Shahid Beheshti University of Medical Sciences,Jan-11,Alzheimer Disease, hypertension
NCT01696123,Phase 2,Alzheimer Disease,Shahid Beheshti University of Medical Sciences,Jan-11,Alzheimer Disease, unstable cardiac disease
NCT01696123,Phase 2,Alzheimer Disease,Shahid Beheshti University of Medical Sciences,Jan-11,Alzheimer Disease, severe obstructive pulmonary disease
NCT01696123,Phase 2,Alzheimer Disease,Shahid Beheshti University of Medical Sciences,Jan-11,Alzheimer Disease, renal or hepatic failure
NCT01696123,Phase 2,Alzheimer Disease,Shahid Beheshti University of Medical Sciences,Jan-11,Alzheimer Disease, and/or other life threatening conditions
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, Severe Alzheimer's disease and other dementias as determined by neuropsychological testing and neurological evaluation.
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, Previous riluzole treatment.
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole," MRI contraindication (severe claustrophobia, metal implants, shunts, pacemaker, joint implants, metal valves)."
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole," Currently taking medications that either have evidence of glutamatergic activity or has previous MRS evidence of effects on brain glutamate levels at the discretion of the PI such as memantine, lamotrigine, lithium, opiates, bupropion, psychostimulants such as amphetamines and methylphenidate, tricyclic antidepressants, benzodiazepines and any other drug that the investigators judge might interfere with the study. (subjects on those medications may still be included in the study however only the values of NAA from MRS will be utilized and not the glutamate measurements)."
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole," Currently a user of the following illicit drugs: cocaine, methylenedioxymethamphetamine (MDMA) ( ecstasy ), heroin and other opioids or has a history of drug or alcohol abuse within the past 5 years."
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, Serum creatinine greater than 1.5 times the upper limit of normal.
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, Abnormal liver function test (greater than 2 times the upper limit of normal for alanine aminotransferase (ALT) or aspartate aminotransferase (AST); or bilirubin greater than 1.5 times the upper limit of normal.
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole," History of brain disease including Parkinson's Disease, severe brain trauma, seizures, history of stroke, clinically significant lacunar infarct in a region important for cognition or multiple lacunes or a cortical infarct or focal lesions of clinical significance, multiple sclerosis, mental retardation, normal pressure hydrocephalus, central nervous system (CNS) tumor, Huntington's disease, subdural hematoma or other serious neurological disorder."
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, Uncontrolled diabetes mellitus (Hba1c higher than 7) or chronically uncontrolled hypertension.
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, Subject must not be taking Namenda (memantine) for 6-weeks prior to study entrance.
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole," Currently taking any concomitant hepatotoxic drugs such as allopurinol, methyldopa and sulfasalazine."
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole," Any unstable serious co-existing medical condition(s) including but not limited to myocardial infarction, coronary artery disease requiring coronary bypass surgery, unstable angina, clinically evident congestive heart failure within 6 months prior to the screening visit."
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole," Current smoker or user of nicotine-containing products, such as chewing tobacco, nicotine patch or gum for the past 2 months."
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, Current untreated major depression defined by Geriatric Depression Scale greater than  20.
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, Participation in any investigational or marketed drug or device trial within 30 days prior to the screening visit.
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole," Significant neuropsychiatric illnesses such as bipolar disorder, schizophrenia, moderate-severe anxiety, vascular dementia, Creutzfeldt-Jakob dementia, HIV dementia, and dementia in other specified diseases."
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, Subjects who have been on donepezil for longer than 5 years.
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, Weightgreater than  300 pounds.
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, Lactose intolerance.
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole," Any medical or social condition that, in the opinion of the Investigator, might pose additional risk to the participant or confound the results of the study."
NCT01703117,Phase 2,Alzheimer's Disease,Icahn School of Medicine at Mount Sinai,unknown,Alzheimer Disease;Riluzole, Positive Hepatitis Serology (Hep. B antigen+ or Hep. C antibody+)
NCT01712074,Phase 2,Alzheimer's Disease,Pfizer,Nov-12,Alzheimer Disease," Demonstrate extreme agitation, physical aggression or violence to themselves, their caregiver, or others, and/or an inability to complete the ADAS-cog assessment at Screening."
NCT01712074,Phase 2,Alzheimer's Disease,Pfizer,Nov-12,Alzheimer Disease, Have major structural brain disease other than Alzheimer's Disease
NCT01712074,Phase 2,Alzheimer's Disease,Pfizer,Nov-12,Alzheimer Disease, Other severe acute or chronical medical or psychiatric condition or laboratory abnormality
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease," 1)Possible, probable, or definite vascular dementia by NINDS-AIREN criteria"
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease," 2)History and/or evidence (result of CT or MRI performed within the past 12 months or at screening) of other CNS disease (cerebrovascular disease, structural or developmental anomaly, epilepsy, contagious, degenerative or infectious/demyelinating CNS condition) as a cause of dementia"
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease," 3)Delusion, delirium, epilepsy and other neurological pathology on neurological examination"
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease," 4)Abnormal test result on vitamin B12, syphilis serology, and thyroid stimulating hormone (TSH) tests that are thought to contribute to the subject's dementia severity or be a cause of dementia"
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease," 5)History of significant psychiatric disease such as schizophrenia or bipolar affective disorder that may interfere with the participation in this study in the opinion of the investigator, or current depression (GDS  18)"
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease," 6)Past history of known or suspected seizures including febrile convulsion, unexplained recent unconsciousness or past history of significant head trauma with unconsciousness."
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease," 7)Gastrointestinal, endocrine and cardiovascular disease not controlled by diet or pharmacologic therapy"
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease," 8)Cardiac disease such as myocardial infarction or valvular disease of heart, arrhythmia within 3 months of the study start"
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 9)Diabetes mellitus not controlled by hypoglycemic agent or insulin-dependent diabetes mellitus
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 10)Past history of alcohol or other drug abuse
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 11)Having taken acetylcholinesterase inhibitor or memantine within the past 3 months
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 12)Hypertension with systolic blood pressure of greater than  165 mmHg or diastolic blood pressure of greater than  96 mmHg
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 13)Severe renal impairment (serum creatinine  1.7 mg/dl)
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease," 14)Severe hepatic impairment (ALT, AST, or bilirubin  2.0 x upper limit of normal)"
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 15)Is taking or expected to take disallowed concomitant medication
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 16)History of clinically significant drug hypersensitivity
NCT01715350,Phase 2,Alzheimer's Disease,VTBIO Co. LTD,May-12,Alzheimer Disease, 17)Is ineligible to participate in this study in the judgment of the investigator
NCT01723670,Phase 2,Alzheimer's Disease,CERESPIR,Dec-12,Alzheimer Disease;Nerve Degeneration;Cognitive Dysfunction;Flurbiprofen, Diagnosis of Alzheimer's disease.
NCT01723670,Phase 2,Alzheimer's Disease,CERESPIR,Dec-12,Alzheimer Disease;Nerve Degeneration;Cognitive Dysfunction;Flurbiprofen, Any medical condition that could explain the subject's cognitive deficits.
NCT01723670,Phase 2,Alzheimer's Disease,CERESPIR,Dec-12,Alzheimer Disease;Nerve Degeneration;Cognitive Dysfunction;Flurbiprofen, MRI scans having evidence of pre-specified brain abnormalities.
NCT01723670,Phase 2,Alzheimer's Disease,CERESPIR,Dec-12,Alzheimer Disease;Nerve Degeneration;Cognitive Dysfunction;Flurbiprofen, History of stroke.
NCT01723670,Phase 2,Alzheimer's Disease,CERESPIR,Dec-12,Alzheimer Disease;Nerve Degeneration;Cognitive Dysfunction;Flurbiprofen, Vitamin B12 or folate deficiency.
NCT01723670,Phase 2,Alzheimer's Disease,CERESPIR,Dec-12,Alzheimer Disease;Nerve Degeneration;Cognitive Dysfunction;Flurbiprofen, Skin cancers and any cancer that is being actively treated.
NCT01723670,Phase 2,Alzheimer's Disease,CERESPIR,Dec-12,Alzheimer Disease;Nerve Degeneration;Cognitive Dysfunction;Flurbiprofen, Diagnosis of schizophrenia or recurrent mood disorder.
NCT01723670,Phase 2,Alzheimer's Disease,CERESPIR,Dec-12,Alzheimer Disease;Nerve Degeneration;Cognitive Dysfunction;Flurbiprofen, Abnormal kidney function.
NCT01723670,Phase 2,Alzheimer's Disease,CERESPIR,Dec-12,Alzheimer Disease;Nerve Degeneration;Cognitive Dysfunction;Flurbiprofen, Concomitant use of any study prohibitive medication.
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Early treatment and/or study discontinuation prior to completion of the Week 73 visit of Genentech Study ABE4869g or ABE4955g
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Early discontinuation from the treatment schedule of a prior version of Study GN28525 for safety reasons. If treatment discontinuation occurred for safety reasons, participants may not re-start dosing on extended treatment schedules offered in amendments to Study GN28525"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Inability to tolerate Magnetic Resonance Imaging (MRI) procedures or contraindication to MRI
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Female participants with reproductive potential: Female participants must either have undergone documented surgical sterilization or have not experienced menstruation for at least 12 consecutive months
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Severe or unstable medical condition that, in the opinion of the investigator or Sponsor, would interfere with the participant's ability to complete the study assessments or would require the equivalent of institutional or hospital care"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, History or presence of clinically evident vascular disease potentially affecting the brain
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," History of severe, clinically significant central nervous system trauma"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, History or presence of clinically relevant intracranial tumor
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Presence of infections that affect the brain function or history of infections that resulted in neurologic sequelae
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, History or presence of systemic autoimmune disorders potentially causing progressive neurologic disease
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, History or presence of a neurologic disease other than Alzheimer's disease that may affect cognition
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Evidence of malignancies (except squamous cell cancer or basal cell cancer of the skin), acute infections, renal failure that requires dialysis, or other unstable medical disease not related to Alzheimer's disease that, in the investigator's opinion, would preclude participant's participation. Cancer that is not being actively treated with anti-cancer therapy or radiotherapy as well as cancers which are considered to have low probability of recurrence are allowed"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," History or presence of atrial fibrillation that, in the investigator's judgment, poses a risk for future stroke"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Chronic kidney disease of Stage greater than or equal to (greater than =) 4, according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) guidelines for chronic kidney disease (CKD)"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Impaired hepatic function
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Impaired coagulation (activated partial thromboplastin time [aPTT] greater than [greater than ] 1.2 times upper limit of normal [ULN])
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Platelet count less than (less than ) 100,000 per microliter (mcL)"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Presence at screening of superficial siderosis of central nervous system, more than 8 cerebral microhemorrhages, or evidence of a prior cerebral macrohemorrhage"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Presence at screening of any other significant cerebral abnormalities, including ARIA-E"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Treatment with anticoagulation medications within 2 weeks prior to enrollment. Clopidogrel, dipyridamole, and aspirin are permitted"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Treatment with anticholinergic antidepressants, typical antipsychotics, or barbiturates within 2 weeks prior to enrollment. All other antidepressants and atypical antipsychotics are allowed with certain restrictions as defined in the protocol"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Chronic use of opiates, opioids, or benzodiazepines"
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Any biologic therapy within 75 weeks prior to enrollment
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Any investigational agent (other than crenezumab) within 75 weeks prior to enrollment
NCT01723826,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Treatment with anticholinergic antidepressants, typical antipsychotics, barbiturates, or narcotics within 5 half-lives or 3 months prior to screening, whichever is longer. All other antidepressants and atypical antipsychotics are allowed. Chronic use of benzodiazepines is not allowed; however, the intermittent use of benzodiazepines is allowed, except within 2 days prior to any neurocognitive assessment"
NCT01735630,Phase 2,Alzheimer's Disease,"OPKO Health, Inc.",Nov-12,Alzheimer Disease;Psychomotor Agitation;Aggression;Inositol," The agitation/aggression is attributable to concomitant medications, environmental conditions, or active medical or psychiatric condition."
NCT01735630,Phase 2,Alzheimer's Disease,"OPKO Health, Inc.",Nov-12,Alzheimer Disease;Psychomotor Agitation;Aggression;Inositol, Current diagnosis of major depressive disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision (DSM IV TR).
NCT01735630,Phase 2,Alzheimer's Disease,"OPKO Health, Inc.",Nov-12,Alzheimer Disease;Psychomotor Agitation;Aggression;Inositol, Has persistent and distressing psychotic symptoms (delusion and/or hallucinations) that require psychiatric hospitalization.
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, History of stroke
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Evidence of a neurological disorder other than the disease being studied (i.e., probable AD)"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, History of seizures or epilepsy within the last 5 years before Screening
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Evidence of a clinically relevant or unstable psychiatric disorder, excluding major depression in remission"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Participant is at imminent risk of self-harm or of harm to others
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, History of alcoholism or drug dependency/abuse within the last 5 years before Screening
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Participant does not have a magnetic resonance imaging (MRI) scan obtained within 12 months of Screening and is unwilling or not eligible to undergo an MRI scan at the Screening Visit. With Sponsor approval, a head computed tomography (CT) scan may be substituted for MRI scan to evaluate eligibility"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, History of hepatitis or liver disease that has been active within the six months prior to Screening Visit
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Recent or ongoing, uncontrolled, clinically significant medical condition within 3 months of the Screening Visit (e.g., diabetes, hypertension, thyroid or endocrine disease, congestive heart failure, angina, cardiac or gastrointestinal disease, dialysis, or abnormal renal function) other than the condition being studied such that participation in the trial would pose a significant medical risk to the subject. Controlled co-morbid conditions are not exclusionary if stable within three months of the Screening Visit"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," History or current evidence of long QT syndrome, corrected QT (QTc) interval 470 milliseconds (for male subjects) or 480 milliseconds (for female subjects), or torsades de pointes"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," History of malignancy occurring within the five years before Screening, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or localized prostate carcinoma; or malignancy which has been treated with potentially curative therapy with no evidence of recurrence for 3 year post-therapy"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Clinically significant vitamin B12 or folate deficiency in the six months before Screening Visit
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Use of any investigational drugs within 30 days (or longer depending on drug) before Screening or participation in studies involving repeated cognitive testing within 30 days before Screening. Participation in an observational study, such as those involving annual cognitive assessments and/or neuroimaging, may be allowed if approved by Sponsor"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, History of a hypersensitivity reaction to more than three drugs
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Has tested positive for human immunodeficiency virus (HIV)
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Close family member (including the caregiver, the spouse or any children) who is among the personnel of the investigational or sponsor staff directly involved with this trial"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Additional Exclusion Criteria for Safety Cohort:
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," History of an ongoing medical condition that has been poorly controlled within 6 months of the Screening Visit (e.g., hypotension, diabetes, hypertension, cerebrovascular disease, thyroid disease, endocrine disturbance, congestive heart failure, cardiac or gastrointestinal disease, dialysis, or abnormal renal function) other than the condition being studied such that a subject's participation in the trial would pose a significant medical risk"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," History of congestive heart failure (moderate or greater severity), myocardial infarction, heart surgery, syncope, bradycardia, or clinically significant hypotension within one year before Screening"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Participant is at imminent risk of self-harm or of harm to others
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Has developed a recent or ongoing, uncontrolled, clinically significant medical condition other than AD"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Has history of or has developed during Part I evidence of long QT syndrome, QTc interval 470 milliseconds (for male subjects) or 480 milliseconds (for female subjects), or torsades de pointes"
NCT01739348,Phase 2/Phase 3,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Has developed a form of dementia that is not AD
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease," Current use, or use within 3 months of baseline, of medium-chain triglyceride-containing products"
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Use of any other investigational agent within 60 days prior to screening
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Known allergy or hypersensitivity to milk or soy products
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease," In the opinion of the investigator, presence or history of advanced, severe, progressive or unstable disease of any type that could interfere with protocol assessments or put the participant at particular risk"
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Any medical or neurological condition other than Alzheimer's disease that could explain the patient's dementia
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, History or clinical laboratory evidence of moderate congestive heart failure
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Clinically significant ECG abnormalities at screening
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, History of new cardiovascular events within 6 months prior to baseline
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, History of or current psychiatric illness
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Major depression as determined by Cornell Scale for Depression in Dementia
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Insulin-dependent diabetics
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Systolic blood pressure greater than  165 mmHg or diastolic blood pressure greater than  95 mmHg
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Drop of 20 mm Hg systolic blood pressure or greater upon standing upright from a seated position within 3 minutes at screening
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Clinically significant anemia at screening
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Clinically significant renal disease or insufficiency at screening
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Laboratory values for liver function tests greater than  2.5 times the upper limit of normal at screening or history of severe liver disease
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Fasting triglycerides greater than  2.5 times the upper limit of normal at screening
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Clinically significant B12 deficiency within 12 month prior to screening
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Inflammatory bowel disease or peptic ulcer disease.
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Participants with current or a history of (within the last 5 years) complicated reflux disease or severe GERD that is not well-controlled by medication.
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease," Irritable bowel syndrome, diverticular disease (e.g., diverticulosis or diverticulitis), or chronic gastritis (exclusionary if there has been a diagnosis or an acute event within 5 years prior to Screening.)"
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Has donated  2 units of blood within the 2 months prior to screening
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease," History of alcohol or drug abuse within 6 months prior to screening, or positive urine drug test at screening"
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease," Participant or caregiver is an immediate family member or employee of the clinical site, sponsor or sponsor's agents"
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, An alternative cause for dementia other than Alzheimer's disease as determined by a required CT or MRI scan within 18 months prior to screening
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease," History of neoplasm or malignancies within 5 years prior to screening, except for basal cell or squamous cell carcinoma of the skin"
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Clinically significant hypothyroidism as determined thyroid function testing at screening
NCT01741194,Phase 2/Phase 3,Alzheimer's Disease,Cerecin,Mar-13,Alzheimer Disease, Participant has scheduled or expected hospitalization and/or surgery during the course of the study
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", History or presence of brain MRI scans indicative of any other significant abnormality
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Alcohol or drug dependence currently or within the past 1 year
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would preclude MRI scan."
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," History or presence of clinically significant cardiovascular disease, hepatic/renal disorders, infectious disease or immune disorder, or metabolic/endocrine disorders"
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Anticoagulants except low dose ( 325 mg) aspirin.
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the past six months.
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years."
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Positive urine or serum pregnancy test or plans or desires to become pregnant during the course of the trial.
NCT01760005,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," Subjects unable to complete all study related testing, including implanted metal that cannot be removed for MRI scanning, required anticoagulation and pregnancy."
NCT01764243,Phase 2,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Nov-12,Alzheimer Disease, Inability to perform cognitive tests (ADAS-cog-13 and MMSE) at screening and at Day 1
NCT01764243,Phase 2,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Nov-12,Alzheimer Disease, Diagnosis of any other disease which may cause dementia
NCT01764243,Phase 2,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Nov-12,Alzheimer Disease," MRI or CT scan within 6 months before screening, with findings inconsistent with the diagnosis of Probable AD"
NCT01764243,Phase 2,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Nov-12,Alzheimer Disease," Diagnosis of major depressive disorder as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) within last five years"
NCT01764243,Phase 2,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Nov-12,Alzheimer Disease, History of or current diagnosis of any psychosis
NCT01764243,Phase 2,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Nov-12,Alzheimer Disease, History of myocardial infarction or unstable angina within six months before screening
NCT01764243,Phase 2,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Nov-12,Alzheimer Disease, History of cerebrovascular disorder within 18 months before screening
NCT01766336,Phase 2,Alzheimer's Disease,"OPKO Health, Inc.",Jan-13,Alzheimer Disease;Psychomotor Agitation;Aggression;Inositol, Is currently using any other investigational or experimental drugs or devices
NCT01766336,Phase 2,Alzheimer's Disease,"OPKO Health, Inc.",Jan-13,Alzheimer Disease;Psychomotor Agitation;Aggression;Inositol, Has significant worsening of medical conditions or dementia such that it may preclude completion of this safety extension study
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Subjects who discontinued from the study drug or from the Core Study for reasons other than the following:
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,ARIA-E
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,"ARIA-H (superficial siderosis, macrohemorrhage, or symptomatic microhemorrhage)"
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Prohibited or restricted medications that were prohibited during Core Study conduct but are no longer prohibited in the Extension Phase
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Subjects who were APOE4 positive and receiving treatment with lecanemab 10 mg/kg biweekly
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,"AE that was considered not related to study drug, and that was not severe or life-threatening"
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Females of childbearing potential who do not agree to use a highly effective method of contraception
NCT01767311,Phase 2,Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease,Severe visual or hearing impairment that would prevent the subject from performing psychometric tests accurately.
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", A diagnosis of dementia other than probable AD
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Probable AD with Down syndrome
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", History of clinically significant stroke
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc"," Current evidence or history in past two years of epilepsy, focal brain lesion, head injury with loss of consciousness or Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV) criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse"
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Sensory impairment that would preclude the participant from participating in or cooperating with the protocol
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Diabetes (type 1 or type II) requiring pharmacologic treatment (including both insulin dependent and non-insulin dependent diabetes mellitus)
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Current or past use of insulin or any other anti-diabetic medication
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc"," Evidence of any significant clinical disorder or laboratory finding that renders the participant unsuitable for receiving investigational drug including clinically significant or unstable hematologic, hepatic, cardiovascular, pulmonary, endocrine, metabolic, renal or other systemic disease or laboratory abnormality."
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc"," Active neoplastic disease, history of cancer five years prior to screening (history of skin melanoma or stable prostate cancer are not excluded)"
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", History of seizure within the past five years
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Pregnancy or possible pregnancy
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc"," Contraindications to Lumbar Puncture (LP) procedure: prior lumbosacral spine surgery, severe degenerative joint disease or deformity of the spine, platelets is less than 100,000 or history of bleeding disorder"
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Use of anticoagulants warfarin (Coumadin) and dabigatran (Pradaxa) due to LP requirement
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc"," Contraindications for MRI (claustrophobia, craniofacial metal implants of any kind, pacemakers)"
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Residence in a skilled nursing facility at screening
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc", Use of an investigational agent within two months or screening visit
NCT01767909,Phase 2/Phase 3,Alzheimer's Disease,University of Southern California,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc"," Regular use of narcotics, anticonvulsants, medications with significant anticholinergic activity, antiparkinsonian medications or any other exclusionary medications"
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene," Any clinically relevant neurological disorder capable of producing a dementia syndrome including Parkinson's disease, stroke, vascular dementia, dementia with Lewy bodies, frontotemporal dementia and others."
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene," 4 or more micro-hemorrhages (amyloid-related imaging abnormalities - hemorrhage type (ARIA-H) on baseline MRI or any evidence of amyloid-related imaging abnormalities - effusion type (ARIA-E) (Sperling et al, 2011)."
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene," History of malignancy within the past five years with the exception of basal cell or squamous cell cancer, in-situ cervical cancer, or localized prostate cancer."
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, History of seizure in the past three years prior to randomization
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, Any contraindication of having brain MRI
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene," Any contraindication of having PET (inability to lie flat and still for the duration of the scan, intolerance to previous PET such as hypersensitivity reaction to PET ligand or imaging agent)"
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene," The subject has any unstable medical illness including hypertension, congestive heart failure, chronic obstructive pulmonary disease, renal failure, liver failure or other organ compromise."
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene," Other clinically important abnormality on vital signs, physical examination, neurologic examination, laboratory results, or electrocardiogram (ECG) examination (e.g. Atrial fibrillation) that could compromise the study or be detrimental to the subject."
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, The subject has received bexarotene previously.
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, The subject has an allergy to bexarotene.
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, Has had a PET scan in the past 12 months.
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, Has had radiotherapy in the past year.
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, Have participated in an investigational drug or device study within 30 days prior to Visit 2.
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene," Have been treated with immunomodulators to treat AD (vaccines, antibodies etc) within 6 months prior to visit 2"
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene, Unable to swallow uncrushed oral medication in capsule form
NCT01782742,Phase 2,Alzheimer's Disease,The Cleveland Clinic,Feb-13,Alzheimer Disease;Bexarotene," Have any condition or reason that, in the opinion of the investigator, which could interfere with the ability of the patients to participate or complete the trials, or places the patient at undue risk or complicates the interpretation of safety or efficacy data."
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Patients on treatment for diabetes mellitus
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,"Any contraindications to the use of liraglutide as per the Summary of Product Characteristics (hepatic impairment, renal impairment with CKD stage 4 and above (eGFR less than 30 ml/min/1.73m2), inflammatory bowel disease). Patients with eGFR less than 45 ml/min/1.73m2 will have the renal function monitored very closely"
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Significant neurological disease other than AD that may affect cognition
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,MRI/CT showing unambiguous aetiological evidence of cerebrovascular disease with regard to their dementia or vascular dementia fulfilling NINCDS-AIREN criteria
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,"Current presence of a clinically significant major psychiatric disorder (e.g., Major Depressive Disorder) according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)"
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Current clinically significant systemic illness that is likely to result in deterioration of the patient's condition or affect the patient's safety during the study
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,"History of epilepsy, where seizures or treatment could have contributed to cognitive impairment"
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Treatment with immunosuppressive medications (e.g. systemic corticosteroids) within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Myocardial infarction within the last 1 year
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,"History of cancer within the last 5 years, except localised skin cancer"
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,"Other clinically significant abnormality on physical, neurological or laboratory examination that could compromise the study or be detrimental to the patient"
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,History of alcohol or drug dependence or abuse within the last 2 years
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,"Current use of anticonvulsant, anti-Parkinson's, anticoagulant (excluding the use of aspirin 325 mg/day or less) or narcotic medications. Subjects on anticoagulants will be allowed, but will not have an arterial line inserted"
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Use of experimental medications for AD or any other investigational medication or device within 60 days. Patients who have been involved in a monoclonal antibody study are excluded unless it is known that they were receiving placebo in that trial
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Women of childbearing potential. Women who could become pregnant will be required to use adequate contraception throughout the trial
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Patients with a personal or family history of medullary thyroid carcinoma (MTC) and patients with multiple endocrine neoplasia type 2 (MEN2)
NCT01843075,Phase 2,Alzheimer's Disease,Imperial College London,unknown,Alzheimer Disease;Liraglutide,Any contraindications to MRI scanning
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, History of clinically significant stroke
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Evidence of a neurological disorder other than the disease being studied (i.e., probable AD)"
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, History of seizures or epilepsy within the last 5 years before Screening
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Evidence of a clinically relevant or unstable psychiatric disorder, excluding major depression in remission"
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Is at imminent risk of self-harm or of harm to others
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, History of alcoholism or drug dependency/abuse within the last 5 years before Screening
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Does not have a magnetic resonance imaging (MRI) scan obtained within 12 months of Screening and is unwilling or not eligible to undergo an MRI scan at Screening
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, History of hepatitis or liver disease that has been active within the six months prior to Screening Visit
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Recent or ongoing, uncontrolled, clinically significant medical condition within 3 months of the Screening Visit (e.g., diabetes, hypertension, thyroid or endocrine disease, congestive heart failure, angina, cardiac or gastrointestinal disease, dialysis, or abnormal renal function) other than the condition being studied such that participation in the trial would pose a significant medical risk to the participant. Controlled co-morbid conditions are not exclusionary if stable within three months of the Screening Visit"
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," History or current evidence of long QT syndrome, corrected QT (QTc) interval 470 milliseconds (for male subjects) or 480 milliseconds (for female subjects), or torsades de pointes"
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," History of malignancy occurring within the five years before Screening, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or localized prostate carcinoma which has been treated with potentially curative therapy with no evidence of recurrence for 3 year post-therapy"
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease," Clinically significant vitamin B12 deficiency, or increased thyroid stimulating hormone (TSH) in the six months before Screening"
NCT01852110,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease, Major surgery within 3 months of Screening
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",Meets Criteria for dementia (DSM-IV) or probable Alzheimer's disease by National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria (NINCDS-ADRDA criteria)
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",Meets criteria for:
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",schizophrenia
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",alcohol or substance dependence or abuse within the last 6 months.
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",Suicidal attempt in last 6 months or current suicidal intent.
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",Patients currently on an effective antidepressant medication
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",Use of cholinesterase inhibitors in the last year.
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram","Neurological disease including stroke, epilepsy, or other neurodegenerative disorders."
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram","An acute, severe or unstable medical condition such as metastatic or active cancer, hepatic disease, or primary renal disease requiring dialysis."
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",Patients who can not tolerate being tapered off antidepressant medication (i.e. greater than a 25% incr. in baseline HAM-D) or has a history indicating patient is unlikely to tolerate psychotropic washout.
NCT01876823,Phase 2/Phase 3,Alzheimer's Disease,New York State Psychiatric Institute,Apr-06,"Alzheimer Disease;Depressive Disorder;Cognitive Dysfunction;Depressive Disorder, Major;Memantine;Citalopram",Patient with a history of non-response to Citalopram or es-citalopram
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease," Has significant neurological or medical disease, other than AD, that may affect cognition, for example, history or evidence of hydrocephalus, or uncontrolled hypo- or hyperthyroidism."
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease," Current, clinically significant major psychiatric disorder (eg, major depressive disorder) according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSMIV), or symptoms (eg, hallucinations) that could affect the subject's ability to complete the study."
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Geriatric depression scale score of more than 6 or has suicidal ideation.
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease," Current clinically significant chronic illness that is likely to result in deterioration of the subject's condition or affect the subject's safety during the study, including uncontrolled diabetes. Subjects with a history of diabetic ketoacidosis will also be excluded. Other cases of diabetes will be decided at the discretion of the study physicians. Subjects with diabetes controlled with exercise and diet may be screened and admission to study will depend on their screening safety laboratory assessments."
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease," History of clinically evident stroke or history of clinically significant carotid or vertebrobasilar stenosis or plaque and other risk factors for thromboembolic stroke (e.g atrial fibrillation, clinically significant low ventricular output, atrial septal defect)."
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, History of seizures.
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease," Clinically significant infection within the last 30 days (eg, chronic persistent or acute infection [eg, upper respiratory infection, urinary tract infection]),prior to screening."
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Myocardial infarction within the last 2 years.
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease," Abnormal screening visit electrocardiogram (ECG), in the opinion of the investigator."
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Uncontrolled hypertension within the last 6 months prior to screening.
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease," History of cancer within the last 3 years, with the exception of nonmetastatic basal cell carcinoma and squamous cell carcinoma of the skin. (Note: cancer must be in remission with no signs of progression.)"
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Use of experimental or other investigational medications/devices for treatment within 90 days prior to screening.
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Laboratory findings of fasting total cholesterol greater than or equal to 240 mg/dL
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Laboratory findings of fasting triglycerides greater than or equal to 200 mg/dL
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Laboratory findings of fasting glucose greater than or equal to 126 mg/dL
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease," Other clinically significant abnormality on physical, neurological, laboratory, vital signs, or ECG examination (eg, changes consistent with recent infarction, ischemia, clinically significant arrhythmias and clinically significant conduction defects) that could be detrimental to the subject or compromise the study."
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Does not have adequate venous access that would allow blood draws.
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Subject or study partner is related to study personnel.
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Subjects who have taken coconut oil as a supplement within the last 30 days.
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Subjects who have taken Axona within the last 30 days.
NCT01883648,Phase 2/Phase 3,Alzheimer's Disease,University of South Florida,Jun-13,Alzheimer Disease, Women who are pregnant. (Women who are of child bearing potential must take precautions to not become pregnant during the study.)
NCT01886820,Phase 3,Alzheimer's Disease,Navidea Biopharmaceuticals,unknown,Alzheimer Disease;Dementia, Scheduled for surgery and/or another invasive procedure within the time period of up to 7 days after [18F]NAV4694 injection.
NCT01886820,Phase 3,Alzheimer's Disease,Navidea Biopharmaceuticals,unknown,Alzheimer Disease;Dementia," Has severe cerebral macrovascular (i.e., multi-stroke) disease or brain tumor (metastasis/brain cancer) as verified by MRI that prohibits sampling of the required pre-specified ROIs."
NCT01886820,Phase 3,Alzheimer's Disease,Navidea Biopharmaceuticals,unknown,Alzheimer Disease;Dementia, Has any history of any transmissible spongiform encephalopathy (prion disease).
NCT01886820,Phase 3,Alzheimer's Disease,Navidea Biopharmaceuticals,unknown,Alzheimer Disease;Dementia," Has received any contrast material (X-ray, MRI) or radiopharmaceutical within 48 hours prior to, or a therapeutic radiopharmaceutical (e.g., 131-I) within 10 days prior to, or any radiopharmaceutical administration within 10 radioactive half-lives prior to the administration of the investigational product or for whom administration of such substances is planned within 7 days after investigational product administration."
NCT01886820,Phase 3,Alzheimer's Disease,Navidea Biopharmaceuticals,unknown,Alzheimer Disease;Dementia, Is allergic to the investigational product or any of its constituents.
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease," Does not have a reliable caregiver who is in frequent contact with the participant (defined as at least 10 hours per week), will accompany the participant to the office and/or be available by telephone at designated times, and will monitor administration of prescribed medications"
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease, Meets National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) criteria for vascular dementia
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease," Has current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study; or has a life expectancy of less than 2 years"
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease, Has had a history within the last 5 years of a serious infectious disease affecting the brain or head trauma resulting in protracted loss of consciousness
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease," Has a history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific antigen posttreatment"
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease," Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions"
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease," Has received acetylcholinesterase inhibitor (AChEIs), memantine and/or other AD therapy for less than 4 months or has less than 2 months of stable therapy on these treatments"
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease," Has received medications that affect the central nervous system (CNS), except treatments for AD, for less than 4 weeks"
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease, Has a history of chronic alcohol or drug abuse/dependence within the past 5 years
NCT01900665,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jul-13,Alzheimer Disease," Has a Visit 1 MRI with results showing greater than 4 Amyloid-related Imaging Abnormality (ARIA), hemorrhage /hemosiderin deposition (ARIA-H) or presence of ARIA-E (edema/effusions)"
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a current diagnosis or history of any type of cognitive impairment or dementia or has a current diagnosis or history of neurological/psychiatric disorder or any other diagnosis that significantly affects cognitive performance (eg, mental retardation, organic mental disorder)."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a current diagnosis of significant psychiatric illness, per Diagnostic  and  Statistical Manual of Mental Disorders, 4th Edition - Text Revision (DSM-IV-TR) (or DSM-V when published) (including but not limited to major depressive disorder, anxiety disorders) and is in an acute phase/episode, or the participant has a current diagnosis or history of schizophrenia or bipolar disorder."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a glycosylated hemoglobin (HbA1c) greater than 8.0% at the time of baseline or requires treatment with insulin, triple oral antidiabetic therapy or a peroxisome proliferator-activated receptor-gamma (PPAR-) agonist. The participant should be on a stable antidiabetic regimen for at least 3 months prior to enrollment."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or cardiovascular, pulmonary, gastrointestinal (including s/p gastric bypass), endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance. History of HIV infection is considered exclusionary for this study."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse/dependence within 2 years prior to the Screening Visit.
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Is an immediate family member, testing center employee, or is in a dependent relationship with a testing center employee who is involved in conduct of this study (eg, spouse, parent, child, and sibling) or may consent under duress."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Has a history of hypersensitivity or allergies to pioglitazone or related compounds.
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Is required to take excluded medications as specified in the Excluded Medications Section.
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Had any of the following values at the Baseline Visit (Visit 2):
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,A serum total bilirubin value greater than 1.5 upper limit of normal (ULN).
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value greater than 2xULN.
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Unexplained microscopic/macroscopic hematuria on one repeat examinations within 2 weeks of the initial assessment.
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Is positive for either Hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV) antibodies at the Baseline Visit (Visit 2).
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a condition or takes medication that, in the opinion of the Investigator, could interfere with the assessments of safety, tolerability, or efficacy, or prevent the participant from adequately participating in the study or continue for the anticipated duration of the study."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has received any investigational compound within 30 days prior to screening or 5 half-lives prior to Screening or is currently participating in another study which entails the administration of an investigational or marketed drug, supplement or intervention including, but not limited to diet, exercise, lifestyle or invasive procedure."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Has a history of any cancer that has been in remission for less than 2 years from the Screening Visit. Participants with basal cell or stage I squamous cell carcinoma of the skin will be eligible. Participants with history of bladder cancer are not eligible irrespective of the remission status.
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Has a history or current diagnosis of macular edema or macular degeneration.
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"If female, has a history of postmenopausal fractures with no or minimal trauma (eg, wrist, hip, lumbar or thoracic vertebral fracture)."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a history or current diagnosis of congestive heart failure (CHF), New York Heart Association Class III-IV."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has been exposed to the cognitive tests performed in this study within 6 months prior to the Screening Visit, with the exception of the MMSE."
NCT01931566,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Participant's Translocase of the Outer Mitochondrial Membrane 40 homolog (TOMM40) rs10524523 or apolipoprotein E (APOE) genotypes or APOE phenotype are known by the participant or the study staff participating in this study.
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, History of stroke within 6 months;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Previous diagnosis of severe (more than 80%) intracranial artery stenosis;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil," History of heart failure, ischemic heart disease (myocardial infarction, unstable angina, and stable angina), hypertrophic cardiomyopathy, and life-threatening arrhythmia;"
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Previous history of coronary artery bypass graft surgery;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil," Severe symptom of orthostatic hypotension (orthostatic syncope or presyncope), especially when patients take alpha-adrenergic blocker (Alfuzosin, Doxazosin, Naftopidil, Tamsulosin, Terazosin, Arotinolol, Carvedilol, Labetalol, Trazodone, typical and atypical antipsychotics);"
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Uncontrolled diabetes mellitus;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Proliferative diabetic retinopathy;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Severe hypotension (blood pressure less than 90/50mmHg) or severe hypertension (blood pressure more than 170/100mmHg);
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Hepatic dysfunction (AST or ALT more than three times of upper normal limit) or renal dysfunction (serum creatinine more than 2.5mg/dL);
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Retinitis pigmentosa;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Previous history of active peptic ulceration within one year before screening;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil," Hematodyscrasia susceptible to priapism including sickle cell anemia, multiple myeloma, leukemia, and various bleeding disorders;"
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, History of drug abuse;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil," Medication including nitrates/nitric oxide donor (ex: nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrate/nitrite, and Sodium nitroprusside), androgen (ex: testosterone), anti-androgen, and anticoagulants;"
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil, Current cancer chemotherapy;
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil," Usage of PDE5i (Zydena, Viagra, Levitra, or Cialis) within two weeks before study start;"
NCT01940952,Phase 3,Alzheimer's Disease,Samsung Medical Center,Sep-13,Alzheimer Disease;Donepezil;Udenafil," History of hypersensitive reaction to PDE5i (Zydena, Viagra, Levitra, or Cialis)"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,History of stroke
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"Evidence of a clinically relevant neurological disorder other than the disease being studied (i.e., prodromal AD)"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,History of seizures or epilepsy within the last 5 years
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"Evidence of a clinically relevant or unstable psychiatric disorder, excluding major depression in remission"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,Participant is at imminent risk of self-harm or of harm to others
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,History of alcoholism or drug dependency/abuse within the last 5 years before Screening
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"Participant does not have a magnetic resonance imaging (MRI) scan obtained within 12 months of Screening and is unwilling or not eligible to undergo an MRI scan at the Screening Visit. With Sponsor approval, a head computed tomography (CT) scan may be substituted for MRI scan to evaluate eligibility"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,History of hepatitis or liver disease that has been active within the 6 months prior to Screening
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"Recent or ongoing, uncontrolled, clinically significant medical condition within 3 months of Screening"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"History of malignancy occurring within the 5 years before Screening, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or localized prostate carcinoma"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,Clinically significant vitamin B12 or folate deficiency in the 6 months before Screening
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,Use of any investigational drugs or participation in clinical trials within the 30 days before Screening
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,History of a hypersensitivity reaction to more than three drugs
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,Has human immunodeficiency virus (HIV) by medical history
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"Participant is unwilling or has a contraindication to undergo PET scanning including but not limited to claustrophobia, excessive weight or girth"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"History or current evidence of long QT syndrome, corrected QT (QTc) interval 470 milliseconds (for male participants) or 480 milliseconds (for female participants), or torsades de pointes"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"Close family member (including the trial partner, spouse or children) who is among the personnel of the investigational or sponsor staff directly involved with this trial"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,Participant is at imminent risk of self-harm or of harm to others
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"Has developed a recent or ongoing, uncontrolled, clinically significant medical or psychiatric condition"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,"Results of safety assessments (e.g., laboratory tests) performed in participant at end of Part 1 that are clinically unacceptable to the Investigator"
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,Has developed a form of dementia that is not AD
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,Has progressed to dementia due to AD per investigator diagnosis in the initial 104-week study (Part 1).
NCT01953601,Phase 3,Prodromal Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Cognitive Dysfunction,Had one or two PET scans with MK-6240 in the initial 104-week study.
NCT01955161,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Oct-13,Alzheimer Disease," The patient has evidence of any clinically significant neurodegenerative disease, or other serious neurological disorders other than AD."
NCT01955161,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Oct-13,Alzheimer Disease," The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) Axis I disorder other than AD."
NCT01955161,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Oct-13,Alzheimer Disease, The patient has evidence of clinically significant disease.
NCT01955161,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Oct-13,Alzheimer Disease, The patient's donepezil therapy is likely to be interrupted or discontinued during the study.
NCT01955161,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Oct-13,Alzheimer Disease, The patient is currently receiving memantine or has taken memantine within 2 months prior to screening.
NCT01955161,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Oct-13,Alzheimer Disease, Other inclusion and exclusion criteria may apply.
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Significant medical, psychiatric, or neurological condition or disorder documented by history, physical, neurological, laboratory, or electrocardiogram (ECG) examination that would place the participant at undue risk in the investigator's judgment or impact the interpretation of efficacy"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, History of stroke. Participants with a history of transient ischemic attack may be enrolled if the event occurred greater than =2 years prior to screening
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," History of severe, clinically significant (persistent neurological deficit or structural brain damage) central nervous system trauma (e.g. cerebral contusion)"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Body weight less than 45 or greater than 120 kilograms (kg)
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, History or presence of atrial fibrillation that poses a risk for future stroke in the investigator's judgment
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Clinically significant laboratory or ECG abnormalities (e.g., abnormally prolonged or shortened QTc interval) in the investigator's judgment"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Current presence of bipolar disorder or other clinically significant major psychiatric disorder according to Diagnostic and Statistical Manual of Mental Disorders 4th Edition Text Revision (DSM-IV-TR) or symptom (e.g., hallucinations, agitation, paranoia) that could affect the participant's ability to complete evaluations"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Clinically significant depression, based in part by a Geriatric Depression Scale (short form) (15-point scale) score greater than 9 at screening"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," History of seizures (excluding febrile seizures of childhood, or other isolated seizure episodes that were not due to epilepsy in the judgment of the investigator, and required at most time-limited anticonvulsant treatment, and which occurred more than 7 years prior to the screening visit)"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Myocardial infarction within 2 years, congestive heart failure, atrial fibrillation, or uncontrolled hypertension"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Pregnant or nursing women, or women who intend to become pregnant or to nurse infants during the conduct of this trial"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Clinically significant infection within the last 30 days prior to screening
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Positive urine test for drugs of abuse at screening
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, History of alcohol or substance dependence within the previous two years
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Use of any other medications with the potential to significantly affect cognition; intermittent or short-term use of these medications may be allowed if deemed medically necessary for the treatment of a non-excluded medical condition with approval from the Medical Monitor. In addition, use of tricyclic antidepressants or benzodiazepines will be permitted if used in stable, low doses for the treatment of a non-excluded medical condition with approval from the Medical Monitor"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Use of typical anti-psychotics or barbiturates
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Use of non-anti-cholinergic antidepressant medications or atypical anti-psychotics unless maintained on a stable dose regimen for at least 6 weeks prior to screening
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Use of any Food and Drug Administration (FDA)/Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)-approved medications for treatment of late onset Alzheimer's disease (LOAD) at screening/baseline. Cholinesterase inhibitors and/or memantine are prohibited during the study except in participants enrolled in the study that develop AD dementia
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Use of anti-coagulant medication (heparinoids, heparin, warfarin, thrombin inhibitors, Factor Xa inhibitors), or known coagulopathy or platelet count less than 100,000 cells/microliter, within 4 weeks of the screening visit; Anti-platelet medications (e.g., aspirin, clopidigrel, dipyridamole) are permitted if on a stable dose for 4 or more weeks prior to screening. Short-term, peri-operative use of anti-coagulants may not result in discontinuation from the study; however, any such use must be discussed with the Medical Monitor"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Treatment with any biologic therapy within five half-lives or 3 months prior to screening, whichever is longer, with the exception of routinely recommended vaccinations, which are allowed"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Use of anti-seizure medication (except in childhood for febrile seizures or if used for non-seizure indications), anti-parkinsonian, or stimulant (e.g., methylphenidate) medications"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Use of investigational drug, device, or experimental medication within 60 days (or five half-lives, whichever is longer) of the screening visit"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Previous treatment with crenezumab or any other therapeutic that targets A-beta
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins"
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Contraindication to MRI scan procedures or clinically significant claustrophobia that would contraindicate a brain MRI scan
NCT01998841,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Contraindication to PET scan procedures
NCT02006641,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Feb-14,Alzheimer Disease," The patient has evidence of any clinically significant neurodegenerative disease, or other serious neurological disorders other than AD."
NCT02006641,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Feb-14,Alzheimer Disease," The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) Axis I disorder other than AD."
NCT02006641,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Feb-14,Alzheimer Disease, The patient has evidence of clinically significant disease.
NCT02006641,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Feb-14,Alzheimer Disease, The patient's donepezil therapy is likely to be interrupted or discontinued during the study.
NCT02006641,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Feb-14,Alzheimer Disease, The patient is currently receiving memantine or has taken memantine within 2 months prior to screening.
NCT02006641,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Feb-14,Alzheimer Disease, Other inclusion and exclusion criteria may apply.
NCT02006654,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Mar-14,Alzheimer Disease," The patient has evidence of any clinically significant neurodegenerative disease, or other serious neurological disorders other than AD."
NCT02006654,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Mar-14,Alzheimer Disease," The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) Axis I disorder other than AD."
NCT02006654,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Mar-14,Alzheimer Disease, The patient has evidence of clinically significant disease.
NCT02006654,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Mar-14,Alzheimer Disease, The patient's current AChEI therapy is likely to be interrupted or discontinued during the study.
NCT02006654,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Mar-14,Alzheimer Disease, The patient is currently receiving memantine or has taken memantine within 2 months prior to screening.
NCT02006654,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,Mar-14,Alzheimer Disease, Other inclusion and exclusion criteria may apply.
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Current clinically significant psychiatric disease
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Evidence of structural brain abnormalities
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, History of moderate or severe traumatic brain injury
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Current clinically significant cardiovascular disease or ECG abnormalities, or additional risk factors for Torsades de Pointes"
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer"
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, History of alcohol or substance abuse or dependence
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception"
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have received or participated in a trial with investigational medications in the past 30 days
NCT02016560,Phase 2/Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session.
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,"Subjects with co-morbid dementia due to other neurological disorders such as Parkinson's disease, vascular dementia, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, or multiple sclerosis, as well as subjects with HIV disease, neurosyphilis, history of significant head trauma with loss of consciousness followed by persistent neurological deficits, known structural brain abnormalities, or any other condition known to interfere with cognitive function."
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,Subjects currently taking any calcium channel blocker or Beta-blocker
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,"Subjects who in the opinion of the investigator, have a medical condition that would preclude them from participating in the study (e.g.hemodynamically significant coronary artery disease., chronic heart failure, syncope within the past year, significant valvular heart disease i.e. severe aortic and mitral stenosis.. symptomatic orthostatic hypotension within the last year, subjects requiring more than one agent to control BP.), or subjects who in the opinion of the investigator are unlikely to complete per protocol due to care issues etc:"
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,"Current Axis I diagnosis of schizophrenia, bipolar disorder, major depression. Subjects who are currently or who have within the past year met criteria for drug or alcohol abuse or dependence."
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,Pregnant women or women who may possibly become pregnant.
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,Subjects with a history of hypersensitivity to nilvadipine (Nivadil).
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,"Subjects who have taken an investigational or other unapproved drug during the 30 days or five half-lives, whichever is longer, prior to baseline."
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,Subjects who are participating in other research studies.
NCT02017340,Phase 3,Alzheimer's Disease,Prof Brian Lawlor,unknown,Alzheimer Disease;Nilvadipine,"Patients with a SBP of  100 mmHg and/or a DBP of  65 mmHg on office based BP measurements, or a SBP  105 mmHg and/or a DBP of  70 mmHg on ABPM will not be included in the study."
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, History of hypotension or unstable hypertension
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, Active hepatic or renal disease
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, Use of another investigational drug within the past two months
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, History of clinically significant stroke
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, History of seizure or head trauma with disturbance of consciousness within the past two years
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol," Major mental illness including psychotic disorders, bipolar disorder, or major depressive episode that is not in remission for less than 12 months"
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, Women of child-bearing age unless using effective birth control or at least one year post-menopausal or surgically menopausal
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, Any ferrous or metallic materials which are contraindicated for MRI
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, Medication Exclusions
NCT02033941,Phase 2,Alzheimer's Disease,Hillel Grossman,Nov-14,Alzheimer Disease;Phenol, Current use of drugs with significant anticholinergic or antihistaminic properties
NCT02035553,Phase 2,Alzheimer's Disease Psychosis,ACADIA Pharmaceuticals Inc.,Nov-13,Alzheimer Disease;Psychotic Disorders;Mental Disorders;Pimavanserin," Patient has a history of significant psychotic disorders prior to or concomitantly with the diagnosis of Alzheimer's disease including, but not limited to, schizophrenia or bipolar disorder"
NCT02035553,Phase 2,Alzheimer's Disease Psychosis,ACADIA Pharmaceuticals Inc.,Nov-13,Alzheimer Disease;Psychotic Disorders;Mental Disorders;Pimavanserin, Patient is unable to communicate verbally
NCT02035553,Phase 2,Alzheimer's Disease Psychosis,ACADIA Pharmaceuticals Inc.,Nov-13,Alzheimer Disease;Psychotic Disorders;Mental Disorders;Pimavanserin," Patient has current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the study"
NCT02035553,Phase 2,Alzheimer's Disease Psychosis,ACADIA Pharmaceuticals Inc.,Nov-13,Alzheimer Disease;Psychotic Disorders;Mental Disorders;Pimavanserin, Patient has had a myocardial infarction in the last six months
NCT02035553,Phase 2,Alzheimer's Disease Psychosis,ACADIA Pharmaceuticals Inc.,Nov-13,Alzheimer Disease;Psychotic Disorders;Mental Disorders;Pimavanserin, Patient has moderate to severe congestive heart failure
NCT02035553,Phase 2,Alzheimer's Disease Psychosis,ACADIA Pharmaceuticals Inc.,Nov-13,Alzheimer Disease;Psychotic Disorders;Mental Disorders;Pimavanserin," Patient has any surgery planned during the screening, treatment, or follow-up periods that could interfere with participation in the study per the protocol assessments"
NCT02035553,Phase 2,Alzheimer's Disease Psychosis,ACADIA Pharmaceuticals Inc.,Nov-13,Alzheimer Disease;Psychotic Disorders;Mental Disorders;Pimavanserin," Patients will be evaluated at screening to ensure that all criteria for study participation are met. These evaluations will include specific measures of psychosis severity, delirium, dementia, cardiovascular condition, and pregnancy status. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all protocol-specified entry criteria)."
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Dementia or neurocognitive disorder (NCD) due to a condition other than AD, including, but not limited to, frontotemporal dementia, Parkinson disease, dementia with Lewy bodies, Huntington disease, or vascular dementia"
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, History or presence of clinically evident vascular disease potentially affecting the brain that in the opinion of the investigator has the potential to affect cognitive function
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, History or presence of stroke within the past 2 years or documented history of transient ischemic attack within the last 12 months
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, History or presence of systemic autoimmune disorders potentially causing progressive neurologic disease with associated cognitive deficits
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," History of schizophrenia, schizoaffective disorder, or bipolar disorder"
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Alcohol and/or substance use disorder (according to the DSM-5) within the past 2 years (nicotine use is allowed)
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, History or presence of atrial fibrillation
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Within the last 2 years, unstable or clinically significant cardiovascular disease (e.g., myocardial infarction, angina pectoris, cardiac failure New York Heart Association Class II or higher)"
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Uncontrolled hypertension
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Chronic kidney disease
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Impaired hepatic function
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," PET imaging substudy, in addition to above:"
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Prior participation in other research study or clinical care within the last year such that the total radiation exposure would exceed the local or national annual limits
NCT02051608,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Part 2 Participants who have been discontinued from the study
NCT02051764,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Current clinically significant psychiatric disease
NCT02051764,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Are claustrophobic
NCT02051764,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Current clinically significant cardiovascular disease or ECG abnormalities, or additional risk factors for Torsades de Pointes"
NCT02051764,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer"
NCT02051764,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception"
NCT02051764,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil," Has ever received acetylcholinesterase inhibitors, memantine, or other symptomatic AD treatment including approved medical foods"
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil," Has an uncontrolled, clinically significant medical condition or situation within 3 months prior to screening"
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has had major surgery within 3 months prior to screening
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has tested positive for human immunodeficiency virus (HIV) or has evidence of an active hepatitis B infection
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has a history of malignancy within the prior 5 years
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Is unwilling or ineligible to undergo an MRI scan
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has a history of clinically important structural changes on screening MRI scan
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has a clinically important history of stroke or a diagnosis of vascular dementia
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has evidence of a clinically relevant non-AD neurological disorder
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil," Has a history of head trauma, or serious infectious disease affecting the brain within the prior 3-5 years"
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil," Has evidence of a clinically relevant or unstable psychiatric disorder, excepting major depression in remission"
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has evidence of a current episode of major depression
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has evidence of Type 4 or Type 5 Suicidal Ideation
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has clinically significant vitamin B12 or folate deficiency in the 6 months prior to screening
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil," Is pregnant, attempting to become pregnant or is nursing children"
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has used any investigational drug or participated in any other clinical trial within the prior 30 days
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil, Has a history of alcoholism or drug dependency/abuse within the last 5 years
NCT02064920,Phase 2,Alzheimer's Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Donepezil," Has a relative contraindication to donepezil including sick sinus syndrome, third degree heart block, active gastrointestinal (GI) bleeding, Zollinger-Ellison syndrome, uncontrolled peptic ulcer disease, or uncontrolled asthma"
NCT02078310,Phase 1/Phase 2,Alzheimer's Disease,"Intra-Cellular Therapies, Inc.",Feb-14,Alzheimer Disease;Dementia, Any clinically significant illness within 6 months before screening
NCT02078310,Phase 1/Phase 2,Alzheimer's Disease,"Intra-Cellular Therapies, Inc.",Feb-14,Alzheimer Disease;Dementia, Any history of cancer within last 5 years
NCT02078310,Phase 1/Phase 2,Alzheimer's Disease,"Intra-Cellular Therapies, Inc.",Feb-14,Alzheimer Disease;Dementia," History of Hepatitis B or C infection and elevated ALT, AST or bilirubin above the upper limit of normal level"
NCT02078310,Phase 1/Phase 2,Alzheimer's Disease,"Intra-Cellular Therapies, Inc.",Feb-14,Alzheimer Disease;Dementia, Any subject considered to be an imminent danger to themselves or others
NCT02079246,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,unknown,Alzheimer Disease, The patient has a moderate or severe ongoing adverse event from the lead-in study considered a potential safety risk by the investigator.
NCT02079246,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,unknown,Alzheimer Disease, The patient has experienced seizures before Completion Visit in the lead-in study.
NCT02079246,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,unknown,Alzheimer Disease, The patient has evidence of clinically significant disease.
NCT02079246,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,unknown,Alzheimer Disease, The patient's donepezil treatment is likely to be interrupted or discontinued during the study.
NCT02079246,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,unknown,Alzheimer Disease, The patient is receiving therapy with another acetylcholinesterase inhibitors (AChEI).
NCT02079246,Phase 3,Alzheimer's Disease,H. Lundbeck A/S,unknown,Alzheimer Disease, Other protocol-defined inclusion and exclusion criteria may apply.
NCT02079909,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Mar-14,Alzheimer Disease," Patients with clinically significant cardiac, hepatic or renal impairment"
NCT02079909,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Mar-14,Alzheimer Disease, Patient have a dementia not of the Alzheimer's type etc (According to the protocol)
NCT02079909,Phase 2,Alzheimer's Disease,"FUJIFILM Toyama Chemical Co., Ltd.",Mar-14,Alzheimer Disease," Patients who are taking any drug other than donepezil or rivastigmine transdermal system for Alzheimer's disease, including olal rivastigmine (Exelon), galantamine (Razadyne)"
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Significant neurological or psychiatric disease other than Alzheimer's disease
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Participants with evidence or history of severe drug allergies (resulting in dyspnea or severe rash).
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease," Any contraindications to MRI (e.g., clinically significant claustrophobia, non-removable ferromagnetic implants). Patients with contraindications to MRI may undergo computed tomography (CT) on approval by sponsor."
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Any contraindications to the FDG-PET study (e.g. allergy to any component of the FDG dose) in the cohort undergoing a PET scan.
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Previous exposure to investigational or non-investigational therapies for Alzheimer's disease within 6 months of screening
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease," History of cancer within the last 5 years except adequately treated cervical carcinoma in-situ, cutaneous basal cell or squamous cell cancer, or non-progressive prostate cancer not requiring treatment"
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Women of childbearing potential
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Uncontrolled blood pressure and/or blood pressure above 160/100
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease, Prescription medical food intended for dietary management of the metabolic processes associated with Alzheimer's disease.
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease," Diagnosis or history of cerebrovascular stroke, severe carotid stenosis, cerebral hemorrhage, intracranial tumor, subarachnoid hemorrhage."
NCT02080364,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease," Patients with unstable, uncontrolled diabetes (HbA1c greater than  7.7%) and those requiring insulin."
NCT02164643,Phase 3,Alzheimer's Disease (AD) and Related Disorders,"University Hospital, Bordeaux",unknown,Alzheimer Disease;Flutemetamol, To have a current clinically significant psychiatric condition that neurologists/geriatricians feel would preclude the ability to have a research PET scan
NCT02164643,Phase 3,Alzheimer's Disease (AD) and Related Disorders,"University Hospital, Bordeaux",unknown,Alzheimer Disease;Flutemetamol, To be pregnant or breastfeading women
NCT02164643,Phase 3,Alzheimer's Disease (AD) and Related Disorders,"University Hospital, Bordeaux",unknown,Alzheimer Disease;Flutemetamol, To have Hypersensitivity to the tracer or to the excipient listed in the summary of the product carateristics (florbetapir Amyvid) or the Investigator's Brochure (flutemetamol)
NCT02164643,Phase 3,Alzheimer's Disease (AD) and Related Disorders,"University Hospital, Bordeaux",unknown,Alzheimer Disease;Flutemetamol," To have a relevant history of severe drug allergy or hypersensitivity (relevant severe drug allergies should be determined by the clinical site investigator or co-clinical site investigator). If a subject has a history of severe drug allergies, it may be dangerous for them to participate in a study with a novel compound"
NCT02164643,Phase 3,Alzheimer's Disease (AD) and Related Disorders,"University Hospital, Bordeaux",unknown,Alzheimer Disease;Flutemetamol," To have ever participated in an experimental study with an amyloid targeting agent (e.g. anti-amyloid immunotherapy, -secretase or -secretase inhibitor) unless it can be documented that the subject received only placebo during the course of the trial"
NCT02164643,Phase 3,Alzheimer's Disease (AD) and Related Disorders,"University Hospital, Bordeaux",unknown,Alzheimer Disease;Flutemetamol," To receive any investigational medications, or have participated in a trial with investigational medications within the last 30 days"
NCT02164643,Phase 3,Alzheimer's Disease (AD) and Related Disorders,"University Hospital, Bordeaux",unknown,Alzheimer Disease;Flutemetamol, To have participated less than 1 year ago in a biomedical research with injection of one of the amyloid radioligand or to be enrolled in an ongoing biomedical research including amyloid PET scan
NCT02164643,Phase 3,Alzheimer's Disease (AD) and Related Disorders,"University Hospital, Bordeaux",unknown,Alzheimer Disease;Flutemetamol, To have had a radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"Any significant neurologic disease other than AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities"
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"Screening/baseline MRI scan with evidence of infection, infarction, or other focal lesions or multiple lacunes or lacunes in a critical memory structure"
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"Subjects that have any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or cardiac pacemaker"
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"Major depression, bipolar disorder as described in DSM-IV within the past 1 year or psychotic features, agitation or behavioral problems within 3 months, which could lead to difficulty complying with the protocol"
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,History of schizophrenia (DSM V criteria)
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,History of alcohol or substance abuse or dependence within the past 2 years (DSM V criteria)
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"Clinically significant or unstable medical condition, including uncontrolled hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic disease in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results, or the subject's ability to participate in the study."
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with normal prostate-specific antigen post-treatment"
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"Clinically significant abnormalities in B12 or TFTs that might interfere with the study. A low B12 is exclusionary, unless follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not physiologically significant."
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,Residence in skilled nursing facility.
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,Use of any excluded medication as described in study protocol
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"Current or recent participation in any procedures involving radioactive agents, including current, past, or anticipated exposure to radiation in the workplace, such that the total radiation dose exposure to the subject in a given year would exceed the limits of annual and total dose commitment set forth in the US Code of Federal Regulations (CFR) Title 21 Section 361.1. This guideline is an effective dose of 5 rem received per year."
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"Neutropenia defined as absolute neutrophils count of less than 1,800/microliter"
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,Thrombocytopenia defined as platelet count less than 120x103/microliter
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"For CSF sub-study participants, a current blood clotting or bleeding disorder, or significantly abnormal PT or PTT at screening"
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,"Clinically significant abnormalities in screening laboratories, including:"
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib, Aspartate aminotransferase (AST) greater than 1.5 times ULN
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib, Alanine aminotransferase (ALT) greater than  1.5 times ULN
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib, Total bilirubin greater than 1.5 times ULN
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib, Serum creatinine greater than 2.0 times ULN
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,History of interstitial lung disease
NCT02167256,Phase 2,Alzheimer's Disease,Yale University,unknown,Alzheimer Disease;Saracatinib,Patients whom the PI deems to be otherwise ineligible
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Patients with complications of dementia or memory impairment other than Alzheimer's type dementia
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Dementia patients with a Modified Hachinski Ischemic Score of 5 or higher
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Patients with psychological symptoms or behavioral disorders that are clearly due to other medical conditions or substances
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Patients with a complication or history of stroke or transient ischemic attack, except for asymptomatic stroke"
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Patients with heart failure classified as New York Heart Asscoiation (NYHA III or IV
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Patients who require drug therapy for arrhythmia or ischemic heart disease
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Body weight of less than 30 kg
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Patients with a high risk of suicide
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Patients with a complication or history of seizure disorder
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Patients with a complication or history of neuroleptic malignant syndrome, tardive dyskinesia, paralytic ileus, or rhabdomyolysis"
NCT02168920,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Patients with thyroid disease (except if the disease has been stabilized with drug therapy for 3 months or longer prior to time of informed consent)
NCT02185053,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Women of child bearing potential.
NCT02185053,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, History or presence of a seizure disorder.
NCT02185053,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia," History of peptic ulcer disease, urinary or gastric retention; asthma or obstructive pulmonary disease."
NCT02185053,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia," History or presence of bladder outflow obstruction, gastrointestinal obstructive disorder or reduced GI motility, or narrow-angle glaucoma."
NCT02185053,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia," History or presence of gastrointestinal, hepatic, or renal disease, or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs."
NCT02185053,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, History or presence of myasthenia.
NCT02185053,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia," Known hypersensitivity to donepezil, solifenacin or related drugs."
NCT02185053,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia," Any other clinically relevant acute or chronic diseases which could interfere with patients' safety during the trial, or expose them to undue risk, or which could interfere with study objectives."
NCT02185053,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Patients who have participated in another clinical trial with an investigational drug within previous 30 days.
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1," Dementia due to any condition other than AD, including vascular dementia"
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1," Significant neuroimaging abnormalities, previously known or discovered on screening MRI scan,"
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1," Evidence of clinically significant unstable cardiovascular, renal, hepatic, gastrointestinal, neurological, or metabolic disease within the past 6 months"
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Use of any drug within 14 days prior to randomization unless the dose of the drug and the condition being treated have been stable for at least 30 days and are expected to remain stable during the study
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Use of tobacco products or nicotine-containing products within 3 months before Day 1
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1," Use of high dose vitamin E, or valproic acid"
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Any medical or psychiatric condition that may require medication or surgical treatment during the study
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Life expectancy less than 6 months
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Use of an investigational drug within 2 months prior to the screening visit
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Clinically significant neurological disease other than AD
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1," Major depression, alcohol or drug dependence or suicidality"
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1," Psychotic episodes requiring hospitalization or antipsychotic therapy for more than 2 weeks within the past 10 years, not linked to AD"
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Agitation sufficient to preclude participation in this trial
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Epilepsy or anti-epileptic drug therapy
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Abnormal laboratory tests that might point to another etiology for dementia;
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1, Acute or poorly controlled medical illness
NCT02221947,Phase 1/Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Jun-14,Alzheimer Disease;Bryostatin 1," Likelihood, according to clinical judgment, of being transferred to a nursing home within 6 months"
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease," Significant neurological disease affecting the central nervous system, other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinsons disease, or epilepsy or recurrent seizures"
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease," History of clinically evident stroke, or multiple strokes based on history or imaging results"
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease, History of clinically important carotid or vertebrobasilar stenosis or plaque
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease, History of multiple concussions with sustained cognitive complaints or objective change in neuropsychological function in the last 5 years
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease," Participants with a current Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of Major Depressive Disorder or any current primary psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the participants ability to complete the study"
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease, History of alcohol or drug abuse or dependence (except nicotine dependence) within 2 years before the screening
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease," Within 1 year before the screening or between screening and baseline, any of the following: myocardial infarction; moderate or severe congestive heart failure, New York Heart Association class III or IV; hospitalization for, or symptom of, unstable angina; syncope due to orthostatic hypotension or unexplained syncope; known significant structural heart disease (eg, significant valvular disease, hypertrophic cardiomyopathy), or hospitalization for arrhythmia"
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease, Congenital QT prolongation
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease," History of cancer within the last 5 years, with the exception of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, non-progressive prostate cancer or other cancers with low-risk of recurrence or spread"
NCT02245737,Phase 2/Phase 3,Alzheimers Disease,AstraZeneca,unknown,Alzheimer Disease," Current serious or unstable clinically important systemic illness that, in the judgment of the investigator, is likely to affect cognitive assessment, deteriorate, or affect the participant's safety or ability to complete the study, including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, or hematologic disorders"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," Patient developed a medical condition during the preceding talsaclidine trial which, in the opinion of the investigator may be worsened by participation in this trial"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Patient experienced any serious drug related adverse event (s) in the preceding talsaclidine trial
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Patient dropped out of the preceding talsaclidine trial
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Patient was a major protocol violator in the preceding talsaclidine trial
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Untreated or non-compensated hypertension (BP systolic greater than  180 and/or diastolic greater than  110 mmHg)
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Hypertension being treated with -blockers
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Severe heart failure (NYHA: III and IV)
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," Any arrhythmias including bradycardia with a rate of less than 50 bpm, arrhythmias due to second or third degree blocks and low II-IV, ECG less than 30 ventricular extra systoles/hour, multifocal or multiform and repetitive forms of ventricular extra systoles"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Bronchial asthma with phases of exacerbation or inducible by aspirin or other NSAIDSs
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," Any patient with diabetes, type I or II, under active treatment with either insulin or any oral agent"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," Renal insufficiency: calculated creatinine clearance below normal range (based on gender, age and weight)"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Acute hepatic disorder (liver enzymes above 50% upper normal limit)
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Patient has obvious symptoms of dehydration
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," Neoplasm currently active or likely to recur (except basal cell carcinoma, squamous cell carcinoma of the skin and clinically significant meningioma)"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Patient is participating in another clinical trial
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," Pregnant and lactating women, women of childbearing potential not using an approved method of contraception"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Insufficient compliance: in the investigator's opinion the patient or caregiver are unable to comply with the protocol requirements
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Exclude subjects with less than 50 kg body weight and/or with a calculated creatinine clearance below 50 ml/min. (It will be calculated by the central laboratory - values below normal range will be flagged by the central laboratory)
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Patients with abnormal urinalysis results such as infection or proteinuria as defined by:
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," A positive urinary bacterial culture, equal or greater than 10exp5 colony forming unit (CFU)/ml or"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, More than 10 leukocytes per high power field and with more than greater than  2 granular casts per low power field or
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, More than 10 red blood cells per high power field or
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, greater than +1 proteinuria (equivalent to greater than 30 mg/dl) and with a ratio of urine protein/urine creatinine greater than 0.3
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," Any patient with a history of chronic urinary tract infection or recent urinary tract infection over the past six months. If the patient developed a lower urinary tract infection during their participation in the study 506.203 without any sign of kidney failure, then they are allowed to enter the study. Patients may continue in the trial only if the infection is confined to the lower urinary tract and without any sign of kidney failure, but must be discontinued otherwise"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Patients with a history of renal stones within the past six months
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Concomitant Therapy exclusion
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," Benzodiazepines (brotizolam, oxazepam, temazepam, or triazolam are allowed)"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Antidepressants including all tricyclics (trazodone is allowed; for clinically relevant depressed mood the Selective Serotonine Re-uptake Inhibitors (SSRIs) fluoxetine or paroxetine or sertraline are allowed)
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Antipsychotics (haloperidol or risperidone are allowed)
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Anticholinergics (topical application and promethazine is allowed)
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Lithium
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Acetylcholinesterase inhibitors
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Monoamine oxidase inhibitors
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia,  blockers including topical application
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," Any concomitant therapy with significant nephrotoxic potential in case of urinary tract infection (e.g. aminoglycoside, antibiotics and/or radiographic contrast agents)"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia, Hypericum perforatum (St John's wort) is excluded
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," Use of neuroleptics within the trial: If the use of any neuroleptic is required during the course of the trial, the reason should be documented as an adverse event and the use of such medication should be limited. Use of neuroleptics should be stopped as soon as the patient's clinical status allows this to happen"
NCT02248116,Phase 2/Phase 3,Alzheimer Disease,Boehringer Ingelheim,May-99,Alzheimer Disease;Dementia," Patients receiving cognitive training prior to study entry are not excluded, but the training should be continued, if possible, throughout the trial"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Any dementia of vascular genesis (Rosen ischemia score greater than  2)
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Magnetic Resonance Imaging (MRI) or Computer Tomogram (CT) findings make the diagnosis of DAT unlikely (with a scan performed within 12 months of study entry)
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Any stroke history
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, All secondary dementia (exclusion diagnosis defined by the NINCDS-ADRDA criteria) as a late complication of:
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Cranio-cerebral trauma
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Intoxication (incl. history of alcohol and drug abuse)
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Cerebral infections (e.g. neurosyphilis)
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Thyroid dysfunction
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Cerebral dysfunction due to metabolic disorders
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," Possible reversible dementias secondary to a deficiency of vitamin B12, folic acid or thyroid hormone. Replacement therapy must be started three months before visit 1 in order to exclude dementia due to these deficiencies."
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," Brain tumour (benign tumours found on CT not felt to be clinically relevant may be included, i.e.: meningioma)"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," Down's syndrome, Parkinson's disease, Huntington's chorea, Diffuse Lewy Body Disease (as measured by the McKeith Criteria and specified in CTM)"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Multiple sclerosis
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Major depression with a score of less than =16 on the Hamilton Depression Rating Scale (HAMD) 17 item scale
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Depressive pseudodementia
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Mental retardation
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Hydrocephalus
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Epilepsy
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Endogenous psychoses (schizophrenia)
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Untreated or poorly compensated hypertension (Blood Pressure systolic greater than  180 and/or diastolic greater than  110 mmHg)
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," Hypertension being treated with reserpine, clonidine or -blockers"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Severe heart disease (NYHA: III and IV)
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," Any cardiac arrhythmias (atrial or ventricular) including bradycardia with a rate of less than  50 bpm, arrhythmias due to second or third degree blocks and Lown: II-IV, Electrocardiogram greater than  30 ventricular extrasystoles/hour, multifocal or multiform and repetitive forms of ventricular extrasystoles, pacemakers are allowed"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," Bronchial asthma with phases of exacerbation, or inducible by aspirin or other Nonsteroidal anti-inflammatory drugs, requiring acute pharmacologic intervention during the previous year"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," Diabetes, type I or II, under active treatment with either insulin or an oral agent, diabetes controlled by diet and exercise alone is not excluded"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Renal insufficiency with a calculated creatinine clearance of less than 50 ml/min
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Abnormal urinalysis results as defined by:
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," a bacterial colony count of greater than 100,000/ml or"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, more than 10 leukocytes per high power field with more than 2 granular casts per low power field or
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, more than 10 red blood cells per high power field or
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, proteinuria greater than + 1 (equivalent to greater than  30 mg/dl) and with a ratio of urine protein/urine creatinine greater than  0.3
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, History of chronic urinary tract infection or recent urinary tract infection over the past six months
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, History of renal stones within the past six months
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Acute hepatic disorder (liver enzymes above 50 % upper normal limit)
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," Chronic hepatitis within the last two years (positive hepatitis titer, Hepatitis A Virus, Hepatitis B Virus, Hepatitis C Virus, cytomegalovirus, Epstein-Barr virus or abnormal immunological values (positive immunoglobulin M(IgM)/IgG) are allowed if all liver enzymes are within the normal range)"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," History of liver disease within 2 years secondary to drug intoxication of any cause including drug intoxication (e.g. narcotics, cytostatics etc.)"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Patients with obvious symptoms of dehydration
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Abuse or dependence on drugs or other hepatotoxic agents by history or drug screen. A history of alcohol abuse within the last 10 years will also exclude the patient
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," Neoplasm currently active or likely to recur, or in need of treatment (except basal cell carcinoma)"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," Participation in another clinical trial within the last four weeks, or previous participation in a talsaclidine trial; patients who have been entered into panel 1 are not eligible for inclusion in panel 2"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," Pregnant and lactating woman, woman with childbearing potential not using an approved method of contraception"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, Poor ability of the patient or caregiver/family to comply with protocol requirements as assessed by the investigator
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," A list of excluded medications is attached to the protocol. These medications have to be replaced at least four weeks before the trial medication is started. If replacement in not clinically advisable, then the patient has to be excluded from the trial"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia," In Germany, patients with the following additional diagnosis are excluded"
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, manifest angina pectoris as well as
NCT02249351,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Dec-99,Alzheimer Disease;Dementia, peripheral arterial circulatory disturbances
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Any dementia of vascular genesis (excluded by Rosen ischemia score greater than  2)
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia," Magnetic Resonance Imaging (MRI) or Computer Tomogram (CT) (more recent than 12 months; if a MRI of CT recording is performed more than 12 months before study entry, it must be repeated) findings make the diagnosis of DAT unlikely"
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Any stroke history
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, All secondary dementia (exclusion diagnosis defined by the NINCDS-ADRDA criteria) as a late complication of:
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Cranio-cerebral trauma
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Intoxication (incl. history of alcohol and drug abuse)
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Cerebral infections (e.g. neurosyphilis)
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Thyroid dysfunction
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia," Cerebral dysfunction due to metabolic disorders (e.g. unstable thyroid dysfunction, or unstable insulin-dependent diabetes mellitus with hypo-/hyper-glycemic episodes)"
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Deficiency of vitamin B12 or folic acid as a reason of dementia
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia," Brain tumour (A patient with an incidental tumour found on CT not felt to be clinically relevant may be included, i.e.: meningioma)"
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia," Down's syndrome, Parkinsonism, Huntington's chorea"
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Multiple sclerosis
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Major depression defined by the Hamilton Depression Rating Scale (HAMD) 17 item scale ( 16)
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Depressive pseudo dementia
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Mental retardation
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Hydrocephalus
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Epilepsy
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Endogenous psychoses (schizophrenia)
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Untreated or non-compensated hypertension (Blood Pressure systolic greater than  180 and/or diastolic greater than  110 mmHg)
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia," Hypertension being treated with reserpine, clonidine or -blockers (these cases have to be adjusted to therapy with e.g. calcium antagonists 4 weeks before start of treatment)"
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Severe heart failure (NYHA: III and IV)
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia," Arrhythmias (Lown: II-IV, Electrocardiogram greater than  30 ventricular extrasystoles/hour, multifocal or multiform and repetitive forms of ventricular extrasystoles)"
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Bronchial asthma with phases of exacerbation or inducible by aspirin or other Nonsteroidal anti-inflammatory drugs
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia," Severe diabetes mellitus: insulin dependent and not stabilised (patient with an HbA1c in normal range, clinically stable diabetes and any case of insulin dose  0.5 UI/kg/day may be included), or other metabolic diseases"
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Renal insufficiency: calculated creatinine clearance is less than 60 ml/min
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Acute hepatic disorder (liver enzymes above 50 % upper normal limit)
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia," Chronic hepatitis within the last two years (positive hepatitis titer, Hepatitis A Virus, Hepatitis B Virus, Hepatitis C Virus, cytomegalovirus, Epstein-Barr virus or abnormal immunological values (positive immunoglobulin M(IgM)/IgG) are allowed if all liver enzymes are within the normal range)"
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia," Recent history of liver disease (2 years) including drug intoxication (e.g. narcotics, cytostatics etc.)"
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Patients with obvious symptoms of dehydration
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia," History of drug or alcohol abuse or dependence on other hepatotoxic agents (if a patient is permanently hospitalised and a drug screen performed at the beginning of hospitalisation, no additional drug screen is necessary)"
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Neoplasm currently active or likely to recur (except basal cell carcinoma)
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Participation in another clinical trial within the last four weeks and re-entering from this or a previous talsaclidine trial
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia," Pregnant and lactating woman, woman with childbearing potential not using an approved method of contraception"
NCT02249403,Phase 2,Alzheimer Disease,Boehringer Ingelheim,Jan-99,Alzheimer Disease;Dementia, Insufficient compliance: in the investigator's opinion the patient or family is unable to comply with the protocol requirements
NCT02260674,Phase 2,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Nov-14,Alzheimer Disease," Participant has evidence of any brain disease, other than potential very early signs of AD (e.g. mild hippocampal atrophy) or typical age-related changes (e.g. mild white matter hyperintensity on magnetic resonance imaging [MRI]) or any other abnormality (e.g. folic acid/Vitamin B12 deficiency) that could explain a possible cognitive deficit (including, but not limited to vascular encephalopathy or strokes including lacuna's (as imaged by cerebral MRI) and Major Depression (as defined by most current Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria)"
NCT02260674,Phase 2,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Nov-14,Alzheimer Disease," Participant has evidence of familial autosomal dominant AD. (Inclusion can be made upon written confirmation by sponsor, when the mutation is known and deemed not to be modulating Beta-secretase [BACE] cleavage)"
NCT02260674,Phase 2,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Nov-14,Alzheimer Disease, Participant with history or presence of significant depression as defined by the most current DSM criteria
NCT02260674,Phase 2,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Nov-14,Alzheimer Disease," Participant has a clinically significant abnormal physical- or neurological examination, vital signs at screening or baseline (Day 1 predose)"
NCT02260674,Phase 2,Alzheimer's Disease,"Janssen Research &amp; Development, LLC",Nov-14,Alzheimer Disease," Participant has a history of or current liver or renal insufficiency; clinically significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, hematologic, rheumatologic, psychiatric, or metabolic disturbances (e.g. unstable situation needing monitoring or regular dose adaptations)"
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Concomitant severe neurological disease Alzheimer Disease.
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,"Presence or history of psychiatric disorders with an emphasis on positive behavioral disorders associated with Alzheimer Disease (aggressiveness, agitation, delusions, hallucinations, anxiety)."
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Current Severe systemic disease that may prevent completion of the study.
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,History STROKE.
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,History of convulsions and use of anticonvulsants.
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,"History of myocardial infarction, angina pectoris, cardiac arrhythmias and other serious cardiovascular disorders such as congestive heart failure, and valvular aneurysms."
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Background Diabetes mellitus and / or pictures of hypoglycemia.
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Uncontrolled hypertension (systolicgreater than  160 mmHg and / or Diastolicgreater than  95 mmHg).
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Systemic hypotension (SBP less than 86 mmHg) or bradycardia (less than 50 beats per minute)
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Bronchial Asthma History or lung diseases that cause bronchospasm or bronchoconstriction
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Kidney failure (patients with medical restrictions or income parenteral intake of fluids).
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Liver failure.
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Respiratory failure (need supplemental oxygen supply)
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Blood donation in the last 90 days or anemia (Hb less than 10g/dL)
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,"Use connection (less than 30 days prior to screening) of antidepressants, sedatives and hypnotics."
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Using Alzheimer Disease experimental drugs in the last 60 days prior to screening.
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Women who are pregnant or fertile
NCT02279511,Phase 2,Alzheimer's Disease,Sara Varea,unknown,Alzheimer Disease;Adenosine,Inadequate venous access to prevent parenteral administration of infusions.
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Completed the pivotal AD-4833/TOMM40_301 study with an adjudicated diagnosis of AD dementia.
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a current diagnosis of significant psychiatric illness, per Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (including but not limited to major depressive disorder, anxiety disorders) and is in an acute phase/episode, or the participant has a current diagnosis or history of schizophrenia or bipolar disorder."
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a glycosylated hemoglobin (HbA1c) greater than 8% at the extension study Baseline Visit or requires treatment with insulin, triple oral antidiabetic therapy or a peroxisome proliferator-activated receptor gamma (PPAR-) agonist."
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or cardiovascular, pulmonary, gastrointestinal (including s/p gastric bypass surgery), endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance."
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, pivotal, child, sibling) or may consent under duress."
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Is required to take excluded medications.
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Has a history of hypersensitivity or allergies to pioglitazone or related compounds.
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Had any of the following values at the extension study Baseline Visit:
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,A serum total bilirubin value greater than 15 x upper limit of normal (ULN).
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value greater than 2 x ULN.
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Unexplained microscopic/macroscopic hematuria on 2 repeat examinations within 2 weeks.
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy, or prevent the participant from adequately participating in the study or continue for the anticipated duration of the study."
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has received any investigational compound, with the exception of treatment during the AD-4833/TOMM40_301 study, within 30 days prior to Baseline or 5 half-lives prior to Baseline or is currently participating in another study that entails the administration of an investigational or marketed drug, supplement, or intervention including, but not limited to diet, exercise, lifestyle, or invasive procedure."
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,Has any cancer that has been in remission for less than 2 years from the extension study Baseline Visit. Participants with basal cell or stage I squamous cell carcinoma of the skin will be eligible. Participants with current diagnosis of bladder cancer are not eligible irrespective of the remission status.
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a current diagnosis of macular edema, degeneration or any maculopathy."
NCT02284906,Phase 3,Mild Cognitive Impairment Due to Alzheimer's Disease,Takeda,unknown,Alzheimer Disease;Cognitive Dysfunction;Pioglitazone,"Has a history or current diagnosis of congestive heart failure (CHF), New York Heart Association class III-IV."
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine," Patients with significant neurological disorder other than AD including hypoxia, stroke, traumatic brain injury"
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, A current psychiatric disorder according the DSM-IV diagnosis of major depression unless successfully treated on a stable dose of an antidepressant for at least 4 weeks and continues on stable dose throughout the study
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, Any other DSM-IV Axis l diagnosis including other primary neurodegenerative dementia schizophrenia or bipolar depression
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, A current diagnosis of uncontrolled diabetes mellitus (glucose values greater than  200 mg/ml).
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, Patients with uncontrolled diabetes will be excluded because high glucose will alter the FDG-PET studies. The clinic that does PET (Columbia University Medical Center) excludes patients if glucose values exceed 200 mg/ml.
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine," A current diagnosis of active, uncontrolled seizure disorder"
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, A current diagnosis of probable or possible vascular dementia according to NINDS-AIREN
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, An investigational drug during the previous 4 weeks
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, A current diagnosis of severe unstable cardiovascular disease
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine," A current diagnosis of acute severe, or unstable asthmatic condition (e.g., severe chronic obstructive pulmonary disease (COPD),"
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine," A current diagnosis of cardiac, renal or hepatic disease"
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine," History of alcoholism, current or within past 5 years"
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine," A disability that may prevent the patient from completing all study requirements (e.g., blindness, deafness, severe language difficulty)"
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, A1C less than or equal to 8
NCT02292238,Phase 2,Alzheimer's Disease,Burke Medical Research Institute,unknown,Alzheimer Disease;Benphothiamine, Current diagnosis of cancer/active treatments
NCT02327182,Phase 3,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Dec-14,Alzheimer Disease, Diagnosis of any other disease which may cause dementia
NCT02327182,Phase 3,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Dec-14,Alzheimer Disease," Diagnosis of major depressive disorder as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) within last five years"
NCT02327182,Phase 3,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Dec-14,Alzheimer Disease, History of or current diagnosis of any psychosis
NCT02327182,Phase 3,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Dec-14,Alzheimer Disease, History of myocardial infarction or unstable angina within six months before screening
NCT02327182,Phase 3,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Dec-14,Alzheimer Disease, History of cerebrovascular disorder within 18 months before screening
NCT02327182,Phase 3,Alzheimer's Disease,Mitsubishi Tanabe Pharma Corporation,Dec-14,Alzheimer Disease, complication of hepatic disorder or renal dysfunction
NCT02359552,Phase 2,Alzheimer's Disease,The Cleveland Clinic,unknown,Alzheimer Disease;Rasagiline, Any non-AD neurological disease
NCT02359552,Phase 2,Alzheimer's Disease,The Cleveland Clinic,unknown,Alzheimer Disease;Rasagiline, MRI findings indication of a non-AD diagnosis
NCT02359552,Phase 2,Alzheimer's Disease,The Cleveland Clinic,unknown,Alzheimer Disease;Rasagiline, Screening laboratory studies that are 1.5 times above or below the highest and lowest range of normal for each test respectively
NCT02359552,Phase 2,Alzheimer's Disease,The Cleveland Clinic,unknown,Alzheimer Disease;Rasagiline," History of melanoma; history of malignancy within the past five years with the exception of basal cell or squamous cell cancer, in-situ cervical cancer, or localized prostate cancer"
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease," Early onset of dementia, i.e. before 60 years old to avoid hereditary AD forms"
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Significant neurological disease other than AD
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Major psychiatric disorder or syndrome (schizophrenia or bipolar disorder)
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Seizure disorders
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease," Other infectious, metabolic or systemic diseases affecting central nervous system"
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Other active clinically significant illness
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Hospitalization or change of chronic concomitant medications one month prior to screening
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease," Patients with severe respiratory, hepatic or renal failure or with any other significantly potentially disabling abnormality detected during screening"
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Known hypersensitivity to the tested treatment including active substance and excipients.
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Patients participating in another study and exposed to any investigational therapy within the 30 days prior to the entry in this study.
NCT02361424,Phase 2,Alzheimer Disease,Pharnext SA,Feb-13,Alzheimer Disease, Patient without medical care insurance
NCT02406027,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease," Any condition or situation which, in the opinion of the Investigator, may put the participant at significant risk, may confound the study results, or may interfere significantly with participant's participation in the study"
NCT02406027,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease, The use of concomitant medications known to prolong the QT/QTc interval
NCT02406027,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease," Participant has a history of moderate or severe hepatic impairment or severe renal insufficiency unless completely resolved for more than a year. Participant has clinically significant ongoing hepatic, renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, hematologic, rheumatologic, psychiatric or metabolic conditions (e.g., requiring frequent monitoring or medication adjustments or is otherwise unstable)"
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Evidence of neurodegenerative disease other than AD
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction," Inability for any reason to undergo MRI scans (e.g. pacemaker, vascular stent or stent graft). Patients who require sedation for screening procedures such as MRI may receive a short-acting sedative."
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Psychiatric disorder that would compromise ability to comply with study requirements
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction," History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years"
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction," Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder or metabolic/endocrine disorders or other disease that would preclude treatment with p38 MAP kinase inhibitor and/or assessment of drug safety and efficacy"
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Recent (less than 90 days) changes to AD medications prescribed for cognitive reasons or with the potential to impact cognition
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Psychotropic drugs taken within 1 month. Anticoagulant drugs taken within 1 week.
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction," Participation in a study of an investigational drug less than 6 months or 5 half-lives of the investigational drug, whichever is longer, before enrollment in the study"
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Male subjects with female partner of child-bearing potential who are unwilling or unable to adhere to contraception requirements
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Female subjects who have not reached menopause or have not had a hysterectomy or bilateral oophorectomy/salpingoophorectomy
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Positive urine or serum pregnancy test or plans desires to become pregnant during the course of the trial
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Donation of greater than 500 mL of blood or blood products within 2 months
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, History of alcohol and/or illicit drug abuse within 6 months.
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction," Infection with hepatitis A, B or C or HIV."
NCT02423200,Phase 2,Alzheimer's Disease,EIP Pharma Inc,Apr-15,Alzheimer Disease;Cognitive Dysfunction, Any factor deemed by the investigator to be likely to interfere with study conduction
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1," Dementia due to any condition other than AD, including vascular dementia (Rosen-modified Hachinski lschemic score  5)"
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1," Evidence of significant central nervous system (CNS) vascular disease on previous neuroimaging including but not limited to: cortical stroke, multiple infarcts, localized single infarcts in the thalamus, angular gyrus, multiple lacunar infarcts or extensive white matter injury"
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1," Clinically significant neurologic disease or condition other than AD, such as cerebral tumor, chronic subdural fluid collections, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, or any other diagnosis that could interfere with assessment of safety and efficacy"
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1," Evidence of clinically significant unstable cardiovascular, pulmonary, renal, hepatic, gastrointestinal, neurologic, or metabolic disease within the 6 months prior to enrollment"
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1," Poorly controlled diabetes, at the discretion of the Principal Investigator"
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1, Creatinine clearance (CL) of less than 45ml/min
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1, Use of an active Alzheimer's vaccine within 2 years prior to screening
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1, Use of a monoclonal antibody for treatment of AD within 1 year prior to screening
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1, Any medical or psychiatric condition that is likely to require initiation of additional medication or surgical intervention during the course of the study
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1, Use of an investigational drug within 30 days prior to screening
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1," Prior exposure to bryostatin, or known sensitivity to bryostatin or any ingredient in the study drug"
NCT02431468,Phase 2,Alzheimer's Disease,"Neurotrope Bioscience, Inc.",Nov-15,Alzheimer Disease;Bryostatin 1," Any other concurrent medical condition, which in the opinion of the PI makes the subject unsuitable for the clinical study"
NCT02434666,Phase 2,Dementia of the Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease,Renal and hepatic dysfunction with:
NCT02434666,Phase 2,Dementia of the Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease, Total Bilirubin: greater than 1.5 x UNL AST: greater than 2.5 x UNL ALT: greater than 2.5 x UNL Serum Creatinine: greater than 1.5 x UNL Creatinine Clearance: less than 30 mL/min (calculated by Cockcroft and Gault equation)
NCT02434666,Phase 2,Dementia of the Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease,History or presence of myasthenia.
NCT02434666,Phase 2,Dementia of the Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease,ECG findings of:
NCT02434666,Phase 2,Dementia of the Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease," Complete Left Bundle Branch Block; Ventricular pacing; 2nd degree or 3rd degree AV block; Atrial fibrillation or atrial flutter; HR less than 45 or greater than 100; PR greater than 220 msec; or QTcF greater than 450 msec in male, greater than 470 msec in female"
NCT02434666,Phase 2,Dementia of the Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease,"Patients considered unlikely to co-operate in the study, and/or poor compliance anticipated by the investigator."
NCT02434666,Phase 2,Dementia of the Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease,"Any other clinically relevant acute or chronic diseases which could interfere with patients' safety during the trial, or expose them to undue risk, or which could interfere with study objectives."
NCT02442765,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation," Participant has dementia predominantly of non-Alzheimer's type (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)"
NCT02442765,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)"
NCT02442765,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Participant with myasthenia gravis
NCT02442778,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation," Participant has dementia predominantly of non-Alzheimer's type (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)"
NCT02442778,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)"
NCT02442778,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,Avanir Pharmaceuticals,Sep-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Participant with myasthenia gravis
NCT02446132,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Dec-15,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)"
NCT02446132,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Dec-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Participants determined to have a high imminent risk of falls during the study based on a clinical evaluation by the investigator
NCT02446132,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",Dec-15,Dementia;Alzheimer Disease;Psychomotor Agitation, Participants who are currently using or were on NUEDEXTA in the 2 weeks preceding baseline
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Modified Hachinski Ischemia Score (MHIS) greater than  4.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression," Changes in AChE inhibitor (donepezil, rivastigmine or galantamine) dosing within 2 months prior to screening."
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Changes in memantine dosing within 2 months prior to the screening.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Changes in antidepressant dosing or addition of another antidepressant medication within 2 months prior to the screening.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Use of antipsychotics at any dose within 1 month prior to screening.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression," Use of benzodiazepines, other than short-acting sleep medications, for night at a maximum of 3 nights/week, within 2 months prior to screening."
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Use of any anticholinergic medication within 2 months prior to screening.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression," Current use (within the 30 days prior to screening) of medications with known relevant alpha-2C AR affinity (e.g. mirtazapine, mianserin, clonidine, guanfacine or tizanidine) or with high noradrenaline transporter affinity (reboxetine, venlafaxine or duloxetine)."
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression," Current use of other psychotropic agents, unless the dosing has been stable during the last 2 months prior to the screening."
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression," Myocardial infarction or other clinically significant ischemic cardiac disease, heart failure, or arrhythmia tendency within the past 2 years."
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Current or history of malignancy within 5 years before screening.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Suicidal ideation in the 6 months before screening or current suicide risk based on the Colombia-Suicide Severity Rating Scale (C-SSRS) (items 4 and 5 exclusionary) or current risk of suicide based on the investigator's judgement.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Specific findings in MRI or CT that could in the opinion of the investigator affect cognitive function (such as cortical infarct or silent lacuna in a region known to affect cognition).
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Supine heart rate less than  48 bpm or greater than  100 bpm.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Systolic blood pressure (SBP) greater than  160 mmHg or diastolic blood pressure (DBP) greater than  100 mmHg after a 5-minute rest.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Symptomatic orthostatic hypotension.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, QTc-Fridericia (QTcF) repeatedly greater than  450 ms in males or greater than  470 ms in females.
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression," Clinically significantly abnormal thyroid-stimulating hormone (TSH), vitamin B12 or folate serum levels at screening."
NCT02471196,Phase 2,Alzheimer's Disease,"Orion Corporation, Orion Pharma",unknown,Alzheimer Disease;Aggression, Resides in a skilled nursing facility.
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine, Subject has/have/is
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine," medical history and/or clinically determined evidence of other central nervous system (CNS) disorders including, but not limited to brain tumor, active subdural hematoma, seizure disorder, multiple sclerosis, dementia with Lewy bodies, vascular dementia, corticobasal syndrome, progressive supranuclear palsy, Parkinson's disease, multiple system atrophy, frontotemporal dementia, normal pressure hydrocephalus, Huntington's disease, or Jakob-Creutzfeldt disease presenting as dementia"
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine," medical history and/or clinically determined disorders: current B12 deficiency, chronic sinusitis, any untreated thyroid disease, significant head trauma and history of difficulty with smell and/or taste prior to AD diagnosis"
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine," history of any of the following: moderate to severe pulmonary disease, poorly controlled congestive heart failure, significant cardiovascular and/or cerebrovascular events within previous 6 months, condition known to affect absorption, distribution, metabolism, or excretion of drugs such as any hepatic, renal or gastrointestinal disease or any other clinically relevant abnormality that inclusion would pose a safety risk to the subject as determined by investigator"
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine, previous nasal and/or oto-pharyngeal surgery and severe deviated septum and/or other anomalies
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine," history of any psychiatric illness, with the exception of major depressive and anxiety disorder (according to Diagnostic and Statistical Manual of Mental Disorders, version 5, Text Revision (DSM-IV TR)) currently in remission or stable with treatment for greater than  2 yrs, or any other psychiatric condition that inclusion would pose a safety risk to the subject as determined by investigator"
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine," currently taking any medications, herbals and food supplements that are medically/clinically contraindicated as determined by investigator in order to comply with procedural testing of cognitive function as well as ensure study safety. See list of prohibited medications and compounds"
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine," undergone a recent change (less than 1mo) in their prescribed acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) or memantine."
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine, undergone a recent change (less than 1mo) in their selective serotonin re-uptake inhibitor (SSRI) or anti-depressant medication
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine, current or recent drug or alcohol abuse or dependence as defined by DSM-IV TR
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine," laboratory results that are medically relevant, in which inclusion would pose a safety risk to the subject as determined by investigator"
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine, participated in any other research study at least 3 mos prior to this study
NCT02503501,Phase 2,Alzheimer's Disease (AD),HealthPartners Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Insulin glulisine, an insulin allergy
NCT02516046,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Sep-15,Alzheimer Disease, Aggressively being treated with life sustaining measures
NCT02516046,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Sep-15,Alzheimer Disease, Known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment
NCT02516046,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Sep-15,Alzheimer Disease, Clinically significant infectious disease
NCT02516046,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Sep-15,Alzheimer Disease, Currently receiving any investigational medications except with permission from the study sponsor
NCT02516046,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Sep-15,Alzheimer Disease, Participated in an experimental study with an amyloid or tau targeting agent
NCT02516046,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Sep-15,Alzheimer Disease, Suspected encephalopathy due to alcoholism or end-stage liver disease
NCT02516046,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Sep-15,Alzheimer Disease, Females of childbearing potential
NCT02516046,Phase 3,Alzheimer's Disease,Avid Radiopharmaceuticals,Sep-15,Alzheimer Disease, History of risk factors for Torsades de Pointes or are currently taking medication known to cause QT prolongation
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen," Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities;"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen," Major depressive episode, as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) within the past 6 months, which could lead to difficulty complying with the protocol;"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, History of schizophrenia or bipolar disorder (DSM-IV criteria);
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, History of alcohol or substance abuse or dependence within the past 3 years (DSM-IV criteria);
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen," Currently taking medications that could lead to difficulty complying with the protocol; subjects must be on a stable dose of current medications for 4 weeks prior to study entry, with the exception of acetylcholinesterase inhibitors and/or memantine, which must be on a stable dose for at least 12 weeks prior to study entry;"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Investigational agents are prohibited one month prior to entry and for the duration of the trial;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and rifampicin);
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen," Currently taking cromolyn, or have taken cromolyn, within the past 12 months;"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen," Chronic daily use of high-dose NSAID for osteoarthritis, rheumatoid arthritis, or other chronic inflammatory diseases ( chronic  defined as 3200 mg/day for greater than 2 weeks);"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Chronic daily use of aspirin exceeding standard of care guidelines for low dose aspirin therapy for prevention of stroke and/or other recommended uses;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen," Allergy to cromolyn (also known as Intal, Nasalcrom, Opticrom, Gastrocrom, etc.);"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen," Allergies to ibuprofen (Advil, Motrin, Nuprin, etc.) or aspirin;"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Clinically significant respiratory disorders with impaired respiratory effort or difficulty taking inhaled drugs;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Uncontrolled chronic asthma;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen," Abnormal pulmonary function test, defined for this protocol as: FEV1/FVC less than  predicted value for subject AND FEV1 less than  70% of predicted value, indicating moderate or severe respiratory obstruction;"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Taking inhaled protein products on a chronic basis;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol;
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen," Pregnancy or lactation for female subjects of child-bearing potential (i.e., less than  two years post-menopausal or not surgically sterile);"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen," For sexually active male subjects, unwillingness or incapability of using appropriate contraception methods;"
NCT02547818,Phase 3,Alzheimer's Disease,"AZTherapies, Inc.",unknown,Alzheimer Disease;Ibuprofen, Severe renal or hepatic impairment.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Women of child bearing potential.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,History or presence of a seizure disorder.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,"Current unstable peptic ulcer disease, urinary or gastric retention; asthma or obstructive pulmonary disease."
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,"History or presence of bladder outflow obstruction, gastrointestinal obstructive disorder or reduced GI motility, or narrow-angle glaucoma."
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,"History or presence of gastrointestinal, hepatic, or renal disease, or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs."
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Renal and hepatic dysfunction with:
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate, Total Bilirubin: greater than 1.5 x UNL
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate, AST: greater than 2.5 x UNL
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate, ALT: greater than 2.5 x UNL
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate, Serum Creatinine: greater than 1.5 x UNL
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate, Creatinine Clearance: less than 30 mL/min (calculated by Cockcroft and Gault equation)
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,History or presence of myasthenia.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,History or family history of Prolonged QT Syndrome.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,History of unexplained syncope or family history of unexplained syncope or sudden death.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Myocardial infarction or hospitalization for congestive heart failure within 6 months.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,ECG findings of:
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate, Complete Left Bundle Branch Block;
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate, Ventricular pacing;
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate, 2nd degree or 3rd degree AV block;
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate, Atrial fibrillation or atrial flutter;
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate, HR less than 45 or greater than 100;
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate, PR greater than 220 msec; or
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate," QTcF greater than 450 msec in male, greater than 470 msec in female"
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,"Known hypersensitivity to donepezil, solifenacin or related drugs."
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,History of drug significant allergy.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,"History of substance abuse, known drug addiction, or positive test for drugs of abuse or alcohol."
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Patients treated with the following medications within 8 weeks of screening
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate," AChEIs (other than donepezil),"
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate," Peripherally acting anticholinergics (such as drugs for the treatment of overactive bladder disorder),"
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate," Psychoactive medications (including antipsychotics, antidepressants, anxiolytics or sedative hypnotics) having significant anticholinergic effects and/or believed to affect cognitive function."
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate," Other medications are acceptable, at the investigators discretion, if dosage is held stable for at least 4 weeks prior to screening and throughout the study."
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,"Patients considered unlikely to co-operate in the study, and/or poor compliance anticipated by the investigator."
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Patients hospitalized within 4 weeks of screening.
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,"Any other clinically relevant acute or chronic diseases which could interfere with patients' safety during the trial, or expose them to undue risk, or which could interfere with study objectives."
NCT02549196,Phase 2,Dementia of Alzheimer's Type,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Dementia;Alzheimer Disease;Donepezil;Solifenacin Succinate,Patients who have participated in another clinical trial with an investigational drug within previous 30 days.
NCT02550665,Phase 3,Alzheimer's Disease,Asan Medical Center,unknown,Alzheimer Disease;Donepezil, patients receiving other concomitant acetylcholinesterase inhibitor
NCT02550665,Phase 3,Alzheimer's Disease,Asan Medical Center,unknown,Alzheimer Disease;Donepezil, uncontrolled psychiatric disorders
NCT02550665,Phase 3,Alzheimer's Disease,Asan Medical Center,unknown,Alzheimer Disease;Donepezil, drug overuse or alcohol abuse history within 5 years
NCT02550665,Phase 3,Alzheimer's Disease,Asan Medical Center,unknown,Alzheimer Disease;Donepezil, significant uncontrolled or active medical conditions
NCT02550665,Phase 3,Alzheimer's Disease,Asan Medical Center,unknown,Alzheimer Disease;Donepezil, uncontrolled epilepsy
NCT02550665,Phase 3,Alzheimer's Disease,Asan Medical Center,unknown,Alzheimer Disease;Donepezil, patients who cannot come at scheduled visits
NCT02551809,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Clinically significant neurological disease other than Alzheimer's disease
NCT02551809,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Major psychiatric disorder
NCT02551809,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Severe systemic disease
NCT02551809,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Serious adverse reactions to any vaccine
NCT02551809,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Other exclusion criteria apply
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Unstable diabetes or insulin use
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Unable to participate in FDG-PET scanning
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Inability to undergo a clinical MRI of the brain
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Diagnosis of significant neurological/psychiatric disease other than AD
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease," History of moderate or severe congestive heart failure, NYHA class III or IV, within 12 months prior to baseline."
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Previous cardiovascular event within the past 6 months prior to baseline
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease," Subject is pregnant, or lactating."
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, ALT and/or AST levels that are twice the upper limit of normal; bilirubin levels that exceed 2 mg/dL; serum creatinine greater than 1.5 mg/dL in men or greater than  1.4 mg/dL in women.
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Current or history of severe or unstable disorder (medical or psychiatric) requiring treatment that may make the subject unlikely to complete the study.
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Current use of fluvoxamine.
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Current unstable use of warfarin.
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease," Current use (within 30 days of baseline, visit 2) of certain highly protein-bound medications"
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease," Malignancy within the last 5 years (other than non-melanoma skin cancer, stable, non-progressive prostate cancer not requiring treatment or in situ cervical cancer)."
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease," Known history of HIV, hepatitis B, or hepatitis C."
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Blood pressure greater than 160/100 mmHg.
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease," Known or suspected intolerance or hypersensitivity to the study drugs, closely related compounds, or any of their stated ingredients."
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease," History of alcohol, drug abuse or dependence (except nicotine dependence) within 2 years."
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Investigational amyloid lowering therapies use within two months prior to baseline
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Have participated in any other investigational study or received an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to baseline
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Any surgical or medical condition which may significantly alter the absorption of any drug substance
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Resides in hospital or moderate to high dependency continuous care facility.
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease," Non ambulatory, or wheelchair-bound"
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, History of swallowing difficulties.
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Evidence of clinically relevant pathology that in the investigator's opinion could interfere with the study results or put the subject's safety at risk.
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Expanded Access Extension :
NCT02560753,Phase 1/Phase 2,Alzheimer's Disease,"T3D Therapeutics, Inc.",Jul-15,Alzheimer Disease, Subjects must continue to meet the main study inclusion/exclusion criteria to insure continued safety to continue on a 6 months study extension
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Has a diagnosis of dementia due to other than Alzheimer's Disease
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Is taking cholinesterase inhibitors other than donepezil HCl or taking doses of donepezil HCl other than 10 mg
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Is taking doses of memantine HCl other than 10 mg bid or Namenda XR 28 mg qd.
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Has uncontrolled cardiac disease or hypertension.
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Has clinically significant renal or hepatic impairment.
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate," Has cancer or a malignant tumor, untreated thyroid disorder or has a history of seizure disorder"
NCT02580305,Phase 2,Alzheimer's Disease,Suven Life Sciences Limited,Sep-15,Alzheimer Disease;Memantine;Donepezil;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate," Is treated or likely to require treatment during the study, with any medications prohibited by the study protocol."
NCT02585934,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease, Other Causes for Dementia
NCT02585934,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease, Diagnosis of vascular dementia
NCT02585934,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease," Atypical clinical features or clinical course of dementia that would lead the investigator to conclude symptoms are more likely due to an alternate dementia diagnosis including, but not limited to, frontotemporal dementia, Lewy body dementia, or others."
NCT02585934,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease, Confounding Medical Conditions
NCT02585934,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease, History of significant psychiatric illness such as schizophrenia or bipolar affective disorder or any other significant psychiatric illness that in the opinion of the investigator would interfere with participation in the study;
NCT02585934,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease," Any clinically relevant concomitant disease, which, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study."
NCT02586909,Phase 3,Alzheimer's Disease,Axovant Sciences Ltd.,unknown,Alzheimer Disease," Any clinically relevant concomitant disease, which, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study."
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Patient has an alternative cause for dementia other than AD as determined by CT or MRI scan
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Patient has evidence of any clinically significant neurodegenerative disease
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Patient has been diagnosed with the following Axis I disorders (DSM V criteria)
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease," Patient has a history of uncontrolled or untreated cardiovascular, endocrine, gastrointestinal, respiratory, or rheumatologic disorders within the past 5 years"
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Patient has severe pain that is likely to interfere with sleep
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Continuous use of benzodiazepines or other sedative-hypnotics during the 2 weeks before Screening
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Use of any kind of melatonin/melatonin agonist during the 2 weeks before Screening
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease, Patient has known or suspected hypersensitivity to exogenous melatonin or melatonin receptor agonists
NCT02615002,Phase 2,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,Nov-15,Alzheimer Disease," Patients with an irregular lifestyle or life pattern (eg, shift workers, patients likely to be jet lagged)."
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, Patients not able to read or write
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression," Patients having participated in a study testing disease modifying therapy for AD, or in another study with administration of investigational drug or device within the previous 3 months prior to selection visit"
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression," Depressive symptoms that, in investigator's judgment, are clearly due to a medical condition other than AD, or are a direct result of non-mood related dementia symptoms"
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, History of epilepsy or solitary seizure
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression," Medical history of Major Depressive Disorder more than 3 years before onset of the disease, treated with antidepressive drugs or electroconvulsive therapy"
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, Severe or unstable disease of any type that could interfere with safety and efficacy assessments
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression," Alcohol abuse or drug abuse or addiction, as judged by the clinician (excluding nicotine)"
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, Clinically relevant lactose intolerance
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, Antidepressant treatment not stopped for at least 3 weeks before inclusion
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression, Significant worsening of depressive symptoms or high suicidal risk according to investigator's judgment
NCT02626572,Phase 2,Alzheimer's Disease,Institut de Recherches Internationales Servier,Feb-15,Alzheimer Disease;Depression," For optional extension phase: medically instable Chronic Obstructive Pulmonary Disease and asthma, known hypersensitivity to donepezil hydrochloride or piperidine derivatives"
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,"Individuals with a known alternate neurologic disorder, previous head injury, or substance abuse."
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,Individuals with bipolar disease and schizophrenia
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,Concurrent medical conditions that contraindicate study procedures.
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,"Women who are pregnant or nursing. Also, any woman who is seeking to become pregnant or suspects she is pregnant will be excluded from enrollment."
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,Claustrophobia
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,Non-MRI compatible implanted devices
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,"For the Ocrelizumab arm, subjects already on Ocrelizumab will be excluded. For the Alemtuzumab arm, subjects already on Alemtuzumab will be excluded."
NCT02649985,Phase 1/Phase 2,Alzheimer's Disease,Brigham and Women's Hospital,unknown,Multiple Sclerosis;Alzheimer Disease;Sclerosis,"For the Ocrelizumab arm and the Alemtuzumab arm, subjects with abnormal serum creatinine will be excluded."
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Any evidence of a condition other than AD that may affect cognition such as other dementias, stroke, brain damage, autoimmune disorders (e.g. multiple sclerosis) or infections with neurological sequelae."
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, History of major psychiatric illness such as schizophrenia or major depression (if not considered in remission)
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, At risk of suicide in the opinion of the investigator
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Any abnormal MRI findings, such as presence of cerebral vascular pathology, cortical stroke, etc or inability to tolerate MRI procedures or contraindication to MRI"
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Unstable or clinically significant cardiovascular (e.g., myocardial infarction), kidney or liver disease"
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Uncontrolled hypertension
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Screening hemoglobin A1c (HbA1C) greater than 8%
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Poor peripheral venous access
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, History of cancer except:
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, If considered to be cured or If not being actively treated with anti-cancer therapy or radiotherapy
NCT02670083,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins"
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen, no current peptic ulcer disease
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen," no history of prior peptic ulcer with bleed, perforation, intestinal obstruction"
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen, no major psychiatric disturbance
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen," no regular use (4 or more doses per week) of aspirin, other non-steroidal anti-inflammatory drug (NSAID), opiate or other pain medication"
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen," no use, present or past, of acetylcholinesterase inhibitors or memantine"
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen, no regular use of vitamin E at dosage of 600 i.u.
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen, no drug or alcohol dependence
NCT02702817,Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,unknown,Alzheimer Disease;Cognitive Dysfunction;Naproxen, no allergy to NSAIDs or sulfa antibiotics
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," Known or identified cognitive disorder diagnosed previously by a physician, psychologist, nurse-clinician, or other health care provider, or by StoP-AD staff"
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," Past or present use of a commercially available acetyl-cholinesterase inhibitor including tacrine, donepezil, rivastigmine, or galantamine"
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol, Past or present use of memantine or other approved cognitive enhancement prescription agent
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," History of heart disease, myocardial infarction or documented acute coronary syndrome, or arrhythmia (including atrial fibrillation)"
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol, Corrected QT interval using Bazett's formula (QTcB) interval greater than  450 msec for males or 470 msec for females as detected by EKG and confirmed by consultant cardiologist
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," Clinically significant hypertension, anemia, liver disease, or kidney disease, in opinion of a study physician (participants with treated hypertension who are normotensive as a result of intervention may be enrolled.)"
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," Concurrent use of over-the-counter or prescription medicines (e.g., tricyclic antidepressants, anti-histamines) known to prolong QTc interval, or to potentiate the tendency of probucol to prolong this interval, in the opinion of a study physician"
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," Any inflammatory or chronic pain condition that necessitates regular use of opiates (e.g., oxycodone, hydrocodone, tramadol, meperidine, hydromorphone), or NSAIDs (more than 4 doses / week)"
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol, Current plasma creatinine greater than  132 mmol/l (1.5 mg/dl)
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," Current alcohol, barbiturate or benzodiazepine abuse or dependence (in opinion of study physician)"
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," Any other medical condition that, in the opinion of a study physician, makes it inadvisable for the participant to be assigned to regular dosage of probucol"
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," Enrolment in any trial or experimental protocol that, in the opinion of a study physician, is likely to interfere with PREVENT-AD or any of its derivative protocols including this one"
NCT02707458,Phase 1/Phase 2,Mild Cognitive Impairment Due to Alzheimer Disease,Douglas Mental Health University Institute,Apr-16,Alzheimer Disease;Cognitive Dysfunction;Probucol," Any other condition that, in the opinion of a study physician, makes it medically inappropriate for the participant to enroll in the program"
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain","Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants with severe chronic back pain might not be able to lie still during the scanning procedures)."
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain",Is deemed likely unable to perform the imaging procedures for any reason.
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain","Has a history of Torsades de Pointes or is taking medications known to prolong QT interval. To determine who will be excluded from this study based on this criterion, we will review participant's medical history and current medications at time of screening. Participants will be excluded from the study if any of the following restricted medications are being taken:"
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain", Disopyramide
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain", Dofetilide
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain", Ibutilide
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain", Procainamide
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain", Quinidine
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain", Sotalol
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain", Bepridil
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain",Has hypersensitivity to F 18 T807 or any of its excipients.
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain","Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate."
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain",Severe claustrophobia.
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain",Currently pregnant or breast-feeding.
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain",For those electing to undergo the optional lumbar puncture: on
NCT02707978,Phase 2,Alzheimer Disease,"Tammie L. S. Benzinger, MD, PhD",unknown,"Alzheimer Disease;Dementia;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain", anticoagulant of any form prior to lumbar puncture.
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Dementia or mild cognitive impairment on screening evaluation
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Current use of fish oil supplements (requires 3 month wash-out period)
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Active liver disease with AST or ALT greater than twice the upper limit of normal
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Elevated creatine kinase greater than twice the upper limit of normal
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Prior adverse reaction to statins or fish oil
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester," Pregnant, nursing, or pregnancy planned"
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Use of medications that interact with icosapent ethyl
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Current use of anticoagulants
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Known hypersensitivity to fish and/or shellfish
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Current use of other investigational drug
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, History of significant atherosclerotic cardiovascular disease or diabetes mellitus
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Low-density lipoprotein (LDL) cholesterol greater than  or =190 mg/dL or less than 80 mg/dL
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Triglycerides greater than  or = 500 mg/dL
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Creatinine greater than 1.8 mg/dL
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Previous lumbar surgery with contraindication to lumbar puncture
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Claustrophobia requiring sedation for MRI
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Pacemaker or other contraindication for MRI
NCT02719327,Phase 2/Phase 3,Alzheimer's Disease,VA Office of Research and Development,unknown,Alzheimer Disease;Eicosapentaenoic acid ethyl ester, Consumption of greater than 200 mg per day omega-3 fatty acids in diet
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Clinically significant abnormalities in vital signs (blood pressure, heart rate, respiration rate and oral temperature), as determined by the investigator."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Clinically significant abnormal haematology, biochemistry and urine examination values, specifically abnormal liver and renal function and Vitamin B12 levels below lower threshold since these parameters may impact cognitive function, as determined by the investigator."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Has had a significant systematic illness or infection within the past 4 weeks prior to randomisation, as determined by the investigator."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Clinically significant neurological disease other than AD, such as (but not limited to) Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumour, progressive supranuclear palsy, seizure disorder, subdural haematoma, multiple sclerosis or a history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Subjects with clinical evidence of peripheral neuropathy or historical evidence of clinically significant nerve conduction abnormalities.
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Has had a stroke within the year prior to randomisation, as determined by the investigator."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Has a lifetime diagnosis of a major psychiatric disorder (other than dementia), based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria. This includes but is not limited to schizophrenia, schizoaffective disorder, bipolar affective disorder, alcohol dependence syndrome or major depressive disorder."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Has a history of disease directly related to the hypothalamus, the pituitary and/or the adrenal glands which affect the hypothalamic-pituitary-adrenal axis function."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Has uncontrolled clinical conditions relating to glucose and lipid metabolism.
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Clinically significant electrocardiogram (ECG) abnormalities, including Corrected QT interval (QTc) greater than  450 ms, following ECG tracings at Screening."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Use of any prohibited medication as detailed in the study protocol.
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,Participation in another clinical study of an investigational drug or device whereby the last investigational drug/device administration is within 60 days of Screening.
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Inability to communicate well with the investigator (i.e. language problem, non-fluent English [as scales will be provided in English only], poor mental development or impaired cerebral function)."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Subject will undergo the tests, Alzheimer's Disease Assessment Scales (ADAS)-Cog v14, CDR-Sum of Boxes (SOB), MMSE, Neuropsychological Test Battery (NTB; executive domain) and RAVLT at the indicated time-points to avoid uncontrolled learning effects. Subjects who need to perform these tests externally to and in parallel with this study will be excluded."
NCT02727699,Phase 2,"Dementia, Alzheimer Type",Actinogen Medical,unknown,Alzheimer Disease;Dementia,"Subject has ingested any food or drink containing grapefruit, Seville oranges, star fruit or derived products (e.g. fruit juice), for at least 3 days prior to the first administration of study drug."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Apnea Hypopnea Index (AHI) score greater than  30 or Periodic Leg Movements with Arousal per hour of Sleep (PLMA) greater than  30.
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Resides in a nursing home (or similar institutional facility); assisted-living facilities are not excluded if full-time nursing care is not required.
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Has a Modified Hachinski Ischemia Scale (MHIS) Score greater than  4 at Screening (i.e., evidence of vascular dementia)"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Has a known history of recent (or past) stroke that in the investigator's opinion confounds the diagnosis of either AD or insomnia
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Has evidence of a clinically relevant neurological disorder other than the disease being studied (i.e., probable AD) at Screening, including but not limited to: vascular dementia, parkinsonism, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, progressive supranuclear palsy, neurosyphilis, dementia with Lewy bodies, other types of dementia, mental retardation, hypoxic cerebral damage, cognitive impairment due to other disorders, or history of head trauma with loss of consciousness that either led to persistent cognitive deficits or in the opinion of the investigator confounds the diagnosis of either AD or insomnia."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Has a history of seizures or epilepsy within the last 5 years before study start
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Has a history or diagnosis of any of the following conditions, in the opinion of the investigator:"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Narcolepsy
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Cataplexy (familial or idiopathic)
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Circadian Rhythm Sleep Disorder
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Rapid eye movement (REM) behavior disorder
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Significant degree of sleep-related Breathing Disorder (i.e., AHI greater than 30, and/or use of Continuous Positive Airway Pressure [CPAP] or Bilevel Positive Airway Pressure [BIPAP])"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Periodic Limb Movement Disorder
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Restless Legs Syndrome
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Primary Hypersomnia
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Excessive Daytime Sleepiness (EDS) characterized by uncharacteristic chronic and persistent sleepiness throughout the day
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Has a clinically significant movement disorder, such as akinesia, that would affect the activity/sleep watch differentiation of sleep and wakefulness"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," In the opinion of the investigator, has difficulty sleeping primarily due to a confounding medical condition. NOTE:  Medical Conditions  may include chronic pain syndromes, chronic migraine, cardiac disease, nocturia (greater than  3 times/night), asthma, gastroesophageal reflux disease (GERD), or hot flashes."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Has evidence of a current episode of major depression based on investigator's judgment. Major depression in remission is not exclusionary.
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Has any of the following based on clinician interview and DSM-5 criteria:
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Lifetime history of bipolar disorder, a primary psychotic disorder, or posttraumatic stress disorder; or,"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," A psychiatric condition requiring treatment with a prohibited medication; or,"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Other psychiatric condition that, in the investigator's opinion, would interfere with the subject's ability to participate in the study."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Is at imminent risk of self-harm, based on clinical interview and responses on the Columbia-Suicide Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Subjects must be excluded if they report suicidal ideation with intent, with or without a plan or method in the past 2 months or suicidal behavior in the past 6 months."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Has a history of alcoholism or drug dependency/abuse within the last 5 years of study start
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Has a recent history (within the 6 months prior to Screening) of regular consumption (3 or more days per week) of either:
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, More than 2 alcoholic beverages per day or alcohol consumption within 3 hours prior to bedtime
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," More than greater than  600 mg caffeine a day (e.g., 4 standard 8-ounce cups of brewed coffee, or consumes caffeine after 4pm (16:00)"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Consumes the equivalent of greater than 15 cigarettes a day and the investigator confirms that the participant's insomnia is in part the result of tobacco consumption (e.g., participants unable to refrain from smoking during the night, participants who interrupt sleep to smoke or use tobacco products, or participants who require a cigarette within 30 minutes of waking in the morning)."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Has a history of excessive daytime napping (defined as more than 3 hours a day for more than 3 days of the week based on trial partner estimates, on average for the past 4 weeks)."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Has a recent or ongoing, uncontrolled, clinically significant medical condition or major surgery where participation in the trial would pose a significant medical risk to the subject within 3 months of study start, such as: conditions including but not limited to diabetes, hypertension, Human Immunodeficiency Virus (HIV) or other relevant infections, thyroid or endocrine disease, Chronic Obstructive Pulmonary Disease (COPD), delirium, congestive heart failure, angina, cardiac or gastrointestinal disease, or renal disease requiring dialysis. Note: controlled co-morbid conditions (including diabetes, hypertension, heart disease, etc.) are not exclusionary if stable within 3 months of the study start. All concomitant medications, supplements, or other substances must be kept as stable as medically possible during the trial. Urinary tract infections at study start are not exclusionary if adequately treated."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Major surgery including not limited to abdominal, thoracic, cardiac or orthopedic surgery, or any procedure requiring general anesthesia"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Has a history of hepatitis or liver disease that, in the opinion of the investigator, has been active within the 6 months prior to study start."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Has a known allergy or hypersensitivity to suvorexant or to any of the formulation components
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Has a history of hypersensitivity or idiosyncratic reaction to more than 3 chemical classes of drugs, including prescriptions and over-the-counter medications."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Has donated blood products or has had phlebotomy of greater than 300 mL within 8 weeks of study start, or intends to donate or receive blood products during participation in the study."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," History of malignancy within the 5 years prior to study start, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, localized prostate cancer, who has undergone potentially curative therapy with no evidence of recurrence for greater than =3 year post-therapy, and who is deemed at low risk for recurrence by her/his treating physician."
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant," Is pregnant, is attempting to become pregnant, or is nursing children"
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Has a Body Mass Index (BMI) greater than  40 kg/m^2
NCT02750306,Phase 3,Alzheimer Disease,Merck Sharp &amp; Dohme LLC,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Suvorexant, Is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent
NCT02756858,Phase 2,Alzheimer's Disease,Anavex Life Sciences Corp.,Mar-16,Alzheimer Disease," Have not previously participated Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period (ANAVEX2-73-002)"
NCT02760602,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jun-16,Alzheimer Disease, Has had MRI or computerized tomography (CT) of brain within previous 2 years showing pathology that would be inconsistent with a diagnosis of AD.
NCT02760602,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jun-16,Alzheimer Disease, Has known allergy to humanized monoclonal antibodies.
NCT02760602,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jun-16,Alzheimer Disease," Has an ongoing clinically significant laboratory abnormality, as determined by the investigator."
NCT02760602,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jun-16,Alzheimer Disease, Has screening MRI with results showing greater than 4 amyloid related imaging abnormalities H (ARIA-H) micro-hemorrhages or presence of ARIA-E.
NCT02760602,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jun-16,Alzheimer Disease," Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI."
NCT02760602,Phase 3,Alzheimer's Disease,Eli Lilly and Company,Jun-16,Alzheimer Disease," Has received treatment with a stable dose of an acetylcholinesterase (AChEI) inhibitor or memantine for less than 2 months before randomization. (If a participant has recently stopped AChEIs and/or memantine, he or she must have discontinued treatment at least 2 months before randomization.)"
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia," Significant and/or current neurological disease affecting the central nervous system, other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, repetitive head trauma, serious infection of the brain, Parkinson's disease, epilepsy, or cervicocranial vascular disease."
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia," Participants with any current primary psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessment, or affect the participant's ability to complete the study. Participants with history of schizophrenia or other chronic psychosis are excluded."
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia," Within 1 year before the screening visit or between screening and randomization, any of the following: myocardial infarction; moderate or severe congestive heart failure, New York Heart Association class III or IV; hospitalization for, or symptoms of, unstable angina; syncope due to orthostatic hypotension or unexplained syncope; known significant structural heart disease (such as, significant valvular disease, hypertrophic cardiomyopathy); or hospitalization for arrhythmia."
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia, Congenital QT prolongation.
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia, Intermittent second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia.
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia, A corrected QT (QTcF) interval measurement greater than 470 milliseconds (men and women) at screening (as determined at the investigational site).
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia, History of malignant cancer within the last 5 years.
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia, History of vitiligo and/or current evidence of post-inflammatory hypopigmentation.
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia, Calculated creatinine clearance less than 30 milliliters per minute (Cockcroft-Gault formula; Cockcroft and Gault 1976) at screening.
NCT02783573,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia, Currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
NCT02791191,Phase 2,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Dementia;Disease Progression," Significant neurological disease affecting the central nervous system (CNS), other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures)."
NCT02791191,Phase 2,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Dementia;Disease Progression, Ocular pathology that significantly limits ability to reliably evaluate vision or the retina.
NCT02791191,Phase 2,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Dementia;Disease Progression, Use of strong inducers of cytochrome P450 3A (CYP3A).
NCT02791191,Phase 2,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Dementia;Disease Progression, Sensitivity to florbetapir or F-AV-1451.
NCT02791191,Phase 2,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Dementia;Disease Progression, Contraindication to MRI or PET or poor venous access for blood draws.
NCT02792257,Phase 2,Alzheimer's Disease,Johns Hopkins University,unknown,Alzheimer Disease;Psychomotor Agitation;Dronabinol,"Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease, which might confound assessment of safety outcomes."
NCT02792257,Phase 2,Alzheimer's Disease,Johns Hopkins University,unknown,Alzheimer Disease;Psychomotor Agitation;Dronabinol,Seizure disorder
NCT02792257,Phase 2,Alzheimer's Disease,Johns Hopkins University,unknown,Alzheimer Disease;Psychomotor Agitation;Dronabinol,Baseline delirium as determined by Confusion Assessment Method (CAM) and Diagnostic and Statistical Manual of Mental Disorders (DSM) -5 criteria
NCT02792257,Phase 2,Alzheimer's Disease,Johns Hopkins University,unknown,Alzheimer Disease;Psychomotor Agitation;Dronabinol,Current use of lithium
NCT02792257,Phase 2,Alzheimer's Disease,Johns Hopkins University,unknown,Alzheimer Disease;Psychomotor Agitation;Dronabinol,Inability to swallow a pill
NCT02795780,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Aug-16,Alzheimer Disease," Current clinically significant cardiovascular disease, ECG abnormalities, risk factors for Torsades de Pointes (TdP), or are taking drugs known to cause QT prolongation"
NCT02795780,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Aug-16,Alzheimer Disease," Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer"
NCT02795780,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Aug-16,Alzheimer Disease," Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception"
NCT02795780,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Aug-16,Alzheimer Disease, Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session
NCT02795780,Phase 2,Alzheimer's Disease,Avid Radiopharmaceuticals,Aug-16,Alzheimer Disease, Have received or participated in a trial with investigational medications in the past 30 days
NCT02817906,Phase 3,"Agitation in Dementia, Including Alzheimer's Disease","Intra-Cellular Therapies, Inc.",unknown,Alzheimer Disease;Dementia;Psychomotor Agitation, Unable to comply with study procedures
NCT02817906,Phase 3,"Agitation in Dementia, Including Alzheimer's Disease","Intra-Cellular Therapies, Inc.",unknown,Alzheimer Disease;Dementia;Psychomotor Agitation, Considered medically inappropriate for study participation
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,Past or present history of certain brain disorders other than MCI or AD.
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,"Certain significant medical conditions, which make study procedures of the current study unsafe."
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,Contraindication to MRI scanning.
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,"Conditions precluding entry into the scanners (e.g., morbid obesity, claustrophobia, etc.)."
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,"Exposure to research related radiation in the past year that, when combined with this study, would place subjects above the allowable limits."
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,Low affinity binding on TSPO genetic screen.
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,Participation in the last year in a clinical trial for a disease modifying drug for AD.
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,Inability to have a catheter in subject's vein for the injection of radioligand.
NCT02831283,Phase 2,Alzheimer's Disease,William Charles Kreisl,Jun-16,Alzheimer Disease;Inflammation,Inability to have blood drawn from subject's veins.
NCT02833792,Phase 2,Alzheimer Dementia,"Stemedica Cell Technologies, Inc.",unknown,Alzheimer Disease;Dementia,Prior treatment with stem cells.
NCT02833792,Phase 2,Alzheimer Dementia,"Stemedica Cell Technologies, Inc.",unknown,Alzheimer Disease;Dementia,"History of intracranial, subdural, or subarachnoid hemorrhage."
NCT02833792,Phase 2,Alzheimer Dementia,"Stemedica Cell Technologies, Inc.",unknown,Alzheimer Disease;Dementia,"Subjects with baseline brain MRI showing more than four (4) cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as  possible  or  definite ), and/or one (1) or more areas of superficial siderosis, and/or evidence of a prior macrohemorrhage. MRI must include fluid-attenuation inversion recovery (FLAIR) and T2*-weighted gradient-recalled-echo (GRE) sequences."
NCT02833792,Phase 2,Alzheimer Dementia,"Stemedica Cell Technologies, Inc.",unknown,Alzheimer Disease;Dementia,"History of cancer within the past 5 years, with the exception of localized basal or squamous cell carcinoma."
NCT02833792,Phase 2,Alzheimer Dementia,"Stemedica Cell Technologies, Inc.",unknown,Alzheimer Disease;Dementia,History of seizure disorder.
NCT02833792,Phase 2,Alzheimer Dementia,"Stemedica Cell Technologies, Inc.",unknown,Alzheimer Disease;Dementia,Diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
NCT02833792,Phase 2,Alzheimer Dementia,"Stemedica Cell Technologies, Inc.",unknown,Alzheimer Disease;Dementia,History of cerebral neoplasm.
NCT02833792,Phase 2,Alzheimer Dementia,"Stemedica Cell Technologies, Inc.",unknown,Alzheimer Disease;Dementia,Myocardial infarction within six months of enrollment.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,Women of child bearing potential.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,History or presence of a seizure disorder.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,"History of uncontrolled peptic ulcer disease, urinary or gastric retention; asthma or obstructive pulmonary disease."
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,"History or presence of uncontrolled bladder outflow obstruction, gastrointestinal obstructive disorder or reduced gastrointestinal motility, or narrow-angle glaucoma."
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,Renal and hepatic dysfunction with:
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Total Bilirubin: greater than 1.5 x UNL
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, AST: greater than 2.5 x UNL
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, ALT: greater than 2.5 x UNL
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Serum Creatinine: greater than 1.5 x UNL
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Creatinine Clearance: less than 30 mL/min (calculated by Cockcroft and Gault equation)
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,History or presence of myasthenia.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,History of Prolonged QT Syndrome.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,History of unexplained syncope.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,Myocardial infarction or hospitalization for congestive heart failure within 6 months.
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,"Patients has implanted cardiac pacemaker, implantable cardiac defibrillator (ICD), or metallic objects located in the eye, neck, ear, brain or blood vessel walls."
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,ECG findings of:
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Complete Left Bundle Branch block;
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Ventricular pacing;
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, 2nd degree or 3rd degree AV block;
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Atrial fibrillation or atrial flutter;
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, Heart rate less than 45 or greater than 100;
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia, PR greater than 220 msec; or
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia," QTcF greater than 450 msec in male, greater than 470 msec in female"
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,Patients treated with the following medications within 8 weeks of screening
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia," AChEIs (other than donepezil),"
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia," Peripherally acting anticholinergics (such as drugs for the treatment of overactive bladder disorder),"
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia," Psychoactive medications (including antipsychotics, antidepressants, anxiolytics or sedative hypnotics) having significant anticholinergic effects and/or believed to affect cognitive function."
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia," Other medications are acceptable, at the investigators discretion, if dosage is held stable for at least 4 weeks prior to screening and throughout the study."
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,Claustrophobia
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,"Patients considered unlikely to cooperate in the study, and/or poor compliance anticipated by the investigator."
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,"Any other clinically relevant acute or chronic diseases which could interfere with patients' safety during the trial, or expose them to undue risk, or which could interfere with study objectives."
NCT02860065,Phase 2,Alzheimer's Disease,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",unknown,Alzheimer Disease;Dementia,Patients who have participated in another clinical trial with an investigational drug within previous 30 days.
NCT02880956,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab," Subject has any contraindications or inability to tolerate brain magnetic resonance imaging (MRI), PET scans or lumbar puncture."
NCT02880956,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab, Subject has evidence of any other clinically significant neurological disorder other than Early AD.
NCT02880956,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab," In the opinion of the investigator, the subject has any clinically significant or uncontrolled medical or psychiatric illness, or has had an infection requiring medical intervention in the past 30 days."
NCT02880956,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab," Subject has had a myocardial infarction, unstable angina, stroke, transient ischemic attack or required intervention for any of these conditions within 6 months of Screening."
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,Past or present history of certain brain disorders other than MCI or AD.
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Certain significant medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries."
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,Contraindication to MRI scanning.
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.)."
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,History of kidney disease or presence of impaired kidney function based on laboratory tests at the screening visit.
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,History of liver disease or presence of impaired liver function based on laboratory tests at the screening visit.
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,Participation in the last year in a clinical trial for a disease-modifying drug for AD.
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,Inability to have a catheter in subject's vein for the injection of radioligand.
NCT02884492,Phase 2,Alzheimer's Disease,William Charles Kreisl,unknown,Alzheimer Disease,Inability to have blood drawn from subject's veins.
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",With large vessel thrombosis (thrombotic stroke occurring in large arteries)
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","With radiological evidence of other brain disorders (subdural hematoma, post-traumatic / post-surgery)"
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","With dementia caused by other brain diseases except Alzheimer's disease and vascular dementia (e.g. Parkinson's disease, demyelinated disease of the central nervous system, tumor, hydrocephalus, head injury, central nervous system infection including syphilis, acquired immune deficiency syndrome, etc.)"
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","With clinical evidence of pulmonary, hepatic, gastrointestinal, metabolic, endocrine or other life threatening diseases judged by investigators not suitable to enter the study"
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","With clinically unstable hypertension, diabetes mellitus, and cardiac disease for the last 3 months"
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",Ever hospitalized for stroke or with acute coronary syndrome in the previous 3 months prior to screening
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",Drug or alcohol abuse within the previous 12 months of screening.
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","With one of the following abnormal laboratory parameters: hemoglobin less than  10 mg/dL or platelet less than  100*109/L; creatinine or total bilirubin more than 1.5 times the upper limit value; alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphates (ALP), -glutamyl transferase (-GT) more than 2 times the upper limit of normal, or thyroid-stimulating hormone (TSH) more than 2.5 times the upper limit value or less than the lower limit value of normal"
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","With severe depression graded by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and Cornell Scale for Depression in Dementia (CSDD)"
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","With any uncontrolled illness (including, but not limited to, any of the following: ongoing or active infection including hepatitis B, C, and HIV, active bleeding, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris or, cardiac arrhythmia) judged by the investigator that entering the trial may be detrimental to the patient"
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",With known or suspected hypersensitivity to any ingredients of study product and vehicle
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",Pregnant or lactating or premenopausal with childbearing potential but not taking reliable contraceptive method(s) during the study period
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular", Note: Reliable contraceptive methods will consider as below:
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","Established use of oral, injected or implanted hormonal methods of contraception greater than  3 months prior to baseline."
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",Placement of an intrauterine device (IUD) or intrauterine system (IUS) greater than  3 months prior to baseline.
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","Partner male sterilization (i.e., vasectomy) greater than  1 month of screening"
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",Enrollment in any investigational drug trial within 4 weeks of screening visit
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",Experienced dosage increment of routinely use in drugs listed as follows within past three months before Screening visit
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",medications/treatments for Alzheimer's disease or vascular dementia
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","antipsychotic medications including but not limited to selective serotonin reuptake inhibitors (SSRIs), benzodiazepine (BZD)"
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",Vitamin B12
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular",drugs for thyroid disease
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","Current antiplatelet drug (antiaggregant) except dosage including but not limited to aspirin less than = 100mg/day, clopidogrel less than = 75mg/day, ticagrelor less than = 180mg/day, dipyridamole less than = 400mg/day"
NCT02886494,Phase 2,Alzheimer's Disease or Vascular Dementia,Charsire Biotechnology Corp.,unknown,"Alzheimer Disease;Dementia;Dementia, Vascular","Caregivers who have psychotic symptoms, are imminently suicidal, have an unstable medical condition (e.g. recent heart attack, recent stroke, episodes of dizziness, fainting attacks) or significant orthopaedic problems."
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"History of or screening brain MRI scan indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct greater than  1 cm3, greater than 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g. abscess or brain tumor such as meningioma)."
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Clinical or laboratory findings consistent with:
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Other primary degenerative dementia,"
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Other neurodegenerative condition
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Seizure disorder
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Other infectious, metabolic or systemic diseases affecting the central nervous system"
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"A current DSM-V diagnosis of active major depression, schizophrenia or bipolar disorder."
NCT02907567,Phase 1/Phase 2,Alzheimer's Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Clinically significant, advanced or unstable disease that may interfere with outcome measures, and which may bias the assessment of the clinical or mental status of the patient or put the patient at special risk"
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Clinically documented history of stroke, focal neurological signs or other major cerebrovascular diseases based on clinical judgment or MRI/CT scans such as evidence of infection, infarction or other brain lesions."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Diagnosis of AD or other type of dementia, or significant neurologic diseases such as Parkinson's disease, seizure disorder, multiple sclerosis, history of severe head trauma or normal pressure hydrocephalus."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Evidence of severe major depression (GDS greater than  12, may be rescreened after 12 weeks or longer if evidence of reactive depression or temporary mood disturbances) or clinically significant psychopathology(e.g. psychosis and schizophrenia); if hospitalized in past year, can be rescreened in 6 months; or presence of a major psychiatric disorder that in the investigator's opinion, could interfere with adherence to research assessments or procedures."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Unstable heart disease based on clinical judgment (e.g., heart attack/cardiac arrest, cardiac bypass procedures within previous 6 months and congestive heart failure),or other severe medical conditions."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"History of atrial fibrillation and evidence on ECG with any of the following: active symptoms of persistent palpitation, dizziness, history of syncope, chest pain, dyspnea, orthopnea, shortness of breath at rest, or paroxysmal nocturnal dyspnea within the past 6 months; resting heart rate of less than  30 or greater than  110 bpm; taking class I or III anti-arrhythmic drugs including flecanide, propafenone, dronedarone, sotalol, dofetilide, and amiodarone; or clinical concerns for safely participating in exercise and lowering blood pressure."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Systolic BP equal or greater than 180 mmHg and/or diastolic BP equal or greater than 110 mmHg, may be rescreened in 1 week."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Orthostatic hypotension, defined as the third standing SBP less than  100mmHg, may be rescreened after 2 weeks."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"History of significant autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, or polymyalgia rheumatic."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,Significant history of alcoholism or drug abuse within the last five years.
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Uncontrolled diabetes mellitus, defined as hemoglobin A1C greater than  7.5%, or requiring insulin treatment."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,Regularly smoking cigarette within the past year.
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Women with a potential for pregnancy, lactation/child bearing (2 year post- menopausal or surgically sterile to be considered not child bearing potential)."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Participant enrolled in another investigational drug or device study, either currently or within the past 2 months."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,Severe obesity with BMI  45; clinical judgment should be applied in all cases to assess patient safety and anticipated compliance.
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Allergy to angiotensin receptor blockers (ARBs), i.e., drugs that have a suffix  -sartan ."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Allergy to other study drugs or their ingredients; for example, clinical history or self-reported allergy or intolerance to atorvastatin."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Abnormal screening laboratory tests (e.g., liver ALT and AST greater than  3 x ULN, CK greater than  3 x ULN, GFR less than  30 or Hct less than  28%); may be rescreened after 2 weeks or longer."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,A medical condition likely to limit survival to less than 3 years.
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Participant has any condition(s) judged by the study investigator to be medically inappropriate, risky or likely to cause poor study compliance. For example:"
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,Plans to move outside the clinic catchment area in the next 2 years;
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Significant concerns about participation in the study from spouse, significant other, or family members;"
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,Lack of support from primary health care provider;
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,Residence too far from the study clinic site such that transportation is a barrier including persons who require transportation assistance provided by the study clinic funds for screening or randomization visits;
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,Residence in a nursing home; persons residing in an assisted living or retirement community are eligible if they meet the other criteria.
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Other medical, psychiatric, or behavioral factors that, in the judgment of the site PI or clinician, may interfere with study participation or the ability to follow the study Protocol."
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,Couples or significant partners who live together cannot be enrolled or participate simultaneously in the study.
NCT02913664,Phase 2/Phase 3,Family History of Alzheimer's Disease,University of Texas Southwestern Medical Center,unknown,Alzheimer Disease;Cognitive Dysfunction;Losartan;Amlodipine;Calcium Channel Blockers;Angiotensin II;Giapreza;Calcium;Angiotensin Receptor Antagonists;Angiotensinogen,"Lack of approval from participant's regular healthcare providers, i.e. a signed letter of agreement for the participants to be enrolled in rrAD."
NCT02916056,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease," The subject is felt by the investigator to be unsuitable (on the basis of health, compliance, caregiver availability, or for any other reason) for inclusion in the study."
NCT02916056,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease," Subjects with serious suicide risk. If there are  yes  answers on items 4, 5 or on any behavioral question of the C-SSRS, a suicide risk assessment must be done by a qualified mental health professional with expertise in the evaluation of suicidality in the elderly (e.g., psychiatrist, geriatrician or neurologist specializing in treatment of patients with AD) to determine whether it is safe for the subject to participate in the study."
NCT02916056,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease," Subjects demonstrating a QTcF greater than  480 msec or a greater than 45 msec change from the TTP488-301 Baseline value based on the locally read ECG performed at the TTP488-301 Month 18 Visit (TTP488-303 Baseline). Participants with known history of bundle branch block (either right or left) are allowed if absolute QTcF value does not exceed 500 msec. Participants with a functioning pacemaker, indicated by an ECG displaying paced rhythm, are allowed with no QTc upper limit."
NCT02916056,Phase 3,Alzheimer's Disease,vTv Therapeutics,unknown,Alzheimer Disease," Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may prevent the subject from completing the 2-year study or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"Has a history of a psychiatric disorder such as schizophrenia, bipolar disorder or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM). Mild depression or history of depression that is stable on treatment with a tricyclic antidepressant SSRI or SNRI medication at a stable dose is acceptable."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"Other neurodegenerative diseases, including Parkinson's disease and Huntington's disease, or cerebral tumor."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"Dementia other than AD, such as Acquired Immunodeficiency Syndrome (AIDS), Creutzfeldt-Jakob disease (CJD), Lewy Bodies dementia (LBD), Cerebrovascular dementia (CVD), Progressive Supranuclear Palsy (PSP), or normal pressure hydrocephalus (NPH)."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,History of a seizure disorder.
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,Clinically significant abnormalities in screening laboratory or ECG results.
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"Has current serious or unstable illness including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions that, in the investigator's opinion, makes them ineligible for participation in this study."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,Has four or more microinfarcts as noted in the MRI scan.
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"Has cancer or has had a malignant tumor within the past 3 years, except patients who underwent potentially curative therapy with no evidence of recurrence. (Patients with stable untreated prostate cancer or skin cancers are not excluded)."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"According to the criteria of the most current version of the DSM, alcohol abuse, alcohol dependence, or drug abuse in the past 5 years."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,"Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 16 weeks prior to screening. (The end of a previous investigational trial is the date the last dose of an investigational agent was taken)."
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,Resides in a skilled nursing facility.
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,Subjects with infection or inflammation of the skin or skin disease at or in proximity to the lumbar puncture site.
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,History of lumbar spine surgery or chronic low back pain (CLBP).
NCT02925650,Phase 1/Phase 2,Alzheimer's Disease,Annovis Bio Inc.,unknown,Alzheimer Disease;Phenserine,Subjects whom the site PI deems to be otherwise ineligible.
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,"Non-AD dementia, probable AD with Down syndrome, APP, PS-1, or PS-2 mutations (known familial AD), LBD and Fronto-temporal dementia (FTD)"
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,History of clinically significant stroke
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,"Current evidence or history in past two years of epilepsy, focal brain lesion, head injury with loss of consciousness or DSM-IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse"
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Sensory impairment that would preclude participation/cooperation with the protocol
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,"Patients with hypokalemia, hypomagnesaemia, or long QTc syndrome."
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,"Concomitant drugs known to prolong the QTc interval (greater than 461ms) and history of cardiovascular disease, including myocardial infarction or cardiac failure, angina, arrhythmia"
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Prescribed strong CYP3A4 inhibitors or a medical history of liver or pancreatic disease
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,"Evidence of any significant clinical disorder or laboratory finding that renders the participant unsuitable for receiving an investigational drug including clinically significant or unstable hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, metabolic, renal or other systemic disease or laboratory abnormality"
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,"Active neoplastic disease, history of cancer five years prior to screening, including breast cancer (history of treated basal or squamous skin cancer, or stable prostate cancer are not exclusionary)"
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Pregnancy or possible pregnancy
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,"Contraindications to LP: prior lumbosacral spine surgery, severe degenerative joint disease or deformity of the spine, platelets less than  100,000, use of Coumadin/warfarin, or history of a bleeding disorder"
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Contraindication to MRI
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Evidence of more than 4 micro hemorrhages and/or hemosiderosis by a recent (12 months) and/or the screening MRI.
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,"A low B12 is exclusionary, unless follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not physiologically significant."
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,Enrolled in another active trial investigating an experimental drug or therapy for AD
NCT02947893,Phase 2,Alzheimer's Disease,Georgetown University,unknown,Alzheimer Disease,HIV positive
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Core Study
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Females who are breastfeeding or pregnant at Screening or Baseline. Females of child-bearing potential must use a highly effective method of contraception throughout the entire study period and for 28 days after study drug discontinuation
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Any condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Participants with a history of seizures within 5 years of Screening
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, History of transient ischemic attacks or stroke within 12 months of Screening
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease," Psychiatric diagnosis or symptoms (example, hallucinations, major depression, delusions etc.)"
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Suicidal ideation or any suicidal behavior within 6 months before Screening or has been hospitalized or treated for suicidal behavior in the past 5 years
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Have any contraindications to magnetic resonance imaging (MRI) scanning or
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease,Have lesions that could indicate a dementia diagnosis other than AD on brain MRI
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease,Exhibit other significant pathological findings on brain MRI.
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease," Participants who have a history of moderate to severe hepatic impairment (example, Child-Pugh Class B or C)"
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Results of laboratory tests conducted during Screening that are outside the following limits:
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease,Absolute lymphocyte count below the lower limit of normal (LLN)
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease,Thyroid stimulating hormone above normal range
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease,Abnormally low Vitamin B12 levels
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Participants at increased risk of infection
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Have received any live vaccine/live attenuated vaccine in the 3 months before randomization
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Any chronic inflammatory disease that is not adequately controlled or that requires systemic immunosuppressive or immunomodulatory therapy
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Any other clinically significant abnormalities
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Severe visual or hearing impairment
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, A prolonged corrected QT (QTc) interval (QT interval with Fridericia's correction [QTcF] greater than 450 milliseconds [ms])
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Malignant neoplasms within 5 years of Screening
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Known or suspected history of drug or alcohol abuse
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease," Taking prohibited medications, which must be reviewed with the Investigator"
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Have participated in a recent clinical study
NCT02956486,Phase 3,Alzheimer's Disease,"Eisai Co., Ltd.",unknown,Alzheimer Disease, Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.
NCT02972658,Phase 3,Alzheimer's Disease,AstraZeneca,unknown,Alzheimer Disease;Dementia, Participants who participate in AMARANTH (NCT02245737) who develop new conditions precluding them from enrolling into I8D-MC-AZFD.
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,"The agitation/aggression is attributable to concomitant medications, environmental conditions, substance abuse, or active medical or psychiatric condition"
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Patient is receiving skilled nursing care for any medical condition other than dementia
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,"Treatment with an antipsychotic medication within 2 weeks of Baseline visit or 5 half lives, whichever is longer"
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,"Patient or study partner/caregiver has a medical condition (e.g., hearing, vision impairments) that would impair the ability to perform the study assessments."
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Has had a myocardial infarction within the last six months
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Has a history or symptoms of long QT syndrome
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,"Has a history of a significant psychotic disorder before or during the diagnosis of probable Alzheimer's disease (including, but not limited to schizophrenia or bipolar disorder)"
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Patient is bedridden or has any significant medical condition that is unstable and would place the patient at undue risk from study drug or study procedures 9. Has a sensitivity to pimavanserin or its excipients
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Has previously participated in a clinical study with pimavanserin
NCT02992132,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,Nov-16,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Has a Global Clinician Assessment of Suicidality (GCAS) score of 3 or 4 based on Investigator's assessment of behavior within the last 3 months at Screening or since last visit at Baseline
NCT03024944,Phase 2,Alzheimer Dementia,Columbia University,unknown,Dementia;Alzheimer Disease;Diabetes Mellitus, Person who are not participating in the MRI and amyloid PET under protocol AAAQ2950
NCT03038035,Phase 2,Alzheimer Disease,"National University Hospital, Singapore",Dec-16,Alzheimer Disease, Patients receiving any investigational product within 60 days or 5 half-lives prior to screening
NCT03038035,Phase 2,Alzheimer Disease,"National University Hospital, Singapore",Dec-16,Alzheimer Disease, Any serious medical or psychiatric condition which in the investigator's judgement may jeopardize the patient by his/her participation in this study or may hamper his/her ability to perform and complete procedures required in the study.
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression," Have a history of significant psychotic disorders (including, schizophrenia, delusional disorder, substance abuse psychosis that lasted over 6 months, major depressive disorder or bipolar disorder with psychotic episodes)"
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression, Has a history of ischemic stroke within the last 12 months or any evidence of hemorrhagic stroke
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression, Have renal impairment as defined by Estimated Glomerular Filtration Rate (eGFR) less than 45 milliliters per minute per 1.73 square meters (ml/min/1.73m2)
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression," Have significant cardiovascular, respiratory, gastrointestinal, renal, hematologic, or oncologic comorbidities that could impact patient safety and study participation over 10 weeks"
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression, Have a history of seizures or other condition that would place the patient at increased risk of seizures.
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression," Are, in the investigator's judgment, at risk for suicide, or as indicated by the Columbia Suicide Severity Rating Scale (C-SSRS)"
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression, Have a Fridericia's corrected QT interval (QTcF) greater than (greater than ) 450 milliseconds (ms) for males or 470 ms for females
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression, Are currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression," Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, at least 3 months (or more) must have passed"
NCT03044249,Phase 2,Alzheimer Dementia,Mediti Pharma Inc.,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Psychotic Disorders;Mental Disorders;Aggression," In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study"
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,A diagnosis of vascular dementia or dementia by other cause according to the criteria of the NINCDS-ADRDA
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Structural brain abnormality or impairment
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,"Schizophrenia, depressive disorder and bipolar disorder"
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,"Any neurological disease except Alzheimer' disease (ex. Parkinson's disease, Huntington's disease, brain tumor, normal-pressure hydrocephalus, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, epilepsy, delusion and head injury required hospitalization)"
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,History of any cancer within previous 5 years
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,History of stroke within previous 2 years
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,"Heart failure required medication or interventional treatment including myocardial infarction, valvular heart disease, arrhythmia within previous 1 year"
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Uncontrollable diabetes
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Uncontrollable hypertension
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Abnormal liver or kidney function
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Patient with significant clinical meaning to affect cognitive function
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Patient who participated in other clinical trial within previous 3 months or has a plan to participate in other clinical trial during study period
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,History of abuse of a drug or alcohol within previous 2 years
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Patient who has administrated other acetylcholinesterase inhibitors except donepezil within previous 4 weeks
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,"Patient who are deemed inadequate to participate in the clinical trial by the investigator(ex. a illiteracy, etc.)"
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,History of hypersensitivity reaction to the main ingredient of the investigational drugs
NCT03055741,Phase 2,Mild-moderate Alzheimer's Disease,"Daehwa Pharmaceutical Co., Ltd.",unknown,Alzheimer Disease;Donepezil,Patient who has administrated other drugs except donepezil for dementia treatment (it is possible to enroll after washout for 28 days)
NCT03062449,Phase 2,Alzheimer Disease,Aleksandra Stark,unknown,Alzheimer Disease,"Diagnosis or previous history of ischemic stroke, astrocytoma, meningioma or oligodendroma."
NCT03062449,Phase 2,Alzheimer Disease,Aleksandra Stark,unknown,Alzheimer Disease,"Diagnosis or previous history of any other comorbid diagnosis of neurodegenerative disease including amyotrophic lateral sclerosis, Parkinson's disease, Lewy Body Disease, Pick's Disease, Huntington's Disease, or Progressive Supra Nuclear Palsy."
NCT03062449,Phase 2,Alzheimer Disease,Aleksandra Stark,unknown,Alzheimer Disease,Undergoing any chemotherapy or radiation therapy for any tumor or carcinoma.
NCT03062449,Phase 2,Alzheimer Disease,Aleksandra Stark,unknown,Alzheimer Disease,Diagnosis or previous history of type I or type II diabetes. Potential subjects with no history of diabetes will be referred to their PCP for a hemoglobin A1C test if they have not had one in the year prior to enrollment.
NCT03062449,Phase 2,Alzheimer Disease,Aleksandra Stark,unknown,Alzheimer Disease,Diagnosis or previous history of psychiatric illness that in the investigator's opinion would affect the subject's ability to successfully participate in the study.
NCT03062449,Phase 2,Alzheimer Disease,Aleksandra Stark,unknown,Alzheimer Disease,"In the Investigator's opinion, subject would be unable to successfully participate in the study for any reason."
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Failure to perform screening or baseline examinations
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Hospitalization or change of chronic concomitant medication one month prior to screening or during screening period
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,"Clinical, laboratory or neuro-imaging findings consistent with:"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease," Other primary degenerative dementia, (dementia with Lewy bodies, fronto-temporal dementia, Huntington's disease, Creutzfeldt-Jakob Disease, Down's syndrome, etc.)"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease," Other neurodegenerative condition (Parkinson's disease, amyotrophic lateral sclerosis, etc.)"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease," Cerebrovascular disease (major infarct, one strategic or multiple lacunar infarcts, extensive white matter lesions greater than  one quarter of the total white matter)"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease," Other central nervous system diseases (severe head trauma, tumors, subdural hematoma or other space occupying processes, etc.)"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease, Seizure disorder
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease," Other infectious, metabolic or systemic diseases affecting central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, serum electrolytes out of normal range, juvenile onset diabetes mellitus, etc.)"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,"A current DSM-IV diagnosis of active major depression, schizophrenia or bipolar disorder"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,"Clinically significant, advanced or unstable disease that may interfere with primary or secondary variable evaluations, and which may bias the assessment of the clinical or mental status of the patient or put the patient at special risk, such as:"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease," chronic liver disease, liver function test abnormalities or other signs of hepatic insufficiency (ALT, AST, Gamma GT, alkaline phosphatase greater than  2.5 ULN)"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease, Respiratory insufficiency
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease," Renal insufficiency (serum creatinine greater than  2mg/dl) or creatinine clearance  30 mL/min according to Cockcroft-Gault formula). In case of creatinine clearance  30mL/min, an alternative verification of the renal function must be completed using Cystatin C analysis. In case of normal level of Cystatin C, the patient can be included"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease," Heart disease (myocardial infarction, unstable angina, heart failure, Cardiomyopathy within six months before screening)"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease, Bradycardia (heart beat less than  50/min.) or tachycardia (heart beat greater than  95/min.)
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease, Hypertension (greater than  180/95 / Czech Republic greater than 160/95) or hypotension (less than  90/60) requiring treatment with more than three drugs
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease," AV block (type II / Mobitz II and type III), congenital long QT syndrome, sinus node dysfunction or prolonged QTcB-interval (males greater than  450 and females greater than  470 msec.)"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease, Uncontrolled diabetes defined by HbA1c greater than  8.5
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease, Malignancies within the last five years except skin malignancies (other than melanoma) or indolent prostate cancer
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease, Metastases
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,"Disability that may prevent the patient from completing all study requirements (e.g. blindness, deafness, severe language difficulty, etc.)"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Women who are fertile and of childbearing potential
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Chronic daily drug intake of  14 days or expected for  14 days:
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease," benzodiazepines (except lorazepam  1mg for sleeping disorders only), neuroleptics or major sedatives"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease, Antiepileptics
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease," Centrally active anti-hypertensive drugs (clonidine, l-methyl DOPA, guanidine, guanfacine, etc.)"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease, Opioid containing analgesics
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Nootropic drugs with exception of Ginko Biloba
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,"Suspected or known drug or alcohol abuse, i.e. more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine / in Czech Republic: 20 g alcohol per day for females (500 ml of beer or 250 ml of wine) and 30g alcohol per day for males (approximately 750 ml of beer or 375 ml of wine)) per day indicated by elevated MCV significantly above normal value at screening"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Suspected or known allergy to any components of the study treatments
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,Enrollment in another investigational study or intake of investigational drug within the previous three months
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,"Any condition, which, in the opinion of the investigator, makes the patient unsuitable for inclusion"
NCT03069014,Phase 1/Phase 2,Mild to Moderate Alzheimer's Disease,PharmatrophiX Inc.,unknown,Alzheimer Disease,If patient is in any way dependent on the sponsor or the principal investigator or if the patient is accommodated in an establishment on judicial or administrative order
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem," Sleep disturbance associated with an acute illness, delirium or psychiatric disease"
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem," Clinically significant movement disorder, such as akinesia, that would affect actigraphic differentiation of sleep and wakefulness"
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Severe agitation
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Unstable medical condition
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Discontinuation of psychotropic or sleep medication within 2 weeks of the screening visit
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Patient unwilling to maintain caffeine abstinence after 2:00pm for the duration of the protocol
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem," Patient unwilling to comply with the maximum limit of 2 alcoholic drinks per day, and only 1 alcoholic drink after 6:00pm for the duration of the protocolo"
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem, Prior use of zolpidem/zoplicone for the treatment os sleep disturbances
NCT03075241,Phase 3,Alzheimer's Disease,Brasilia University Hospital,unknown,Alzheimer Disease;Sleep Initiation and Maintenance Disorders;Sleep Wake Disorders;Parasomnias;Zolpidem," Caregiver deemed to be unreliable to supervise the wearing of the actigraph, to administer study capsules at the proper time, to maintain the sleep diary, or to bring the patient to the scheduled visits"
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,"Heart lung kidney disease, may interfere to evaluate the efficacy and safety of patients at risk or special disease,for example:Congestive heart failure et al."
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,According to NINDS-AIREN standard (Roman GC et al 1993) is currently diagnosed as possible vascular dementia
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,Improved Hachinski ischemic scale scoreMHIS4
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,"Diagnosis of severe depression, schizophrenia, and other major neurodegenerative disorders, according to the DSM-IV axis"
NCT03090516,Phase 2/Phase 3,Alzheimer's,The First Affiliated Hospital with Nanjing Medical University,unknown,Alzheimer Disease;Donepezil,"Neurological or other medical disorders that affect the function of the central nervous system,like Moderate anemia,Vitamin B12 or folic acid deficiency, et al. Not with the cognitive function examination (including blindness, deafness, severe language disorders)."
NCT03101085,Phase 1/Phase 2,Alzheimer Disease,Russell Swerdlow,unknown,Alzheimer Disease;Equol, Reside in a nursing home or dementia special care unit
NCT03101085,Phase 1/Phase 2,Alzheimer Disease,Russell Swerdlow,unknown,Alzheimer Disease;Equol," Have a potentially confounding, serious medical risk such as insulin-requiring diabetes, any history of cancer that required a chemotherapy or radiation therapy intervention within the past 5 years, or a recent cardiac event"
NCT03101085,Phase 1/Phase 2,Alzheimer Disease,Russell Swerdlow,unknown,Alzheimer Disease;Equol, Have any clinically significant abnormal safety laboratory values at the SEAD2 screening visit
NCT03101085,Phase 1/Phase 2,Alzheimer Disease,Russell Swerdlow,unknown,Alzheimer Disease;Equol," Have any clinically significant abnormal findings on vital signs measurements, or on physical or neurological examination at the SEAD2 screening visit"
NCT03101085,Phase 1/Phase 2,Alzheimer Disease,Russell Swerdlow,unknown,Alzheimer Disease;Equol, Use any type of systemic estrogen or testosterone replacement therapy
NCT03101085,Phase 1/Phase 2,Alzheimer Disease,Russell Swerdlow,unknown,Alzheimer Disease;Equol, Has participated in another clinical trial or received any investigational drug or investigational therapy within 30 days before the screening visit
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Any evidence of a condition other than AD that may affect cognition such as other dementias, stroke, brain damage, autoimmune disorders (e.g. multiple sclerosis) or infections with neurological sequelae."
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, History of major psychiatric illness such as schizophrenia or major depression (if not considered in remission)
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, At risk of suicide in the opinion of the investigator
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Any abnormal MRI findings, such as presence of cerebral vascular pathology, cortical stroke, etc or inability to tolerate MRI procedures or contraindication to MRI"
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Unstable or clinically significant cardiovascular (e.g., myocardial infarction), kidney or liver disease"
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Uncontrolled hypertension
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Screening hemoglobin A1c (HbA1C) greater than 8%
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Poor peripheral venous access
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, History of cancer except:
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, If considered to be cured or If not being actively treated with anti-cancer therapy or radiotherapy
NCT03114657,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins"
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine, Labile blood pressure or new antihypertensive medication started within 3 weeks
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine, Severe coronary insufficiency or myocardial infarction in previous 6 months
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine, History of unexplained syncope within the preceding 12 months
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine, Cardiac Conduction Block
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine, Severe Hepatic Impairment (ALT greater than  120 (Upper Limit of Normal (ULN) is 40) OR Alkaline Phosphatase greater than  390 (ULN 130)) OR Both ALT and total bilirubin greater than  ULN OR Total bilirubin greater than  60 (ULN 30)
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine, Severe Renal Impairment (eGFR less than  40)
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine," Treatment with other medications known to potentiate guanfacine's hypotensive effects or cause arrhythmia (specifically antipsychotics (including sultopride, chlorpromazine, thioridazine, amisulpiride, sulpiride, haloperidol), and moxifloxacin, baclofen, verapamil, quinidine, hydroquinidine, dispyramide, amiodarone, dofetilide, ibutilide, sotalol, pimazide, bepridil, cisapride, diphemanil, erythromycin, halofantrine, pentamidine, sparfloxacin, vincamine, alfuzosin, prazosin, terazosin, tamsulosin, amifostine"
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine, Weight less than 45kg
NCT03116126,Phase 3,Alzheimer Disease,Imperial College London,unknown,Alzheimer Disease;Guanfacine," Pregnancy (Pre-menopausal women will only be entered into the study of they are surgically sterile or using effective birth control methods: These are abstinence for the period of the study, intrauterine contraception/device, male sexual partners with vasectomy)"
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease," Subjects who are females who are pregnant, nursing, or of childbearing potential while not practicing effective contraception"
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Subjects who have signs of delirium
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Subjects who have had cortical stroke within the preceding 2 years
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Subjects who have a prolonged QTc interval; greater than 450 msec in male or greater than 470 msec in female at screening
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease," Subjects who have diagnosis of severe white matter hyperintensity (WMH), which is defined as  25mm of the deep white matter and  10mm of the periventricular capping/banding in lengths"
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Subjects who have diagnosis of dementia or cause of cognitive impairment other than Alzheimer's disease
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease," Subjects who have a significant abnormal result in laboratory tests, in the opinion of the investigator"
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease," Subjects who have participated in any investigational drug, stem cell therapy, or device trial within the previous 3 months at screening"
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease," Subjects with any current psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the subjects ability to complete the study"
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Subjects who are known to have autosomal dominant mutation-associated presenile AD
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease," Subjects who show signs of AIDS (Acquired Immunodeficiency Syndrome), HBV (Hepatitis B Virus), HCV (Hepatitis C), VDRL (Venereal Disease Research Laboratory)"
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease," Subjects who have any conditions that would contraindicate an MRI, such as the presence metallic objects in the eyes, skin, or heart"
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease," Subjects who have greater than  4 cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as  possible  or  definite ), a single area of superficial siderosis, or evidence of a prior microhemorrhage as assessed by MRI"
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease," Subjects who have history of malignant cancer within the last 5 years (The following is a partial list of conditions that are permissible for study entry: non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical, or non-progressive prostate cancer)"
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Subjects who have suspected active lung disease based on chest X-ray
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Subjects who are hypersensitive to fetal bovine serum or penicillin
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease," Subjects who are currently using immunosuppressants, cytotoxic drug, corticosteroids or similar steroidal anti-inflammatory medication (e.g., Prednisone) on a regular basis (exceptions allowed include; regular use of steroidal nasal sprays, topical steroids, and estrogen-replacement therapy)"
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Subjects for whom the investigator judges the liposuction can cause any problems
NCT03117738,Phase 1/Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease, Subjects who have history of local anesthetic allergy
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Patient was significantly non-compliant in Study ACP-103-032
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,"The Investigator becomes aware of an impending and unexpected change in the patient's living situation (e.g., change in caregiver, change in facility, moving from home to facility, moving from one family member or caregiver's home to another) that may cause a major disruption in the patient's behavior"
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,"Patient or study partner/caregiver has a medical condition (e.g., hearing, vision impairments) that would impair the ability to perform the study assessments."
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Patient is bedridden or has any significant medical condition that is unstable and would place the patient at undue risk from study drug or study procedures
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Has clinically significant laboratory abnormalities that would jeopardize the safe participation of the patient in the study
NCT03118947,Phase 2,Agitation and Aggression in Alzheimer's Disease,ACADIA Pharmaceuticals Inc.,unknown,Alzheimer Disease;Psychomotor Agitation;Aggression;Pimavanserin,Has a Global Clinician Assessment of Suicidality (GCAS) score of 3 or 4 based on Investigator's assessment of behavior since the last assessment
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520, Any disability that could have prevented the participants from completing all study requirements. -
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520, Current medical or neurological condition that could have impacted cognition or performance on cognitive assessments.
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520," Advanced, severe progressive or unstable disease that could have interfered with the safety, tolerability and study assessments, or put the participant at special risk."
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520," History of malignancy of any organ system, treated or untreated, within the past 60 months."
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520," Indication for, or current treatment with ChEIs and/or another AD treatment (e.g. memantine)."
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520, Contraindication or intolerance to MRI.
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520," Brain MRI results showing findings unrelated to AD that, in the opinion of the Investigator might be a leading cause to future cognitive decline, could have posed a risk to the participant, or could have prevented a satisfactory MRI assessment for safety monitoring."
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520," Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years."
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520," A positive drug screen at Screening, if, in the Investigator's opinion, was is due to drug abuse."
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520," Significantly abnormal laboratory results at Screening, not as a result of a temporary condition."
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520, Current clinically significant ECG findings.
NCT03131453,Phase 2/Phase 3,Alzheimers Disease,Novartis Pharmaceuticals,unknown,Alzheimer Disease;CNP520," Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism, vitiligo) or active / history of chronic urticaria in the past year."
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Any other cause of dementia shown by CT / MRI findings and neurological examination within 12 months of screening visit
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Possible, probable or definite vascular dementia according to the NINDS-AIREN"
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Other central nervous system diseases that may cause cognitive impairment (cerebrovascular disease including cerebrovascular dementia, Parkinsonism, Huntington's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, Creutzfeldt-Jakob disease, etc.)"
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Neurological deficits such as delusions, delirium, epilepsy"
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Vitamin B12, folic acid, syphilis serology, and thyroid stimulating hormone (TSH) results are thought to contribute to the severity of dementia or cause dementia"
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,A patient who are considered ineligible for this study by investigator due to concurrent or history of significant psychiatric conditions (eg. schizophrenia or bipolar affective disorder)
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"A patient with a history of known or suspected seizures including febrile seizures, a history of significant head trauma with loss of consciousness or recent unconsciousness that is not explained"
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"A patient with acute or unstable cardiovascular disease, active peptic ulcer, uncontrolled hypertension, uncontrolled diabetes or insulin dependent patients or any medical condition that may interfere with the completion of clinical trials"
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Hypersensitivity to investigational medicinal products
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"History of alcohol, substance abuse or dependence (except nicotine dependence) within the last 2 years"
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Concurrent malignancies or invasive cancers diagnosed within the past 5 years except for non-metastatic basal cell carcinoma or squamous cell carcinoma of skin, in situ carcinoma of the uterine cervix or non-metastatic prostate cancer"
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Renal impairment (creatinine clearance (CLcr) less than 30 mL / min)
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Severe liver dysfunction (ALT or ASTgreater than  2 times the upper limit of normal)
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,A patient taking other drugs other than donepezil to treat Alzheimer's disease or other cognitive impairment
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"A patient taking other drugs other than anticholinergic drugs, cholinergic drugs (local usages are allowable, such as pilocarpine eye drops), antidepressants (tricyclic antidepressant, MAO inhibitor) antipsychotics, donepezil to treat Alzheimer's disease"
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Women at childbearing age who do not consent using medicinally acceptable contraception (such as surgical sterilization, intrauterine contraceptive device, condom or diaphragm, an injectable or inserted contraceptive) during the study"
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Pregnancy or breast feeding
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,A patient who participated in other clinical trials within 4 weeks prior to this study
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,35 kg weight or below
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,A patient who had experienced this study drug
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,A patient who had participated in a clinical trial for Alzheimer dementia vaccine within last 6 months
NCT03184467,Phase 2,Alzheimer Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Any other patients who are considered to be ineligible for this study by an investigator
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease," Treatment with another Study Drug, biological agent, or device within one-month of Screening or 5 half-lives of investigational agent, whichever is longer"
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease, Clinically significant medical condition which would make the patient unsuitable for inclusion or could interfere with the patient participating in or completing the study
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease, Use of a disallowed CNS-active or antipsychotic medication within 4 weeks prior to Screening punctures
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease, participants from Cohorts C and D will seamlessly transition to Part 2):
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease," Treatment with another Study Drug, biological agent, or device within one-month of Screening or 5 half-lives of investigational agent, whichever is longer"
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease, Clinically significant medical condition which would make the patient unsuitable for inclusion or could interfere with the patient participating in or completing the study
NCT03186989,Phase 1/Phase 2,Mild Alzheimer's Disease,"Ionis Pharmaceuticals, Inc.",unknown,Alzheimer Disease, Use of a disallowed CNS-active or antipsychotic medication within 4 weeks prior to Screening punctures
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"Possible, probable, or definite vascular dementia according to National Institute of Neurological Disorders and Stroke/Association Internationale pur la Recherche et I'Enseignement en Neurosciences (NINDS-AIREN)"
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"History and/or evidence (computed tomography [CT] or magnetic resonance imaging [MRI] findings obtained within the past 12 months or at screening) of other central nervous system (CNS) disorders (cerebrovascular disease, structural or developmental anomaly, epilepsy, or communicable, degenerative, or infectious/demyelinating CNS conditions) as a cause of dementia Note: greater than 3 lacunar infarcts over 10 mm each, or severe white matter disease equaling a rating of 3 on the age-related white matter changes (ARWMC scale) should be excluded in the study."
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Illiteracy
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"Treatment with other anti-dementia drugs (galantamine, memantine, rivastigmine, tacrine), except donepezil, within the past 3 months from the date of informed consent"
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Treatment with any of the following drugs within the past 2 weeks from the date of informed consent
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil," CNS stimulants: methylphenidate, modafinil, pemoline, atomoxetine"
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil," Typical antipsychotics: bromperidol, chlorpromazine, haloperidol"
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil," Anticholinergics: atropine, glycopyrrolate, scopolamine, homatropine, ipratropium (short term [within 3 days] use of anticholinergics for the purpose of antispasmodic action on the digestive system is permitted.)"
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Abnormal blood test findings as follows at the screening test:
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil, Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) 2.5 x upper limit of normal
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil," A serum creatinine level of 1.5  ULN for the reference laboratory, or a calculated creatinine clearance by the Cockcroft-Gault equation of 50mL/min"
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"Clinically significant abnormal vitamin B12, syphilis serology, or thyroid stimulating hormone (TSH) test findings considered to contribute to the severity of dementia or to be attributable to dementia"
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil, Note:
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Clinically significant untreated B12 should be excluded in the study. Subjects are eligible if B12 deficiency is stable after the treatment.
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"If the subject has tested False positive for syphilis test, based on the investigator's judgment, further test can be performed to get the final result."
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,TSH greater than 10mIU/L should be excluded in the study.
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"Diagnosis of serious mental disease based on DSM-5 criteria, including depressive disorder,, schizophrenia, alcoholism, drug dependency, etc."
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Parkinson's disease or parkinsonian syndrome
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"Clinically significant electrocardiogram (ECG) abnormalities at screening (heart rate less than 50 beats/min, atrial and ventricular conduction disorders such as 2nd degree atrioventricular block, QTc interval greater than 480ms)"
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"History of unstable angina pectoris, myocardial infarction, transient ischemic attack, or coronary intervention including coronary bypass within the past 6 months from the date of informed consent"
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,History of severe traumatic head injury with loss of consciousness within the past 6 months from the date of informed consent
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Asthma or obstructive pulmonary disease requiring medication
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"Gastrointestinal disorders that may affect the absorption, distribution, and metabolism of the study drug (e.g., inflammatory bowel disease, gastric or duodenal ulcer, hepatic disease)"
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Uncontrolled diabetes mellitus (defined as HbA1cgreater than 9.0%)
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Administration of other investigational products within 3 months prior to treatment with the investigational product (Day 0)
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"Hypersensitivity reactions to donepezil HCl, piperidine derivatives, or any of the components of the study drug"
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Pregnant or lactating woman or woman of childbearing potential who does not agree to use an effective method of contraception.
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil," : Recommended effective methods of birth control include diaphragm plus spermicide or male condom plus spermicide, oral contraceptive in combination with a second method, contraceptive implant, injectable contraceptive, indwelling intrauterine device, sexual abstinence, and vasectomized partners. The subject/investigator can discuss any other best method that suits the subject."
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"Hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption"
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,Human immunodeficiency virus (HIV) positive or Acquired Immune Deficiency Syndrome (AIDs)
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"History of malignant disease, including solid tumors and hematologic malignancies (except basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured, and cervical carcinoma in situ). Cancer survivors not on maintenance therapy that had no malignant disease history within the past 5 years could be recruited."
NCT03197740,Phase 3,Alzheimer Disease,Icure Pharmaceutical Inc.,unknown,Alzheimer Disease;Donepezil,"Individual considered by the investigator to be ineligible for study participation for other reasons, including having a condition that may affect the assessment of study results"
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,"Clinically significant haematological disorder, including moderate or severe anaemia (blood haemoglobin less than 110 g/L, WHO definition)"
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Iron deficiency (serum ferritin less than  10 ng/mL)
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Clinically significant abnormal haematological results (sufficiently outside the normal range to warrant further investigation). Mild anaemia (haemoglobin 110 g/L) is not an exclusion.
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Clinically significant abnormal renal or liver function results (sufficiently outside the normal range to warrant further investigation)
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,"Presence of non-AD condition that may affect cognition, such as but not limited to Parkinson's Disease (PD), normal pressure hydrocephalus, sleep apnoea requiring O2 treatment"
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,"Clinically evident vascular disease that could potentially affect the brain, such as but not limited to significant carotid or vertebral stenosis, aortic aneurysm, cerebral haemorrhage"
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,"History of any stroke in the past 2 years, or transient ischemic attack within the last 6 months"
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,"History of persistent neurologic deficit, intracranial tumour or structural brain damage"
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,History of infection that could affect brain function (eg HIV and syphilis)
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,"Autoimmune disorders that potentially cause progressive neurologic disease with associated cognitive deficits, such as but not limited to multiple sclerosis, lupus"
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Major psychiatric illness (depression is acceptable if patient has not had an episode within the past year or is considered in remission or controlled by treatment)
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,A history of relapsing neutropenia.
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Presence of agranulocytosis or with a history of agranulocytosis
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Known hypersensitivity to DFP or excipients.
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Alcohol and/or substance abuse
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,"MRI evidence of clinically-significant cerebrovascular pathology. Focal white matter lesions,  2 lacunar infarcts in non-critical sites and other minor pathology assessed by the investigator to not be causing the current cognitive impairment, will not lead to exclusion."
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Active major medical illness
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,FCBP not using adequate method of contraception or who is pregnant or nursing
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Inability to provide informed consent
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Participation in another clinical trial within 3 months prior to inclusion in the study
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,"Subjects for whom MRI is contraindicated (severe claustrophobia, pacemaker, incompatible surgical material, unmovable electronic pump implant)"
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Negative amyloid PET scan or CSF in the last 2 years.
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Hospital Anxiety and Depression Scale (scores greater than  8/21 are disqualified).
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Subject cannot commit to regular blood tests with the interval between tests not exceeding 10 days from the scheduled visit for the duration of the study.
NCT03234686,Phase 2,Mild Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease;Dementia;Cognitive Dysfunction;Deferiprone,Subject has planned surgery which does not permit regular blood tests with the interval between tests not exceeding 10 days from the scheduled visit.
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine,"Significant neurodegenerative disorder of the central nervous system other than Alzheimer's disease, e.g., Lewy body dementia, Parkinson's disease, multiple sclerosis, progressive supranuclear palsy, hydrocephalus, Huntington's disease, any condition directly or indirectly caused by Transmissible Spongiform Encephalopathy (TSE), Creutzfeldt-Jakob Disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), or new variant Creutzfeldt-Jakob Disease (nvCJD)"
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine,The patients has history of seizure (with the exception of febrile seizures in childhood)
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine,"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revision (DSM IV-TR) criteria met for any of the following within specified period:"
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine, Major depressive disorder (current)
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine, Schizophrenia (lifetime)
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine," Other psychotic disorders, bipolar disorder, or substance (including alcohol) related disorders (within the past 5 years)"
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine,"Metal implants in the head (except dental), pacemaker, cochlear implants, or any other non-removable items that are contraindications to MR imaging."
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine,"Evidence of clinically significant disease including but not limited to pulmonary, gastrointestinal, renal, hepatic, endocrine, cardiovascular or metabolic disorder (Patients with controlled diabetes, or hypertension, or complete/partial right bundle branch block may be included in the study)."
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine,Treatment currently or within 6 months before Baseline with any of the following medications:
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine," Typical and atypical antipsychotics (i.e. Clozapine, Olanzapine)"
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine," Antiparkinson agents (e.g., levodopa, dopamine agonists, COMT inhibitors, amantadine, monoamine oxidase B inhibitors, anticholinergics etc)"
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine," Carbamazepine, Primidone, Pregabalin, Gabapentin"
NCT03250741,Phase 2,Alzheimer Disease,I.R.C.C.S. Fondazione Santa Lucia,unknown,Alzheimer Disease;Rotigotine, Memantine
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"Brain MRI examination showed significant focal lesions, moderate-to-severe white matter lesions, and key parts lacunar infarction such as the thalamus, hippocampus, entorhinal cortex, cortical and subcortical gray matter nuclei;"
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,Other type of dementia except AD;
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"Suffered from nervous system diseases (including stroke, optic myelopathy, Parkinson's disease, epilepsy, etc);"
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"Psychotic patients, according to the DSM-5 criteria, include schizophrenia or other psychiatry disorders, bipolar disorder, major depression disorder, or delirium;"
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"Abnormal laboratory test results: HBsAg and HBeAg and/or HbcAb positive and active stage of hepatitis B, liver function (ALT, AST) more than 1.2 times of the upper limit of the normal range, Cr exceeds the upper limit of normal, white blood cell count less than 4 x 109/L or platelet less than 100 x 109/L, hemoglobin less than 100g/L, blood glucose concentration of diabetic subjects (random) is more than 13.9mmol/L;"
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"Systolic pressure was more than 160mmHg or less than 90mmHg, diastolic blood pressure was more than 100mmHg or less than 60mmHg;"
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"With unstable or serious heart, lung, liver, kidney and hematopoietic system diseases (including unstable angina, myocardial infarction, uncontrolled asthma, gastric cancer, et al), or resting heart rate after 10 minutes of rest was less than 60 BPM, or QTc (QTc B (Bazett's correction value) or QTc F (Fridericia's correction value)) was equal or greater than 450msec, or with bundle branch block, the QTc B or QTc F was equal or greater than 480msec, or the researchers estimate there were abnormal EKG results which cannot be randomized to the study;"
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"There was uncorrected of visual and auditory disturbances, and neuropsychological tests and scale assessments cannot be completed by the subject;"
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,Subject was currently using Alzheimer's disease drugs and cannot be terminate the treatment;
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,Subjects that cannot take the test drug according to the prescription should be excluded;
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,Alcohol abuse or drug abuse;
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,Pregnant or lactating women;
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,Participated in other clinical pharmacological tests within 30 days before screening visit;
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,The researchers believe that the subject was impossible to complete the study;
NCT03283059,Phase 3,Alzheimer Disease,Shanghai Mental Health Center,unknown,Alzheimer Disease;Donepezil,"Participants were employees of the study and immediate family members, employees of CRO company or sponsor and their immediate family members."
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Patients who lack adequate premorbid literacy, vision, or hearing to complete the required psychometric testing in the investigator's opinion"
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Females of childbearing potential who are not surgically sterile, not refraining from sexual activity, or not using reliable contraception methods. Females of childbearing potential must not be pregnant (negative serum -Human Chorionic Gonadotropin [HCG] at screening and negative urine -HCG prior to flortaucipir F 18 injection) or breastfeeding at screening. Females should agree to avoid becoming pregnant by refraining from sexual activity or using reliable contraceptive methods for 24 hours following flortaucipir F 18 injection administration."
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Have significant neurological disease affecting the Central Nervous System (CNS) (other than AD) that may affect cognition or ability to complete the study, including but not limited to, other types of dementia, serious brain infections, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures)."
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Patients with any current primary psychiatric diagnosis other than AD if, in the opinion of the investigator, the disorder/symptom is likely to confound interpretation of drug effect, affect cognitive assessment, or affect the patient's ability to complete the study (patients with history of schizophrenia or other chronic psychosis are excluded)."
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Intend to use drugs known to significantly prolong the QT interval within 14 days or 5 half-lives (whichever is longer) of a scheduled screening/baseline flortaucipir F 18 PET scan, or have medical history of risk factors for Torsades du Pointes."
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have an average electrocardiography (ECG) corrected QT (QTcF) interval measurement greater than  450 msec (men) or greater than  470 msec (women) at screening (as determined at the investigational site).
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have ocular pathology that significantly limits ability to reliably evaluate vision or the retina.
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have a history of alcohol or drug disorder (except tobacco use disorder) within 2 years before the screening visit
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Have a current serious or unstable illness including retinal, cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of less than 24 months."
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Has a history of cancer within the last five years, with the exception of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, non-progressive prostate cancer, or other cancers with low risk of recurrence or spread"
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Patients with a past history (suspected or confirmed) of Hepatitis B or Hepatitis C
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, History of vitiligo and/or current evidence of post-inflammatory hypopigmentation
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have had prior treatment with a passive anti-amyloid immunotherapy less than five half-lives prior to randomization.
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have previously participated in any other study investigating active immunization against amyloid beta (A)
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Patients that are currently enrolled in any other interventional clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Contraindication to PET
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Has hypersensitivity to flortaucipir F 18 or any of its excipients
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Present or planned exposure to ionizing radiation that, in combination with the planned administration of study PET ligands, would result in a cumulative exposure that exceeds local recommended exposure limits"
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Has previous magnetic resonance imaging (MRI) evidence of significant abnormality that would suggest another potential etiology for progressive dementia or a clinically significant finding that may impact patient's potential to safely participate in study
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Have contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker"
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Have poor venous access
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Are investigator site personnel directly affiliated with this study and/or immediate families; immediate family is defined as a spouse, parent, child, or sibling (biological or legally adopted)"
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Are Lilly employees or are employees of third-party organizations (TPOs) involved in a study that requires exclusion of their employees
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Are otherwise unsuitable for a study of this type in the opinion of the investigator
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Have received treatment with a stable dose of an acetylcholinesterase inhibitor (AChEI) and/or memantine for less than two months before randomization (if a patient has recently stopped an AChEI and/or memantine, he/she must have discontinued treatment at least two months before randomization)."
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Current use of strong inducers of CYP3A
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease, Are currently on medication(s) known to significantly prolong the QT interval
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Have allergies to either monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisolone"
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Have known allergies to LY3002813, related compounds, or any components of the formulation; or history of significant atopy"
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Have known allergies to LY3202626, related compounds, or any components of the formulation"
NCT03322462,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease," Changes in concomitant medications that could potentially affect cognition and their dosing should be stable for at least one month before screening, and between screening and randomization (does not apply to medications discontinued due to exclusions or with limited duration of use, such as antibiotics)"
NCT03363269,Phase 2,Alzheimer Disease,IlDong Pharmaceutical Co Ltd,unknown,Alzheimer Disease,Patients diagnosed or accompanied with Dementia due to other Neurodegenerative disorders other than Alzheimer's disease
NCT03363269,Phase 2,Alzheimer Disease,IlDong Pharmaceutical Co Ltd,unknown,Alzheimer Disease,Chronic alcohol and/or drug abuse within the past 5 years
NCT03363269,Phase 2,Alzheimer Disease,IlDong Pharmaceutical Co Ltd,unknown,Alzheimer Disease,Subjects who have medical history of significant renal disease (ccrless than 30ml/min) or hepatic disease( 3*ULN less than = ALT or AST)
NCT03363269,Phase 2,Alzheimer Disease,IlDong Pharmaceutical Co Ltd,unknown,Alzheimer Disease,"Has received choline agonists, anticholinergics, anticonvulsants, antidepressants, antipsychotic drugs, Ginko biloba extract, Vitamin E, hormone replacement therapy etc. in the previous 4 weeks"
NCT03367403,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Have a history of long QT syndrome.
NCT03367403,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Have received treatment with a stable dose of an acetylcholinesterase inhibitor (AChEI) and/or memantine for less than 2 months before randomization.
NCT03367403,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Contraindication to MRI.
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Past or present history of certain brain disorders other than MCI or AD.
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Certain significant medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries."
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Contraindication to magnetic resonance imaging (MRI) scanning.
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.)."
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,History of kidney disease or presence of impaired kidney function based on laboratory tests at screening visit.
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,History of liver disease or presence of impaired liver function based on laboratory tests at screening visit.
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Participation in the last year in a clinical trial for a disease modifying drug for AD.
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Inability to have a catheter in subject's vein for the injection of radioligand.
NCT03373604,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Inability to have blood drawn from subject's veins.
NCT03393520,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with dementia predominantly of the non-Alzheimer's type (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)"
NCT03393520,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with symptoms of agitation that are not secondary to AD (e.g., secondary to pain, other psychiatric disorder, or delirium)"
NCT03393520,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)"
NCT03393520,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Participants with myasthenia gravis
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, Taken memantine within 2 months prior to screening.
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast," Current diagnosis of any psychiatric disorder, depression that is not well-controlled, clinically significant or unstable systemic disease, or severe medical procedures"
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation.
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast," Patients at imminent risk of self-harm, based on clinical interview and response on S-STS"
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast," History of malignancy occurring within 5 years immediately prior to screening, except for a subject who has been adequately treated for (1) basal cell or squamous cell skin cancer, (2) in situ cervical cancer, (3) localized prostate carcinoma, or (4) who has undergone potentially curative therapy with no evidence of recurrence for more than 3 years post-therapy, and who is deemed at low risk for recurrence by her/his treating physician"
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, History of any of the following cardiovascular conditions that an unstable:
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, Hypotension
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, Hypertension
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, Active cardiovascular disease
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, Evidence of cerebrovascular disease
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, Have used or plan to use the following medications from 30 days prior to Visit 1 through the end of the study:
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, Narcotic analgesics more frequently than on three days per week as needed for pain;
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast," Daily antipsychotic (except for risperidone, quetiapine and aripiprazole, and only if at a stable and controlled dose)"
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast," Daily anxiolytic use; however, occasional use as needed for acute agitation or to be used as a rescue anxiolytic (i.e., lorazepam and oxazepam) is acceptable as long as not used within 24 hours of a clinic visit window;"
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast," Daily antidepressants (except for citalopram, escitalopram, venlafaxine, trazodone, sertraline, and mirtazapine, and only if at a stable and controlled dose);"
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, Low potency antipsychotic agents (eg chlorpromazine) - not permitted at any time during the study;
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast," Anti-parkinson's disease medications (selegiline, levodopa, amantadine) for the treatment of Parkinson's Syndrome Complex;"
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, Lithium;
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, Clozapine;
NCT03402503,Phase 2,Alzheimer Disease,IntelGenx Corp.,unknown,Alzheimer Disease;Montelukast, Previously treated with or currently using montelukast
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"Evidence that the primary basis for cognitive impairment is neurodegenerative disease other than AD, including, but not limited to, vascular dementia, dementia with Lewy bodies, and Parkinson's disease."
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"Suicidality, defined as active suicidal thoughts within 6 months before Screening or at Baseline, defined as answering yes to items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS), or history of suicide attempt in previous 2 years, or, in the Investigator's opinion, at serious risk of suicide."
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"History of major and active psychiatric disorder, moderate to severe depressive symptoms, and or other concurrent medical condition that, EIP-VX17-745-304, Version 1.0, 17 November, 2017 Page 7 of 46 EIP Pharma, LLC Confidential in the opinion of the Investigator, might compromise safety and/or compliance with study requirements."
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,Diagnosis of alcohol or drug abuse within the previous 2 years.
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"History of cancer within the last 5 years, except basal cell carcinoma, squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years."
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,Poorly controlled clinically significant medical illness.
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"History of serum B12 abnormality, anemia with hemoglobin 10 g/dL, thyroid function abnormality, electrolyte abnormality, or positive syphilis serology that have not been corrected and/or otherwise addressed."
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,History of epilepsy or unexplained seizure within the past 5 years.
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3  the upper limit of normal (ULN), total bilirubin greater than 2  ULN, and/or International Normalized Ratio (INR) greater than 1.5"
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"Known human immunodeficiency virus, hepatitis B, or active hepatitis C virus infection."
NCT03402659,Phase 2,Alzheimer Disease,EIP Pharma Inc,unknown,Alzheimer Disease,"Subject participated in a study of an investigational drug less than 3 months or 5 half-lives of the investigation drug, whichever is longer, before enrollment in this study."
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,CSF cut-off values identified during routine Neurochemical Dementia Diagnostics
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"History or evidence of other significant neurological disease of the Central Nervous System (such as Parkinson's disease, multi-infarct dementia, fronto-temporal dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supra nuclear palsy, epilepsy, myasthenia gravis, subdural hematoma or multiple sclerosis)"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,History of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"Significant neuroimaging abnormalities, previously known or discovered on the MRI scan, including evidence of infection, infarction (greater than  3 mm in size), brain tumors (other than small meningiomas), or other focal lesions, multiple lacunas or lacunas in a critical memory structure or severe confluent microvascular disease (but not mild white matter changes, which are frequent with aging)"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,History or evidence of moderate congestive heart failure defined by the New York Heart Association criteria (class I-IV)
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"Clinical relevant ECG findings, abnormalities, e.g. pro-arrhythmic potential/effects on QT interval (QTc greater than 450 msec for males, greater than 470 msec for females, confirmed by manual assessment of ECG parameters)"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,History of new cardiovascular event within the last 6 months
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"Resting sitting vital signs: Systolic blood pressure  100 mmHg or  165 mmHg, Diastolic blood pressure  60 mmHg or  100 mmHg, heart rate  50 beats/min or  90 beats/min9. Clinically significant renal disease or insufficiency, including but not limited to creatinine value of greater than 1.5 mg/dl"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), total bilirubin, or alkaline phosphatase greater than 2.5 times the upper limit of normal laboratory range, or history of severe hepatobiliary disease (e.g. hepatitis B or C, or cirrhosis) without enzyme elevation"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Positive tested for hepatitis B surface antigen (HBsAG) or hepatitis C virus/antibodies (anti-HCV) for the first time within the last 6 months prior to the Screening Visit
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Positive tested for human immunodeficiency virus (HIV) at Screening Visit
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Fasting triglycerides greater than 2.5 times of the upper limit of normal
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Uncontrolled diabetes (FBG greater than  150 mg/dl)
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Coagulopathy or any kind of anti-coagulant therapy
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Extrapyramidal syndrome
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"Elevation of prolactin, e.g. subject with prolactin-dependent breast cancer or pituitary tumor"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,History of severe psychiatric disease like psychotic disorder or current anxiolytic or neuroleptic therapy (for dementia-related or other psychiatric disorder) within the last 3 months of enrolment
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"Chronic depression or bipolar disorder or history of major depression within the past 2 years or history of any episode of treatment-resistant depression (requiring greater than  1 antidepressants, Electroconvulsive Therapy (ECT) etc.)"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Significant history of alcohol abuse or drug abuse within the past 6 months (at the judgment of the investigator)
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Current treatment with TEP or treatment up to 24 month prior to screening
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Known incompatibility of TEP or phenothiazines
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,"Subject is receiving the following treatment that may interact with TEP, e.g. adrenaline, tricyclic antidepressants, narcotics, bromocriptine, MAO (monoamine oxidase) inhibitors, CYP2D6 inhibitors, tramadol, pentetrazol, levodopa, anticonvulsants, medication causing extrapyramidal symptoms increases the likelihood of central nervous system side effects"
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Participation in a clinical trial involving another investigational drug within 4 weeks prior to screening visit
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Women of child bearing potential or women who are pregnant or nursing
NCT03417986,Phase 2,Alzheimer Disease,Immungenetics AG,unknown,Alzheimer Disease;Dementia;Thiethylperazine,Male subjects with reproductive potential who refuse to use adequate means of contraception during and up to 3 months after stopping treatment with TEP
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation,  Evidence of neurodegenerative disease other than AD
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation, Inability for any reason to undergo MRI scans (e.g. pacemaker). Patients who require sedation for screening procedures such as MRI may receive a short-acting sedative.
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation, Psychiatric disorder that would compromise ability to comply with study requirements
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation," History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years"
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation," Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder or metabolic/endocrine disorders or other disease that would preclude treatment with p38 MAP kinase inhibitor and/or assessment of drug safety and efficacy"
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation, Recent (less than 60 days) changes to AD medications prescribed for cognitive reasons or with the potential to impact cognition
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation, Psychotropic drugs taken within 1 month. Anticoagulant drugs taken within 1 week.
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation," Participation in a study of an investigational drug less than 6 months or 5 half-lives of the investigational drug, whichever is longer, before enrollment in the study"
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation, Male subjects with female partner of child-bearing potential who are unwilling or unable to adhere to contraception requirements
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation, Female subjects who have not reached menopause or have not had a hysterectomy or bilateral oophorectomy/salpingoophorectomy
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation, Positive urine or serum pregnancy test or plans desires to become pregnant during the course of the trial
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation, History of alcohol and/or illicit drug abuse within 6 months.
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation," Infection with hepatitis A, B or C or HIV."
NCT03435861,Phase 2,Alzheimer Disease,"University Hospital, Toulouse",unknown,Infectious Encephalitis;Alzheimer Disease;Encephalitis;Inflammation, Any factor deemed by the investigator to be likely to interfere with study conduction
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Significant central nervous system disorder other than probable AD or MCI-AD
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Significant intracranial focal or vascular pathology seen on brain MRI scan that would lead to a diagnosis other than probable AD or MCI-AD
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Clinical evidence or history of cerebrovascular accident; transient ischemic attack; significant head injury, for example, associated loss of consciousness, skull fracture or persisting cognitive impairment; other unexplained or recurrent loss of consciousness for 15 minutes"
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Epilepsy (a single prior seizure greater than 6 months prior to Screening is considered acceptable)
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria met for major depressive disorder; schizophrenia; other psychotic disorders, bipolar disorder; substance (including alcohol) related disorders"
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Metal implants in the head, pacemaker, cochlear implants, or any other non-removable items that are contraindications to MRI"
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Resides in hospital or moderate to high dependency continuous care facility
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Any physical disability that would prevent completion of study procedures or assessments
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, History of swallowing difficulties
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Pregnant or breastfeeding
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Glucose-6-phosphate dehydrogenase (G6PD) deficiency
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, History of significant hematological abnormality or current acute or chronic clinically significant abnormality
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Abnormal serum chemistry laboratory value at Screening deemed to be clinically significant by the Investigator
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Clinically significant cardiovascular disease or abnormal electrocardiogram assessments
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue, Pre-existing or current signs or symptoms of respiratory failure
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Concurrent acute or chronic clinically significant immunologic, hepatobiliary, or endocrine disease and/or other unstable or major disease other than probable AD or MCI-AD"
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Diagnosis of cancer (excluding basal cell carcinoma, squamous cell carcinoma, or prostate carcinoma in situ [Stage 1]) within the past 2 years or a previous (greater than 2 years) diagnosis of cancer that has required any form of intervention or treatment within the past 2 years"
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Prior intolerance or hypersensitivity to methylthioninium (MT)-containing drug or methemoglobinemia induced by MT-containing drug, similar organic dyes, or any of the excipients"
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Treatment currently or within 90 days before Baseline with Souvenaid, clozapine, carbamazepine, primidone, valproate, or drugs for which there is a warning or precaution in the labeling about methemoglobinemia at approved doses"
NCT03446001,Phase 3,Alzheimer Disease,TauRx Therapeutics Ltd,unknown,Alzheimer Disease;Methylene Blue," Current or prior participation in any clinical trial of TRx0237; a clinical trial of a product for cognition prior to Baseline in which the last dose was received within 90 days prior to Baseline unless confirmed to have been randomized to placebo; or a clinical trial of any other investigational drug, biologic, device, or medical food in which the last dose was received within 28 days prior to Baseline"
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception. Females of childbearing potential must not be pregnant (negative serum -HCG [beta human chorionic gonadotropin] at screening and negative urine -HCG prior to flortaucipir F 18 injection) or breastfeeding at screening. Females should agree to avoid becoming pregnant by refraining from sexual activity or using reliable contraceptive methods for 24 hours following administration of flortaucipir F 18 injection;"
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Patients who lack, in the investigator's opinion, adequate premorbid literacy, adequate vision, or adequate hearing to complete the required psychometric testing;"
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Have significant neurological disease affecting the central nervous system (CNS), other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures);"
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Patients with any current primary psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessment, or affect the patient's ability to complete the study [Patients with history of schizophrenia or other chronic psychosis are excluded.];"
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Have a current serious or unstable illness including, cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of less than 24 months;"
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Has a history of cancer within the last 5 years, with the exception of nonmetastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, non-progressive prostate cancer, or other cancers with low risk of recurrence or spread;"
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Have a past history (suspected or confirmed) of Hepatitis B or Hepatitis C;
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Are clinically judged by the investigator to be at serious risk for suicide as assessed by medical history, examination, or the Columbia-Suicide Severity Rating Scale (C-SSRS)."
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Have a history of alcohol or drug disorder (except tobacco use disorder) within 2 years before the screening visit;
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Have a history of clinically significant multiple or severe drug allergies or severe post treatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis)"
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Have known positive serologic findings for human immunodeficiency virus (HIV) antibodies. Local laws and regulations may apply to whether testing is required.
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Has previous MRI evidence of significant abnormality that would suggest another potential etiology for progressive dementia or a clinically significant finding that may impact the patient's ability to safely participate in the study;
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Have any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker;"
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Have any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, ECG, or clinical laboratory test results that could be detrimental to the patient, could compromise the study, or show evidence of other etiologies for dementia."
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Has hypersensitivity to flortaucipir F 18 or any of its excipients;
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Intend to use drugs known to significantly prolong the QT interval within 14 days or 5 half-lives, whichever is longer, of a scheduled screening/baseline flortaucipir F 18 PET scan, or have medical history of risk factors for torsades de pointes."
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Have an ECG corrected QT (QTcF) interval measurement greater than 450 msec (men) or greater than 470 msec (women) at screening (as determined at the investigational site).
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Have poor venous access;
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Contraindication to PET;
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Present or planned exposure to ionizing radiation that, in combination with the planned administration of study PET ligands, would result in a cumulative exposure that exceeds local recommended exposure limits;"
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Patients that are currently enrolled in any other interventional clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Have participated, within the last 30 days in a clinical trial involving an investigational product. If the previous investigational product is scientifically or medically incompatible with this study and has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed prior to screening (Participation in observational studies may be permitted upon review of the observational study protocol and approval by the sponsor)."
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Are investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as spouse, parent, child, or sibling whether biological or legally adopted;"
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Are Lilly employees or are employees of third-party organizations (TPOs) involved in a study that requires exclusion of their employees;
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"In the opinion of the investigator, are otherwise unsuitable for a study of this type."
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Have received treatment with a stable dose of an acetylcholinesterase inhibitor (AChEI) and/or memantine for less than 1 months [If a patient has recently stopped an AChEI and/or memantine, he or she must have discontinued treatment at least 1 months prior]."
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Have changes in concomitant medications that could potentially affect cognition and their dosing should be stable for at least 1 month before screening, (does not apply to medications with limited duration of use, such as antibiotics)."
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Have received active immunization agents for the treatment of Alzheimer's Disease
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Have known allergies to LY3303560, related compounds, or any components of the formulation; or history of significant atopy"
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,"Have allergies to either monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisolone;"
NCT03467477,Phase 2,Alzheimer Disease,Avid Radiopharmaceuticals,unknown,Alzheimer Disease,Are receiving Immunoglobulin G therapy (also known as gamma globulin or intravenous immunoglobulin [IVIG])
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Use of anticonvulsant medications or excluded psychotropic medications within 3 months prior to the baseline visit
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,"Participation in a therapeutic clinical study for any medical or psychiatric indications within 3 months (6 months for biologics) of the screening visit, or at any time during the study."
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction," Subjects must understand that they may only enroll in this clinical study once; they may not enroll in any other clinical study while participating in the current study, and they may not participate in a clinical study of a drug, biologic, therapeutic device, or medical food, in which the last dose/administration was received within 3 months (6 months for biologics) prior to screening."
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,History of hypersensitivity or lack of tolerability to AGB101 (levetiracetam)
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Severe renal impairment (creatinine clearance of less than 30 mL/minute) or undergoing hemodialysis
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,"Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder (lifetime history; infant febrile seizures are not exclusionary), subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities"
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,"Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body"
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,"Diagnosis of major depression or bipolar disorder, as described in the Diagnostic and Statistical Manual of Mental Disorders, 5th Ed (DSM-5), within the past 3 years."
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction," Psychotic features, agitation, or behavioral problems within the last 3 months that could lead to difficulty complying with the protocol. Subjects must not have a major depressive disorder or other types of depression that could confound diagnosis of MCI due to AD, or clinical assessments, in the opinion of the investigator. The geriatric depression scale (long form score greater than 9 suggests depression) results should be reviewed by the investigator to assist in this determination."
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Modified Hachinski Ischemic Scale (HIS) score greater than 4
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,History of schizophrenia (DSM-5 criteria)
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,History of alcohol or substance abuse or dependence within the past 3 years (DSM-5 criteria)
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Any significant systemic illness or unstable medical condition that could lead to difficulty in complying with the protocol requirements.
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,Clinically significant abnormalities in B12 or thyroid function test that might interfere with the study.
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction," A low B12 (below normative range for elderly) is exclusionary, unless follow-up labs (homocysteine and methylmalonic acid) indicate that it is not physiologically significant. If the B12 deficiency is treated, subjects may become eligible to participate in the study."
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,"Residence in a skilled nursing facility. Individuals in independent living communities, assisted living facilities, residential care facilities, or continuing care communities are eligible provided they engage in a sufficient spectrum of activity to permit assessment of all 6 domains contributing to the CDR-SB. Individuals in these facilities must also have a caregiver who has the ability to observe the subject during the study and can participate in clinical evaluations."
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,"Any use of excluded medications (e.g., antiepileptics, certain antidepressants or antipsychotics, antihistamines with anticholinergic properties, opiates)"
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,"Participation in clinical studies using the ISLT, Behavioral Pattern Separation (BPS-O) task, or the trail making test (A, B) within 1 month of screening"
NCT03486938,Phase 2/Phase 3,Prodromal Alzheimer's Disease,AgeneBio,unknown,Alzheimer Disease;Cognitive Dysfunction,"Female subjects must not be pregnant, lactating, or of childbearing potential (i.e., they must be 2 years post menopause or surgically sterile)"
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Patients who discontinued treatment permanently in Study BN29552 or BN29553 for safety reasons.
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Impaired coagulation.
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Evidence of more than 10 microbleeds and/or ARIA-H (amyloid-related imaging abnormalities-hemosiderin deposition) at the Study BN29552 or BN29553 Week 105 visit, as assessed by central review of MRI."
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Diagnosed with three recurrent, symptomatic ARIA-E (amyloid-related imaging abnormalities-edema/effusion) events or exacerbations of previous events."
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Presence of intracranial lesion that could potentially increase the risk of CNS (Central Nervous System) bleeding.
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, At risk of suicide in the opinion of the investigator.
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Alcohol and/or substance abuse or dependence within the past 2 years and during the study.
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Inability to tolerate MRI procedures or contraindication to MRI, including, but not limited to, presence of pacemakers not compatible with MRI, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin, or body that would contraindicate an MRI scan; or any other clinical history or examination finding that, in the judgment of the investigator, would pose a potential hazard in combination with MRI."
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Pregnant or lactating, or intending to become pregnant during the study."
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Any other severe or unstable medical condition that, in the opinion of the investigator or Sponsor, could be expected to progress, recur, or change to such an extent that it could put the patient at special risk, bias the assessment of the clinical or mental status of the patient to a significant degree, or interfere with the patient's ability to complete the study assessments."
NCT03491150,Phase 3,Alzheimer's Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Chronic use of anticoagulants or participation in any other investigational drug treatment trial.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease, Participants will be excluded from the study if any of the following conditions apply:
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Hospitalization or change of chronic concomitant medication within one month prior to screening.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Patients living in a continuous care nursing facility
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Screening MRI of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct greater than  1 cm3, greater than 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g. abscess or brain tumor such as meningioma)."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"MRI incompatible implants and other contraindications for MRI, such as pacemaker, artificial joints, non-removable body piercings, etc. Additionally, participants who meet the following imaging exclusion criteria will not be included in this study:"
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Claustrophobia that will result in significant anxiety and difficulty lying still for brain imaging (MRI or PET).
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the participant to exceed the yearly dose limits for healthy volunteers.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,History of IV drug use that would prevent venous access for PET tracer injection.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Severe motor problems that prevent the participant from lying still for brain imaging.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Severe chronic pain (e.g., as the result of rheumatoid arthritis) that would prevent them from lying still during brain imaging."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Clinical or laboratory findings consistent with:
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Other primary degenerative dementia, (dementia with Lewy bodies, fronto-temporal dementia, Huntington's disease, Jacob-Creutzfeld Disease, Down's syndrome, etc.)"
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Other neurodegenerative condition (Parkinson's disease, amyotrophic lateral sclerosis, etc.)"
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Seizure disorder
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Other infectious, metabolic or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, other laboratory values) etc.)"
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"A current DSM-V diagnosis of active major depression, schizophrenia or bipolar disorder. Patients with depressive symptoms successfully managed by a stable dose of an antidepressant are allowed entry."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Clinically significant, advanced or unstable disease that may interfere with outcome evaluations, such as:"
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Chronic liver disease, liver function test abnormalities or other signs of hepatic insufficiency (ALT, AST, total bilirubin greater than  1.5 x ULN)"
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Respiratory insufficiency
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Renal insufficiency eGFR less than  45 mL/min based on the CKD-EPI formula (https://www.questdiagnostics.com/home/physicians/egfr-calculator)Heart disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy within six months before screening)"
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Bradycardia (less than 45/min.) or tachycardia (greater than 100/min.)
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Poorly managed hypertension (systolic greater than 160 mm Hg and/or diastolic greater than 95 mm Hg) or hypotension (systolic less than 90 mm Hg and/or diastolic less than 60 mm Hg)
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Uncontrolled diabetes defined by HbA1c greater than 8
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,History of cancer within 3 years of screening with the exception of fully excised non-melanoma skin cancers or non-metastatic prostate cancer that has been stable for at least 6 months.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Seropositive for human immunodeficiency virus (HIV).
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,History of acute/chronic hepatitis B or C and/or carriers of hepatitis B (seropositive for Hepatitis B surface antigen [HbsAg] or anti-Hepatitis C [HCV] antibody).
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Clinically significant abnormalities in screening laboratory tests, including:"
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,hematocrit less than 33% for males and less than 30% for females
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"absolute neutrophil cell count of 1200/uL (with the exception of a documented history of a chronic benign neutropenia), or platelet cell count of less than  120,000/uL"
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"INR greater than 1.4 or other coagulopathy, confirmed by repeat."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Disability that may prevent the patient from completing all study requirements (e.g. blindness, deafness, severe language difficulty, etc.)"
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Women who are fertile and of childbearing potential.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Within 4 weeks of screening visit or during the course of the study, concurrent treatment with antipsychotic agents (except risperidone 1.5 mg/day, quetiapine 100 mg/day, olanzapine 5 mg/day, and aripiprazole 10 mg/day), antiepileptics (except gabapentin and pregabalin for nonseizure indications), centrally active anti-hypertensive drugs (e.g., clonidine, l-methyl dopa, guanidine, guanfacine, etc.), opiate analgesics, systemic corticosteroids, psychostimulants, antiparkinsonian medications (except for non-parkinsonian indications) and mood stabilizers (e.g., valproate, lithium), sedatives and anxiolytics with the exception that use of short- to medium-acting benzodiazepines for treatment of insomnia is permitted, however, use of sedatives or hypnotics should be avoided for 8 hours before administration of cognitive tests."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Any disorder that could interfere with the absorption, distribution, metabolism or excretion of drugs (e.g. small bowel disease, Crohn's disease, celiac disease, or liver disease.)"
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Nootropic drugs except stable AD meds (acetylcholinesterase inhibitors and memantine
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Suspected or known drug or alcohol abuse, i.e. more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day indicated by elevated MCV significantly above normal value at screening."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Suspected or known allergy to any components of the study treatments.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Enrollment in another investigational study or intake of investigational drug within the previous 30 days or five half-lives of the investigational drug, whichever is longer."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Previous exposure to anti A vaccines
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Exposure to passive immunotherapies for AD (e.g. monoclonal antibodies) or BACE inhibitors within the previous 180 days.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Contraindication to undergoing an LP including, but not limited to: inability to tolerate an appropriately flexed position for the time necessary to perform an LP; international normalized ratio (INR) greater than  1.4 or other coagulopathy; platelet count of less than  120,000/L; infection at the desired lumbar puncture site; taking anti-coagulant medication within 90 days of screening (Note: low dose aspirin is permitted); degenerative arthritis of the lumbar spine; suspected non-communicating hydrocephalus or intracranial mass; prior history of spinal mass or trauma."
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Use of NSAIDs more than 2 days in within any 7-day period. Each incidence of use must be recorded in the source and CRF.
NCT03493282,Phase 1/Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Any condition, which in the opinion of the investigator or the sponsor makes the patient unsuitable for inclusion."
NCT03503331,Phase 2,Alzheimer Disease,University of Alabama at Birmingham,unknown,Alzheimer Disease,Meets any exclusion criteria for the UAB-ADC study (IRB-300000169).
NCT03503331,Phase 2,Alzheimer Disease,University of Alabama at Birmingham,unknown,Alzheimer Disease,Inability or contraindication for undergoing MRI and/or PET imaging
NCT03503331,Phase 2,Alzheimer Disease,University of Alabama at Birmingham,unknown,Alzheimer Disease,Inability to participate in the imaging studies due to severity of dementia
NCT03518073,Phase 2,Alzheimer Disease (AD),Eli Lilly and Company,unknown,Alzheimer Disease," Participants must not have significant neurological disease affecting the nervous system, other than AD, that affects cognition or may affect completion of the study."
NCT03518073,Phase 2,Alzheimer Disease (AD),Eli Lilly and Company,unknown,Alzheimer Disease, Participants must not have serious or unstable illness that could interfere with the analysis of the study or has a life expectancy less than 24 months.
NCT03518073,Phase 2,Alzheimer Disease (AD),Eli Lilly and Company,unknown,Alzheimer Disease," Participants must not have history of cancer within the last 5 years with the exception of certain types of skin, cervical, prostate, and other cancers that are not likely to recur or spread."
NCT03518073,Phase 2,Alzheimer Disease (AD),Eli Lilly and Company,unknown,Alzheimer Disease, Participants must not have serious risk for suicide.
NCT03518073,Phase 2,Alzheimer Disease (AD),Eli Lilly and Company,unknown,Alzheimer Disease, Participants must not have history of drug or alcohol use disorder within the last 2 years.
NCT03518073,Phase 2,Alzheimer Disease (AD),Eli Lilly and Company,unknown,Alzheimer Disease, Participants must not have multiple severe drug allergies
NCT03518073,Phase 2,Alzheimer Disease (AD),Eli Lilly and Company,unknown,Alzheimer Disease," Participants must not have HIV, Hepatitis B or Hepatitis C"
NCT03518073,Phase 2,Alzheimer Disease (AD),Eli Lilly and Company,unknown,Alzheimer Disease, Participants must not be receiving gamma globulin (IgG) or intravenous immunoglobulin (IVIG) therapy
NCT03520998,Phase 2,Mild to Moderate Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, Evidence of clinically relevant neurological disorder(s) other than probable AD
NCT03520998,Phase 2,Mild to Moderate Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease," History of blood coagulation disorders or hypercoagulability; any concurrent use of an anticoagulant therapy. (e.g., heparin, warfarin, thrombin inhibitors, Factor Xa inhibitors). Use of antiplatelet drugs (e.g., aspirin or clopidogrel) is acceptable."
NCT03520998,Phase 2,Mild to Moderate Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease," Initiation or change in the dosage of cholinesterase inhibitors (AChEI), memantine, Axona, vitamin E supplementation or selegiline within 3 months prior to screening."
NCT03520998,Phase 2,Mild to Moderate Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease," Heart disease (or history thereof), as evidenced by myocardial infarction, unstable, new onset or severe angina, or congestive heart failure (New York Association Class II, III or IV) in the 6 months prior to dosing; uncontrolled high blood pressure (systolic blood pressure of 160 mmHg or higher and/or diastolic blood"
NCT03520998,Phase 2,Mild to Moderate Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, Prior hypersensitivity reaction to any human blood product or intravenous infusion; any known clinically significant drug allergy.
NCT03520998,Phase 2,Mild to Moderate Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease," Treatment with any human blood product, including transfusions and intravenous immunoglobulin, during the 6 months prior to screening."
NCT03520998,Phase 2,Mild to Moderate Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease," History of immunoglobulin A (IgA), haptoglobulin or C1 inhibitor deficiency; stroke, anaphylaxis, or thromboembolic complications of intravenous immunoglobulins."
NCT03520998,Phase 2,Mild to Moderate Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, Hemoglobin less than 10 g/dL in women; and less than 11 g/dL in men.
NCT03531710,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Clinically significant neurological disease other than Alzheimer's disease
NCT03531710,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Major psychiatric disorder
NCT03531710,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Severe systemic disease
NCT03531710,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Serious adverse reactions to any vaccine
NCT03531710,Phase 2,Alzheimer's Disease,United Neuroscience Ltd.,unknown,Alzheimer Disease, Other exclusion criteria apply
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,"Any CNS disease other than suspected AD, such as clinical stroke, brain tumor, normal pressure hydrocephalus, multiple sclerosis, significant head trauma with persistent neurological cognitive deficits or complaints, Parkinson's disease, frontotemporal dementia, or other neurodegenerative diseases"
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Abnormal liver function defined as AST and/or ALT greater than  3 times the upper limit of normal
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Renal insufficiency as defined by a serum creatinine greater than  1.5 times the upper limit of normal
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,History of cholecystectomy or biliary disease
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Clinically significant unstable medical condition (other than AD) that in the Site Investigator opinion would pose a risk to the participant if they were to participate in the study
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Any contraindication to undergo MRI studies such as:
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,History of a cardiac pacemaker or pacemaker wires
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Metallic particles in the body
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Vascular clips in the head
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Prosthetic heart valves
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Severe claustrophobia impeding ability to participate in an imaging study
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,"Major active or chronic psychiatric illness (e.g. depression, bipolar disorder, obsessive compulsive disorder, schizophrenia) within the previous year prior to baseline"
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Any significant neurodevelopmental disability
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Current suicidal ideation or history of suicide attempt within five years of baseline or significant change from the screening and baseline C-SSRS at the discretion of the Site Investigator
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,History of alcohol or other substance abuse or dependence within the past two years
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Any significant systemic illness or medical condition that could affect safety or compliance with study at the discretion of the Site Investigator
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,"Laboratory abnormalities in B12, TSH, or other common laboratory parameters that might contribute to cognitive dysfunction"
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,"Current use of medications with psychoactive properties that may deleteriously affect cognition (e.g., anticholinergics, centrally-acting antihistamines, antipsychotics, sedative hypnotics, anxiolytics)"
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Use of any small molecule investigational therapy being used or evaluated for the treatment of AD is prohibited beginning three months (84 days) prior to the Baseline Visit and throughout the study.
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Use of any immunotherapy investigational therapy is prohibited beginning one year (365 days) prior to the Baseline Visit and throughout the study.
NCT03533257,Phase 2,Alzheimer Disease,Amylyx Pharmaceuticals Inc.,unknown,Alzheimer Disease;Ursodoxicoltaurine;4-phenylbutyric acid,Use of other investigational agents one month (28 days) prior to the Baseline Visit and for the duration of the trial.
NCT03542656,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage"," Patients could not receive the PET and MRI studies, including but not limited to poor cooperative agitation impeding adequate study, allergy to contrast medium, hemodynamic instability, implantation of cardiac pacemaker, past history of receiving aneurysm clipping, panic mood to MRI study."
NCT03542656,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage", Patients with pregnancy or recently having a plan for pregnancy.
NCT03542656,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage", Patient or family who does not agree to participate in the study.
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Subjects with dementia or other memory impairment not due to Alzheimer's disease.
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole," Subjects with a history of stroke, well-documented transient ischemic attack, or pulmonary or cerebral embolism."
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole," Subjects who had an insufficient response, based on the investigator's judgment, to 2 or more previous antipsychotic medications."
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Subjects who have been diagnosed with an Axis I disorder.
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole," Subjects who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal, or psychiatric disorders."
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole," Subjects with uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension."
NCT03548584,Phase 3,Alzheimer Dementia,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Subjects with diabetes mellitus (insulin-dependent and non-insulin-dependent) may be eligible for the trial if their condition is stable and well-controlled.
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Dementia due to any condition other than AD, including vascular dementia (Rosen-Modified Hachinski Ischemic score  5)"
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Evidence of significant central nervous system (CNS) vascular disease on previous neuroimaging including but not limited to: cortical stroke, multiple infarcts, localized single infarcts in the thalamus, angular gyrus, multiple lacunar infarcts or extensive white matter injury"
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Clinically significant neurologic disease or condition other than AD, such as cerebral tumor, chronic subdural fluid collections, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, or any other diagnosis that could interfere with assessment of safety and efficacy"
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Evidence of clinically significant unstable cardiovascular, pulmonary, renal, hepatic, gastrointestinal, neurologic, or metabolic disease within the 6 months prior to enrollment. . If there is a history of cancer the subject should be clear of cancer for at least 2 years prior to screening. More recent history of basal cell or squamous cell carcinoma and melanoma in situ (Stage 0) may be acceptable after review by the Medical Monitor."
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Creatinine clearance (CL) of less than 45ml/min
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Poorly controlled diabetes, at the discretion of the Principal Investigator"
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Concomitant treatment with NMDA receptor antagonists such as but not limited to memantine or drug combinations containing memantine, dextromethorphan (a cough suppressant), ketamine, phencyclidine (PCP), methoxetamine (MXE), nitrous oxide (N2O) and the following synthetic opioids: penthidine, levorphanol, methadone, dextropropoxyphene, tramadol, and ketobemidone."
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Use of vitamin E greater than  400 International Units (IU) per day within 14 days prior to screening
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Use of valproic acid within 14 days prior to screening
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Use of an active Alzheimer's vaccine within 2 years prior to screening
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Use of a monoclonal antibody for treatment of AD within 1 year prior to screening
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Any medical or psychiatric condition that is likely to require initiation of additional medication or surgical intervention during the course of the study
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Any screening laboratory values outside the reference ranges that are deemed clinically significant by the PI
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Use of an investigational drug within 30 days prior to screening
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Suicidality defined as active suicidal thoughts during the 6 months prior to screening or at Baseline [Type 4 or 5 on C-SSRS], or history of suicide attempt in previous 2 years, or at serious suicide risk in PI's judgment"
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Major psychiatric illness such as current major depression according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition , current or past diagnosis of bipolar disorder, schizophrenia, or any other psychiatric disorder that might interfere with the assessments of safety or efficacy at the discretion of the PI"
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Diagnosis of alcohol or drug abuse within the last 2 years
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Abnormal laboratory tests that suggest an alternate etiology for dementia. If the patient has prior history of serum B12 abnormality, anemia with hemoglobin 10g /dl, thyroid function abnormality, electrolyte abnormality, or positive syphilis serology the patient should be revaluated to determine if these potential causes of dementia have been addressed. Only if these causes have been ruled out as the cause of the dementia can the patient be enrolled."
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,History of prolonged QT or prolonged QT on screening ECG (QTcB or QTcF greater than 499 per central reader)
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Acute or poorly controlled medical illness: blood pressure greater than  180 mmHg systolic or 100 mmHg diastolic; myocardial infarction within 6 months; uncompensated congestive heart failure [New York Heart Association (NYHA) Class III or IV]
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Known to be seropositive for human immunodeficiency virus (HIV)
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Known to be seropositive for Hepatitis B or C, unless successful curative treatment for Hepatitis C (e.g., Harvoni) has been received and there is documentation that there is no Hep B/C virus detected 3 months after completion of treatment"
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,AST or ALT greater than 3x upper limit of normal (ULN) and total bilirubin greater than 2x ULN or International Normalized Ratio (INR) greater than 1.5
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Prior exposure to bryostatin, or known sensitivity to bryostatin or any ingredient in the study drug"
NCT03560245,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Any other concurrent medical condition, which in the opinion of the PI makes the subject unsuitable for the clinical study"
NCT03594123,Phase 3,Alzheimer's Disease,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Alzheimer Disease;Dementia;Psychomotor Agitation;Brexpiprazole, Subjects with a substantial protocol violation during the course of their participation in the double-blind trial 331-14-213.
NCT03613844,Phase 2,Brain DHA Delivery and Alzheimer's Disease Risk,University of Southern California,unknown,Alzheimer Disease, Diagnosis of dementia as assessed by the investigator
NCT03613844,Phase 2,Brain DHA Delivery and Alzheimer's Disease Risk,University of Southern California,unknown,Alzheimer Disease, Use of omega-3 preparations in the last 3 months
NCT03613844,Phase 2,Brain DHA Delivery and Alzheimer's Disease Risk,University of Southern California,unknown,Alzheimer Disease, greater than  200 mg/day of DHA consumption using a validated questionnaire
NCT03613844,Phase 2,Brain DHA Delivery and Alzheimer's Disease Risk,University of Southern California,unknown,Alzheimer Disease," Use of donepezil, rivastigmine, galantamine and/or memantine"
NCT03613844,Phase 2,Brain DHA Delivery and Alzheimer's Disease Risk,University of Southern California,unknown,Alzheimer Disease, Alcohol or drug abuse
NCT03613844,Phase 2,Brain DHA Delivery and Alzheimer's Disease Risk,University of Southern California,unknown,Alzheimer Disease, A concomitant serious disease such as active cancer treatment or HIV.
NCT03613844,Phase 2,Brain DHA Delivery and Alzheimer's Disease Risk,University of Southern California,unknown,Alzheimer Disease, Participation in a clinical trial in the last 30 days
NCT03613844,Phase 2,Brain DHA Delivery and Alzheimer's Disease Risk,University of Southern California,unknown,Alzheimer Disease, Use of anticoagulants such as Plavix or Coumadin or the newer generation blood thinners.
NCT03620981,Phase 2/Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Patients who have dementia other than dementia of the Alzheimer's type
NCT03620981,Phase 2/Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Patients diagnosed with delirium between 30 days before the screening examination and baseline evaluation according to DSM-5.
NCT03620981,Phase 2/Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Patients diagnosed with any of the following disorders according to DSM-5:
NCT03620981,Phase 2/Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Schizophrenia spectrum and other psychotic disorders
NCT03620981,Phase 2/Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Bipolar and related disorders
NCT03620981,Phase 2/Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Major depressive disorder
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,Lack of peripheral venous access.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Uncorrected impairment of vision or hearing that would preclude the subject from taking tests, or subjects lacking the ability to communicate."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Inability to tolerate MRI procedures or contraindication to MRI, including but not limited to MRI incompatible pacemakers; implantable cardioverter defibrillators; cochlear implants; cerebral aneurysm clips; implanted infusion pumps; implanted nerve stimulators; metallic splinters in the eye; other magnetic, electronic, or mechanical implants; or any other clinical history or examination finding that, in the judgment of the Investigator, would pose a potential hazard in combination with MRI."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Severe or unstable medical condition that, in the opinion of the Investigator or Sponsor, would interfere with the subject's ability to complete the study assessments."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"History or presence of clinically evident vascular disease potentially affecting the brain (eg, stroke, clinically significant carotid or vertebral stenosis or plaque, aortic aneurysm, intracranial aneurysm, cerebral hemorrhage, arteriovenous malformation)."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system trauma (eg, cerebral contusion)."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"History or presence of intracranial tumor (eg, meningioma, glioma)."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Presence of infections that affect the brain function or history of infections that resulted in neurologic sequelae (eg, syphilis, neuroborreliosis, viral or bacterial meningitis/encephalitis,human immunodeficiency virus encephalopathy)."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"History or presence of systemic autoimmune disorders potentially causing progressive neurologic disease (eg, multiple sclerosis, lupus erythematosus, anti-phospholipid antibody syndrome, Behet disease)."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"History or presence of psychiatric disease other than AD that may affect cognition or prevent completion of study procedures, including but not limited to clinically significant major psychiatric disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) (eg, major depression, schizophrenia, bipolar disorder)."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,  A history of major depression is acceptable if no episode has been reported within the previous 5 years.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"History or presence of a neurologic disease other than AD that may affect cognition, including but not limited to Parkinson's disease, corticobasal degeneration, dementia with Lewy bodies, Creutzfeldt-Jakob disease, progressive supranuclear palsy, frontotemporal degeneration, Huntington's disease, normal pressure hydrocephalus, and hypoxia."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,History of seizures with the exception of childhood febrile seizures.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,Known or suspected history of alcohol or drug abuse within the previous 5 years (DSM-V criteria).
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Evidence of malignancies, acute infections, renal failure that requires dialysis, or other unstable medical disease not related to AD that in the Investigator's opinion would preclude subject participation."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"  This does not include any cancer (except adequately treated basal or squamous cell skin cancer) that is not being actively treated with anti-cancer drugs or radiotherapy as well as cancers that are considered to have low probability of recurrence (with supporting documentation of this from the treating oncologist, if possible)."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,History or presence of atrial fibrillation that poses a risk for future stroke in the Investigator's judgment.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Severe heart disease (history of myocardial infarction, congestive heart disease, history of unstable angina pectoris, clinically significant ECG abnormality) within 6 months prior to screening. Subjects with peripheral arterial disease will not be excluded if they are stable for at least 6 months prior to screening."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Clinically significant vital signs, laboratory, or ECG abnormalities (eg, abnormally prolonged or shortened heart rate, clinical significant arrhythmias, corrected QT interval [QTcF] greater than 450 ms) in the Investigator's judgement. ECG abnormalities should be confirmed by Investigator based on the central read results provided by the ECG core laboratory (Medpace Cardiovascular Core Laboratory [MCCL])."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Subjects must not have an estimated glomerular filtration rate of less than 30 mL/min/1.73 m2, at screening."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Impaired hepatic function, as indicated by transaminases greater than 2 times the upper limit of normal or abnormalities in synthetic function tests judged by the Investigator to be clinically significant."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,Evidence of poorly-controlled diabetes (glycosylated hemoglobin greater than 8.0%).
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Presence of superficial siderosis of central nervous system, or greater than 4 cerebral microhemorrhages, or evidence of a prior cerebral macrohemorrhage as assessed by T2*-weighted gradient-recalled-echo (GRE) MRI."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,Presence of significant cerebral vascular pathology as assessed by MRI.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Treatment with any investigational agent within 5 half-lives or 4 weeks prior to screening, whichever is longer."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Cognitive dysfunction that might be due to past or current medication (eg, chemotherapy, steroids)."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Treatment with any biologic therapy within 5 half-lives or 3 months prior to screening, whichever is longer, or any subject who has been in an Alzheimer A or tau vaccination trial unless known to have received only placebo."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Treatment with anticholinergic antidepressants, typical antipsychotics, or barbiturates."
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,"Chronic use of opiates, opioids, or benzodiazepines:"
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,  Intermittent short-term use is allowed except within 5 half-lives prior to any neurocognitive assessment.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,Use or intention to use any medications/products that are cytochrome P450 (CYP)3A4 substrates with narrow therapeutic indexes.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,Use or intention to use any medications/products that are known to be strong inducers/inhibitors of CYP3A4 within 7 days prior to the first dose and throughout the period of study drug administration.
NCT03625401,Phase 2,"Alzheimer Disease, Early Onset",Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease,Consumption of grapefruit juice or grapefruit-containing products within 7 days prior to the first dose and throughout the period of study drug administration.
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"Subjects who are female who are pregnant, nursing, or of childbearing potential and not practicing effective contraception."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Subjects who have signs of delirium.
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Subjects who have had a cortical stroke within the preceding 2 years.
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"Subjects who have any diagnosis of dementia other than that related to Alzheimer's Disease, including concomitant vascular dementia."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Subjects who have a PET scan performed after onset of symptoms with negative amyloid results.
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"Subjects with a history of myocardial infarction, unstable angina, New York Heart Association (NYHA) class III or IV heart failure or stroke within the last 12 months."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Subjects with uncontrolled hypertension (systolic blood pressure greater than 160mm Hg or diastolic blood pressure greater than  95mm Hg) or hypotension (systolic blood pressure less than 90mm Hg or diastolic blood pressure less than 50mm Hg).
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Subjects who have clinically significant renal impairment (creatinine greater than  1.5x ULN) or hepatic impairment (AST or ALT greater than  2.5x ULN or total bilirubin greater than  1.5x ULN).
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Subjects who have history of cancer or malignant tumor within 5 years prior to screening with the exception of:
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Basal or squamous cell carcinoma of the skin or cervical dysplasia which has been adequately treated.
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"In situ Grade 1 cervical cancer, fully treated at least 2 years prior to screening and without recurrence."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"Prostate cancer, confined to the prostate gland, which has been adequately treated (surgery and/or radiation) with normal or low and stable PSA levels for 2 years prior to screening."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Subjects who have history of untreated thyroid disorder or a seizure disorder.
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"Subjects who are being treated, or likely to require treatment during the study, with any medications prohibited by the study protocol."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"Subjects who have participated in any investigational drug or device trial within the previous 30 days or five half-lives of the investigational drug at screening, whichever one is longer."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"Subjects who have any other clinically significant abnormal result in laboratory tests such as abnormally low B12 or high TSH levels, as determined by the Investigator."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"Subjects with any current psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the subject's ability to complete the study."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"Subjects whose treatment with FDA-approved AD medication (donepezil, galantamine, memantine, rivastigmine or their combinations) has not been stable for at least 3 months prior to screening. Treatment and dosing should remain stable, with no changes throughout the trial."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Subjects who are currently receiving (or unable to stop use for at least 21 days [3 weeks] prior to receiving the first dose of the AR1001 and throughout the study) prescription or non-prescription medications or other products known to be moderate or potent inhibitors/inducers of CYP3A4.
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"Subjects who have had any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first administration of the AR1001 and throughout the study."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,"Subjects, in the opinion of the Investigator, who are unsuitable to participate in the study."
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease, Extension Phase Continuation Criterion
NCT03625622,Phase 2,Mild to Moderate Alzheimer's Disease,"AriBio Co., Ltd.",unknown,Alzheimer Disease,Subjects enrolled in AR1001-ADP2-US01 and completed 26 weeks of assigned dosing.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject has underwent any of the following treatment modalities with the respective time frames:
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,"Anti-epileptic agents: Within 12 weeks of the screening visit,"
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,"Narcotic: within 12 weeks of the screening visit,"
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,"Immunosuppressants: within 12 weeks of the screening visit,"
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,"Hypnotics: within 24 hours of the screening visit or the randomization visit,"
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,"Lithium: within 2 weeks of the randomization visit,"
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,"Succinylcholine-type muscle relaxants: within 2 weeks of the randomization visit,"
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,"Drugs or treatments known to cause major organ system toxicity: within 42 weeks of the randomization visit,"
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,"Tricyclic and tetracyclic anti-depressants: within 4 weeks of the screening visit,"
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,"Antiparkinsonian: Within12 weeks of the screening visit (Not including dopaminergic agent or peripheral anticholinergic agent at stable dose for at least 4 weeks of randomization visit),"
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Any medications for cognition enhancement: Within13 weeks of the screening visit(except for donepezil that has been maintained with a stable regimen for at least 12 weeks).
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,"Subject is lactating, pregnant or plans to become pregnant,"
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,"Subject is cared primarily by nursing home,"
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject's AST or ALT is greater than 2 times of the upper limit or normal range.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject with diabetic history and with HbA1c greater than  8.5 %.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,"Subject with clinically significant medical or neurological disorders, other than AD, that may affect cognition (e.g., abnormal thyroid function tests, Vitamin B12 or folate deficiency, post-traumatic conditions Huntington's disease, Parkinson's disease, syphilis, probable/possible vascular dementia according to NINDS-AIREN criteria, active/uncontrolled seizure)."
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject with major psychiatric disorders.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject with spleen related disorders.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject with sickle cell disease.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject with myelodysplastic syndrome.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject with current diagnosis of acute stroke or history of acute stroke within 1 year.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject with allergy history to E. coli-derived proteins or G-CSF or donepezil.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject with cancer history and has received related therapy(ies) with in 2 years of entering this study.
NCT03656042,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Lenograstim,Subject has participated other investigational study within 4 weeks of entering this study.
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Criteria related to diseases:
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Known presence of dementia or Alzheimer's disease (DSMIV criteria);
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Dependency for basic activities of daily living (ADL score less than 4);
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction," Presence of serious diseases, which could be life-threatening in the short term."
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Criteria related to treatments:
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Taking of supplements containing omega-3 (apart from food) within the past 6 months and/or taking omega-3 at inclusion.
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Criteria related to subjects:
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Visual or hearing impairments incompatible with performance and/or interpretation of the neuropsychological tests;
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction," History or presence of any previous condition (severe depression or generalized anxiety) that could, in the opinion of the investigator, interfere with the results of the study or expose the subject to an additional risk;"
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction," Subjects deprived of their liberty by administrative or judicial decision, or under guardianship or admitted to a healthcare or social institution (subjects in non-assisted living facilities could be recruited);"
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Participation in another clinical study in the previous month or participation scheduled during the study;
NCT03691519,Phase 3,Alzheimer Disease,"University Hospital, Toulouse",unknown,Alzheimer Disease;Cognitive Dysfunction, Food allergy.
NCT03712787,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab," The subject has any significant change in his/her medical condition since participation in Study M15-566 (NCT02880956) that could interfere with the subject's participation in Study M15-570, could place the subject at increased risk, or could confound interpretation of study results"
NCT03712787,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab, More than 8 weeks have elapsed since the subject received his/her last dose of study drug in Study M15-566 (NCT02880956)
NCT03712787,Phase 2,Alzheimer's Disease,AbbVie,unknown,Alzheimer Disease;Tilavonemab, The subject is concurrently enrolled in another interventional clinical study involving a therapeutic agent with the exception of Study M15-566 (NCT02880956)
NCT03724942,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Patients who had a serious adverse event which the principal investigator or sub-investigator assessed as related to the investigator product during the double-blind trial.
NCT03724942,Phase 3,Agitation Associated With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Co., Ltd.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;Brexpiprazole, Patients who had delirium during the double-blind trial.
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,Past or present history of certain brain disorders other than MCI or AD.
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,"Certain significant medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries."
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,Contraindication to MRI scanning
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,"Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.)."
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,"Exposure to research related radiation in the past year that, when combined with this study, would place you above the allowable limits."
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,Participation in the last year in a clinical trial for a disease modifying drug for AD.
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,Inability to have a catheter in your vein for the injection of radioligand.
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,Inability to have blood drawn from your veins.
NCT03744312,Phase 1/Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease;Inflammation,"Taking anticoagulant medication (e.g., warfarin)."
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," Exposure to an experimental drug, experimental biologic or experimental medical device within the longer of 5 half-lives or 3 months before screening"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Residence in a skilled nursing facility
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Clinically significant laboratory test results
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," Clinically significant untreated hypothyroidism (if treated, thyroid-stimulating hormone level and thyroid supplementation dose must be stable for at least 6 months before screening)"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Insufficiently controlled diabetes mellitus or requiring insulin
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Renal insufficiency (serum creatinine greater than 2.0 mg/dL)
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Malignant tumor within 3 years before screening (except squamous and basal cell carcinoma or cervical carcinoma in situ or localized prostate cancer or localized stage 1 bladder cancer)
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, History of ischemic colitis or ischemic enterocolitis
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Unstable medical condition that is clinically significant in the judgment of the investigator
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Alanine transaminase (ALT) or aspartate transaminase (AST) greater than 2 times the upper limit of normal or total bilirubin greater than the upper limit of normal.
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, History of myocardial infarction or unstable angina within 6 months before screening
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, History of more than 1 myocardial infarction within 5 years before screening
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," Clinically significant cardiac arrhythmia (including atrial fibrillation), cardiomyopathy, or cardiac conduction defect (patients with a pacemaker are acceptable)"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," Symptomatic hypotension, or uncontrolled hypertension"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," Clinically significant abnormality on screening electrocardiogram (ECG), including but not necessarily limited to a confirmed corrected QT value greater than = 450 msec for males or greater than = 470 msec for females."
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," Stroke within 18 months before screening, or history of a stroke concomitant with onset of dementia"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, History of brain tumor or other clinically significant space-occupying lesion on CT or MRI
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Head trauma with clinically significant loss of consciousness within 12 months before screening or concurrent with the onset of dementia
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," Onset of dementia secondary to cardiac arrest, surgery with general anesthesia, or resuscitation"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," Specific degenerative CNS disease diagnosis other than Alzheimer's disease (eg, Huntington's disease, Creutzfeld-Jacob disease, Down's syndrome, Frontotemporal Dementia, Parkinson's disease)"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Wernicke's encephalopathy
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Active acute or chronic Central Nervous System infection
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Donepezil 23 mg or greater quaque die currently or within 3 months prior to enrollment in the study
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Discontinued AChEI less than  30 days prior to enrollment in the study
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," Antipsychotics; low doses are allowed only if given for sleep disturbances, agitation and/or aggression, and only if the subject has received a stable dose for at least 3 months before enrollment in the study"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Tricyclic antidepressants and monoamine oxidase inhibitors; all other antidepressants are allowed only if the subject has received a stable dose for at least 3 months before enrollment in the study
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," Anxiolytics or sedative-hypnotics, including barbiturates (unless given in low doses for benign tremor); low doses of benzodiazepines and zolpidem are allowed only if given for insomnia/sleep disturbance, and only if the subject has received a stable dose for at least 3 months before enrollment in the study"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Peripherally acting drugs with effects on cholinergic transmission
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," Immunosuppressants, including systemic corticosteroids, if taken in clinically immunosuppressive doses (Steroid use for allergy or other inflammation is permitted.)"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Antiepileptic medications if taken for control of seizures
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Chronic intake of opioid-containing analgesics
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Sedating H1 antihistamines
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," Nicotine therapy (all dosage forms including a patch), varenicline (Chantix), or similar therapeutic agent within 30 days before screening"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Clinically significant illness within 30 days of enrollment
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease," History of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease"
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Positive serum hepatitis B surface antigen (HBsAg) or positive hepatitis C virus (HCV) antibody test at screening
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Positive HIV test at screening
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Loss of a significant volume of blood (greater than  450 mL) within 4 weeks prior to the study
NCT03748706,Phase 2,Alzheimer Disease,Pain Therapeutics,unknown,Alzheimer Disease, Metformin or cimetidine.
NCT03752463,Phase 2,Alzheimer Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease, Hachinski Ischemic Score greater than  4
NCT03752463,Phase 2,Alzheimer Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease, Substance abuse/dependence
NCT03752463,Phase 2,Alzheimer Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease," Parkinson disease, epilepsy, dementia with psychotic features"
NCT03752463,Phase 2,Alzheimer Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease, Major depressive disorder
NCT03752463,Phase 2,Alzheimer Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease, Major physical illnesses
NCT03752463,Phase 2,Alzheimer Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease, Severe visual or hearing impairment
NCT03765762,Phase 2,Severe Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, Evidence of clinically relevant neurological disorder(s) other than probable AD
NCT03765762,Phase 2,Severe Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease," History of blood coagulation disorders or hypercoagulability; any concurrent use of an anticoagulant therapy. (e.g., heparin, warfarin, thrombin inhibitors, Factor Xa inhibitors). Use of antiplatelet drugs (e.g., aspirin or clopidogrel) is acceptable."
NCT03765762,Phase 2,Severe Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease," Unstable coronary heart disease, e.g. myocardial infarction or severe or unstable angina in the 6 months prior to dosing."
NCT03765762,Phase 2,Severe Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, Moderate to severe congestive heart failure (New York Association Class III or IV).
NCT03765762,Phase 2,Severe Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease," Poorly controlled high blood pressure (systolic blood pressure of 160 mmHg or higher and/or diastolic blood pressure of 100 mmHg or higher) despite treatment during the 3 months prior to dosing, or treatment refractory high blood pressure, defined as treatment requiring 3 or more antihypertensives from different classes."
NCT03765762,Phase 2,Severe Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, Prior hypersensitivity reaction to any human blood product or intravenous infusion; any known clinically significant drug allergy.
NCT03765762,Phase 2,Severe Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease," Treatment with any human blood product, including transfusions and intravenous immunoglobulin, during the 6 months prior to screening."
NCT03765762,Phase 2,Severe Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease," History of immunoglobulin A (IgA), haptoglobulin or C1 inhibitor deficiency; stroke, anaphylaxis, or thromboembolic complications of intravenous immunoglobulins."
NCT03765762,Phase 2,Severe Alzheimer Disease,"Alkahest, Inc.",unknown,Alzheimer Disease, Hemoglobin less than 10 g/dL in women; and less than 11 g/dL in men.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Patients who have a progressive medical or neurological condition that in the opinion of the investigator would interfere with the conduct of the study. Exception: If diagnosed with seizures, must be on stable anti-seizure medication for at least 3 months prior to screening."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Current clinically significant systemic illness that is likely to result in deterioration of the patient's condition or affect the patient's safety during the study.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, History or clinically evident stroke or clinically significant carotid or vertebrobasilar stenosis or plaque.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," History of neurologic (e.g. stroke, traumatic brain injury) or psychiatric condition that the investigator deems may interfere with interpretability of data."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," History of untreated thyroid disorder, Type 1 diabetes, and insulin dependent or uncontrolled Type II diabetes, as determined by the investigator (e.g. non-insulin-controlled Type II diabetes, whose HbA1c value is higher than 8.0%)."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Body Mass Index (BMI) greater than  30.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, History of clinical hepatic dysfunction.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Current symptomatic and unstable/uncontrolled gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, hematological or hormonal disorders."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Indication of liver disease, defined by serum levels of ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3x upper limit of normal (ULN) as determined during screening."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Significant history of drug addiction (with the exception of nicotine dependence) or abuse (including alcohol, as defined in DSM-V or in the opinion of the investigator) within the last two years prior to informed consent, or a positive urine drug screen for cocaine, opioid, phencyclidine (PCP), amphetamine or marijuana at screening. Prescription medication yielding a positive drug screen are acceptable except for tricyclic antidepressants (e.g. Amitriptyline, Amoxapine, Desipramine, (Norpramin) Doxepin, Imipramine (Tofranil), Nortriptyline (Pamelor), Protriptyline (Vivactil), Trimipramine (Surmontil))."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Clinically significant infection within the last 30 days prior screening (e.g., chronic persistent or acute infection, urinary tract infections (UTI))."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Treatment with immunosuppressive medications (e.g., systemic corticosteroids) within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Myocardial infarction within the last year.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," History of cancer within the last 3 years, with the exception of basal cell carcinoma and non-metastatic squamous cell carcinoma of the skin and prostate cancer with currently normal PSA."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Other clinically significant abnormality on physical, neurological, laboratory, or electrocardiogram (ECG) examination (e.g., atrial fibrillation) that could compromise the study or be detrimental to the participant."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Hemoglobin less than  11 g/dL.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Have any contraindication to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (e.g., in skull and cardiac devices or severe claustrophobia)."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Smoking greater than  1 pack of cigarettes per day (as assessed for the 30 days prior to screening).
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Alcohol use of more than 2 drinks per day.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Current use of over-the-counter (OTC) supplements or nutraceuticals unless they are on stable dose for at least 3 months prior to screening and are documented in the eCRF.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Use of over the counter (OTC) or prescription medication for sleep on 2 or more occasions per week.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Being treated with psychoactive medications on a stable dose for less than 3 month.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Any prior exposure to ANAVEX2-73.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Individuals enrolled in previous AD clinical trial involving an investigational drug treatment less than 3 months ago (longer than 3 month ago allowed).
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Any known hypersensitivity to any of the excipients contained in the study drug formulation.
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Any other criteria (such as a clinically significant screening blood test result), which in the opinion of the Investigator causes the participant not to qualify for the study."
NCT03790709,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Evidence of cerebrovascular dementia with a Hachinski score of 4 or more.
NCT03790982,Phase 2,Alzheimer's Disease,Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease," Visual, hearing and verbal communication of subjects cannot meet the needs of cognitive function evaluation."
NCT03790982,Phase 2,Alzheimer's Disease,Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease," Inability to tolerate MRI procedures or contraindication to MRI, (such as implanted in the body, MRI incompatible pacemakers, implantable cardioverter defibrillators, cochlear implants, aneurysm clips, implanted injection pump, implanted nerve stimulator, metallic splinters in the eye, other magnetic, electrical and other metal implants) [note], or any other situation, in the judgment of the Investigator, is not suitable for magnetic resonance imaging (MRI)."
NCT03790982,Phase 2,Alzheimer's Disease,Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease, The investigators believe that other severe or unstable conditions may interfere with the cognitive evaluation in clinical trials.
NCT03790982,Phase 2,Alzheimer's Disease,Zhejiang Hisun Pharmaceutical Co. Ltd.,unknown,Alzheimer Disease," Dementia caused by other reasons: vascular dementia, central nervous system infection, endocrine system diseases (such as thyroid disease, parathyroid gland disease) and other reasons."
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Received an investigational product in another clinical study during the last 4 weeks prior to screening
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Diagnosis of Type 1 diabetes
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,"Diagnosis of Type 2 diabetes treated with insulin, sulfonylureas, glucagon like peptide1 receptor agonists (GLP-1), thiazolidinedione (TZD) or SGLT2 inhibitors (metformin monotherapy is allowed)."
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Estimated Glomerular Filtration Rate (eGFR; MDRD) less than 45 mL/min at screening or unstable renal disease.
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,"Any condition when MRI is contraindicated such as, but not limited to, having a pacemaker or claustrophobia."
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Severe hepatic injury and/or significant abnormal liver function defined as aspartate aminotransferase (AST) greater than 3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) greater than 3x ULN. Total bilirubin greater than 2.0 mg/dL (34.2 mol/L)
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Intolerance or allergy to dapaglifozin or any other SGLT2 inhibitor or any other substance in the tablets.
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Dementia due to causes other than AD
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,History of recurrent urinary tract infection
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Active mycotic genital infection
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,History of bladder cancer
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,History of diabetic ketoacidosis
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,"Potentially confounding, serious, or unstable medical conditions such as:"
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,"cancer within the past 3 years (except basal cell, squamous cell, or localized prostate cancer)"
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,"a recent cardiac event (i.e. heart attack, angioplasty, etc. within the 3 months prior to screening visit)"
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,other conditions that pose a potential safety risk or confounding factor in the investigator's opinion
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Any abnormal physical examination assessment or vital sign assessment at the screening visit that is deemed to be clinically significant by the principal investigator.
NCT03801642,Phase 1/Phase 2,Alzheimer Disease,"Jeff Burns, MD",unknown,Alzheimer Disease;Dapagliflozin,Any abnormal clinical laboratory test result at the screening visit that is deemed to be clinically significant by the principal investigator.
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," Clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular system diseases"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," Other neurological disorders, including but not limited to stroke, Parkinson's Disease, seizure disorder, or head injury with loss of consciousness within the past 5 years"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," DSM-IV Axis I disorder other than Alzheimer's Disease, including amnesic disorders, schizophrenia or schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, or post-traumatic stress disorder"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," CT scan or MRI evidence of hydrocephalus, stroke, a space-occupying lesion, cerebral infection, or any other clinically significant central nervous system disease"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Dementia complicated by another organic disease
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Dementia complicated by the presence of predominant delusions
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," Patients with a hematological malignancy or solid tumor who are undergoing treatment, who have completed treatment within the past 6 months, or who still have evidence of active disease"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Current drug or alcohol dependency including nicotine addiction (smokers)
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Subjects receiving immune-suppressants tricyclic antidepressants anticoagulants or chemotherapeutic agents
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Hypertension that is poorly controlled or managed
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," Any medical or neurological/neurodegenerative condition (other than AD) that, in the opinion of the Investigator, might be a contributing cause to the participant's cognitive impairment or could lead to discontinuation, lack of compliance, interference with study assessments, or safety concerns"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," Clinically significant, unstable psychiatric illness"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," History of unstable angina, myocardial infarction, chronic heart failure or clinically significant conduction abnormalities within 1 year prior to Screening Visit 1"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Indication of impaired renal or liver function
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Clinically significant systemic illness or serious infection within 30 days prior to or during the screening period
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," Use of allowed medications for chronic conditions at doses that have not been stable for at least 4 weeks prior to Screening Visit 1, or use of AD medications at doses that have not been stable for at least 8 weeks prior to Screening Visit 1"
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia," Use of any medications that, in the opinion of the Investigator, may contribute to cognitive impairment, put the participants at higher risk for adverse events (AEs), or impair the participant's ability to perform cognitive testing or complete study procedures."
NCT03806478,Phase 2,Alzheimer Disease 3,Aphios,unknown,Alzheimer Disease;Dementia, Contraindications to study procedures
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,Any medical or neurological condition (other than early stage AD) that might be a contributing cause to the subject's cognitive impairment.
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"History of stroke or multiple (greater than 3 discreet episodes) Transient Ischemic Attacks (TIAs), severe head trauma with cognitive sequelae, uncontrolled seizures, or unexplained prolonged loss of consciousness (greater than  1 minute) during the past year."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,Clinically significant major psychiatric illness during the past 6 months.
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"History of unstable angina, myocardial infarction, chronic heart failure, or clinically significant conduction abnormalities during the past year."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,Clinically significant liver or renal disease.
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"Clinically significant abnormality, in the Investigator's judgment, in hematology, chemistry, or urinalysis."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,Positive serology results for hepatitis B surface antigen (HbsAg) or hepatitis C virus (HCV).
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,Abnormal liver function test at the Screening Visit (aspartate aminotransferase or alanine aminotransferase greater than 2
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"  the upper limit of normal [ULN], or total bilirubin greater than 1.7  ULN, based on appropriate age and gender normal values). Subjects may be re-screened once."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"Marked hypotension (systolic blood pressure [BP] 90 mmHg or diastolic BP 50 mmHg) or hypertension (systolic BP 160 mmHg or diastolic BP 100 mmHg) based on sitting values. O ut-of-range results may be repeated once at Screening, and eligibility must be confirmed at Baseline."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"Marked bradycardia (heart rate 45 beats per minute [bpm]) or tachycardia (heart rate 115 bpm) based on supine ECG values. Out-of-range results may be repeated once at Screening, and eligibility must be confirmed at Baseline."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"Clinically important conduction abnormalities on ECG, or evidence or history of long QT syndrome based on supine ECG values obtained at Screening. Out-of-range results may be repeated once and eligibility confirmed at Baseline."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,Active gastric or duodenal ulcers or other diseases of the gastrointestinal tract that could interfere with absorption of study drug. Note: Subjects with a history of appendectomy or cholecystectomy may be enrolled.
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,Active acute or chronic infectious diseases that would interfere with subject's participation in the study.
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"Unable to discontinue centrally active medications (other than cholinesterase inhibitors), including memantine, psychotropic drugs other than SSRIs (which must have been stable for 2 months and remain stable throughout the study), sedative antihistamines or other centrally active medications with potential cognitive effects (e.g., CNS-penetrant beta blockers)."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"Unable to discontinue moderate to strong inhibitors or inducers of CYP3A4, CYP2D6, or other cytochromes at least 14 days prior to the first dose of study drug. A complete listing of such inhibitors or inducers may be found in http://medicine.iupui.edu/clinpharm/ddis/main-table (Other prescription or non-prescription drugs such as antihypertensive or cholesterol lowering agents are allowed, if, in the Investigator's judgement, they would not interfere with the study medication or the cognitive testing.)"
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,A suicidal ideation intensity score of 3 or higher per screening Columbia Suicide Severity Rating Scale (CSSRS) assessment on Day 1 (Baseline) and/or any suicidal behavior within the past 28 days.
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"History of chronic alcohol or other substance abuse, including marijuana, within the previous year prior to the Screening visit (per the current edition of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5), or regular (daily) consumption of alcohol exceeding two bottles of beer, or the equivalent amount of other forms of alcohol (1 serving = 12 oz beer, 5.0 oz wine, or 1.5 oz distilled spirits)."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"Inability or unwillingness to comply with the protocol, including performing the cognitive function tests, or likely inability to complete the study."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,Participation in other clinical studies involving investigational drug within the previous 30 days prior to the Screening Visit.
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"Donation of blood within 4 weeks, or blood products within 2 weeks, prior to first study drug administration."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,"History of clinically significant drug allergy that includes symptoms such as shortness of breath, rash, or edema."
NCT03817684,Phase 2,Alzheimer's Disease,Tetra Discovery Partners,unknown,Alzheimer Disease,Clinically significant B12 deficiency within 12 months prior to Visit 1 (Screening). Participants on stable replacement therapy for a minimum of 3 consecutive months immediately prior to Visit 1 (Screening) may be included
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Pregnant or breastfeeding
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Inability to tolerate MRI procedures or contraindication to MRI
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Contraindication to PET imaging
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Residence in a skilled nursing facility
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or bias the assessment of the clinical or mental status of the participant to a significant degree"
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Any evidence of a condition other than AD that may affect cognition
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Substance abuse within the past 2 years
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Use of any experimental therapy within 90 days or 5 half-lives prior to screening, whichever is greater, or any passive immunotherapy against tau"
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Use of any passive immunotherapy (immunoglobulin) against A, unless the last dose was at least 1 year prior to screening or any active immunotherapy (vaccine) that is under evaluation to prevent or postpone cognitive decline"
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Any other biologic therapy or previous treatment with medications specifically intended to treat Parkinsonian symptoms or any other non-AD neurodegenerative disorder within 1 year of screening
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Systemic immunosuppressive therapy within 12 months of screening through the entire study period
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease, Typical antipsychotic or neuroleptic medication within 6 months of screening
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Daily treatment with any of the following classes of medication (except for intermittent short-term use): opiates or opioids, benzodiazepines, barbiturates, hypnotics, or any medication with clinically significant centrally-acting antihistamine or anticholinergic activity"
NCT03828747,Phase 2,Alzheimer's Disease,"Genentech, Inc.",unknown,Alzheimer Disease," Stimulant medications, unless the dose has been stable within the 6 months prior to screening and is expected to be stable throughout the study"
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Past history of C diff infection
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin," Assessment, laboratory examination, physical examination or any other medical condition or circumstance making the volunteer unsuitable for participation in the study in the judgment of the study clinicians"
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Allergy to Rifaximin
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Antibiotic use or hospitalization in the last 6 months
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Are taking medications that interact with rifaximin and/or pose a safety risk in the judgment of the PI
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Clinically significant abnormal hepatic or renal function
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Uncorrected thyroid or B12 abnormalities
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Participation in another investigational drug trial in the past 30 days
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, History of febrile illness within 5 days prior to the study period
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin, Known Hyperammonemia caused by:
NCT03856359,Phase 2,Alzheimer's Disease,Duke University,unknown,Alzheimer Disease;Rifaximin," Valproic acid Chemotherapy Lung transplant Bariatric surgery Ureterosigmoidoscopy Hyperalimentation Urinary tract infection Errors of metabolism: urea cycle, enzyme deficiencies, organic acidemias, fatty acid oxidation, amino acid transport defects"
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, Failure to perform screening or baseline examinations
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, Hospitalization or change of concomitant medication 1 month prior to Screening visit or during Screening Period
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease," Clinical, laboratory or neuroimaging findings consistent with:"
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease,Other primary degenerative dementia;
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease,Other neurodegenerative condition;
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease,Cerebrovascular disease;
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease,Other central nervous system diseases;
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease," A current Diagnostic and Statistical Manual-5 (DSM-5) diagnosis of major depression, schizophrenia or bipolar disorder"
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease," Positive results for tuberculosis, human immunodeficiency virus (HIV), hepatitis C or hepatitis B (hepatitis B surface antigen [HbsAg]) serology at the Screening Visit"
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease," Clinically significant, advanced or unstable disease that may interfere with evaluation."
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, Disability that may prevent the patients from completing all study requirements.
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, Chronic drug intake of forbidden concomitant medication.
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease," Treatment with anti-amyloid beta or anti-Tau protein monoclonal antibodies or other disease modifying strategies within three months or five half-lives, whichever is longer, prior to the Screening Visit"
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, Treatment with an active vaccine targeting amyloid beta or Tau protein
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, Suspected or known drug or alcohol abuse
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, Metallic implants or any other cause precluding the performance of brain MRI
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, Enrolment in another investigational study or intake of investigational drug within the previous 3 months since the last dose
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease," Suicide attempt within the last year or significant risk of suicide (in the opinion of the investigator, defined as a  yes  to suicidal ideation questions 4 or 5, or answering  yes  to suicidal behavior on the Columbia-Suicide Severity Rating Scale within the past 12 months)"
NCT03867253,Phase 2,Mild to Moderate Alzheimer's Disease,Oryzon Genomics S.A.,unknown,Alzheimer Disease, Any condition that in the opinion of the investigator makes the patient unsuitable for inclusion in the study
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease, Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's Alzheimer's disease
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," History of transient ischemic attacks (TIA), stroke, or seizures within 12 months of Screening"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Any psychiatric diagnosis or symptoms (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease, Geriatric Depression Scale (GDS) score greater than =8 at Screening
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (example in skull and cardiac devices other than those approved as safe for use in MRI scanners)"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease, Evidence of other clinically significant lesions on brain MRI at Screening that could indicate a dementia diagnosis other than Alzheimer's disease
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Other significant pathological findings on brain MRI at screening, including but not limited to: more than 4 microhemorrhages (defined as 10 millimeter [mm] or less at the greatest diameter); a single macrohemorrhage greater than 10 mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and less than 1 centimeter [cm] at their greatest diameter need not be exclusionary)"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Any immunological disease which is not adequately controlled, or which requires treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressants, or plasmapheresis during the study"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Participants with a bleeding disorder that is not under adequate control (including a platelet count less than 50,000 or international normalized ratio [INR] greater than 1.5 for participants who are not on anticoagulant treatment, example, warfarin). Participants who are on anticoagulant therapy should have their anticoagulant status optimized and be on a stable dose for 4 weeks before Screening. Participants who are on anticoagulant therapy are not permitted to participate in cerebrospinal fluid (CSF) assessments"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Any other medical conditions (example, cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Participation in a clinical study involving any therapeutic monoclonal antibody, protein derived from a monoclonal antibody, immunoglobulin therapy, or vaccine within 6 months before screening unless it can be documented that the participant was randomized to placebo"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease, Participation in a clinical study involving any anti-amyloid therapies (including any monoclonal antibody therapies and any -site amyloid precursor protein cleaving enzyme [BACE] inhibitor therapies) unless it can be documented that the participant only received placebo
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease, Participants who have any known prior exposure to lecanemab
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease, Participants who were dosed in a clinical study involving any new chemical entities for Alzheimer's disease (AD) within 6 months prior to screening unless it can be documented that the participant was in a placebo treatment arm
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease, Extension Phase: Exclusion Criteria
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease, Participants who discontinued early from the Core Study
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease, Participants who develop the following conditions from the time of Screening for the Core Study to the start of the Extension Phase
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease, Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Any psychiatric diagnosis or symptoms, (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (example, in skull and cardiac devices other than those approved as safe for use in MRI scanners)"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Other significant pathological findings on brain MRI during the Core Study including but not limited to: cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors will be exclusionary if based on the opinion of the investigator, with consultation of medical monitor, these findings may interfere with the study procedures or safety"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Hypersensitivity to BAN2401 or any of the excipients, or to any monoclonal antibody treatment"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Any immunological disease which is not adequately controlled, or which requires chronic treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressants, or plasmapheresis during the study"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or ECG, which in the opinion of the investigator require further investigation or treatment or which may interfere with study procedures or safety."
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Malignant neoplasms (except for basal or squamous cell carcinoma in situ of the skin, or localized prostate cancer in male participants) that are not stably and adequately controlled or which, based on the opinion of the investigator, may interfere with the participant's safety or participation in the study"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease," Any other medical conditions (example, cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments"
NCT03887455,Phase 3,Early Alzheimer's Disease,Eisai Inc.,unknown,Alzheimer Disease, Severe visual or hearing impairment that would prevent the participant from performing psychometric tests accurately
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction, The subject must be excluded from participating in the trial if the subject fulfil any single criteria described below:
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction,General Exclusion Criteria
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction," Based on the investigators' judgement, if the patient is not capable of communicating with the site personnel, if the patient is not proficient in the language in which the psychometric tests will be completed, or if the patient is not sufficient for compliance with the study procedures."
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction," The patient has an abnormal physical examination or abnormal laboratory test results at the screening that are clinically significant to affect results of the research, as judged by the investigator."
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction, If the patient has or is suspicious of having a hypersensitivity or allergy to [18F] PI-2620 or its derivatives.
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction," The patient is pregnant, is attempting to become pregnant, or is nursing (breast-feeding) children."
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction, The patient has a history of alcoholism or drug dependency/abuse within the last 2 years before screening.
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction," The patient has contraindications to undergo positron emission computed tomography or MRI, which include but are not restricted to the examples below: claustrophobia, cardiac pacemaker, metal devices around the eye or spinal cord, cochlear implant, etc.) at the screening visit."
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction, The patient has been treated with any investigational medicinal product (IMP) within 1 years prior to the screening visit.
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction,Cognitively normal individuals
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction,Subjects with Mild Cognitive Impairment
NCT03903211,Phase 2,Alzheimer Disease,Jae Seung Kim,unknown,Alzheimer Disease;Cognitive Dysfunction,Subjects with Alzheimer Disease
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Any other cause of dementia shown by MRI/CT findings and neurological examination within 12 months of randomization.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Possible, probable, or definite vascular dementia according to the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherch et l'Enseignement en Neurosciences (NINDS-AIREN) criteria."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Evidence of significant abnormality that would suggest another potential etiology for dementia (eg, evidence of cerebral contusion, encephalomalacia, aneurysm, vascular malformation, greater than 5 microhemorrhages, macrohemorrhage, single infarct greater than 1cm3)."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Other central nervous system diseases that may cause cognitive impairment (eg, cerebrovascular disease including cerebrovascular dementia, Parkinsonism, Huntington's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, Creutzfeldt-Jakob disease)."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Concurrent or history of clinically significant psychiatric conditions (eg. Schizophrenia or bipolar affective disorder) that in the Investigator's opinion prevents the participant from participating, or is likely to confound interpretation of drug effect or affect cognitive assessments."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Vitamin B12, folic acid, syphilis serology, and thyroid stimulating hormone (TSH) results that are thought to contribute to the severity of dementia or cause dementia. Participants may be enrolled if in the Investigator's medical judgment the abnormal laboratory values are not the cause of the cognitive symptoms."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"History of known or suspected seizures including febrile seizures (excluding self-limited childhood febrile seizures), a history of significant head trauma with loss of consciousness or recent unconsciousness that is not explained."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Acute or unstable cardiovascular disease, active peptic ulcer, uncontrolled hypertension, uncontrolled diabetes or insulin dependent patients or any medical condition that may interfere with the completion of the clinical study."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Known allergies, hypersensitivity, or intolerance to GV1001 or similar products or excipients."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"History of alcohol, substance abuse or dependence as per DSM-V criteria (except nicotine dependence) within the last 2 years."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Concurrent malignancies or invasive cancers diagnosed within the past 5 years except for non-metastatic basal cell carcinoma or squamous cell carcinoma of skin, in situ carcinoma of the uterine cervix or non-metastatic prostate cancer"
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Sexually-active WOCBP or man capable of fathering a child who do not consent to using medicinally acceptable contraception (such as surgical sterilization, intrauterine contraceptive device, condom or diaphragm, an injectable or inserted contraceptive) during the study and for 3 months after the last dose of study treatment."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Pregnant, breast feeding, or planning a pregnancy or fathering a child while enrolled in the study or for 3 months after the las dose of study treatment."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Use of anxiolytics, narcotics, or sleep aids in a manner that would interfere with cognitive testing, in the opinion of the Investigator. Atypical antipsychotics may be used at the discretion of the Investigator. Tricyclic antidepressants and monoamine oxidase (MAO) inhibitors are prohibited."
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Previous treatment with GV1001.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Received an investigational product for AD within last 6 months.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Participated in another clinical study within 4 weeks prior to this study.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Renal impairment (creatinine clearance [CrCL] less than 30 mL/min).
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Severe liver dysfunction (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] greater than 2 times the upper limit of normal [ULN]).
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Body weight 35 kg.
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Resides in a moderate to high dependency continuous care facility (residence in low grade assisted living facility where there is sufficient autonomy to permit valid evaluation of activities of daily living is allowed).
NCT03959553,Phase 2,Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Any other reason that in the opinion of the Investigator would make the participant ineligible to participate or to complete this study.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage", ICH
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage","patients with potential causes of hemorrhage including trauma, structural lesion, brain tumor, or coagulopathy due to systemic disease or medication."
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage","Patients could not receive the PET and MRI studies, including but not limited to poor cooperative agitation impeding adequate study, allergy to contrast medium, hemodynamic instability, implantation of cardiac pacemaker, past history of receiving aneurysm clipping, panic mood to MRI study, impaired kidney function."
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Patients with pregnancy or recently having a plan for pregnancy.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Patients with breast feeding or recently having a plan for breast feeding.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage","Patients with history of allergy to 11C-PiB and 18F-T807, or severe allergy history."
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Patient or family who does not agree to participate in the study.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",patient with high risk by doctor evaluate.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage", AD
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage","Patients could not receive the PET and MRI studies, including but not limited to poor cooperative agitation impeding adequate study, allergy to contrast medium, hemodynamic instability, implantation of cardiac pacemaker, past history of receiving aneurysm clipping, panic mood to MRI study, impaired kidney function."
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Patients with pregnancy or recently having a plan for pregnancy.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Patients with breast feeding or recently having a plan for breast feeding.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage","Patients with history of allergy to 11C-PiB and 18F-T807, or severe allergy history."
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Patient or family who does not agree to participate in the study.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",patient with high risk by doctor evaluate.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage", Control
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage","History of neurological or psychiatric disease, abnormal neurological examination."
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage","Patients could not receive the PET and MRI studies, including but not limited to poor cooperative agitation impeding adequate study, allergy to contrast medium, hemodynamic instability, implantation of cardiac pacemaker, past history of receiving aneurysm clipping, panic mood to MRI study, impaired kidney function."
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Patients with pregnancy or recently having a plan for pregnancy.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Patients with breast feeding or recently having a plan for breast feeding.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage","Patients with history of allergy to 11C-PiB and 18F-T807, or severe allergy history."
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",Patient or family who does not agree to participate in the study.
NCT03969732,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,"Alzheimer Disease;Intracranial Hemorrhages;Cerebral Amyloid Angiopathy;Cerebral Amyloid Angiopathy, Familial;Amyloidosis;Hemorrhage",patient with high risk by doctor evaluate.
NCT03977584,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Contraindication to PET scan procedures, possibly including, but not limited to current, past, or planned participation in studies involving radioactive agents, including the main Study NCT01998841 (GN28352) and this Tau PET substudy, such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361."
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Significant neurological or psychiatric disease other than Alzheimer's disease
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Previous clinical trial participation within 90 days of screening
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Previous exposure to putative disease modifying therapy for Alzheimer's disease within 1 year of screening
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance," History of cancer within the last 5 years except adequately treated cervical carcinoma in-situ, cutaneous basal cell or squamous cell cancer, or non-progressive prostate cancer not requiring current treatment"
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Women of childbearing potential
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Uncontrolled blood pressure and/or blood pressure above 140/90
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Participants receiving medications that may negatively impact cognitive function
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, History of diabetic ketoacidosis within the past year
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, History of chronic pancreatitis
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Stage 4 kidney disease
NCT03980730,Phase 2,Alzheimer Disease,vTv Therapeutics,unknown,Alzheimer Disease;Glucose Intolerance, Use of insulin therapy
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,Intolerance to Montelukast;
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,"Current diagnosis of bronchial asthma or exercise-induced bronchospasm and currently on Montelukast or other leukotriene receptor antagonists (Zafirlukast, Pranlukast);"
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,"Liver disease (elevated liver enzymes (greater than 2x normal): Alanine aminotransferase (ALT), AST, alkaline phosphatase, total bilirubin);"
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,"Renal disease (Creatinine greater than 2.0 mg/dl), plateletsless than 50,000/l, or INRgreater than 1.9;"
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,"Diagnosis of any neurological or psychiatric disorders that affects cognition such as uncontrolled depression, schizophrenia, Parkinson's disease or use of anti-Parkinsonian therapies (unless used for essential tremor), multiple sclerosis, or other active medical condition that in the judgment of the study physicians would affect the safety of the subject or scientific integrity of the study;"
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,Other contributing factors to cognitive impairment such as uncontrolled hypothyroidism (TSH greater than 10 mU/l) or untreated low vitamin B12 (less than 250 ng/mL);
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,Uncontrolled congestive heart failure reflected by poor exercise tolerance and shortness of breath at rest or with some exertion;
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,Actively undergoing chemotherapy or radiation therapy for cancer treatment;
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,History of stroke in the past 3 years;
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,"Severely impaired cognition (MoCA 10, FAST greater than 5 or CDR greater than 2);"
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,"Inability to have MRI and LP e.g. for MRI, metal implants or cardiac pacemaker or for LP, bleeding diathesis from disease states or from use of anticoagulants such as warfarin, heparin and related products, Rivaroxaban or Xarelto, Apixaban or Eliquis, Edoxaban or Savaysa, Dabigatraban or Pradaxa. Subjects who can have either one lumbar puncture (LP) or MRI will be enrolled;"
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,"Inability to have cognitive assessment due to hearing, vision, or language issues or due to severe impairment;"
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,History of increased intracranial pressure (ICP);
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,"In those who are unable to demonstrate that they understood the details of the study using the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC) instrument modified for EMERALD (i.e. lack of decisional-capacity to consent), a study partner/surrogate who can sign on their behalf will be required; otherwise, they will be excluded;"
NCT03991988,Phase 2,Alzheimer Disease,Emory University,unknown,Alzheimer Disease;Montelukast,Use of phenobarbital or rifampin due to drug interaction.
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, Imaging suggestive of potential seizure focus or alternative cause of dementia
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, Previous Epilepsy diagnosis
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, Use of anti-epileptic medication for any indication within previous three months
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, History of head trauma with loss of consciousness more than 30 minutes
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, Alcohol/Substance abuse within 5 years of dementia onset or previous 5 years
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, History of Korsakoff's syndrome
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, History of encephalitis/meningitis
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam," Female participant who is pregnant, lactating or planning pregnancy during trial"
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, Scheduled elective surgery or other procedures requiring general anesthesia during the trial
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, Participant with life expectancy of less than 12 months
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, Any cancer requiring current chemotherapy
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, Known allergy or history of previous adverse reaction to levetiracetam
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, Major depression or other significant behavioral disturbance preceding Alzheimer's Disease diagnosis
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam, Enrollment in another clinical treatment trial
NCT04004702,Phase 2,Alzheimer Disease,Walter Reed National Military Medical Center,unknown,Alzheimer Disease;Epilepsy;Levetiracetam," Laboratory evidence of an alternative cause of dementia or which might preclude treatment, including untreated vitamin B12 deficiency, untreated hypothyroidism, syphilis, positive human immunodeficiency virus testing, end-stage renal disease on dialysis, significant renal impairment (creatinine clearance less than 75 ml/minute), or liver function tests greater than 2x upper limit of normal within the preceding three months"
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,"Hearing, vision, or motor deficits despite corrective devices;"
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,Alcohol or drug abuse;
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,MRI contraindications;
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,"Myocardial infarction, angina, stroke or transient ischemic attack in the past 6 months; QT interval greater than 440 on ECG will not be enrolled. Chronic heart failure will be exclusionary;"
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,Participants with coagulation disorders;
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,"Neurologic, musculoskeletal, or other condition that limits subject's ability to complete study physical assessments;"
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,Uncontrolled diabetes (HbA1c greater than  7% or the current use of insulin);
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,"Current or chronic history of liver disease, or known hepatic or biliary abnormalities;"
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,"Use of anti-arrhythmic medications known to cause QTc prolongation, anti-platelet or anti-coagulant medication;"
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,Current use of quinolone antibiotics.
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,"Poorly controlled blood pressure (systolic BPgreater than 160, diastolic BPgreater than 90 mmHg)."
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,"Active inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, and psychiatric disease."
NCT04063124,Phase 1/Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Dasatinib;Quercetin,"History of or MRI-positive for any space occupying lesion, including mass effect or abnormal intracranial pressure, which would indicate contraindication to lumbar puncture"
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has a Rosen-modified Hachinski Ischemia Score greater than  4 at the screening visit.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has a known history of stroke or evidence from screening MRI that is clinically significant in the investigator's opinion.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"The subject has evidence of a clinically relevant neurological disorder other than probable AD at the screening visit, including: vascular dementia, Parkinson's disease, dementia with Lewy bodies, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, mental retardation, hypoxic cerebral damage, or head trauma with loss of consciousness that led to persistent cognitive deficits."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"The subject has evidence of a clinically relevant or unstable psychiatric disorder, based on DSM-5 criteria, including schizophrenia or other psychotic disorder, bipolar disorder, delirium, or major depression. (Major depression in remission is not exclusionary.) A score on the 15-item Geriatric Depression Scale (GDS) of 5 or more requires an assessment by an appropriate health care professional to evaluate for the presence of major depression. Subjects with a score of 5 or more who are not diagnosed with major depression following such an assessment may be included in the trial."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has a history of alcoholism or drug dependency/abuse within the last 5 years before screening.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has been treated with any investigational product within 60 days or 5 half-lives (whichever is longer) prior to the screening visit.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has been treated with anti-amyloid-beta or anti-tau protein monoclonal antibodies within one year prior to the screening visit.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has been treated with an active vaccine targeting amyloid-beta or tau protein.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has received a live/live-attenuated bacterial or viral vaccine within 3 months prior to the screening visit.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"The subject has been treated with immunosuppressive medications, such as azathioprine, cyclosporine, methotrexate, tacrolimus, or mycophenylate, within 2 months prior to the screening visit."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has been treated with a course of corticosteroids longer than 5 days within 2 months prior to the screening visit.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject is taking or is anticipated to require treatment with estrogens.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"The subject is taking or is anticipated to require treatment with an anticoagulant medication, including warfarin, dabigatran, rivaroxaban, apixaban, edoxaban, heparin, or enoxaparin."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject is taking or is anticipated to require treatment with aspirin at a dose higher than 325 mg daily.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has a history of asthma or chronic obstructive pulmonary disease.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"The subject has had a myocardial infarction, unstable angina, stroke, transient ischemic attack or required intervention for any of these conditions (e.g., coronary artery bypass graft, percutaneous coronary intervention via cardiac catheterization, thrombolytic therapy) within 6 months prior to the screening visit."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has had an infection requiring medical intervention within 30 days prior to the screening visit.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has serologic evidence of current or prior hepatitis B virus (HBV) infection based on hepatitis B surface antigen or hepatitis core antibody blood tests at the screening visit.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has serologic evidence of hepatitis C virus (HCV) infection based on hepatitis C antibody blood test at the screening visit.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has serologic evidence of human immunodeficiency virus (HIV) infection based on HIV antigen/antibody test at the screening visit.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"The subject has a platelet count less than 50,000 per microliter (mL) at the screening visit."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has a creatinine clearance less than 30 mL/minute at the screening visit.
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"The subject has a history or evidence of a malignancy (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or localized prostate carcinoma) within the 2 years prior to the screening visit."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"The subject has had any other unstable/uncontrolled medical illness within 12 weeks prior to the screening visit such that, in the judgment of the investigator, participation in the trial would pose a significant medical risk to the subject."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"The subject has significant visual or auditory impairment, or limited English proficiency, that in the investigator's opinion would preclude collection of outcome measures."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"The subject has any contraindication to or inability to tolerate brain MRIs (e.g., a pacemaker or any other implanted device or condition that would preclude proximity to a strong magnetic field)."
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,The subject has any contraindication to or inability to tolerate a PET scan (includes current or recent participation in any procedures involving radioactive agents such that the total radiation dose exposure to the subject in any given year would exceed acceptable limits of annual and total dose).
NCT04070378,Phase 2,Alzheimer Disease,"Marc L Gordon, MD",unknown,Alzheimer Disease;Daratumumab,"The subject has a history of allergy to dexamethasone, diphenhydramine, acetaminophen, montelukast, or acyclovir."
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," Exposure to an experimental drug, experimental biologic or experimental medical device within the longer of 5 half-lives or 3 months before screening"
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Enrollment in the previous PTI-125 trial
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, A medical condition that would interfere with a lumbar puncture
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Residence in a skilled nursing facility and requiring 24 h care.
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Clinically significant laboratory test results
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Clinically significant untreated hypothyroidism
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Insufficiently controlled diabetes mellitus
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Renal insufficiency (serum creatinine greater than  ULN)
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Malignant tumor within 3 years before screening (except squamous and basal cell carcinoma or cervical carcinoma in situ or localized prostate cancer or localized stage 1 bladder cancer)
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, History of ischemic colitis or ischemic enterocolitis
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Unstable medical condition that is clinically significant in the judgment of the investigator
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Alanine transaminase (ALT) or aspartate transaminase (AST) greater than  ULN or total bilirubin greater than  ULN.
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, History of myocardial infarction or unstable angina within 6 months before screening
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, History of more than 1 myocardial infarction within 5 years before screening
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," Clinically significant cardiac arrhythmia (including atrial fibrillation), cardiomyopathy, or cardiac conduction defect (patients with a pacemaker are acceptable)"
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," Symptomatic hypotension, or uncontrolled hypertension"
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," Clinically significant abnormality on screening electrocardiogram (ECG), including but not necessarily limited to a confirmed corrected QT interval value greater than = 450 msec for males or greater than = 470 msec for females."
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," Stroke within 18 months before screening, or history of a stroke concomitant with onset of dementia"
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, History of brain tumor or other clinically significant space-occupying lesion on CT or MRI
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Head trauma with clinically significant loss of consciousness within 12 months before screening or concurrent with the onset of dementia
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," Onset of dementia secondary to cardiac arrest, surgery with general anesthesia, or resuscitation"
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," Specific degenerative Central Nervous System disease diagnosis other than Alzheimer's disease (eg, Huntington's disease, Creutzfeld-Jacob disease, Down's syndrome, Frontotemporal Dementia, Parkinson's disease)"
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Wernicke's encephalopathy
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Active acute or chronic Central Nervous System infection
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Donepezil 23 mg quaque die currently or within 3 months prior to randomization
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Discontinued AChEI less than  30 days prior to randomization
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Antipsychotics; low doses are allowed only if the subject has received a stable dose for at least 3 months before randomization
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Tricyclic antidepressants and monoamine oxidase inhibitors
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," Anxiolytics or sedative-hypnotics, including barbiturates (unless given in low doses for benign tremor); low doses of benzodiazepines and zolpidem are allowed"
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," Immunosuppressants, including systemic corticosteroids, if taken in clinically immunosuppressive doses (Steroid use for allergy or other inflammation is permitted.)"
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Antiepileptic medications if taken for control of seizures
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Chronic intake of opioid-containing analgesics
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Sedating H1 antihistamines
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," Nicotine therapy (all dosage forms including a patch), varenicline (Chantix), or similar therapeutic agent within 30 days before screening"
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Clinically significant illness within 30 days of enrollment
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease," History of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease"
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Positive serum hepatitis B surface antigen (HBsAg) or positive hepatitis C virus HCV antibody test at screening
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Positive HIV test at screening
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Positive urine drug test at screening
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Loss of a significant volume of blood (greater than  450 mL) within 4 weeks prior to the study
NCT04079803,Phase 2,Alzheimer Disease,"Cassava Sciences, Inc.",unknown,Alzheimer Disease, Suicidality on C-SSRS at screening
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Already receive outpatient clinic follow-ups with diseases that may affect the cognitive evaluation or presentation that include but not limited to Parkinsonism, Parkinson's disease dementia, schizophrenia, major depression, epilepsy, alcohol or drug abuse, major head trauma with consciousness loss"
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Severe progressive or unstable systemic disease that may interfere with the follow-up and test results. These included but not limited to cancer in the past 5 years, end stage renal or liver dysfunction, clinical significant myocardial infarction (New York Heart Association Functional Classification III-IV), Active disease that received admission in the past one year and unstable angina. Other diseases that were not listed but may interfere with the follow-up or test will be judged by the principle investigator."
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Any treatment that suggests any of the aforementioned disease will be excluded.
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Depression with ongoing diagnosis and treatment, suicide idea or suicide behavior in the past 6 months."
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Contraindications or previously failure for receiving brain magnetic resonance imaging or PET scan.
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,History of risk factors for torsades de pointes (a cardiac dysrhythmia associated with sudden death) or taking medications known to prolong the QT interval.
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Have an ECG obtained prior to the 18F-PM-PBB3 PET scan that in the opinion of the investigator is clinically significant regarding the subject's participation in the study.
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Pregnant, lactating or breastfeeding."
NCT04169126,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Patients with severe liver disease (such as ALT greater than  3x upper limit of normal).
NCT04174287,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Amyloidosis, All participants must not meet the following criteria:
NCT04174287,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Amyloidosis,"Already receive outpatient clinic follow-ups with diseases that may affect the cognitive evaluation or presentation that include but not limited to Parkinsonism, Parkinson's disease dementia, epilepsy, schizophrenia, major depression, major psychiatric disorders, alcohol or drug abuse, major head trauma with consciousness loss."
NCT04174287,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Amyloidosis,"Severe progressive or unstable systemic disease that may interfere with the follow-up and test results. These included but not limited to cancer in the past 5 years, end stage renal or liver dysfunction, clinically significant myocardial infarction (New York Heart Association Functional Classification III-IV), Active disease that received admission in the past one year and unstable angina. Other diseases that were not listed but may interfere with the follow-up or test will be judged by the principle investigator."
NCT04174287,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Amyloidosis,Any treatment that suggests any of the aforementioned disease will be excluded.
NCT04174287,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Amyloidosis,"Depression with ongoing diagnosis and treatment, suicide idea or suicide behavior in the past 6 months."
NCT04174287,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Amyloidosis,Contraindications or previously failure for receiving brain magnetic resonance imaging or PET scan.
NCT04174287,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Amyloidosis,"Pregnant, lactating or breastfeeding."
NCT04174287,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease;Amyloidosis,Patients with severe liver disease (such as ALT greater than  3x upper limit of normal).
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Current use or use within 3 months of Visit 3 (Baseline), of Axona or other MCT-containing products. Use of coconut oil up to 15 mL (1 tablespoon) per day is allowed. Use of MCT-containing products is not allowed at any time during trial participation."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Use of any other investigational agent within 60 days prior to Screening Visit 1.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Has a known allergy or hypersensitivity to triglycerides.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"In the opinion of the Investigator, has presence or history of an advanced, severe, progressive, or unstable disease of any type that could interfere with efficacy and safety assessments, or put the subject at risk."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Has any medical or neurological condition, other than AD, that could explain the subject's dementia (e.g., structural abnormality, traumatic brain injury, stroke, epilepsy, Parkinson's disease, alcohol-related dementia, etc.)"
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Has a modified Hachinski Ischemia score greater than (greater than ) 4 at Screening Visit 2.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Has a history or clinical laboratory evidence of cerebrovascular disease (stroke, transient ischemic attack, haemorrhage), or diagnosis of possible, probable, or definite vascular dementia at Screening Visit 1 in accordance with National Institute of Neurological Disorders and Stroke criteria."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Brain MRI performed at Screening (prior to Visit 3) (per centrally read MRI) that shows evidence of any of the following:
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Acute, sub-acute or chronic haemorrhage."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Cortical infarct (defined as greater than  1.5 cm in diameter).
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,greater than  1 lacunar infarct (defined as less than  1.5 cm in diameter).
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Superficial siderosis.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,History of diffuse white matter disease as defined by a score of 3 on the age-related white matter changes scale [26].
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Any finding that, in the opinion of the Investigator, might be a contributing cause of subject's dementia, might pose a risk to the subject, or might prevent a satisfactory MRI assessment for safety monitoring."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Has a history or clinical laboratory evidence of moderate congestive heart failure defined by the New York Heart Association Criteria (Class I to IV).
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Clinically significant ECG abnormalities at Screening Visit 2, for example:"
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Evidence of atrial fibrillation on ECG or history of atrial fibrillation that is not currently controlled
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"QTcF at greater than  450 ms in males or greater than  470 ms in females, or low or flat T waves making measurement of QT interval unreliable"
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Has a history of new ischemic or congestive cardiovascular event within the 3 months prior to Visit 3 (Baseline).
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Has a history of or current major psychiatric illness such as schizophrenia or bipolar affective disorder.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Has a clinician-administered Patient Health Questionnaire (PHQ)-9 score of  10 or in the Investigator's opinion, depression of a severity that would impact cognitive assessments."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Subjects with insulin dependent diabetes.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Subjects with uncontrolled hypertension defined as:
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"average of 3 systolic blood pressure [SBP]/diastolic blood pressure [DBP] readings greater than  165/100 mmHg at Screening Visit 2 (blood pressure measurements exceeding these limits may be repeated as warranted by the Investigator, but values must be within the specified limits for the subject to be eligible for the study),"
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"or persistent SBP/DBP readings greater than  180/100 mmHg 3 months prior to Baseline (Visit 3, Day 1) that in the opinion of the Investigator are indicative of chronic uncontrolled hypertension."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Subjects with orthostatic hypotension, defined as a drop of greater than 20 mmHg systolic blood pressure upon standing upright from a seated position within 3 minutes, at Screening Visit 2; testing for orthostatic hypotension may be repeated at Investigator's discretion if there is reason to believe the condition is temporary after addressing the temporary cause."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"At Screening Visit 2, clinically significant:"
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,anaemia (haemoglobin less than  11 g/dL for males or less than  10 g/dL for females)
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"renal disease or insufficiency, including but not limited to a creatinine value of greater than  1.9 mg/dL (greater than  170 mol/L)"
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,hypothyroidism
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"At Screening Visit 2, laboratory test values (potential to repeat at Investigators discretion):"
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"ALT, AST, total bilirubin, or alkaline phosphatase greater than  2.5 times the ULN laboratory range, or history of severe hepatobiliary disease (e.g., hepatitis B or C, or cirrhosis [Childs-Pugh Classes B/C] without enzyme elevation)"
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Fasting triglycerides greater than  2.5 times the ULN
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Cholesterol greater than  240 mg/dL
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Clinically significant Vitamin B12 deficiency within 12 months prior to Visit 1; however, subjects on stable replacement therapy for a minimum of 1 month immediately prior to Visit 1 may be included."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,The following GI conditions are exclusionary as described below:
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease), GI bleed (upper or lower), or peptic ulcer disease; any of these conditions are exclusionary, if active in the past 5 years. Subjects with remote quiescent disease, at Investigators discretion (and CER Committee) are not excluded."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Subjects with current or a history of (within the last 5 years) any of the following conditions are excluded: complicated reflux disease (e.g., Barrett's oesophagus, stricture, ulcer, haemorrhage), or severe GERD that, in the opinion of the Investigator, is not well-controlled by medication."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Irritable bowel syndrome, diverticular disease (e.g., diverticulosis, or diverticulitis), or chronic gastritis; any of these conditions are exclusionary if there has been an acute event within 1 year prior to Screening Visit 1."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Has donated  2 units of blood within the 1 month prior to Screening Visit 1.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Has a history of alcohol or drug abuse within the 6 months prior to Visit 1 or has tested positive upon urine drug screen at Screening Visit 2.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Subject or caregiver is an immediate family member or employee of the clinical site, Sponsor, or of the Sponsor's agents."
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,"Has any current or history of neoplasm or malignancy, other than excised or treated basal cell carcinoma. The following exceptions may be made after discussion with the Medical Monitor:"
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Subjects with cancers in remission more than 5 years prior to Screening.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Subjects with a history of excised or treated squamous carcinoma of the skin.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Subjects with prostate cancer in situ.
NCT04187547,Phase 3,Alzheimer's Disease,Cerecin,unknown,Alzheimer Disease,Subject has a scheduled (or is expected to have scheduled) hospitalisation and/or surgery during the trial
NCT04229927,Phase 3,Moderate-to-severe Alzheimer's Disease,"Hyundai Pharmaceutical Co., LTD.",unknown,Alzheimer Disease," Magnetic resonance imaging (MRI) or computed tomography (CT) findings obtained within the past 12 months (ie, 48 weeks) from screening or at screening, as a cause of dementia other than probable AD."
NCT04229927,Phase 3,Moderate-to-severe Alzheimer's Disease,"Hyundai Pharmaceutical Co., LTD.",unknown,Alzheimer Disease," History of other organic disease, such as vascular dementia, CNS infections (e.g., human immunodeficiency virus [HIV], syphilis), head injury, Creutzfeldt-Jakob disease, Niemann-Pick's disease, Huntington's disease, Parkinson's disease, epilepsy, or stroke."
NCT04229927,Phase 3,Moderate-to-severe Alzheimer's Disease,"Hyundai Pharmaceutical Co., LTD.",unknown,Alzheimer Disease, Evidence of other neurological disorders which include seizure disorder that may interfere with the patient's cognition or ability to perform the study procedures.
NCT04229927,Phase 3,Moderate-to-severe Alzheimer's Disease,"Hyundai Pharmaceutical Co., LTD.",unknown,Alzheimer Disease, Use of Memantine Hydrochloride within 1 month prior to screening
NCT04249869,Phase 1/Phase 2,Alzheimer Disease,"Taipei Veterans General Hospital, Taiwan",unknown,Alzheimer Disease,"Other types of dementia, such as Frontotemporal dementia, Dementia with Lewy Bodies, Vascular Dementia, and mixed type, et al;"
NCT04249869,Phase 1/Phase 2,Alzheimer Disease,"Taipei Veterans General Hospital, Taiwan",unknown,Alzheimer Disease,"Known of other neurological diseases, cranial nervous system cancer"
NCT04249869,Phase 1/Phase 2,Alzheimer Disease,"Taipei Veterans General Hospital, Taiwan",unknown,Alzheimer Disease,"Severe liver or kidney dysfunction (alanine aminotransferasegreater than 200 IU/L, aspartate transaminasegreater than 200 IU/L or serum creatinine greater than 2.5 mg/dl);"
NCT04249869,Phase 1/Phase 2,Alzheimer Disease,"Taipei Veterans General Hospital, Taiwan",unknown,Alzheimer Disease,"Severe cardiovascular disease (heart failure, coronary heart disease"
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Have a current diagnosis of a significant psychiatric illness per the Diagnostic and Statistical Manual of Mental Disorders V (DSM-V)
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, With untreated clinical depression (GDS greater than /= 6 at screening and baseline)
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Have a current diagnosis of a neurological disease other than AD
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, With glycosylated hemoglobin (HbA1c) greater than /= 7.7 at screening
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, With a diagnosis of unstable diabetes
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, With clinically significant thyroid disease at screening TSH greater than 5
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Have any of the following values at the screening visit:
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, ALT and/or AST value that is twice the upper limit of normal
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Total bilirubin value that exceeds 2 mg/dL
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Creatinine level greater than 1.5 mg/dL in men or greater than  1.4 mg/dL in women
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Positive urinalysis (other than trace result) unless a cause other than renal impairment
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Glomerular filtration rate (GFR) values less than 54 mL/min/1.73 m2
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Gamma-glutamyl transpeptidase (GGT) value that is twice the upper limit of normal
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Is positive for hepatitis B or anti-hepatitis C virus antibodies at the screening
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease," Have a history of moderate or severe congestive heart failure, NYHA class III or IV"
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease," Have experienced a previous cardiovascular event (myocardial infarct, by-pass surgery, or PTCA) within the past 12 months prior to the baseline"
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Have blood pressure reading at screening that is greater than 160/100 mmHg
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Have a clinically significant unstable illness
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Have a history of HIV infection
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease," Have a history of alcohol, drug abuse or dependence"
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Have a history of cancer within 5 years of the screening
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Have any surgical or medical condition which may significantly alter the absorption of any drug substance
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease," Females who are pregnant, nursing or of childbearing potential and not practicing effective contraception"
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Is required to take excluded medications as specified protocol
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease," Have a known or suspected intolerance or hypersensitivity to the study drug, closely related compounds"
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Resides in hospital or moderate to high dependency continuous care facility
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease," Are non-ambulatory, or wheelchair-bound"
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, Have evidence of clinically relevant pathology that in the investigator's opinion could interfere with the study results or put the subject's safety at risk
NCT04251182,Phase 2,Alzheimer Disease,"T3D Therapeutics, Inc.",unknown,Alzheimer Disease, History of swallowing difficulties
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease," 1) Implantation of metal devices including cardiac pacemaker, intravascular metal devices."
NCT04305210,Phase 2,Alzheimer's Disease,Chang Gung Memorial Hospital,unknown,Alzheimer Disease," 2) Major systemic diseases including coronary arterial disease, heart failure, uremia, hepatic failure, prominent strokes, acute myocardial infarction, poorly controlled diabetes, previous head injury, intracranial operation, hypoxia, sepsis or severe infectious diseases 3) Major psychiatric disorders, drug or alcohol abuse and major depression 4) Pregnant women or breast- feeding women 5) Subjects in whom MRI was contraindicated 6) History of severe allergic or anaphylactic reactions particularly to the tested drugs 7) History of positive test for human immunodeficiency virus (HIV) 8) Indication of impaired liver function as shown by an abnormal liver function profile at screening (eg. repeated values of aspartate aminotransferase [AST] and alanine aminotransferase [ALT]  3X the upper limit of normal values)"
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Life expectancy less than 1 year.
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Clinically significant abnormal laboratory values (such as AST/ALT greater than = 3X of upper normal limits).
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Clinically significant or unstable medical or psychiatric illness.
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Epilepsy history.
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Cognitive impairment resulting from trauma or brain damage.
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Substance abuse or alcoholism in the past 3 months.
NCT04309253,Phase 2,"Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia",Chang Gung Memorial Hospital,unknown,"Alzheimer Disease;Dementia;Tauopathies;Frontotemporal Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Plaque, Amyloid;Cognitive Dysfunction", Stroke history within the recent 3 months.
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Meets National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) criteria for vascular dementia
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Has current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses of safety and pharmacologic effect in this study; or has a life expectancy of less than  2 years"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Has had a history within the last 5 years of a serious infectious disease affecting the brain or head trauma resulting in protracted loss of consciousness
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Has a history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate specific antigen post treatment"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe post treatment hypersensitivity reactions"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Has a  yes  answer to Columbia Suicide Severity Rating Scale (C-SSRS) suicidal ideation item 4 or 5, or any suicidal behavior assessment within 6 months of Screening, or has been hospitalized or treated for suicidal behavior in the past 5 years before Screening"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Has received acetylcholinesterase inhibitor (AChEIs), memantine, and/or other AD therapy for less than 4 months or has less than 2 months of stable therapy on these treatments"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Has not been stable on medications that affect the Central nervous system (CNS), for at least 4 weeks (including antidepressants, hypnotics, antipsychotics, etc.) except occasional use of benzodiazepine (definition of occasional use - not more than twice in a week or three times in a month during the past 3 months)."
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Has a history of chronic alcohol or drug abuse/dependence within the past 5 years
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Any medical or neurological/neurodegenerative condition (other than AD) that, in the opinion of the investigator, might be a contributing cause to the subject's cognitive impairment (e.g., current history of substance abuse, uncontrolled vitamin B12 deficiency or abnormal thyroid function, stroke or other cerebrovascular condition, Parkinson's disease, Lewy body dementia, or frontotemporal dementia)"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Transient ischemic attack or stroke or any unexplained loss of consciousness within 1 year prior to Screening Visit
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"History of bleeding disorder or predisposing conditions, blood clotting, or clinically significant abnormal results on coagulation profile at Screening, as determined by the investigator"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"History of unstable angina, myocardial infarction, chronic heart failure (New York Heart Association Class III or IV), or clinically significant conduction abnormalities (e.g., unstable atrial fibrillation) within 1 year prior to Screening Visit"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Clinically significant 12 lead Electrocardiogram (ECG) abnormalities, as determined by the investigator"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Indication of impaired liver function as shown by an abnormal liver function profile at Screening (e.g., repeated values of Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT)  2  the upper limit of normal [ULN]) and/or indication of impaired renal function at Screening (e.g., repeated values of creatinine and blood urea nitrogen [BUN]  1.5  Upper limit of normal (ULN) or estimated glomerular filtration rate less than  45 mL/minute/1.73 m2 and corroborating medical history and physical examination)"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Contraindications to having a brain Magnetic resonance imaging (MRI) (e.g., MRI incompatible pacemaker; MRI incompatible aneurysm clips, artificial heart valves, or other metal foreign body; claustrophobia that cannot be medically managed); if the MRI compatibility of implanted devices is unknown, the subject must be excluded from the study"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Contraindication to having a PET brain scan (e.g., inability to lie flat or still for the duration of the scan) or intolerance to previous PET scans (i.e., previous hypersensitivity reactions to any PET ligand or imaging agent, failure to participate in and comply with previous PET scans)"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Contraindication to having an FDG PET scan, including uncontrollable glucose levels, inability to fast for the prescribed number of hours prior to the FDG PET scan, inability to withhold all insulin and oral diabetic medication after midnight prior to the PET scan"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Inability to refrain from using sleep medication for the 24 hours prior to each FDG PET scan or to refrain from use of antipsychotics, sedatives, or other strong acting neuropsychiatric medication on the day of each PET scan prior to the scan"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Current or recent participation (within 12 months before screening) in any procedures involving radioactive agents such that radiation exposure of the, in the judgement of the investigator (upon review of medical history), subject in any given year would exceed the whole-body limits of annual and total dose commitment of 5 rems set forth in the US Code of Federal Regulations (CFR) Title 21 section 361.1."
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Any contraindications to lumbar puncture (LP), e.g., increased bleeding risk (platelet count less than 100,000/L, coagulopathies, anticoagulant drugs), lumbar spine deformity that might interfere with the procedure evidence on MRI contraindicating LP, risk for cerebral herniation, space occupying lesion with mass effect, abnormal intracranial pressure due to increased CSF pressure, Arnold Chiari malformation, local infections at the puncture site and patient fear of LP; abnormalities in the screening CSF profile that are considered by the Investigator to be clinically significant are exclusionary"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Any major surgery within 12 weeks of Screening Visit or during the Screening Period
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,Has active ocular condition that in the opinion of the investigator may alter visual acuity during the course of the study.
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Use of any drugs that are strong inhibitors of Cytochrome (CYP)450 (2D6 or 2C19) within 7 days or 5 half lives of the inhibitor (whichever is longer), prior to administration of the first dose of Investigational medicinal product (IMP) and/or plan to use throughout the study"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Participation within the 12 months prior to Screening Visit in a study of any agent(s) with a purported disease modifying effect in AD (e.g., anti beta amyloid,  secretase inhibitors,  secretase inhibitors), unless documentation of receipt of placebo is available"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Has taken other investigational drugs or participated in any clinical study within 30 days or 5 half lives (if known) of the investigational drug, whichever is longer, prior to first dose of IMP in this study or is currently participating in another clinical study"
NCT04311515,Phase 2,Alzheimer Disease,"Samus Therapeutics, Inc.",unknown,Alzheimer Disease;Dementia;Fluorodeoxyglucose F18,"Other unspecified reasons that, in the opinion of the investigator or Samus, and/or its delegated medical monitor, make the subject unsuitable for the study"
NCT04314934,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Adverse events (AEs) from the previous study (ANAVEX2-73-AD-004) that have not resolved, are moderate or severe, judged to be possibly related or related to study drug, and considered by the investigator to be a contraindication to extension study participation"
NCT04314934,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Any condition or laboratory abnormality that would make the subject, in the judgment of the investigator, unsuitable for the study"
NCT04314934,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease," Significant history of drug addiction (with the exception of nicotine dependence) or abuse (including alcohol, as defined in DSM-V or in the opinion of the investigator) within the last two years prior to informed consent, or a positive urine drug screen for cocaine, opioid, phencyclidine (PCP), amphetamine or marijuana at screening. Prescription medication yielding a positive drug screen are acceptable except for tricyclic antidepressants (e.g. Amitriptyline, Amoxapine, Desipramine, (Norpramin) Doxepin, Imipramine (Tofranil), Nortriptyline (Pamelor), Protriptyline (Vivactil), Trimipramine (Surmontil))."
NCT04314934,Phase 2/Phase 3,Alzheimer Disease,Anavex Life Sciences Corp.,unknown,Alzheimer Disease, Any known hypersensitivity to any of the excipients contained in the study drug formulation.
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Prematurely discontinued from the OLEs of studies WN25203 or WN28745 or from study drug for any reason
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Any medical condition that may jeopardize the participant's safety if he or she continues to receive study treatment
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," If the participant is unlikely to benefit from gantenerumab therapy, based on disease progression or other factors, or if study participation is otherwise not in the participant's best interest"
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Any investigational treatment other than gantenerumab during or since completion of the OLEs of studies WN25203 or WN28745
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Pregnancy
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," Evidence of disseminated leptomeningeal hemosiderosis (i.e., more than three focal leptomeningeal hemosiderosis)"
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Evidence of intracerebral macrohemorrhage
NCT04339413,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Part 2: Participants who have been discontinued from Part 1 of the study
NCT04374253,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,"Alzheimer Disease;Antibodies, Monoclonal"," Pregnant or breastfeeding, or intending to become pregnant during the study or within at least 16 weeks after the final dose of study drug"
NCT04374253,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,"Alzheimer Disease;Antibodies, Monoclonal", Prematurely discontinued from Study WN29922 or WN39658
NCT04374253,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,"Alzheimer Disease;Antibodies, Monoclonal", Any medical condition that may jeopardize the participant's safety if he or she continues to receive study treatment
NCT04374253,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,"Alzheimer Disease;Antibodies, Monoclonal"," Received any investigational treatment other than gantenerumab during or since completion of Study WN29922 or WN39658, either its double-blind or OLE part"
NCT04374253,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,"Alzheimer Disease;Antibodies, Monoclonal", Evidence of disseminated leptomeningeal hemosiderosis
NCT04374253,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,"Alzheimer Disease;Antibodies, Monoclonal", Evidence of intracerebral macrohemorrhage
NCT04374253,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,"Alzheimer Disease;Antibodies, Monoclonal", Use of prohibited medication
NCT04374253,Phase 3,Alzheimer Disease,Hoffmann-La Roche,unknown,"Alzheimer Disease;Antibodies, Monoclonal"," Evidence of ARIA-E on the last MRI scan report in Study WN29922 or WN39658, either its double-blind or OLE part"
NCT04408755,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with dementia predominantly of the non-Alzheimer's type (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)"
NCT04408755,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with symptoms of agitation that are not secondary to Alzheimer's dementia (e.g., secondary to pain, other psychiatric disorder, or delirium)"
NCT04408755,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., malignancy [except skin basal-cell carcinoma], poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)"
NCT04408755,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Participants with myasthenia gravis
NCT04437511,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Contraindication to MRI or PET scans
NCT04437511,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Current treatment with immunoglobulin G (IgG) therapy
NCT04464564,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with dementia predominantly of the non-Alzheimer's type (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)"
NCT04464564,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with symptoms of agitation that are not secondary to Alzheimer's dementia (e.g., secondary to pain, other psychiatric disorder, or delirium)"
NCT04464564,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation," Participants with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., malignancy [except skin basal-cell carcinoma], poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)"
NCT04464564,Phase 3,Agitation in Patients With Dementia of the Alzheimer's Type,"Otsuka Pharmaceutical Development &amp; Commercialization, Inc.",unknown,Dementia;Alzheimer Disease;Psychomotor Agitation, Participants with myasthenia gravis
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil," Female patients who are pregnant, nursing, or of childbearing potential while not practicing effective contraception"
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil, Patients who have signs of delirium
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil, Patients who have had a cortical stroke within the preceding 2 years
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil, Patients who have a prolonged QTc interval at screening; greater than 450 msec for males or greater than 470 msec for females
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil," Patients who have a diagnosis of severe white matter hyperintensity (WMH), which is defined as 25mm of the deep white matter and 10mm of the periventricular capping/banding in lengths"
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil, Patients who have a diagnosis of dementia or cause of cognitive impairment other than AD
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil," Patients who have a significant abnormal result in laboratory tests, in the opinion of the investigator"
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil," Patients who have participated in any investigational drug, stem cell therapy, or device trial within the previous 3 months at screening"
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil," Patients with any current psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the subjects ability to complete the study"
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil, Patients who are known to have autosomal dominant mutation-associated presenile AD
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil," Patients who show signs of Acquired Immunodeficiency Syndrome (AIDS), Hepatitis B Virus (HBV), Hepatitis C (HCV), Venereal Disease Research Laboratory (VDRL)"
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil," Patients who have any conditions that would contraindicate an MRI, such as the presence metallic objects in the eyes, skin, or heart"
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil," Patients who have greater than 4 cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as  possible  or  definite ), a single area of superficial siderosis, or evidence of a prior microhemorrhage as assessed by MRI"
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil," Patients who have history of malignant cancer within the last 5 years (The following is a partial list of conditions that are permissible for study entry: non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical, or non-progressive prostate cancer)"
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil, Patients who have suspected active lung disease based on chest X-ray
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil, Patients who are hypersensitive to fetal bovine serum or penicillin
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil," Patients who are currently using immunosuppressants, cytotoxic drug, corticosteroids or similar steroidal anti-inflammatory medication (e.g., Prednisone) on a regular basis (exceptions allowed include; regular use of steroidal nasal sprays, topical steroids, and estrogen-replacement therapy)"
NCT04482413,Phase 2,Alzheimer Disease,Nature Cell Co. Ltd.,unknown,Alzheimer Disease;Donepezil, Patients for whom the investigator judges the liposuction may cause a problem
NCT04520412,Phase 3,Alzheimer Disease,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",unknown,Alzheimer Disease, Diagnosis of a dementia-related central nervous system disease other than AD.
NCT04520412,Phase 3,Alzheimer Disease,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",unknown,Alzheimer Disease, Major structural brain disease as judged by MRI.
NCT04520412,Phase 3,Alzheimer Disease,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",unknown,Alzheimer Disease, A resting heart rate of less than  50 beats per minute (bpm) after 5 minutes of rest in sitting or supine position.
NCT04520412,Phase 3,Alzheimer Disease,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",unknown,Alzheimer Disease, Major medical illness or unstable medical condition within 6 months of screening.
NCT04520412,Phase 3,Alzheimer Disease,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",unknown,Alzheimer Disease," Concomitant use of AChEIs and/or memantine within 30 days before first MMSE score, and during the study."
NCT04520412,Phase 3,Alzheimer Disease,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",unknown,Alzheimer Disease, Inadequate hepatic function.
NCT04520412,Phase 3,Alzheimer Disease,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",unknown,Alzheimer Disease, Inadequate organ and marrow function.
NCT04520412,Phase 3,Alzheimer Disease,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.",unknown,Alzheimer Disease, ECG clinically significant abnormalities.
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1, Eligibility Criteria:
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1, Inclusion
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Written informed consent from caregiver and subject (if possible) or legally acceptable representative if different from caregiver 2. Male and female subjects 55-85 years of age inclusive 3. Cognitive deficit present for at least 2 years that meet the diagnostic criteria for probable Alzheimer's dementia. The diagnosis must be confirmed at the time of the screening visit 4. MMSE-2 score of 10-18 inclusive (applies to Screening Visit only) 5. Patients must have a baseline SIB total score of at least 60 and may not have a SIB score greater than 93 at screening 6. Neuroimaging computerized tomography (CT) or Magnetic Resonance Imaging (MRI) within the last 24 months consistent with a diagnosis of probable AD without any other clinically significant co-morbid pathologies. If there has been a significant change in the subject's clinical status since the last imaging study that is not consistent with progression of the subject's AD, an imaging study should be performed to confirm eligibility 7. Reliable caregiver(s) or informant(s) who attends the subject at least an average of 3 hours or more per day for 3 or more days per week and who will agree to accompany the subject to the clinic visits and reliably complete the caregiver questions 8. Adequate vision and motor function to comply with testing 9. If taking an approved cholinesterase inhibitor for treatment of Alzheimer's disease, must be on a stable dose for at least 3 months prior to entry into study and the dose must not change during the study unless a change is required due to an adverse effect of the prescribed medication or a clinically significant change in the patient's status 10. Subjects who are memantine nave or have been off memantine for at least 90 days prior to initial treatment with study drug 11. Subjects on neuroleptic medications must be on a stable dose for 4 weeks at screening (dose adjustments will be permitted if medically necessary at the discretion of the PI) 12. Females participating in the study must meet one the following criteria:"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy or tubal ligation) for at least 6 months or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year) or"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"If not postmenopausal, agree to use a double method of contraception, one of which is a barrier method (e.g., intrauterine device plus condom, spermicidal gel plus condom) 30 days prior to dosing until 30 days after last dose and have negative human chorionic gonadotropin (-hCG) test for pregnancy at screening 13. Males who have not had a vasectomy must use appropriate contraception methods (barrier or abstinence) from 30 days prior to dosing until 30 days after last dose 14. In the opinion of the PI subjects should be in reasonably good health over the last 6 months and any chronic disease should be stable Exclusion"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Dementia due to any condition other than AD, including vascular dementia (Rosen-Modified Hachinski Ischemic score  5)"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Evidence of significant central nervous system (CNS) vascular disease on previous neuroimaging including but not limited to: cortical stroke, multiple infarcts, localized single infarcts in the thalamus, angular gyrus, multiple lacunar infarcts or extensive white matter injury"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Clinically significant neurologic disease or condition other than AD, such as cerebral tumor, chronic subdural fluid collections, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, or any other diagnosis that could interfere with assessment of safety and efficacy"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Evidence of clinically significant unstable cardiovascular, pulmonary, renal, hepatic, gastrointestinal, neurologic, or metabolic disease within the 6 months prior to enrollment. If there is a history of cancer the subject should be clear of cancer for at least 2 years prior to screening. More recent history of basal cell or squamous cell carcinoma and melanoma in situ (Stage 0) may be acceptable after review by the Medical Monitor."
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Creatinine clearance (CL) of less than 45ml/min
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Poorly controlled diabetes, at the discretion of the Principal Investigator"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Concomitant treatment with NMDA receptor antagonists such as but not limited to memantine or drug combinations containing memantine, dextromethorphan (a cough suppressant), ketamine, phencyclidine (PCP), methoxetamine (MXE), nitrous oxide (N2O) and the following synthetic opioids: penthidine, levorphanol, methadone, dextrpropoxyphene, tramadol, and ketobemidone."
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Use of vitamin E greater than  400 International Units (IU) per day within 14 days prior to screening
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Use of acetaminophen within 14 days prior to screening
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Use of gabapentin within 14 days prior to screening
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Use of valproic acid within 14 days prior to screening
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Use of an active Alzheimer's vaccine within 2 years prior to screening
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Use of a monoclonal antibody for treatment of AD within 1 year prior to screening
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Any medical or psychiatric condition that is likely to require initiation of additional medication or surgical intervention during the course of the study
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Any screening laboratory values outside the reference ranges that are deemed clinically significant by the PI
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Use of an investigational drug within 90 days prior to screening
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Suicidality defined as active suicidal thoughts during the 6 months prior to screening or at Baseline [Type 4 or 5 on C-SSRS], or history of suicide attempt in previous 2 years, or at serious suicide risk in PI's judgment"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Major psychiatric illness such as current major depression according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition , current or past diagnosis of bipolar disorder, schizophrenia, or any other psychiatric disorder that might interfere with the assessments of safety or efficacy at the discretion of the PI"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Diagnosis of alcohol or drug abuse within the last 2 years
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Abnormal laboratory tests that suggest an alternate etiology for dementia. If the patient has prior history of serum B12 abnormality, anemia with hemoglobin 10g/dl, thyroid function abnormality, electrolyte abnormality, or positive syphilis serology the patient should be revaluated to determine if these potential causes of dementia have been addressed. Only if these causes have been ruled out as the cause of the dementia can the patient be enrolled."
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,History of prolonged QT or prolonged QT on screening ECG (QTcB or QTcF greater than 499 per central reader)
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Acute or poorly controlled medical illness: blood pressure greater than  180 mmHg systolic or 100 mmHg diastolic; myocardial infarction within 6 months; uncompensated congestive heart failure [New York Heart Association (NYHA) Class III or IV]
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,Known to be seropositive for human immunodeficiency virus (HIV)
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Known to be seropositive for Hepatitis B or C, unless successful curative treatment for Hepatitis C (e.g., Harvoni) has been received and there is documentation that there is no Hep B/C virus detected 3 months after completion of treatment"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,AST or ALT greater than 3x upper limit of normal (ULN) and total bilirubin greater than 2x ULN or International Normalized Ratio (INR) greater than 1.5
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Prior exposure to bryostatin, or known sensitivity to bryostatin or any ingredient in the study drug"
NCT04538066,Phase 2,Alzheimer Disease,"Neurotrope Bioscience, Inc.",unknown,Alzheimer Disease;Bryostatin 1,"Any other concurrent medical condition, which in the opinion of the PI makes the subject unsuitable for the clinical study -"
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,Any medical or neurologic condition (other than Alzheimer's Disease) that might be a contributing cause of the subject's cognitive impairment
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,Clinically significant unstable psychiatric illness in the past six months
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,"Significant hearing, vision, or motor deficits that interfere with participation"
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,Alcohol or drug abuse/dependence in the past six months
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,"Stroke, transient ischemic attack, or unexplained loss of consciousness in the past six months"
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,"Unstable angina, myocardial infarction, advanced chronic heart failure, or clinically significant conduction abnormalities within the past six months"
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,"Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities"
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,"Diagnosis of HIV infection or AIDS (CD4 count less than  200), HIV/Hepatitis B Virus (HBV) co-infection, HBV or human T-cell leukemia virus infection"
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,History of impaired renal or liver function
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,Current use of memantine or sorbitol-containing products
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,"Individuals with HIV, HBV, or who have current/previous use of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) or non-NRTIs."
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,"Poorly controlled blood pressure (BP) (systolic BP greater than  160, diastolic BP greater than  90 mmHg)"
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,"Uncontrolled diabetes (HbA1c greater than  8%, or the current use of insulin)"
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,Significant systematic illness or infection in the past 30 days
NCT04552795,Phase 1/Phase 2,"Alzheimer Disease, Early Onset","Bess Frost, PhD",unknown,Alzheimer Disease;Lamivudine,Pregnant women
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine," Patients who refuse to adopt a low caffeine diet (eviction of tea, caffeinated sodas, chocolate in large quantities)"
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, Current major depressive episode according to DSM-5 criteria
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, Another chronic pathology of the central nervous system
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, Major anxiety according to the clinician (consistent with the corresponding nPI-R items that must indicate a severity greater than 2 and an impact greater than 3)
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, Sleep disorders defined by severity and an impact on NPI-R; a patient fitted for OSA may be included if the device has been in use for 3 months and well tolerated (stable)
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine," Decompensated heart disease or severe rhythm disorder (excluding slow, treated and stable chronic atrial fibrillation)"
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, Active smoking
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, For childbearing women : pregnancy in progress or planned (A pregnancy test will be performed)
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, Patients who take forbidden treatment :
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, Psychotropic treatments introduced or modified less than  2 months before inclusion
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, Chronic use of CYP1A2 inducing or inhibiting drugs
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, All caffeine-containing specialties
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, Drugs that influence caffeine metabolism
NCT04570085,Phase 3,Alzheimer Disease,"University Hospital, Lille",unknown,Alzheimer Disease;Caffeine, Drugs that may interact with caffeine
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Past or present history of a brain disorder other than Alzheimer's disease (including presence of cortical infarct on MRI even in absence of clinical stroke).
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Serious medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries."
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Contraindication to MRI scanning.
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.)."
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Exposure to research related radiation in the past year that, when combined with this study, would place subjects above the allowable limits."
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Participation in the last year in a clinical trial for a disease modifying drug for AD.
NCT04576793,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Taking immunosuppressive medication (e.g., glucocorticoids, cytostatics, antibodies, drugs acting on immunophilins, interferons, tumor necrosis factor inhibitors). Nonsteroidal anti-inflammatory drugs (NSAIDs) are not exclusionary."
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Any evidence of a condition other than AD that may affect cognition.
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, History or presence of clinically evident systemic vascular disease that in the opinion of the investigator has the potential to affect cognitive function.
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, History or presence of clinically evident cerebrovascular disease.
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, History or presence of posterior reversible encephalopathy syndrome.
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack."
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," History of severe, clinically significant CNS trauma."
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, History or presence of intracranial mass that could potentially impair cognition.
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Presence of infections that affect brain function or history of infections that resulted in neurologic sequelae.
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, History or presence of systemic autoimmune disorders that potentially cause progressive neurologic disease with associated cognitive deficits.
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease," History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder."
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, At risk for suicide in the opinion of the investigator.
NCT04592341,Phase 2,Alzheimer Disease,Hoffmann-La Roche,unknown,Alzheimer Disease, Alcohol and/or substance abuse or dependants in past 2 years.
NCT04592874,Phase 2,Alzheimer Disease,Alector Inc.,unknown,Alzheimer Disease," Dementia due to a condition other than AD including, but not limited to, FTD, Parkinson's disease, dementia with Lewy bodies, Huntington disease, or vascular dementia."
NCT04592874,Phase 2,Alzheimer Disease,Alector Inc.,unknown,Alzheimer Disease," Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins."
NCT04592874,Phase 2,Alzheimer Disease,Alector Inc.,unknown,Alzheimer Disease," Current uncontrolled hypertension, diabetes mellitus or thyroid disease. Clinically significant heart disease, liver disease or kidney disease."
NCT04592874,Phase 2,Alzheimer Disease,Alector Inc.,unknown,Alzheimer Disease, History or evidence of clinically significant brain disease other than AD.
NCT04592874,Phase 2,Alzheimer Disease,Alector Inc.,unknown,Alzheimer Disease," Females who are pregnant or breastfeeding, or planning to conceive within the study period."
NCT04592874,Phase 2,Alzheimer Disease,Alector Inc.,unknown,Alzheimer Disease, Any experimental vaccine or gene therapy.
NCT04592874,Phase 2,Alzheimer Disease,Alector Inc.,unknown,Alzheimer Disease, History of unresolved cancer.
NCT04592874,Phase 2,Alzheimer Disease,Alector Inc.,unknown,Alzheimer Disease, Current use of anticoagulant medications.
NCT04592874,Phase 2,Alzheimer Disease,Alector Inc.,unknown,Alzheimer Disease," Residence in a skilled nursing facility, convalescent home, or long term care facility at screening; or requires continuous nursing care."
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction, I. Vascular cognitive impairment patients:
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Have other illnesses, including people with drug / alcohol abuse / addictivity within three months."
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Patient cannot accept brain magnetic resonance imaging or 11C-PiB PET, such as agitation and inability to cooperate, allergy to contrast agents, hemodynamic instability (blood pressure, pulse, or blood oxygen is not in the normal range), and a heart rhythm regulator has been implanted , Have ever undergone intracranial aneurysm clamp surgery, claustrophobia and hemodynamic instability."
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Pregnant woman or intends to be pregnant in the near future.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Patient who is breast feeding or intends to.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Allergic to 11C-PiB, or with severe drug allergy history."
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Patient or the family refuses to participate in the study.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction, II. Alzheimer's disease (AD) patients:
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Have other illnesses, including:"
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Cognitive disorders caused by cerebrovascular diseases (the decline in cognitive function is closely related to the time of stroke, multiple large-scale necrosis, and severe white matter lesions)."
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,The main manifestation of dementia is Lewy body dementia
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Symptoms are behavioral variation of frontotemporal dementia.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,The symptoms are obviously semantic progressive aphasia.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Symptoms are not fluent in primary progressive aphasia.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Other comorbidities that affect cognitive function (including other active neurological diseases, or non-neurological diseases but the disease or the treatment used will affect cognitive function)"
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Patient cannot accept brain magnetic resonance imaging or 11C-PiB PET, such as agitation and inability to cooperate, allergy to contrast agents, hemodynamic instability (blood pressure, pulse, or blood oxygen is not in the normal range), and a heart rhythm regulator has been implanted , Have ever undergone intracranial aneurysm clamp surgery, claustrophobia and hemodynamic instability."
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Pregnant woman or intends to be pregnant in the near future.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Patient who is breast feeding or intends to.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Allergic to 11C-PiB, or with severe drug allergy history."
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Patient or the family refuses to participate in the study.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction, III. Normal controls:
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Patient cannot accept brain magnetic resonance imaging or 11C-PiB PET, such as agitation and inability to cooperate, allergy to contrast agents, hemodynamic instability (blood pressure, pulse, or blood oxygen is not in the normal range), and a heart rhythm regulator has been implanted , Have ever undergone intracranial aneurysm clamp surgery, claustrophobia and hemodynamic instability."
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Pregnant woman or intends to be pregnant in the near future.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Patient who is breast feeding or intends to.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,"Allergic to 11C-PiB, or with severe drug allergy history."
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,Patient or the family refuses to participate in the study.
NCT04604600,Phase 3,Alzheimer Disease,National Taiwan University Hospital,unknown,Alzheimer Disease;Cognitive Dysfunction,high risk as assessed by a doctor.
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", History or presence of brain MRI scans indicative of any other significant abnormality
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Alcohol or drug dependence currently or within the past 1 year
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would preclude MRI scan."
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," History or presence of clinically significant cardiovascular disease, hepatic/renal disorders, infectious disease or immune disorder, or metabolic/endocrine disorders"
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Anticoagulants except low dose ( 325 mg) aspirin.
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the past six months.
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years."
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal", Positive urine or serum pregnancy test or plans or desires to become pregnant during the course of the trial.
NCT04623242,Phase 2/Phase 3,"Alzheimers Disease, Familial",Washington University School of Medicine,unknown,"Alzheimer Disease;Dementia;Antibodies, Monoclonal"," Subjects unable to complete all study related testing, including implanted metal that cannot be removed for MRI scanning, required anticoagulation and pregnancy."
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Diabetes (HBA1c6.5% or antidiabetic medications)
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,History of skin ulcers or poor wound healing
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Current tobacco or illicit drug use or alcohol abuse
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Use of anti-platelet or anti-coagulant medications other than aspirin
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Current medications that affect cytochrome 450 3A4 (CYP3A4)
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Immunosuppressant therapy within the last year
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Chemotherapy or radiation treatment within the last year
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Current or chronic history of liver or kidney disease or known hepatic or biliary abnormalities
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Untreated hypertriglyceridemia (fasting triglycerides less than  250 mg/dl)
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Current or chronic history of pulmonary disease or abnormal pulse oximetry (less than 90%)
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Chronic heart failure
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Pregnancy or lactation
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,"Recent history (past six months) of myocardial infarction, active coronary artery disease, intestinal disorders, stroke, or transient ischemic attack"
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Significant neurological conditions other than AD or MCI
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,"Poorly controlled blood pressure (systolic BPgreater than 160, diastolic BPgreater than 90 mmHg - based on two readings)"
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,"Active inflammatory, COVID-19, autoimmune, infectious, hepatic, gastrointestinal, malignant, and/or severe mental illness"
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,"History of, or MRI, or CT positive for, any space occupying lesion, including mass effect or abnormal intracranial pressure, which would indicate contraindications to lumbar puncture"
NCT04629495,Phase 2,Alzheimer Disease,The University of Texas Health Science Center at San Antonio,unknown,Alzheimer Disease;Cognitive Dysfunction;Sirolimus,Organ transplant recipients
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant," Any sleep disorders other than insomnia, such as history or reported symptoms suggestive of restless legs syndrome, narcolepsy, parasomnia, or other sleep disorders."
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Actigraphic sleep efficiency 85%.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Abnormal movement of the non-dominant arm (would affect actigraphy data in unpredictable ways).
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, No history of sleep-disordered breathing and STOP-Bang score greater than  3.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, AHI greater than 15.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Stroke.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, History of hepatic or renal impairment.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, HIV/AIDS.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Body mass index greater than 35.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, History of substance abuse or alcoholism in the proceeding 6 months.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, History of regular alcohol consumption 3 or more days a week over the last 6 months. Regular alcohol consumption is defined as having more than 2 alcoholic beverages within 3 hours of bedtime
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant," History of presence of any clinically significant medical condition, behavioral or psychiatric disorder, or surgical history based on medical record or participant report that could affect the safety of the participant or interfere with study assessments or in the judgement of the Principal-Investigator (PI) if participant is not a good candidate."
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant," Has any medical condition that, in the PI's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g. participants with severe chronic back pain might not be able to lie still during the scanning procedures). Potential medical conditions that will be exclusionary at the PI's discretion:"
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Cardiovascular disease requiring medication except for controlled hypertension.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Pulmonary disease.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Type I diabetes.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Neurologic or psychiatric disorder requiring medication.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Tobacco use.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Use of sedating medications.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Abnormal safety labs
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, History of current suicidal ideations.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant," Contraindications to PET, CT, or MRI (e.g. electronic medical devices, inability to lie still for extended periods) that make it unsafe for the individual to participate."
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Retained metal in any body part included implanted medical devices or metal near the orbit or skull.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant," All participants will be screened and excluded for neurologic or psychiatric co-morbidities that could affect cognition as well as medical co-morbidities that may prevent participants from undergoing PET/MRI, or cause excessive motion during scanning."
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Has hypersensitivity to AV-1451 and PIB or any of its excipients.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Severe claustrophobia.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Currently pregnant or breast-feeding. Women must agree to avoid becoming pregnant and must agree to refrain from sexual activity or to use reliable contraceptive methods for 24 hours following administration of Flortaucipir injection.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant," In the opinion of the PI, the participant should be excluded due to an abnormal physical examination."
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Must not participate in another drug or device study prior to the end of this study participation.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1.
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant, Exclusion criteria for optional lumbar punctures
NCT04629547,Phase 2,Alzheimer Disease,Washington University School of Medicine,unknown,Alzheimer Disease;Suvorexant,  Contraindication to lumbar puncture (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery).
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, Other cause of dementia.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, Previous use of symptomatic treatment for Alzheimer's disease.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, Hypersensitivity to donepezil hydrochloride or to any of the excipients listed in the SPC.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil," Cardiological contraindication after possible opinion of a cardiologist, at the initiative of the investigator, in particular bradycardia, sinus disease or other supra-ventricular conduction abnormalities such as sinoatrial or atrioventricular block."
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil," Patients at particular risk of ulcer, known ulcer disease or receiving concomitant treatment with non-steroidal anti-inflammatory drugs."
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, Patient at risk of urinary retention.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, History of epileptic disease.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, History of neuroleptic malignant syndrome.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, History of asthma or obstructive bronchopulmonary disease.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, Severe hepatic impairment.
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, Taking one of the following treatments:
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil," CYP3A4 inhibitors, such as ketonazole."
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil," 2D6 inhibitors, such as quinidine."
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil," CYP3A4 inhibitors, such as itraconazole and erythromycin."
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil," CYP2D6 inhibitors, such as fluoxetine."
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil," Enzyme inducers such as rifampicin, phenytoin, carbamazepine."
NCT04661280,Phase 3,"Alzheimer Disease, Early Onset",Assistance Publique - Hpitaux de Paris,unknown,Alzheimer Disease;Donepezil, Participation in another interventional study.
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Has prior brain imaging inconsistent with probable AD 2. A history of a stroke that resulted in a cognitive or motor deficit or, MRI or CT evidence of a moderate or large cerebral infarct."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Should there be any evidence of neurologic symptoms between the date of the scan confirming diagnosis and Screening (V1), rescanning is necessary."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Has clinically relevant abnormal laboratory tests including serum vitamin B12 deficiency, thyroid function abnormality, severe anemia, or electrolyte abnormality."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,Diagnosis of type 1 diabetes or type 2 diabetes requiring insulin treatment or the need to use continuous glucose monitoring. Subjects who become insulin dependent during the study may not continue to participate in the study.
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"History of epilepsy or seizure disorder requiring ongoing treatment, or any seizure or loss of consciousness within 12 mo prior to Screening (V1)."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Subjects are ineligible, if in the opinion of the investigator, they have deficits in speech, comprehension, auditory functioning, or vision which would adversely impact their ability to perform the study's cognitive test procedures, complete rating scales, or engage in interviews."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,Has any of the following laboratory findings at Screening (V1):
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Alanine aminotransferase greater than 3  upper limit of normal (ULN), aspartate aminotransferase greater than 3  ULN, or history of clinically significant liver disease in the Investigator's medical judgment."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,Hemoglobin 10 g/dL.
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"International normalized ratio greater than 1.5 if not on anticoagulant medication; if the subject is on anticoagulant medication, the anticoagulant medication should be optimized and on a stable dose for 4 wk prior to Screening (V1)."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,Creatinine clearance (Cockcroft Gault formula) of less than 45 mL/min.
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Known to be seropositive for human immunodeficiency virus (1 and 2), hepatitis B, or hepatitis C. Subjects with hepatitis C who had spontaneous resolution or received successful curative treatment (e.g., HARVONI [ledipasvir/sofosbuvir]) with a documentation of undetectable viral load for at least 3 mo may be allowed. Serological testing will not be performed as part of this study."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Female subjects with child-bearing potential (premenopausal, menstrual bleeding within the last 12 months) or who are pregnant or breastfeeding."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"History of any medical illness such as cancer requiring systemic therapy in the last 5 y, except for localized basal cell carcinoma of the skin, in situ cervical cancer successfully treated with surgical excision, and stable (for 90 d prior to Screening [V1]) prostate cancer."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"History of breast cancer. 11. History of severe heart failure (Grade 2 or higher on the New York Heart Association scale), major stroke, uncontrolled seizure disorder, or other medical illness that, in the Investigator's opinion, will increase the subject's risk of participation in the study or confound study assessments."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Any surgery requiring general anesthesia that is planned to occur during the study. Local anesthesia during outpatient surgery is permitted if, in the opinion of the Investigator, the operation will not interfere with study procedures and subject safety."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"History or current evidence of major psychiatric illness such as schizophrenia, bipolar disorder, or major depressive disorder that may interfere with the subject's ability to perform the study and all assessments."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,Geriatric Depression Scale Short Form (GDS SF) score greater than 8 at Screening (V1). NOTE: Mild depression or depressive mood arising in the context of AD are not criteria for exclusion. The use of anti epileptic medication for non-seizure-related treatment or the use of antidepressants is allowed if the dose has remained stable for 60 d prior Screening (V1).
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Violent or aggressive behavior that may interfere with study participation 15. History of active suicidal thoughts (Type 4 or 5 on the C SSRS) in the 6 mo prior to Screening (V1) or at Baseline (V2), history of a suicide attempt in the previous 2 y or greater than 1 lifetime suicide attempt, or are at serious suicide risk, in the Investigator's clinical judgment."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,History of alcohol or drug abuse or dependence within 24 mo of Screening (V1) as defined by the Diagnostic and Statistical Manual of Mental Disorders 5.
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Positive urine screen for drugs of abuse that include methadone, cocaine, and amphetamines; positive urine screen for opiates, barbiturates, or benzodiazepines without a prescription."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"Has participated in another Investigational New Drug research study involving small molecule drugs within 60 d or biological drugs within 90 d prior to the first dose of study drug in this study (Baseline [V2]) or within 5 half-lives of the other investigational medicinal product, whichever is longer."
NCT04669028,Phase 3,Alzheimer Disease,BioVie Inc.,unknown,Alzheimer Disease,"History of Covid-19 (SARS-CoV-2) infection within 6-weeks prior to screening. Subjects with unresolved symptoms of Covid-19 infection or ongoing cognitive or other deficits attributable to post-Covid-19, that may affect participant safety or interfere with efficacy assessments, based on the Investigator's clinical judgment."
NCT04693520,Phase 2,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease,Brain MRI at screening indicative of significant abnormality
NCT04693520,Phase 2,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease,Diagnosis of neurodegenerative disorder other than AD
NCT04693520,Phase 2,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease,Current diagnosis of Major Depressive Disorder (MDD)
NCT04693520,Phase 2,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease,Concomitant treatment with memantine.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Hospitalization (except for planned procedures) or change of chronic concomitant medication within 1 month prior to screening.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Participants living in a continuous care nursing facility.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Contraindications to the MRI examination for any reason.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct greater than  1 cm3, greater than  3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (eg, abscess or brain tumor such as meningioma)."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Clinical or laboratory findings consistent with:
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Other primary degenerative dementia, (dementia with Lewy bodies, fronto-temporal dementia, Huntington's disease, Creutzfeldt-Jakob Disease, Down syndrome, etc)."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Other neurodegenerative condition (Parkinson's disease, amyotrophic lateral sclerosis, etc)."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Seizure disorder.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Other infectious, metabolic or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, other laboratory values etc)."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"A current DSM-V diagnosis of active major depression, schizophrenia or bipolar disorder. Participants with depressive symptoms successfully managed by a stable dose of an antidepressant are allowed entry."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Clinically significant, advanced or unstable disease that may interfere with outcome evaluations, such as:"
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Chronic liver disease, liver function test abnormalities or other signs of hepatic insufficiency (ALT, AST, alkaline phosphatase greater than  1.5 ULN, lactate dehydrogenase (LDH) greater than  1.5 x ULN)."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Respiratory insufficiency.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Renal insufficiency eGFR less than  50 mL/min based on the CKD-EPI formula,"
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Heart disease (myocardial infarction, unstable angina, heart failure, cardiomyopathy within 6 months before screening)."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Bradycardia (less than  50/min.) or tachycardia (greater than  100/min.).
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Poorly managed hypertension (systolic greater than  160 mm Hg and/or diastolic greater than  95 mm Hg) or hypotension (systolic less than  90 mm Hg and/or diastolic less than  60 mm Hg).
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Uncontrolled diabetes in known diabetics, as defined by hemoglobin A1c (HbA1c) greater than  7.5."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,History of cancer within 3 years of screening with the exception of fully excised non-melanoma skin cancers or non-metastatic prostate cancer that has been stable for at least 6 months.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Seropositive for human immunodeficiency virus (HIV).
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,History of acute/chronic hepatitis B or C and/or carriers of hepatitis B (seropositive for hepatitis B surface antigen [HbsAg] or anti-hepatitis C [HCV] antibody).
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Clinically significant abnormalities in screening laboratory tests, including:"
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease," a) Hematocrit less than 35% for males and less than 32% for females, absolute neutrophil cell count of less than 1500/uL (with the exception of a documented history of a chronic benign neutropenia), or platelet cell count of less than  120,000/uL; international normalized ratio (INR) greater than  1.4 or other coagulopathy, confirmed by repeat assessment."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Disability that may prevent the participant from completing all study requirements (e.g., blindness, deafness, severe language difficulty, etc)."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Within 4 weeks of screening visit or during the study, concurrent treatment with antipsychotic agents, antiepileptics, centrally active anti-hypertensive drugs (e.g., clonidine, l-methyl dopa, guanidine, guanfacine, etc), sedatives, opioids, mood stabilizers (e.g., valproate, lithium); or benzodiazepines, with the following exception:"
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease," a) Low dose lorazepam may be used for sedation prior to MRI scan for those participants requiring sedation. At the discretion of the Investigator, 0.5 to 1 mg may be given orally prior to scan with a single repeat dose given if the first dose is ineffective. No more than a total of 2 mg lorazepam may be used for the MRI scan."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Any disorder that could interfere with the absorption, distribution, metabolism or excretion of drugs (eg, small bowel disease, Crohn's disease, celiac disease, or liver disease)."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Nootropic drugs except stable AD meds (acetylcholinesterase inhibitors and memantine).
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Suspected or known drug or alcohol abuse, ie, more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) per day."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,Suspected or known allergy to any components of the study treatments.
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Enrollment in another investigational study or intake of investigational drug within the previous 30 days or 5 half-lives of the investigational drug, whichever is longer."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Intake of drugs or substances potentially involved in clinically significant induction or inhibition of CYP3A4 or P-gp mediated drug interactions with CT1812, within 4 weeks or 5 half-lives of the interacting drug prior to administration of CT1812 and throughout the study. Grapefruit juice should be avoided in the 2 weeks prior to dosing and throughout the study. See Appendix A for a complete list of prohibited substances."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Exposure to immunomodulators, anti A vaccines, passive immunotherapies for AD (e.g., monoclonal antibodies) within the past 180 days and/or exposure to BACE inhibitors within the past 30 days"
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Anticipated use of nonsteroidal anti-inflammatory drugs (NSAIDs) on more than 14 days from Baseline/Day 1 to Day 182. Contraindication to undergoing an LP including, but not limited to: inability to tolerate an appropriately flexed position for the time necessary to perform an LP; international normalized ratio (INR) greater than  1.4 or other coagulopathy; platelet count of less than  120,000/L; infection at the desired LP site; taking anti-coagulant medication within 90 days of screening (low-dose aspirin is permitted); degenerative arthritis of the lumbar spine; suspected non-communicating hydrocephalus or intracranial mass; prior history of spinal mass or trauma."
NCT04735536,Phase 2,Alzheimer Disease,Cognition Therapeutics,unknown,Alzheimer Disease,"Any condition, which in the opinion of the Investigator or the Sponsor, makes the participant unsuitable for inclusion."
NCT04770220,Phase 3,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease," Brain magnetic resonance imaging (MRI) indicative of significant abnormality per central reader, other than AD related atrophy. Computed tomography (CT) scan acceptable for subjects who can not undergo MRI."
NCT04770220,Phase 3,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease, Diagnosis of neurodegenerative disorder other than AD.
NCT04770220,Phase 3,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease, Diagnosis of major depressive disorder (MDD) within one year prior to screening.
NCT04770220,Phase 3,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease, Currently taking memantine or has taken memantine within 12 weeks prior to the Screening - Part 2 Visit.
NCT04770220,Phase 3,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease, History of suicidal behavior within one year prior to screening or has ongoing suicidal ideation.
NCT04770220,Phase 3,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease," History of seizures, excluding febrile seizures of childhood or a single distant seizure (greater than  10 years)."
NCT04770220,Phase 3,Early Alzheimer's Disease,Alzheon Inc.,unknown,Alzheimer Disease, Medically confirmed history of recent cerebral infarct or transient ischemic attack within one year prior to screening.
NCT04777396,Phase 3,Early Alzheimer's Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," Brain MRI (or CT) scan suggestive of clinically significant structural CNS disease confirmed by central read (e.g. cerebral large-vessel disease [large vessel (cortical) infarcts greater than 10 mm in diameter], prior macro-haemorrhage [greater than 1 cm^3], cerebral vascular malformations, cortical hemosiderosis, intracranial aneurism(s), intracranial tumours, changes suggestive of normal pressure hydrocephalus)."
NCT04777396,Phase 3,Early Alzheimer's Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," Brain MRI (magnetic resonance imaging) (or CT) scan suggestive of significant small vessel pathology confirmed by central read and defined as greater than1 lacunar infarct and/or ARWMC (age-related white matter changes) greater than 2, (WM (white matter) greater than 20 mm) in the deep white matter and periventricular regions."
NCT04777396,Phase 3,Early Alzheimer's Disease,Novo Nordisk A/S,unknown,Alzheimer Disease, Brain MRI (or CT) scan suggestive of strategic infarcts defined as bilateral thalamic lacunar infarcts and singular paramedian thalamic infarcts confirmed by central read.
NCT04777396,Phase 3,Early Alzheimer's Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," Evidence of a relevant neurological disorder other than MCI or mild dementia of the Alzheimer's type at screening, including but not limited to Parkinson's disease, Lewy body disease, frontotemporal dementia of any type, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, HIV (human immunodeficiency virus), learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits"
NCT04777396,Phase 3,Early Alzheimer's Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," Evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or whose depression is controlled with treatment can be included in the trial per investigator's judgement."
NCT04777409,Phase 3,Early Alzheimers Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," Brain MRI (or CT) scan suggestive of clinically significant structural CNS (central nervous system) disease confirmed by central read (e.g. cerebral large-vessel disease [large vessel (cortical) infarcts greater than10 mm in diameter], prior macro-haemorrhage [greater than1 cm^3], cerebral vascular malformations, cortical hemosiderosis, intracranial aneurism(s), intracranial tumours, changes suggestive of normal pressure hydrocephalus)."
NCT04777409,Phase 3,Early Alzheimers Disease,Novo Nordisk A/S,unknown,Alzheimer Disease, Brain MRI (magnetic resonance imaging) (or CT) scan suggestive of strategic infarcts defined as bilateral thalamic lacunar infarcts and singular paramedian thalamic infarcts confirmed by central read.
NCT04777409,Phase 3,Early Alzheimers Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," Evidence of a relevant neurological disorder other than MCI or mild dementia of the Alzheimer's type at screening, including but not limited to Parkinson's disease, Lewy body disease, frontotemporal dementia of any type, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, HIV (human immunodeficiency virus), learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits."
NCT04777409,Phase 3,Early Alzheimers Disease,Novo Nordisk A/S,unknown,Alzheimer Disease," Evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or whose depression is controlled with treatment can be included in the trial per investigator's judgement."
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,Unwilling/unable to comply with study procedures.
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,"Other diagnosis of dementia (i.e., not Alzheimer's type), history of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, intellectual disability, or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders)."
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,"History of significant cardiovascular or cerebrovascular pathology (e.g., myocardial infarction; stroke)."
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,Clinically unstable systemic medical disorders.
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,"Current DSM-5 diagnosis of alcohol or drug use disorder or other major psychiatric illness (e.g., schizophrenia, bipolar, PTSD, depression)."
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,Clinical or laboratory evidence of hypothyroidism.
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,Clinically significant abnormal findings of laboratory parameters or at physical examination.
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,"Medications affecting cognition (e.g., narcotic analgesics; chronic use of medications with anticholinergic activity, anti-Parkinsonian medications, antipsychotic meds, etc.). Stable use (i.e.,  6 months) of memantine or acetylcholinesterase inhibitors will be allowed."
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,Family history of early onset (less than 60 y/o) dementia.
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,Body size and shape not allowing for a comfortable fit in PET and MRI scanners.
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,Past intolerance or hypersensitivity to t-PBM.
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,Significant skin conditions on the subject's scalp in the area of the procedure sites.
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment.
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,"Any type of implants in the head, whose functioning might be affected by t-PBM, or any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging."
NCT04784416,Phase 2,Alzheimer Disease,NYU Langone Health,unknown,Alzheimer Disease;Cognitive Dysfunction,Claustrophobia or metallic foreign bodies that would preclude MRI.
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Unwilling or unable to give informed consent
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Pregnancy
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,QTc greater than  450 msec on baseline ECG
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,MRI contraindications
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Presence of uncontrolled psychiatric disorder (as per clinical judgment)
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Presence of uncontrolled systemic lupus erythematosus (as per clinical judgment)
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Substance or alcohol abuse (current alcohol use greater than  3 alcoholic beverage/day or greater than  21 per week and as per clinical judgment)
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,"Hearing, vision, or motor deficits despite corrective devices (as per clinical judgment)"
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,"Myocardial infarction, angina, stroke, or transient ischemic attack in the past 6 months"
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Chronic heart failure (as per clinical judgment)
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,"Neurologic, musculoskeletal, or other condition that limits subject's ability to complete study physical assessments (as per clinical judgment)"
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Positive SARS-CoV-2 test within 30 days prior to enrollment
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,AST/ALT greater than  2.5x upper limit normal
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Presence of significant liver disease with total bilirubin greater than  2X upper limit or as per clinical judgment
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Inability to tolerate oral medication (as per clinical judgment)
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Abnormality in any of the screening laboratory studies (see section 6.21.2) or as per clinical judgment
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Malabsorption (as per clinical judgment)
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Known human immunodeficiency virus infection (as per clinical judgment)
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Known active hepatitis B or C infection
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Invasive fungal or viral infection (as per clinical judgment)
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Known hypersensitivity or allergy to D or Q
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Uncontrolled pleural/pericardial effusions or ascites (as per clinical judgment)
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,New/active invasive cancer except non-melanoma skin cancers
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Inability to tolerate oral medications (as per clinical judgment)
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Currently taking AND unable to safely hold any of the medications listed in Appendix 1 during the days IP is administered and for 36 hours after IP administration.
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Uncontrolled diabetes (defined as HbA1c greater than  7% or as per clinical judgment).
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Gastric bypass/reduction
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Crohn's disease
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,"Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase or ESR) (as per clinical judgment)"
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,eGFR less than  10 ml/ min/ 1.73 m2
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Creatinine clearance less than  60 mL/min/1.73 m2
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,"Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.)"
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,"On antiplatelet agents (e.g., full dose Aspirin, Clopidogrel etc.). Baby aspirin (81 mg), if absolutely necessary from cardiac perspective, will be allowed"
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin,Presence of any condition that the Investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial
NCT04785300,Phase 1/Phase 2,Alzheimer Disease,"James L. Kirkland, MD, PhD",unknown,Alzheimer Disease;Cognitive Dysfunction;Dasatinib;Quercetin," Involvement of special vulnerable populations: We will not involve special vulnerable populations, such as fetuses, neonates, pregnant women, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations except for patients with dementia. Therefore, availability and consent from a LAR is an inclusion criterion."
NCT04786223,Phase 2,Alzheimer Disease,Val Lowe,unknown,Alzheimer Disease;Dementia, Participants unable to lie down without moving for 20 minutes.
NCT04786223,Phase 2,Alzheimer Disease,Val Lowe,unknown,Alzheimer Disease;Dementia, Women who are pregnant or cannot stop breast feeding for 24 hours.
NCT04786223,Phase 2,Alzheimer Disease,Val Lowe,unknown,Alzheimer Disease;Dementia," Actively taking daily anti-inflammatory medications (NSAIDs, corticosteroids, etc.) except for a small control group."
NCT04786223,Phase 2,Alzheimer Disease,Val Lowe,unknown,Alzheimer Disease;Dementia," Generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning (only acute medication use as an exclusion so as to limit medication interaction but preserve possible chronic systemic inflammation interaction)."
NCT04786223,Phase 2,Alzheimer Disease,Val Lowe,unknown,Alzheimer Disease;Dementia," Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc., since the quantitative PET data analysis is based on anatomic criteria that are established uniquely for each subject by registration to his/her MRI."
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,"Severe visual, auditory, social, or cognitive impairment"
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,"Dementia-related disorder other than AD or vascular dementia (eg, Parkinson's disease, Huntington's disease, frontotemporal dementia, schizophrenia, Lewy body dementia)"
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,"Symptomatic large-vessel disease, symptomatic carotid artery disease, large vessel infarcts, or strategic lacunar infarcts or infarctsgreater than 15 mm"
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,History of significant central nervous system (CNS) trauma that has affected brain function
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,"Low blood pressure (BP), defined as systolic BP 90 mmHg or diastolic BP 60 mmHg."
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Orthostatic hypotension.
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Unable to undergo MRI
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Unable to undergo lumbar puncture procedure
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Unable to participate in electroencephalography (EEG) protocol due to hearing impairment or inability to tolerate EEG cap or headphones
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Uncontrolled or unstable chronic disease
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Kidney impairment requiring dialysis; history of renal transplant
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Needs continuous direct medical care and nursing supervision.
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Family history of short QT syndrome or long QT syndrome
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Clinically significant cardiac involvement
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,"History of cancer. Exceptions: localized cutaneous basal or squamous cell carcinoma in the last 5 years, low-grade localized prostate/cervical cancers, or previous localized prostate/cervical cancers that have a low likelihood of recurrence"
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease,Is not suited for study participation in the clinical judgment of the investigator
NCT04798989,Phase 2,Alzheimer's Disease With Vascular Pathology,Cyclerion Therapeutics,unknown,Alzheimer Disease," Additional inclusion and exclusion criteria apply, per protocol."
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," Unstable medical illnesses including hepatic insufficiency (elevated ALT, AST, or GGT; or low albumin attributable to liver disease), renal insufficiency (CK-EPI stage 4 or higher, or estimated GFR less than 30)"
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," Unstable ischemic cardiovascular disease, respiratory failure, moderate or severe congestive heart failure - New York Heart Association class III or IV, cancer, unstable hematologic disease or a life expectancy of less than 3 years"
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Use of experimental AD treatments
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," Unable to undergo MRI scanning (e.g. pacemaker, metallic implants, severe claustrophobia)"
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," History of chronic psychiatric illness (e.g. schizophrenia), any episode of major depression within last 2 years, or current Geriatric Depression Scale (GDS) greater than  6, any recent suicide attempts or suicidal ideation. Subjects with a diagnosis of bipolar disorder may be included if they have been clinically stable for a minimum of 3 years prior to the Screening visit. Clinical stability to be determined by the Principal Investigator."
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," History of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis), head trauma resulting in any persistent cognitive deficit"
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, History of alcohol or drug abuse/dependence within the past 5 years
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Known allergy to chemically related compounds (e.g. clotrimazole)
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," Lack of good venous access, such that multiple blood draws would be precluded"
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," Regular use of any of these CNS active medications: benzodiazepines, antipsychotics, narcotics, or anti-epileptic drugs. Exceptions may be allowed by the Principal Investigator for regular use of low doses of CNS active medications. Subjects using any of these treatments will be instructed to hold their dose on the evening prior and the day of the efficacy visits (Baseline, Week 26 and Week 52). Stable doses (greater than  6 weeks) of cholinesterase inhibitors or memantine will be allowed, as will stable doses of anti-depressants."
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Female subjects who are pregnant or breastfeeding or who plan to become pregnant during participation in this trial
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Inability to swallow oral tablets
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Exclusions for Cerebrospinal Fluid (CSF) Sub-study:
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," History of bleeding diathesis or coagulopathy,"
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," On anticoagulant therapy (within 14 days of lumbar puncture (LP), including but not limited to warfarin, heparin, dabigatran, rivaroxaban, and apixaban,"
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," Requires daily antiplatelet therapy, including but not limited to aspirin (unless less than  81mg/day), clopidogrel, dipyridamole, and ticlopiidinegrel. However, the investigators will not exclude those who can safely hold antiplatelet therapy for 7 days prior to LP. Safety will be determined by the participant's Primary Care Provider and study PI."
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," For those who take antiplatelet therapy intermittently (e.g. aspirin as needed for pain), the investigators will exclude any doses within 48 hours of the LP or more than two dosses within 7 days of LP."
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," platelet count less than the lower limit of normal (platelet counts between 100,000 and 150,000 mm3 are permissible as long as the investigator confirms there is no evidence of current bleeding diathesis or coagulopathy)"
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, The investigators will require INR/PT and aPTT labs to be done within 14 days of LP and will exclude those with INR greater than  1.30 or abnormally elevated aPTT.
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Exclusions for PET Sub-Study:
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction," Does not have good venous access, such that multiple blood draws would be precluded"
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Prior radiation exposure of greater than  2 rem total within last 12 months.
NCT04804241,Phase 2,Alzheimer Disease,"University of California, Davis",unknown,Alzheimer Disease;Cognitive Dysfunction, Probable AD dementia patients with a global cortical SUVr less than  1.08.
NCT04840979,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Past or present history of certain brain disorders other than MCI or AD.
NCT04840979,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Certain significant medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries."
NCT04840979,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Contraindication to MRI scanning
NCT04840979,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.)."
NCT04840979,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Exposure to research related radiation in the past year that, when combined with this study, would place subjects above the allowable limits."
NCT04840979,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Participation in the last year in a clinical trial for a disease modifying drug for AD.
NCT04840979,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Inability to have a catheter in subject's vein for the injection of radioligand.
NCT04840979,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,Inability to have blood drawn from subject's veins.
NCT04840979,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Taking anticoagulant (e.g., warfarin) or immunosuppressive/immunomodulatory medication. Nonsteroidal anti-inflammatory drugs (NSAIDs) are not exclusionary. Use of steroids in the 30 days preceding the PET scan."
NCT04840979,Phase 2,Alzheimer Disease,William Charles Kreisl,unknown,Alzheimer Disease,"Having a diagnosis of a chronic inflammatory disease (for example, multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, psoriasis, systemic lupus erythematosus) or a chronic infectious disease such as H.I.V."
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine," Non-Alzheimer primary dementia diagnosis (e.g., vascular dementia, Lewy body dementia, frontotemporal dementia, vitamin B-12 deficiency, hypothyroidism)."
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine," Diagnosis of any of the following conditions; major depression, delirium, alcohol or psychoactive substance abuse or dependency, schizophrenia, or delusional disorder as defined by Diagnostic and Statistical Manual (DSM)-IV."
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine, Diagnosis of systemic illnesses that would interfere with participation in the study or decrease the life expectancy to less than one year.
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine, Currently being treated with hydralazine or a history of intolerance to oral therapy with hydralazine
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine," Any intravenous treatment for heart failure, except IV furosemide (e.g. IV inotropes, pressors, nitrates or nesiritide) at the time of screening."
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine," Systolic blood pressure less than 100 mmHg, reversible etiology of acute heart failure such as myocarditis, acute myocardial infarction-over the past 4 weeks, arrhythmia and existence of pacing device (Acute myocardial infarction is defined as symptoms and major electrocardiogram (ECG) changes (i.e., ST segment elevations), and arrhythmia includes unstable heart rates above 120/min or below 50/min)."
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine, Existence of severe congenital heart disease (such as uncorrected tetralogy of fallot or transposition of the aorta) and severe aortic or mitral stenosis or severe rheumatic mitral regurgitation.
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine," Concurrent use of phosphodiesterase type 5 (PDE5) inhibitors (e.g. Viagra, Etc.)"
NCT04842552,Phase 3,Alzheimer Disease,Shahid Sadoughi University of Medical Sciences and Health Services,unknown,Alzheimer Disease;Hydralazine," Cardiac revascularization within the last 3 months or likelihood of requiring coronary revascularization within the study period. eGFR (Glomerular Filtration Rate) less than  15ml/min/1.73m2, or on regular dialysis, or planned dialysis within the study period."
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease," For women, pregnant, lactating or breastfeeding, or intention to become pregnant"
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease," Evidence of unstable or untreated clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, alternative neurological, immunodeficiency, pulmonary, or other disorder or disease."
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease," Stable, treated chronic medical conditions like hypertension, hypercholesterolemia, diabetes mellitus, non-metastatic dermatologic or prostatic cancer, etc. are acceptable as long as they do not, in the study investigator's opinion, contribute to cognitive dysfunction or limit participation in study procedures."
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease, Any illness or other consideration that makes it unlikely that the subject will be able to complete the 24-month study.
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease, Current or prior history (within past 5 years) of significant alcohol or substance abuse as determined by the investigator.
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease," Psychiatric disorders that may interfere with the study including current major Axis I DSM-V disorders including but not limited to severe Major depression, current or history of bipolar I disorder, or schizophrenia."
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease," Current use of the anti-seizure medication Levetiracetam, also known as Keppra, Spritam or Roweepra"
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease," MRI exclusion criteria include findings from previous MRI's within the ADRC/WRAP research program that may be responsible for neurologic status of the subject such as evidence of cerebrovascular disease with multiple infarcts, infectious disease, space-occupying lesion, normal pressure hydrocephalus, CNS trauma, or any other structural abnormality that may impact cognition or image analysis, as judged by the investigator."
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease," MRI-incompatible implants or devices such as certain cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI that prevents completion of MRI protocol."
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease, Lack of decisional capacity at the time of informed consent
NCT04871074,Phase 2,Alzheimer Disease,"University of Wisconsin, Madison",unknown,Alzheimer Disease," Lumbar puncture exclusion criteria include: previous lumbar spine surgery, currently taking blood-thinning anti-platelet medications, taking immunosuppressive medications, currently being treated or were recently treated for an infection or virus within the last 2 to 3 months."
NCT04886063,Phase 2,Alzheimer Disease,Athira Pharma,unknown,Alzheimer Disease," Subject has experienced a serious adverse event during the parent study, which could present an increased safety risk during the open label extension."
NCT04886063,Phase 2,Alzheimer Disease,Athira Pharma,unknown,Alzheimer Disease, New diagnosis of severe major depressive disorder even without psychotic features.
NCT04886063,Phase 2,Alzheimer Disease,Athira Pharma,unknown,Alzheimer Disease, Any subject with formalized delusions or hallucinations.
NCT04886063,Phase 2,Alzheimer Disease,Athira Pharma,unknown,Alzheimer Disease, Significant suicide risk.
NCT04886063,Phase 2,Alzheimer Disease,Athira Pharma,unknown,Alzheimer Disease," Newly-diagnosed malignant tumor, except for the following conditions that are stable in the judgement of the investigator:"
NCT04886063,Phase 2,Alzheimer Disease,Athira Pharma,unknown,Alzheimer Disease," Adequately treated squamous and basal cell carcinoma, or squamous and basal cell carcinoma in situ"
NCT04886063,Phase 2,Alzheimer Disease,Athira Pharma,unknown,Alzheimer Disease, Prostate carcinoma in situ
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Individuals with a first degree relative diagnosed with AD before 55 years of age.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, BMI 35.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Is unable to read/write at a 6th grade level.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Is a prisoner.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Modified Hachinski Ischemic Score greater than 4.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Other neurological or psychiatric condition (other than AD) that can impact cognition, as well as atypical presentations of AD and AD related dementias, including logopenic primary progressive aphasia (PPA), or posterior cortical atrophy (PCA); or, CT/MRI evidence of potentially significant intracranial abnormalities not related to AD (e.g., evidence of major stroke or lacune in an area critical to cognition, infections, cancer, hydrocephalus, multiple sclerosis, etc.); or abnormal CSF not consistent with AD."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Presence of current, serious mood or anxiety disorder, and/or a psychotic disorder, and/or a substance-related disorder according to Diagnostic and Statistical Manual of Psychiatric Disorders, Edition IV, text revision (DSM-IV-TR) or DSM-V that, in the opinion of the Principal Investigator, might impact cognitive assessment, affect participants ability to complete the study, or confound interpretation of the study drug effect; or is considered suicidal or shows suicidal ideation as assessed by the study physician"
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," History of deep vein thrombosis, pulmonary embolism, familial predisposition for deep vein thrombosis, or pulmonary embolism."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Active cancer / malignant neoplasm within 5 years of screening other than non-melanoma skin cancers (e.g. Basal cell or squamous cell). Previous diagnosis of Leukemia, despite remission state or length of time, is considered exclusionary."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, History of a latex or yeast allergy.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Presence/history of drug hypersensitivity; or known hypersensitivity to sargramostim, yeast-derived products, any other component of the product, or benzyl alcohol (present in bacteriostatic water or saline for injection)."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," History of asplenia, hyposplenia, or splenectomy"
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," History of, or treatment for, an autoimmune disease (e.g. Rheumatoid Arthritis, Multiple Sclerosis, Myasthenia Gravis, etc.)."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Untreated or unstable medical condition that could interfere with the study assessments in the opinion of the study physician, or may require immune-stimulating, immune-suppressive, or immune-modulating treatment(s) during the conduct of the study."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, History of seizures (except infant febrile seizures).
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Pregnant or breastfeeding female, or female of childbearing potential and not protected by highly effective contraceptive method of birth control (i.e., oral or depot contraceptives or intrauterine device (IUD) or participant was surgically sterilized) and/or unwilling or unable to be tested for pregnancy; Male refusing to use condoms, if partner can get pregnant."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, MRI evidence of greater than 4 micro-hemorrhages; participants who may be prone to spontaneous ARIA-H and/or may be more susceptible to adverse effects of the ARIA-H.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Laboratory results that are, in the judgement of the investigator, indicative of an untreated medical or hematologic condition that could increase risk or interfere with study assessments"
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Evidence of:
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Clinically significant pre-existing fluid retention (clinical or radiological);
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," respiratory symptoms (e.g., dyspnea), moderate-to-severe lung disease (e.g. COPD, pulmonary infiltrates)"
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," cardiovascular symptoms or electrocardiographic evidence of cardiac disease that warrant therapeutic intervention (e.g., congestive heart failure, supraventricular arrhythmia, heart block, uncontrolled atrial fibrillation, etc.)"
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," a resting pulse less than 50, as reviewed by the study physician;"
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," prolonged QTc interval greater than 470 ms in females, 450 ms in males)."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, screening blood pressure measurement of greater than 160 systolic and/or 95 diastolic
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Known renal dysfunction or serum creatinine greater than 150 mol/L, or Glomerular Filtration Rate (GFR) less than 55 ml/min"
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Known hepatic dysfunction (apart from Gilbert's syndrome) or serum ALT 3 times the upper limit of normal (ULN)
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Positive serology for hepatitis B surface antigen (HBs Ag), anti-hepatitis C virus (anti-HCV), anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab) or spirochetal infection (e.g. syphilis)"
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Contraindication to lumbar dural puncture, including coagulopathy, concomitant anticoagulation therapy (except daily 81 mg aspirin), prior spinal surgery, significant deformity of the lumbar/sacral region, or any other factor that, in the opinion of the investigator, precludes safe LP procedure."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Contraindication or inability to complete magnetic resonance imaging (e.g., cardiac pacemaker/defibrillator, ferromagnetic metal implants) or PET scan."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Sensitivity to fluorodeoxyglucose F 18
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Having past or planned exposure to ionizing radiation that would, together with the radiation resulting from the administrations of the PET tracer(s) used in this study, exceed applicable institutional, local, or national recommendations for annual or lifetime exposure."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Poor venous access.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Chronic use of no-n-steroidal anti-inflammatory drugs (NSAIDs), excepting 81 mg daily aspirin therapy."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Chronic use of an anti-cholinergic drug(s)
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Taking any prohibited medication or therapy
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Be the recipient of an investigational drug within 60 days of screening, or within 5 times the elimination half-life of that drug, whichever is the longest."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim," Prior treatment with an investigational anti-amyloid or anti-tauopathy therapy, or AD vaccine, unless it can be documented that they were on placebo."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Participation in the treatment phase of an investigational sargramostim clinical trial within 6-months of screening.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim, Any interested participant who:
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim,"Is in the judgement of the Principal Investigator likely to be non-compliant with study protocol, including, but not limited to, leaving the area of the study for any extended period; or separate from the designated caregiver/informant, without acceptable replacement, for any of the scheduled assessment visits during the study."
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim,Is unable to cooperate because of a language problem or because of a developmental disability.
NCT04902703,Phase 2,Alzheimer Disease,"University of Colorado, Denver",unknown,Alzheimer Disease;Molgramostim;Sargramostim,"Oversees or implements any aspect of the study, or is employed by Partner Therapeutics or its affiliates or subsidiaries, or is an employee of the University of Colorado Alzheimer's and Cognition Center and is engaged in the conduct of the study, or first degree relative of such."
NCT04926272,Phase 2,Alzheimer's Disease,First Affiliated Hospital of Fujian Medical University,unknown,Alzheimer Disease," Nervous system diseases: including brain tumors, craniocerebral trauma, multiple sclerosis, epilepsy, etc.;"
NCT04926272,Phase 2,Alzheimer's Disease,First Affiliated Hospital of Fujian Medical University,unknown,Alzheimer Disease," Psychiatric disorders: including anxiety disorder, affective disorder, severe psychosis, or drug-induced psychosis;"
NCT04926272,Phase 2,Alzheimer's Disease,First Affiliated Hospital of Fujian Medical University,unknown,Alzheimer Disease, Pregnancy or lactation.
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Clinically significant illness that required medical treatment within 8 weeks before the first dose or a clinically significant infection that required medical treatment within 4 weeks before first dose
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Females who are breastfeeding or pregnant at Screening or Baseline
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Females of childbearing potential who:
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction," Within 3 months before screening, did not use a highly effective method of contraception"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's Alzheimer's disease (AD)
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"History of transient ischemic attacks, stroke, or seizures within 12 months of Screening"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"History of clinically important carotid or vertebrobasilar stenosis, plaque, or other prominent risk factor for stroke or cerebral haemorrhage (including atrial fibrillation and anticoagulation). Low dose aspirin (less than or equal to [less than =] 325 milligram [mg] daily) is not exclusionary"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"Any current psychiatric diagnosis or symptoms, (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Geriatric Depression Scale (GDS) score greater than or equal to 8 at Screening
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"Contraindications to MRI scanning, including but not limited to pacemaker/cardiac defibrillator, neurostimulators, ferromagnetic metal implants (example, in skull and cardiac devices other than those approved as safe for use in MRI scanners)"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Evidence of other clinically significant lesions on brain MRI at Screening that could indicate a dementia diagnosis other than AD
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Other significant pathological findings on brain MRI at Screening
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"Hypersensitivity to E2814 or any of the excipients, or to any monoclonal antibody (mAb) treatment"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"Any immunological disease which is not adequately controlled, or which requires treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressants, or plasmapheresis during the study"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"With a bleeding disorder of current chronic use of anticoagulants (example, warfarin, dabigatran, rivaroxaban or apixaban) or of clopidogrel is exclusionary. Limited (occasional or isolated) use of anticoagulants/antiplatelet compounds in cases such as surgical procedures"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Have thyroid stimulating hormone outside of normal range. Other tests of thyroid function with results outside the normal range should only be exclusionary if they are considered clinically significant by the investigator
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Hemoglobin A1c (HgbA1c) greater than (greater than ) 8 percent (%) (retesting is permitted if slightly elevated) or poorly controlled insulin-dependent diabetes (including hypoglycemic episodes). Participants may be rescreened after 3 months to allow optimization of diabetic control
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Abnormally low serum vitamin B12 levels for the testing laboratory
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"History of human immunodeficiency virus (HIV) infection, history of hepatitis B infection within the past year, history of hepatitis C infection which has not been adequately treated, or history of spirochete infection of the central nervous system (example, syphilis, Lyme, or borreliosis)"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or ECG at Screening or Baseline which in the opinion of the investigator require further investigation or treatment or which may interfere with study procedures or safety"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"Malignant neoplasms within 3 years of Screening (except for basal or squamous cell carcinoma in situ of the skin, or localized prostate cancer in male participant, or localized breast cancer in female participants)"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"Answers  yes  to Columbia-Suicide Severity Rating Scale (C-SSRS) suicidal ideation Type 4 or 5, or any suicidal behavior assessment within 6 months before Screening, at Screening, or at the Baseline Visit, or has been hospitalized or treated for any suicidal behavior in lifetime"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Known or suspected history of drug or alcohol abuse or dependence within 2 years before Screening or a positive urine drug test at Screening
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,"Any other medical conditions (example, cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator could affect the participant's safety or interfere with the study assessments"
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Concurrent participation in a clinical study involving any anti-amyloid therapies (including any mAb therapies) within 6 months before Screening
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Concurrent participation in a clinical study involving any anti-tau therapies
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Participated in any other investigational medication or device study in the 3 months or 5 half-lives (whichever is longer) of the medication before Screening
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Planned surgery which requires general anesthesia that would take place during the study
NCT04971733,Phase 1/Phase 2,Alzheimer Disease,Eisai Inc.,unknown,Alzheimer Disease;Cognitive Dysfunction,Visual or hearing impairment that would prevent the participant from performing psychometric tests accurately
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,Abnormalities in vital signs at screening or baseline
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,"Clinically significant abnormal hematology or biochemistry values, as determined by the investigator at screening and/or baseline."
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,"Previous clinically significant systemic illness or infection within the past 4 weeks prior to screening or baseline, as determined by the investigator"
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,Clinically significant ECG abnormalities
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,Use of tobacco- or nicotine-containing products in the past month or unwillingness to abstain during study participation
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,Participation in another clinical study of a drug or device
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,Known allergy to the study drug (Xanamem) or any of the excipients
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,Subjects who are likely to be unable to comply with the study schedule and/ or subjects with an inability to communicate well with the investigator
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,"Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C antibodies at screening"
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,Subjects with a history of drug abuse or addiction in the past 5 years.
NCT04983368,Phase 1/Phase 2,Alzheimer's Disease,Actinogen Medical,unknown,Alzheimer Disease;Cognitive Dysfunction,Evidence of alcohol abuse (defined as greater than 21 standard units per week for males and greater than 14 standard units per week for females)
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",A diagnosis of dementia other than Alzheimer's disease (AD)
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",History of a clinically significant stroke
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc","Current evidence or history in past two years of epilepsy, head injury with loss of consciousness, any major psychiatric disorder including psychosis, major depression, bipolar disorder"
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",Diabetes (type I or type II) insulin-dependent and non-insulin-dependent diabetes mellitus
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",Current or past regular use of insulin or any other anti-diabetic medication within 2 months of screening visit
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",History of seizure within past five years
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",Pregnancy or possible pregnancy
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",Use of anticoagulants
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",Residence in a skilled nursing facility at screening
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc",Use of an investigational agent within two months of screening visit
NCT05006599,Phase 2,"Alzheimer Disease, Early Onset",Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc","Regular use of alcohol, narcotics, anticonvulsants, anti-parkinsonian medications, or any other exclusionary medications (exceptions may be made on a case by case basis by the study physician)"
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Mild cognitive impairment or dementia, or significant other neurodegenerative disease that can affect cognition."
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease that could interfere with the analysis of the study or a life expectancy of approximately 5 years."
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, History of cancer with high risk of recurrence and preventing completion of the trial.
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease," History of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis)."
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Have any clinically important abnormality at screening on magnetic resonance imaging (MRI) or clinical laboratory test results that could be detrimental to the participant or study integrity.
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Have any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker."
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Have a centrally read MRI demonstrating presence of amyloid-related imaging abnormalities (ARIA-E), greater than 4 cerebral microhemorrhages, more than 1 area of superficial siderosis, any macrohemorrhage or severe white matter disease at screening."
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Have had prior treatment with a passive anti-amyloid immunotherapy less than 5 half-lives prior to randomization.
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Have received active immunization against amyloid beta (A) in any other study.
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Have received active immunization against A in any other study.
NCT05026866,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Current or previous use of prescription medications used as treatment for mild cognitive impairment (MCI) or AD.
NCT05063539,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Contraindication to MRI or PET scans
NCT05063539,Phase 2,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Have known allergies to LY3372689, related compounds, or any components of the formulations"
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,A current clinical condition or requires a medication that raises the pH of their urine.
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,Severe renal or hepatic impairment.
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,"Any other abnormality that could cause a possible cognitive deficit (including, but not limited to, vascular encephalopathy or large strokes)."
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,"Contraindications for MRI (e.g., prostheses, implants, claustrophobia, pacemaker) or PET imaging."
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,Neurodegenerative disorder known to cause neurocognitive decline
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,"Relevant history of or current neurological disease other than preclinical AD, which may make interpretation of possible new neurological signs or symptoms difficult."
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,"Clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine, or cardiovascular system disease"
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,Ongoing cancer treatment
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,Clinically significant and active psychiatric disorder
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,Use of an investigational medical device within 3 months before the planned start of study.
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,Current participation in an interventional study with an investigational drug component.
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,"Major surgery (e.g., requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgery, or has major surgery planned during the time the subject is expected to participate in the study."
NCT05063851,Phase 2,Alzheimer Disease,University of Virginia,unknown,Alzheimer Disease;Memantine,"Requires treatment with an AChE inhibitor or any of the following: acetazolamide, methazolamide, amantadine, ketamine, dextromethorphan."
NCT05074498,Phase 1/Phase 2,Alzheimer's Disease,"TrueBinding, Inc.",unknown,Alzheimer Disease," Any medical or neurological condition other than AD that in the opinion of the investigator could be a contributing cause of the participant's dementia (e.g., medication use, vitamin B12 deficiency, abnormal thyroid function, stroke or other cerebrovascular condition, diffuse Lewy body disease, head trauma)"
NCT05074498,Phase 1/Phase 2,Alzheimer's Disease,"TrueBinding, Inc.",unknown,Alzheimer Disease," History within the past 6 months or evidence of clinically significant psychiatric illness (e.g., major depression, schizophrenia, or bipolar affective disorder)"
NCT05074498,Phase 1/Phase 2,Alzheimer's Disease,"TrueBinding, Inc.",unknown,Alzheimer Disease," Diagnosis of a dementia-related central nervous system (CNS) disease other than AD (e.g., Parkinson's Disease, Huntington's Disease, frontotemporal dementia, multi-infarct dementia, dementia with Lewy bodies, normal pressure hydrocephalus)"
NCT05074498,Phase 1/Phase 2,Alzheimer's Disease,"TrueBinding, Inc.",unknown,Alzheimer Disease," Identification of other known cause of dementia or any other clinically significant contributing co-morbid pathologies at screening magnetic resonance imaging (MRI), in the opinion of the investigator"
NCT05074498,Phase 1/Phase 2,Alzheimer's Disease,"TrueBinding, Inc.",unknown,Alzheimer Disease," Participation in any other drug, biologic, device, or clinical study or treatment with any investigational drug or approved therapy for investigational use within 30 days (or 5 half lives, whichever is longer) prior to screening, and/or participation in any other clinical study involving experimental medications for AD within the 60 days (or 5 half lives, whichever is longer) prior to screening"
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",A diagnosis of dementia other than Alzheimer's disease (AD)
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",History of a clinically significant stroke
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin","Current evidence or history in past two years of epilepsy, head injury with loss of consciousness, any major psychiatric disorder including psychosis, major depression, bipolar disorder"
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",Diabetes (type I or type II) insulin-dependent and non-insulin-dependent diabetes mellitus
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",Current or past regular use of insulin or any other anti-diabetic medication within 2 months of screening visit
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",History of seizure within past five years
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",Pregnancy or possible pregnancy
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",Use of anticoagulants
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",Residence in a skilled nursing facility at screening
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin",Use of an investigational agent within two months of screening visit
NCT05081219,Phase 2,Alzheimer Disease,Wake Forest University Health Sciences,unknown,"Alzheimer Disease;Cognitive Dysfunction;Insulin;Insulin, Globin Zinc;Empagliflozin","Regular use of alcohol, narcotics, anticonvulsants, anti-parkinsonian medications, or any other exclusionary medications (exceptions may be made on a case by case basis by the study physician)"
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction," Significant neurological disease affecting the central nervous system (other than AD), that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, history of transient ischemic attack or stroke, or epilepsy or recurrent seizures (except febrile childhood seizures)."
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction," Current serious or unstable medical illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, psychiatric (including actively suicidal or deemed at risk of suicide, or current alcohol or substance abuse), immunologic, infectious, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of approximately"
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction, 24 months.
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction," History of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis)."
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction, History of bleeding disorder or use of medications with platelet anti-aggregant or anti-coagulant properties (unless aspirin at 325 milligram (mg).
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction, Have had prior or current treatment with donanemab or aducanumab
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction," Have known allergies to donanemab or aducanumab, related compounds, or any components of the formulation"
NCT05108922,Phase 3,Alzheimer Disease,Eli Lilly and Company,unknown,Alzheimer Disease;Cognitive Dysfunction, Prior or current participation in any immunotherapy study targeting Amyloid beta
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Subjects who are on anti-amyloid therapy (i.e. vaccine or antibody) or who were receiving anti-amyloid vaccines (i.e. aducunamab) or anti-tau vaccines less than 3 months before Screening.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Women of childbearing potential (WCBP). NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing)."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the subject's AD.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Any psychiatric diagnosis or symptoms, (e.g., hallucinations, major depression, or delusions) that could interfere with study procedures in the subject."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Geriatric Depression Scale (GDS) score greater than or equal to 8 at Screening.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (e.g., in skull and cardiac devices other than those approved as safe for use in MRI scanners)."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Evidence of other clinically significant lesions on brain MRI that could indicate a dementia diagnosis other than AD.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Other significant pathological findings on brain MRI, including but not limited to: more than 4 micro hemorrhages (defined as 10mm or less at the greatest diameter); a single macro hemorrhage greater than 10mm at greatest diameter; an area of superficial siderosis; evidence of vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions; evidence of multiple lacunar infarcts or stroke involving a major vascular territory, severe small vessel, or white matter disease; space occupying lesions; or brain tumors (however, lesions diagnosed as meningiomas or arachnoid cysts and less than 1cm at their greatest diameter need not be exclusionary)."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Patients with hypokalemia, hypomagnesaemia, or long QT syndrome- QTc481 ms"
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Concomitant drugs known to prolong the QTc interval and history of any cardiovascular disease, including myocardial infraction or cardiac failure, angina, arrhythmia"
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Presence of cardiac conditions including:
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Cardiovascular or cerebrovascular event (e.g. myocardial infarction, unstable angina, or stroke)"
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Congestive heart failure
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Second- or third-degree atrioventricular block, sick sinus syndrome, or other serious cardiac rhythm disturbances"
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Any history of Torsade de Pointes
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Treatment with any of the following drugs at the time of Screening or the preceding 30 days, and/or planned use over the course of the trial:"
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Treatment with Class IA or III antiarrhythmic drugs (e.g. quinidine)
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Treatment with QT prolonging drugs (www.crediblemeds.org)- excluding Selective Serotonin Reuptake Inhibitors (SSRIs) (e.g. Citalopram, Paxil, Zoloft, Cymbalta, Sertraline, etc...)"
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Strong CYP3A4 inhibitors (including grapefruit juice). The concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) must be avoided. Grapefruit products may also increase serum concentrations of Nilotinib (Tasigna). Should treatment with any of these agents be required, therapy with Nilotinib BE should be interrupted."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Anticoagulants, including Coumadin (warfarin), heparin, enoxaparin, daltiparin, xarelto, etc."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"St. John's Wort and the concomitant use of strong other CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital) must be avoided since these agents may reduce the concentration of Nilotinib."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Any immunological disease which is not adequately controlled, or which requires treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressant's, or plasmapheresis during the study."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Subjects with a bleeding disorder that is not under adequate control (including a platelet count less than 50,000 or international normalized ratio [INR] greater than 1.5 for subjects who are not on anticoagulant treatment, e.g., warfarin). Subjects who are on anticoagulant therapy should have their anticoagulant status optimized and be on a stable dose for 4 weeks before Screening."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Have thyroid stimulating hormone above normal range. Other tests of thyroid function with results outside the normal range should only be exclusionary if they are considered clinically significant by the investigator. This applies to all subjects whether or not they are taking thyroid supplements.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Abnormally low serum vitamin B12 levels for the testing laboratory (if subject is taking vitamin B12 injections, level should be at or above the lower limit of normal [LLN] for the testing laboratory)."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Known to be human immunodeficiency virus (HIV) positive.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or ECG at Screening or Baseline which in the opinion of the investigator require further investigation or treatment or which may interfere with study procedures or safety."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Subjects with malignant neoplasms within 3 years of Screening (except for basal or squamous cell carcinoma in situ of the skin, or localized prostate cancer in male subjects). Subjects who had malignant neoplasms but who have had at least 3 years of documented uninterrupted remission before Screening need not be excluded."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Answer  yes  to C-SSRS suicidal ideation Type 4 or 5, or any suicidal behavior assessment within 6 months before Screening, at Screening, or at the Baseline Visit, or has been hospitalized or treated for suicidal behavior in the past 5 years before Screening."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Known or suspected history of drug or alcohol abuse or dependence within 2 years before Screening.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Any other medical conditions (e.g., cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator(s) could affect the subject's safety or interfere with the study assessments."
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Subjects who are taking prohibited medications.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Participation in a clinical study involving any anti-amyloid therapies (including any monoclonal antibody therapies and any -site amyloid precursor protein cleaving enzyme [BACE] inhibitor therapies) unless it can be documented that the subject only received placebo.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Subjects who were dosed in a clinical study involving any new chemical entities for AD within 3 months prior to Screening unless it can be documented that the subject only received placebo.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Participated in any other investigational medication or device study in the 8 weeks or 5 half-lives (whichever is longer) of the medication before randomization unless it can be documented that the subject only received placebo.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Planned surgery which requires general anesthesia that would take place during the study. Planned surgery which requires only local anesthesia and which can be undertaken as day case without inpatient stay postoperatively need not result in exclusion if in the opinion of the investigator this operation does not interfere with study procedures and subject safety.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Severe visual or hearing impairment that would prevent the subject from performing psychometric tests accurately.
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,"Any concomitant medication or medication excluded that could put subject at risk, or interfere with study evaluations"
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease,Exclusion criteria specific for the biomarker sub-study:
NCT05143528,Phase 3,Alzheimer Disease,"KeifeRx, LLC",unknown,Alzheimer Disease," Contraindications to LP: prior lumbosacral spine surgery, severe degenerative joint disease or deformity of the spine, platelets less than  100,000, use of Coumadin/warfarin, or history of a bleeding disorder."
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease," Other than AD, disorder that may impair cognition"
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, Contra-indication for MRI
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease," History of neurological, psychiatric or mental conditions;"
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, history stroke
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, MI
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, Type 1 diabetes  and  Type 2 with HbA1cgreater than 8%
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, BP greater than  150/90 mmHg
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, renal or hepatic impaired
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, hyperaldosteronism
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, cancer
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, depression
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, laboratory abnormalities
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, not able to undergo lumbar puncture
NCT05161715,Phase 2,Early Alzheimer's Disease,NewAmsterdam Pharma,unknown,Alzheimer Disease, taking certain medications including lipid altering
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Any other cause of dementia shown by MRI/CT findings within 2 years of screening and neurological examination at screening and Day 1.
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Possible, probable, or definite vascular dementia according to the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherch et l'Enseignement en Neurosciences (NINDS-AIREN) criteria."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Evidence of significant abnormality that would suggest another potential etiology for dementia (eg, evidence of cerebral contusion, encephalomalacia, aneurysm, vascular malformation, greater than 5 microhemorrhages, macrohemorrhage, single infarct greater than 1 cm3)."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Other central nervous system diseases that may cause cognitive impairment (eg, cerebrovascular disease including cerebrovascular dementia, Parkinsonism, Huntington's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, Creutzfeldt-Jakob disease)."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Concurrent or history of clinically significant psychiatric conditions (eg, schizophrenia or bipolar affective disorder) that in the Investigator's opinion prevents the participant from participating, or is likely to confound interpretation of drug effect or affect cognitive assessments."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Vitamin B12, folic acid, syphilis serology, and thyroid stimulating hormone (TSH) results that are thought to contribute to the severity of dementia or cause dementia. Participants may be enrolled if in the Investigator's medical judgment, the abnormal laboratory values are not the cause of the cognitive symptoms."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"History of known or suspected seizures including febrile seizures (excluding self-limited childhood febrile seizures), a history of significant head trauma with loss of consciousness or recent unconsciousness that is not explained."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Acute or unstable cardiovascular disease, active peptic ulcer, uncontrolled hypertension, uncontrolled diabetes or insulin dependent patients or any medical condition that may interfere with the completion of the clinical study."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Known allergies, hypersensitivity, or intolerance to GV1001 or similar products or excipients."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"History of alcohol, substance abuse or dependence as per DSM-V criteria (except nicotine dependence) within the last 2 years."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Concurrent malignancies or invasive cancers diagnosed within the past 5 years except for non-metastatic basal cell carcinoma or squamous cell carcinoma of skin, in situ carcinoma of the uterine cervix or non-metastatic prostate cancer."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Sexually-active WOCBP or man capable of fathering a child who do not consent to using medicinally acceptable contraception (such as surgical sterilization, intrauterine contraceptive device, condom or diaphragm, an injectable or inserted contraceptive) during the study and for 3 months after the last dose of study treatment."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Pregnant, breast feeding, or planning a pregnancy or fathering a child while enrolled in the study or for 3 months after the last dose of study treatment."
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Use of anxiolytics, narcotics, or sleep aids in a manner that would interfere with cognitive testing, in the opinion of the Investigator. Atypical antipsychotics may be used at the discretion of the Investigator. Tricyclic antidepressants and monoamine oxidase (MAO) inhibitors are prohibited"
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Previous treatment with GV1001.
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Received an investigational product for AD within the last 6 months.
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Participated in another clinical study within 4 weeks prior to this study.
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Treated with aducanumab or participated in a clinical study with aducanumab.
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Renal impairment (creatinine clearance [CrCL] less than 30 mL/min).
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Severe liver dysfunction (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] greater than 2 times the upper limit of normal [ULN]).
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Body weight 35 kg.
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Resides in a moderate to high dependency continuous care facility (residence in low grade assisted living facility where there is sufficient autonomy to permit valid evaluation of activities of daily living is allowed).
NCT05189210,Phase 2,Mild to Moderate Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Any other reason that in the opinion of the Investigator would make the participant ineligible to participate or to complete this study.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,"Presence of clinically significant disorders of the central nervous system other than Alzheimer's disease, such as Lewy Body Disease, Parkinson's disease, hydrocephalus, epilepsy, demyelinating disease, brain tumors, or psychiatric disorders (such as schizophrenia, or severe affective disorders)."
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,"Serious or unstable hematologic, hepatic, renal, pulmonary, cardiac, or other medical disease."
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Abnormal liver function tests (ALT or AST) or creatine kinase (CK) upon repeat testing.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,"Chronic hepatitis B or C infection, indicated by positive HBSAg, or HCV-Ab with HCV RNA presence."
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Known history of human immunodeficiency virus (HIV) infection.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Known immune disorder that has a history of requiring treatment with immunosuppressive drugs within the past 1 year.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Have a drug or alcohol abuse within 12 months prior to screening.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Clinically significant laboratory abnormalities at screening.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,"Screening ECG showing repeated QTcF greater than  480 msec, or other clinically significant ECG abnormalities."
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,"Clinically significant structural brain abnormalities, such as hydrocephalus or intra-axial brain tumors."
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,"Participation in another investigational study within 30 days or 5 half-lives prior to screening, whichever is greater."
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,Participation in another study that would have cognitive testing during the duration of this study.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,History of Covid19 or other viral infections within 3 months.
NCT05194163,Phase 2,Alzheimer Disease,Neurokine Therapeutics,unknown,Alzheimer Disease,"Have a clinically significant medical, surgical, laboratory, or behavioral abnormality, which in the judgment of the Investigator makes the subject unsuitable for the study."
NCT05227820,Phase 2,Alzheimer Disease,Neurological Associates of West Los Angeles,unknown,Alzheimer Disease;Dementia," In order for a subject to be considered for this study, he/she may NOT have any of the following:"
NCT05227820,Phase 2,Alzheimer Disease,Neurological Associates of West Los Angeles,unknown,Alzheimer Disease;Dementia," Subjects with contraindications for lumbar puncture, such as bleeding abnormalities, use of anticoagulant medications, and local skin or spine abnormalities"
NCT05227820,Phase 2,Alzheimer Disease,Neurological Associates of West Los Angeles,unknown,Alzheimer Disease;Dementia," Reversible causes of cognitive impairment that explains the clinical status entirely, such as hypothyroidism, depression"
NCT05227820,Phase 2,Alzheimer Disease,Neurological Associates of West Los Angeles,unknown,Alzheimer Disease;Dementia, Advanced stages of any terminal illness or any active cancer that requires chemotherapy
NCT05227820,Phase 2,Alzheimer Disease,Neurological Associates of West Los Angeles,unknown,Alzheimer Disease;Dementia, History of breast cancer
NCT05227820,Phase 2,Alzheimer Disease,Neurological Associates of West Los Angeles,unknown,Alzheimer Disease;Dementia, Women with child-bearing potential who are not willing to use a double-barrier birth control method
NCT05227820,Phase 2,Alzheimer Disease,Neurological Associates of West Los Angeles,unknown,Alzheimer Disease;Dementia, Males not willing to use a double-barrier birth control method with female sex partners with child-bearing potential
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," Diagnosed with frontotemporal dementia (FTD), dementia due to Acquired Immunodeficiency Syndrome (AIDS), Creutzfeldt-Jakob disease (CJD), Lewy Bodies dementia (LBD), Progressive Supranuclear Palsy (PSP), multiple cerebral infarctions, or normal pressure hydrocephalus."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Any other neurodegenerative disease.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, History of a seizure disorder.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Evidence of: a prior macrohemorrhage; at least 4 cerebral microhemorrhages (regardless of anatomical location or diagnostic characterization as  possible  or  definite ); or at least 1 area of superficial siderosis.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," Unwillingness or inability to have MRIs scans (no contrasting agent will be used), or condition that contraindicates MRI, such as the presence metallic objects in the eyes, skin, or heart."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Any conditions that contraindicates PET with a beta-amyloid tracer.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," Significant intestinal malabsorption surgery, e.g., gastric bypass."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Serum B12 and/or folate levels below normal range.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Clinically abnormal free T4 or thyroid-stimulating hormone (TSH).
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Resting blood oxygen saturation less than 93%.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," Resting systolic blood pressure greater than 180 mm Hg, or diastolic blood pressure greater than 110 mm Hg."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," Regularly (greater than  4 weeks) using high-doses of corticosteroids or other steroidal anti-inflammatory medication (e.g., Prednisone) on a regular basis, with the exception of steroidal nasal sprays, asthma inhalers, topical steroids, and hormonal-replacement therapy."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," Regularly (greater than  4 weeks) using anti-cytokine antibody or targeting therapy, e.g., anti-TNF-."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," Be an organ transplant recipient, or have active or expected future listing for any organ/tissue transplant while scheduled to be on trial, except for corneal, bone, skin, ligament, or tendon."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," Diagnosed with malignancy within the past 2 years, with the exception of curatively treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ, or cervical carcinoma."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Known hypersensitivity to dimethyl sulfoxide (DMSO).
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," Test positive for hepatitis B virus surface antigen, viremic hepatitis C virus, HIV, or syphilis."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease, Any condition that is projected to limited life expectancy to less than  12 months.
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," Be pregnant, nursing, or of childbearing potential while not practicing effective contraception."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," Be currently participating in any other investigational therapeutic or device trial, or have participated within one within the previous 30 days to screening, or in the opinion of the investigator, the patient should be excluded for such participation within the past 5 years."
NCT05233774,Phase 2,Mild Alzheimer's Disease,Longeveron Inc.,unknown,Alzheimer Disease," In the opinion of the investigator, the patient has any other illness or condition that: may compromise the participant's safety, compliance, or ability to successfully complete the study; may compromise the validity of the study; or otherwise should exclude the participant from enrollment."
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, Participant in other clinical trial during the last 30 days.
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, Any disorder which in the investigator's opinion might jeopardize subject's safety or compliance with the protocol.
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, Patients whose agitation can be attributed to a somatic disorder (Ex. urinary tract infection or urinary retention)
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, Patient with uncontrolled congestive heart failure.
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol," Patients who get the following medications: opiates, Primidone, Phenobarbitol, carbamazepine, Rifampicin, Rifabutin, Troglitazone and Hypericum perforatum."
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, Male patients who in the opinion of the investigator are at risk of urinary retention due to the anticholinergic proprieties of THC
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol," Subjects with known sensitivity to the active substance dronabinol or to any of the components of the drug (sesame oil, gelatin, glycerol, titanium dioxide"
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, Subjects that previously suffered from cannabinoids' related adverse effects.
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, Subjects with a history of diagnosed Mental or Psychiatric diseases
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol," Patients who in the opinion of the investigator are at risk of falling beyond the risk associated with AD (example: postural hypotension, unstable blood pressure, with or without administration of anti-hypertensive medication, 1 blocker drugs used to treat benign prostatic hyperplasia"
NCT05239390,Phase 2,Alzheimer Disease,The Israeli Medical Center for Alzheimer's,unknown,Alzheimer Disease;Dronabinol, Patients diagnosed with epilepsy
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Declines whole genome screening for 2:107,510,000-107,540,000 polymorphism and APOE4 genotyping."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Patient is 2:107,510,000-107,540,000 polymorphism carrier."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has an alternative cause for dementia other than AD.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," A past or recent CT or MRI scan or report indicating any cortical infarct defined as greater than  1.5 cm3; more than 2 lacunar infracts defined as  1.5 cm3; or diffuse white matter disease), Fazekas score of more than 1 on MRI and number of micro hemorrhages (MCH) to be greater than  4 (more details Appendix 3)."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Patient has evidence of any clinically significant neurodegenerative disease, or other serious neurological disorders other than AD as detailed in Appendix 3,"
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Patient has a concurrent psychiatric disorder that prevents his/her participation in the trial including but not limited to Schizophrenia, Bipolar and related disorders, Substance use disorders within the past 2 years, major depression, etc."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Patient has a history of uncontrolled or untreated cardiovascular, endocrine, gastrointestinal, respiratory, or rheumatologic disorders within the past 5 years."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has a history of severe agitation and medically treated agitation.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has a history of serious infectious disease including:
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Neurosyphilis
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Meningitis
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Encephalitis
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Patient has a history of a primary or recurrent malignant disease that has not been in remission for greater than  5 years prior to the Screening visit, with the exceptions of excised cutaneous squamous cell carcinoma in situ, basal cell carcinoma without recurrences; and history of intraductal breast cancer, cervical carcinoma in situ, or in situ prostate cancer resected over 5 years previously. (For resected in situ prostate cancer, i.e., high grade intraepithelial neoplasia, the patient must have a normal prostate specific antigen [PSA] prior to Screening and no increase in PSA since his resection surgery)."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has severe pain that is likely to interfere with sleep (in the opinion of the investigator).
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Patient has any concomitant documented progressive disease likely to interfere with the conduct of the study, particularly:"
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Liver disease with aspartate aminotransferase (AST), alanine aminotransferase (ALT) or gamma glutamyltransferase (GGT) greater than  3 times the upper limits of normal (ULN)"
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Total bilirubin greater than  3 times the ULN
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Mean corpuscular volume greater than  95 3 if due to chronic alcoholism
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Renal failure with creatinine less than  30 ml / min
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patients that are taking prohibited medications according to Appendix 2 See also section 12.9.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Continuous use of benzodiazepines or other sedative hypnotics during the 2 weeks before Screening (see Section 12.9).
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has a history of chronic use (more than 3 months of continuous use) and abuse of benzodiazepines or other sedative hypnotics.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Use of any kind of melatonin/melatonin agonist during the 2 weeks before Screening (see Section 12.9).
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has known or suspected hypersensitivity to exogenous melatonin or melatonin receptor agonists.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has clinically significant abnormal laboratory findings that have not been approved by the study safety officer.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has persistent bradycardia (heart beat less than  50 bpm) or tachycardia (heart beat greater than  100 bpm).
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Patient has atrioventricular block (type II/Mobitz II and type III), congenital long QT syndrome, sinus node dysfunction or a marked prolongation of QTc interval (repeated demonstration in ECGs of QTc interval greater than  450 msec for males and greater than  470 msec for females using Fridericia's formula: QTc = QT/cube root of RR)."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Patient has other serious diseases that could interfere with patient assessment, in the opinion of the investigator."
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has untreated B12 and/or folic acid deficiency.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient has participated in a clinical trial with any investigational agent within 3 months before Screening. Participants in any former monoclonal antibody clinical trial for AD are not eligible until 6 months after the last visit of the previous study. Patients who have received active vaccine for AD in the past will be excluded.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patient with a body mass index (BMI) above 35 or below 18.
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Lifestyle exclusions:
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patients unwilling to limit alcohol intake to less than 30 g of pure alcohol per day (see Appendix 1) and to abstain after 2000h throughout the study
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patients unwilling to be exposed to at least 2 hours of daylight each day
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Divergence from the accepted level of study medication compliance (70% 130% of expected consumption) as verified at Visit 2 (see Section 12.10)
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia, Patients consuming more than 7 cups of tea or coffee (or equivalent amount of caffeine [650 mg] in other caffeinated beverages) per day
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Patients with an irregular lifestyle or life pattern (e.g., shift workers, patients likely to be jet lagged)"
NCT05267535,Phase 2/Phase 3,Alzheimer's Disease,Neurim Pharmaceuticals Ltd.,unknown,Alzheimer Disease;Dementia," Patients with evidence of serious risk of suicide based on the Columbia-Suicide Severity Rating Scale, i.e., active suicidal ideation with some intent to act, with or without a specific plan (a positive response to Suicidal Ideation Items 4 or 5) in the 6 months prior to Screening, OR with evidence of suicidal behavior in the 2 years prior to Screening (a positive response to any of the 5 Suicidal Behavior Items {actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior}), OR who, in the opinion of the investigator, present a serious risk of suicide."
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"During screening, MRI examination showed significant focal lesions, fulfilling one of the following conditions:"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,  There were more than 2 infarcts with diameter greater than  2 cm at any site;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"  MRI examination showed that there were infarcts with arbitrary diameter in key parts (such as thalamus, hippocampus, entorhinal cortex, paraolfactory cortex, angular gyrus, cortex and other subcortical gray matter nuclei);"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,  Fazekas scale grade of white matter lesions  2;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,  There are other imaging evidences that do not support mild and moderate AD;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"Dementia caused by other reasons: vascular dementia, central nervous system infection, Creutzfeldt Jakob disease, Huntington's disease, Parkinson's disease, Lewy body dementia, traumatic dementia, other physical and chemical factors (such as drug poisoning, alcoholism, carbon monoxide poisoning, etc.), important physical diseases (such as hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial space occupying lesions (such as subdural hematoma, brain tumor), endocrine disorders (such as thyroid disease, parathyroid disease), and vitamin B12, folic acid deficiency or any other known cause;"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"Have suffered from central nervous system diseases (including stroke, optic neuromyelitis, epilepsy, etc.);"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"Subjects who were diagnosed with psychiatric disorders according to DSM-V criteria, including schizophrenia or other mental diseases, bipolar disorder, severe depression or delirium;"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"Abnormal laboratory indexes: liver function (ALT and AST) exceeded 1.5ULN, renal function (CR) exceeded 1.5ULN, and creatine kinase exceeded 2ULN;"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"Untreated hypertensive and hypotensive subjects at screening, or hypertensive subjects with uncontrolled hypertension after treatment; subjects with good blood pressure control after treatment can be determined by the investigator to be suitable for inclusion in this study;"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"Within 1 month of the screening visit, the subject has new or ongoing unstable or serious heart, lung, liver, kidney and hematopoietic diseases according to the judgment of the researcher, and does not meet the conditions for clinical research;"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"Clinically, people with significant allergic reaction history, especially drug allergy history, or known allergy to this product and its excipients;"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"Dyspepsia, esophageal reflux, gastric bleeding or peptic ulcer disease, frequent heartburn ( once a week) or any surgical operation that may affect drug absorption (such as partial / total gastrectomy, partial / total small bowel resection and cholecystectomy) within 6 months before screening;"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,Alcohol or drug abusers;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,Human immunodeficiency virus antibody (ant HIV) and Treponema pallidum antibody (ant TP) are positive;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,Those who are currently using and cannot stop using drugs for Alzheimer's disease;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"Screening for cholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists (NMDA antagonists), mental retardants, antiparkinsonian drugs and opioid analgesics taken within 1 month before the visit;"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,"There are uncorrectable visual and auditory disorders, and the neuropsychological test and scale evaluation cannot be completed;"
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,Female subjects with positive pregnancy test or lactation and subjects unable to take effective contraceptive measures or have family planning;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,Participated in other clinical trials within 3 months before the screening visit;
NCT05269173,Phase 2,Alzheimer Disease,Capital Medical University,unknown,Alzheimer Disease,There are other situations that the researcher believes are not suitable to participate in this study.
NCT05291234,Phase 1/Phase 2,Alzheimer's Disease (AD),AbbVie,unknown,Alzheimer Disease, Clinically significant and/or unstable medical conditions or any other reason that the Investigator determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive ABBV-916.
NCT05291234,Phase 1/Phase 2,Alzheimer's Disease (AD),AbbVie,unknown,Alzheimer Disease," Screening magnetic resonance imaging (MRI) show evidence of intracranial hemorrhage, cerebrovascular aneurysm, arteriovenous malformation, carotid artery occlusion, stroke, or significant abnormality."
NCT05291234,Phase 1/Phase 2,Alzheimer's Disease (AD),AbbVie,unknown,Alzheimer Disease," Significant pathological findings on brain MRI at screening including, but not limited to, evidence of vasogenic edema, 4 or more microhemorrhages, any macrohemorrhages, superficial siderosis, or severe white matter disease."
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who have other causes of dementia as listed below according to CT/MRI test and neurologic examination within 12 months of screening or at the time of screening.
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Subjects with possible, probable or definite vascular dementia according to NINDS-AIREN criteria"
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Subjects with other central nervous system diseases that can cause the impairment of cognitive function (cerebrovascular disease including cerebrovascular dementia, Parkinsonism, Huntington's disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, Creutzfeldt-Jakob disease, etc.)"
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Subjects with neuropathy such as delusion, delirium, epilepsy, etc."
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Subjects who have abnormal test results which are considered to contribute to the severity of their dementia or be the cause of dementia in the vitamin B12, folic acid, the syphilis serology, and the thyroid stimulating hormone (TSH) tests"
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who have a history of significant psychiatric illness such as schizophrenia or bipolar affective disorders which may interfere with the participation of this clinical trial according to the investigator's judgment or who are suffering from depression
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Subjects with a history of known or suspected seizures including febrile seizure, recent loss of consciousness which is not explained or history of significant head trauma accompanied by loss of consciousness"
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Subjects in any medical condition that may interfere with the evaluation and progression of the clinical trial according to the investigator's judgment (acute or unstable cardiovascular disease, uncontrolled hypertension (greater than 160/100 mmHg) at Visit 1 and Visit 2, insulin-dependent or uncontrolled diabetes at Visit 1 (HbA1cgreater than  8% on screening test), etc.)."
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who are hypersensitive to the components of the investigational product.
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects with a history of alcohol and drug abuse or dependence (except nicotine dependence) within the last 2 years.
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Subjects with a history of cancer within the past 5 years (however, non-metastatic skin basal cell carcinoma and/or skin squamous cell carcinoma, carcinoma in suit of uterine cervix or non-progressive prostate cancer may be acceptable and If cancer is considered to have been treated at the judgement of the investigator, if subjects are not taking anticancer or radiation therapy and are considered that treatment is not required for the next 5 years at the discretion of the investigator, enrollment is possible)"
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects with renal dysfunction (Creatinine Clearance (Clcr) less than  30 mL/min)
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects with serious hepatic dysfunction (ALT or AST  2.0 normal upper limit)
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who are taking prohibited drugs or expected to be administered during clinical trial period
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease, Drugs for the treatment of Alzheimer's Disease or other cognitive impairment other than donepezil and memantine
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Anticholinergic drugs, antidepressant drugs (tricyclic antidepressants, MAO inhibitors), orthopedic antipsychotic drugs, etc."
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects with previous administration of all clinical trial vaccines for Alzheimer's disease
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who consented to lumbar puncture (LP) for CSF examination only check the following exclusion criteria
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease," Subjects who are not contraindicated (e.g. platelet count less than 100,000/L, lumbar deformity, etc.) for performing lumbar puncture. Subjects can participate in clinical trials even if they are contraindicated in performing a lumbar puncture."
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,"Female subjects with childbearing potential who do not agree to contraception using a medically accepted method (surgical sterilization, intrauterine device or Intrauterine system), fallopian tube ligation, double blocking (combined use of blocking methods such as male condom, female condom, cervical cap, contraceptive diaphragm, contraceptive sponge), single blocking method using spermicide during the clinical trial period and until 90 days after clinical trial end(stop)."
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Pregnant or lactating women
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who participated in another clinical trial within 4 weeks before participation in this clinical trial
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects in less than 12 months after the administration of the Investigational product for this clinical trial
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who participated in any clinical trial for Alzheimer type dementia treatment within 6 months at screening
NCT05303701,Phase 3,Moderate to Severe Alzheimer's Disease,GemVax &amp; Kael,unknown,Alzheimer Disease,Subjects who are judged by the investigator to be ineligible for participation in this clinical trial
NCT05307692,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease," Participant fulfils diagnostic criteria for non-Alzheimer's Dementia: example, Frontotemporal Dementia (FTD), Diffuse Lewy Body Dementia (DLBD), and post-stroke dementia, based on clinical history. (Participants may be included with mixed AD/vascular dementia)"
NCT05307692,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease, Participant has a clinically significant acute illness within 7 days prior to study intervention administration
NCT05307692,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease, Participants with a history of delirium within 30 days prior to or during screening
NCT05307692,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease, Participant with a cause of agitation that is not secondary to dementia (such as pain) or significant history of aggression prior to dementia based on investigator judgment
NCT05307692,Phase 2,Alzheimer Disease,"Janssen Research &amp; Development, LLC",unknown,Alzheimer Disease, Participants who are not stable on concomitant medications or take prohibited medications
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,A known history of stroke that is clinically important in the investigator's opinion.
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"Evidence of a clinically relevant neurological disorder other than AD at screening, including but not limited to: vascular dementia, Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, progressive supranuclear palsy, dementia with Lewy bodies, other types of dementia, neurosyphilis or head trauma with loss of consciousness that led to persistent cognitive deficits."
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,A history of seizures or epilepsy within the last 5 years before screening.
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"Evidence of a clinically relevant or unstable psychiatric disorder, based on the 5th edition after text revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5TM) criteria, including schizophrenia or other psychotic disorder, bipolar disorder, major depression, or delirium. Major depression in remission is not exclusionary."
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,Renal impairment as indicated by a creatinine clearance of less than 50 mL/min as calculated by the Cockcroft Gault equation.
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,Patient has a history of any of the following conditions:
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"Clinically significant hepatic disease,"
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"AST or ALT levels of  2 times upper limit of normal (ULN),"
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"Biliary tract disease,"
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"Patient has a positive screening test for HIV, hepatitis B or C."
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,Presence of any of the following clinical conditions:
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"Unstable cardiac, pulmonary, endocrine, hematologic or active infectious disease,"
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"Unstable psychiatric illness defined as psychosis, untreated major depression within 90 days of the screening visit,"
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"A history of cancer within 3 years prior to screening, except adequately treated squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated."
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"History or signs/symptoms of lumbar spine/disc disease including but not limited to scoliosis, herniation, or any other contraindication to lumbar puncture."
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"History of known sensitivity or intolerability to edaravone, related substances of edaravone, or to any of the excipients."
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,"Use of Organic Anion Transporter (OAT)-3 inhibitors such as probenecid, cimetidine, and diclofenac."
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,Current substance or alcohol dependence.
NCT05323812,Phase 2,Alzheimer Disease,Treeway B.V.,unknown,Alzheimer Disease;Edaravone,Exposure to any investigational drug within 30 days of the screening visit.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Presence of a neurologic or neuropsychiatric condition or imaging finding associated with a neurologic or neuropsychiatric condition other than AD that can be associated with dementia or confound the evaluation of dementia, including but not limited to Parkinson's disease, Huntington's disease, frontotemporal dementia, cerebrovascular disease, seizure disorders, inflammatory or infectious disorders of the central nervous system, normal pressure hydrocephalus, traumatic brain injury, uncontrolled major depression, psychosis, bipolar disorder, and long-term sequelae of alcohol or substance abuse."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,History of stroke or transient ischemic attack (TIA) within 12 months of screening.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Epileptic or epileptiform seizure within 12 months of screening.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Current participation in another clinical trial or completed participation in an interventional trial less than 30 days prior to the screening visit (90 days for a biological treatment).
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Involvement in an A or tau vaccination trial for AD unless known to have received only placebo.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Current diagnosis and/or healthcare professional-recommended treatment (medication and/or diet) of diabetes mellitus type 1 or type 2.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Hemoglobin A1c (HbA1c)  6.5% at the screening visit
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Prior treatment with SLS-005, any other IV trehalose formulation, or known hypersensitivity to trehalose."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Is receiving aducanumab or any other immunotherapy for treatment of dementia including AD.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Regular use ( 3 days per week) of prescribed or pharmacy-purchased opiates, opioids, or benzodiazepines."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Pregnant or breastfeeding.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,History of alcohol or drug abuse within the last 2 years.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Chronic liver disease including Hepatitis B; Hepatitis C unless successful curative treatment is documented; human immunodeficiency virus (HIV) infection.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Prior history of drug-induced liver injury (DILI) and/or laboratory results at screening that indicate inadequate liver function (e.g., alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transferase [GGT] greater than  2 times the upper limit of normal [x ULN] and/or total bilirubin level greater than  2 x ULN)."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Laboratory results at screening that indicate inadequate renal function (e.g., estimated creatinine clearance of less than  60 mL/min calculated by the Cockcroft and Gault formula)."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Any current cardiovascular disease or abnormality on 12-lead ECG at screening that, in the investigator's opinion, is clinically significant and could be a potential safety risk to the participant, including risk factors for stroke (e.g., atrial fibrillation, cardiomyopathy)."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"History of cancer (currently active or in remission) within 5 years prior to screening, excluding treated basal or squamous skin cancer, or stable prostate cancer."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Lack of reliable venous access for the weekly administration of study drug.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Contraindications to the lumbar puncture (LP) procedure such as prior lumbosacral spine surgery, severe degenerative joint disease or deformity of the spine, platelet count less than  100,000, use of an anticoagulant (e.g., warfarin), or history of a bleeding disorder."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Any current psychiatric or neurological disorder other than AD that, in the investigator's opinion, may interfere with the participant's ability to provide informed consent or appropriately complete the study's safety or efficacy assessments."
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,Significant suicide risk as indicated by a  yes  response to #4 or #5 under Suicidal Ideation or any  yes  response under Suicidal Behavior on the Columbia Suicide Severity Rating Scale (C-SSRS) during the screening visit.
NCT05332678,Phase 2,Alzheimer's Disease,Neuroscience Trials Australia,unknown,Alzheimer Disease,"Any other medical condition or abnormal finding during screening that, in the investigator's opinion, could confound collection or interpretation of safety or efficacy data or be a potential safety risk to the participant."
NCT05336695,Phase 1/Phase 2,Dementia of Alzheimer Type,Massachusetts General Hospital,unknown,Alzheimer Disease;Dementia," MR contraindications such as: electrical implants such as cardiac pacemakers or perfusion pumps; ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants, ferromagnetic objects such as jewelry or metal clips in clothing"
NCT05336695,Phase 1/Phase 2,Dementia of Alzheimer Type,Massachusetts General Hospital,unknown,Alzheimer Disease;Dementia," Preexisting medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest"
NCT05336695,Phase 1/Phase 2,Dementia of Alzheimer Type,Massachusetts General Hospital,unknown,Alzheimer Disease;Dementia, Subjects whose estimated glomerular filtration rate (eGFR) less than  60 mL/min will be excluded from receiving the gadolinium-based contrast agent
NCT05336695,Phase 1/Phase 2,Dementia of Alzheimer Type,Massachusetts General Hospital,unknown,Alzheimer Disease;Dementia, Research-related radiation exposure exceeding current Massachusetts General Hospital (MGH) Radiology Department guidelines (i.e. 50 millisievert in the prior 12 months)
NCT05336695,Phase 1/Phase 2,Dementia of Alzheimer Type,Massachusetts General Hospital,unknown,Alzheimer Disease;Dementia,In line with published MGH IRB guidelines for pregnancy must be ruled out by urine -HCG if answers to screening questions suggest that pregnancy is possible and if female participants are premenopausal and of child-bearing age. Subjects will not be able to enroll if they are breastfeeding.
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil, Any clinically significant abnormal finding at physical examination at screening.
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil," Clinically significant abnormal laboratory test results or positive serology test results for human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus at screening."
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil, Positive pregnancy test at screening or Day -1 or lactating female subject.
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil, Positive drug or alcohol screen at screening or Day -1.
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil, Any history of malignancy or neoplastic disease.
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil," History of significant allergic reactions (e.g., drug reaction, anaphylactic reaction, hypersensitivity, angioedema) to donepezil, piperidine derivatives, dimenhydrinate or derivatives, benzatropine or derivatives, or other related drugs, or to any excipient present in the formulation for any study drug."
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil," Presence of hereditary disorders including galactose intolerance, lactase deficiency, and glucose-galactose malabsorption (for Part B only)."
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil," Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin greater than 1.5x the upper limit of normal (ULN) at screening or Day -1."
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil, Estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73m2 as calculated by the 2021 Chronic Kidney Disease-Epidemiology (CKD-EPI) equation at screening or Day -1.
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil," Clinically significant ECG abnormalities (QTc greater than 450 ms or PR interval greater than 220 ms) or vital sign abnormalities (systolic blood pressure less than 90 or greater than 140 mmHg, diastolic blood pressure less than 40 or greater than 90 mmHg, or heart rate less than 50 or greater than 100 bpm) at screening or Day 1."
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil, History of significant bradycardia or atrioventricular (AV) block.
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil, History of significant asthma (except for fully resolved childhood asthma) or chronic obstructive pulmonary disease (COPD).
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil," History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 14 units of alcohol per week (1 unit = 375 mL of beer 3.5%, 100 mL of wine 13.5%, or 30 mL of spirit 40%)."
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil," History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 month, or use of codeine within 3 months prior to screening."
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil, Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 30 days prior to dosing.
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil," Consumption of high levels of caffeine (equivalent to 3 regular cups of coffee or 2 energy drinks, per day)."
NCT05345509,Phase 1/Phase 2,Alzheimer Disease,"Inventage Lab., Inc.",unknown,Alzheimer Disease;Donepezil," Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study."
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease," Female who is breastfeeding, pregnant, planning to become pregnant during study"
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease, Kidney disease (eGFR less than 50 mL/minute/1.73 m2)
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease, History of untreated thyroid dysfunction that may be independently associated with cognitive impairment
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease," Uncontrolled tachy/brady arrhythmias, atrial fibrillation or coronary heart failure"
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease, Any medical condition that in the Investigator's judgement would affect patient safety and scientific integrity of the studySystemic related exclusions:
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease," History of allergy or AE(s) associated with the study treatments, including lithium and salicylates"
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease," Pre-existing peptic ulcer, hemorrhagic gastritis, or duodenitis"
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease, Magnetic resonance imaging (MRI)-related exclusion criteria
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease, Treatment with haloperidol
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease, Hyponatremia
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease, Suspected of having or at risk for Brugada Syndrome
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease," Prescribed or over-the-counter use of a salicylate-containing product other than low dose aspirin for cardioprotection (eg, aspirin, bismuth sub-salicylate, salicylazosulfapyridine [sulfasalazine]) from 1 week before first dose to 1 week after last dosing; treatment with haloperidol"
NCT05363293,Phase 1/Phase 2,Alzheimer's Disease,"Alzamend Neuro, Inc.",unknown,Alzheimer Disease, Aspirin/nasal polyposis/asthma syndrome
NCT05393388,Phase 3,Alzheimer Disease,University of Pennsylvania,unknown,Alzheimer Disease;Cognitive Dysfunction,"Have any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study, including major depression and prior head trauma."
NCT05393388,Phase 3,Alzheimer Disease,University of Pennsylvania,unknown,Alzheimer Disease;Cognitive Dysfunction,Have evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan.
NCT05393388,Phase 3,Alzheimer Disease,University of Pennsylvania,unknown,Alzheimer Disease;Cognitive Dysfunction,Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician.
NCT05393388,Phase 3,Alzheimer Disease,University of Pennsylvania,unknown,Alzheimer Disease;Cognitive Dysfunction,Have a history of significant ongoing alcohol or substance abuse or dependence based on self-report.
NCT05393388,Phase 3,Alzheimer Disease,University of Pennsylvania,unknown,Alzheimer Disease;Cognitive Dysfunction,Women of child bearing potential
NCT05393388,Phase 3,Alzheimer Disease,University of Pennsylvania,unknown,Alzheimer Disease;Cognitive Dysfunction, The inclusion / exclusion criteria will be ascertained through self-report in conjunction with any medical history available through the participant's medical or research records (EPIC or the ADC database)*
NCT05397639,Phase 3,Alzheimer's Type Dementia,Suven Life Sciences Limited,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate," Participants with dementia predominantly of the non-Alzheimer's type (e.g., vascular dementia, parkinson's disease, lewy body disease, frontotemporal dementia)"
NCT05397639,Phase 3,Alzheimer's Type Dementia,Suven Life Sciences Limited,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate," Has symptoms of agitation that are not secondary to Alzheimer's disease (eg, pain, other psychiatric disorder, or delirium due to a metabolic disorder, systemic infection, or substance-induced)."
NCT05397639,Phase 3,Alzheimer's Type Dementia,Suven Life Sciences Limited,unknown,Dementia;Alzheimer Disease;Psychomotor Agitation;1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate, Participant (or caregiver) is deemed otherwise ineligible for participation in this study in the investigator's judgement.
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Having other causes of dementia.
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Having substantial concomitant cerebrovascular disease (defined by a history of a stroke
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, / intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment) per investigator judgement.
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Medical history or diagnosis of any of the following symptomatic and unstable / uncontrolled conditions per investigator's judgement:
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," Uncontrolled cardiovascular illnesses such as chronic congestive heart failure (with or without edema), tachycardia, arrhythmias, uncontrolled hypertension."
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," Significant ischemic heart disease, myocardial infarction within the last two years and/or with residual angina, orthopnea, conduction defects (ECG), or any other clinical significant heart disease classified as New York Heart Association (NYHA) III or IV."
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," Significant gastrointestinal disorders (for example gastrointestinal bleeding within the last two years, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease)."
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Uncontrolled endocrine disease such as uncontrolled diabetes mellitus or hyperthyroidism.
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Unstable/Uncontrolled major depression.
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," Has neurological disease (other than dementia of Alzheimer's type, such as: Lewy body dementia - primary diagnosis, Huntington's disease, Parkinson's Disease, encephalitis, epilepsy, vascular or multiinfarct dementia, stroke, congenital mental deficiency, multiple sclerosis)."
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Significant pulmonary disease predisposing to hypoxia.
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," Has major physical illnesses (e.g. brain tumor, craniocerebral trauma, thyroid disease)"
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," Any other psychiatric disorders such as schizophrenia, or mental retardation."
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," Any suicidal actions in the past 2 years (per investigator judgement i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior)."
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Hachinski Ischemic Score greater than  4
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," Significant history of drug dependence or abuse (including alcohol, as defined in Diagnostic and Statistical Manual of Mental Disorders [DSM-V] or in the opinion of the investigator)"
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease, Clinically significant uncompensated hearing loss in the judgment of the investigator. Use of hearing aids is allowed.
NCT05413655,Phase 2,Alzheimer Disease,Excelsior,unknown,Alzheimer Disease," Has other condition(s) that in the opinions of investigators to be ineligible to participate in this study, e.g. Subject who cannot swallow the capsule whole."
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Patient with genetic form of AD (known genetic mutation);
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Patient with major physical or neurosensory problems likely to interfere with the tests; contraindication or refusal to perform functional brain imaging examinations;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Absence of caregivers to complete psychological and behavioral scales and/or questionnaires;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Patient with illiteracy and/or inability to perform psychological and behavioral evaluations;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease," Pathologies involving short term vital prognosis (progressive cancer, unstable heart failure, severe liver, kidney or respiratory diseases);"
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Primary chronic psychosis or psychotic episodes not associated with the AD pathology;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Addiction to alcohol or drugs;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Pregnancy or breast-feeding;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Epilepsy or other neurodegenerative disorders;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Vitamin B12 or folic acid deficiency without supplementation;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Patient participating in another drug trial;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Thyroid disorders not treated;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Patient living in institution;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease, Patient deprived of liberty by law;
NCT05423522,Phase 2,Alzheimer's Disease,Medesis Pharma SA,unknown,Alzheimer Disease," Patient with contraindications to drugs containing lithium: heart failure, renal failure, Addison disease, and Brugada syndrome."
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Significant neurological disease affecting the central nervous system (CNS) other than AD, that may affect cognition or ability to complete the study."
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Current serious or unstable illnesses that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of less than 24 months."
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, History of cancer with high risk of recurrence and preventing completion of the trial.
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Participants with any current primary psychiatric diagnosis other than AD that in the investigator's opinion, is likely to confound interpretation of the drug effect, affect cognitive assessment, or affect the participant's ability to complete the study."
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, History of of clinically significant multiple or severe drug allergies.
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Have any clinically important abnormality at screening, as determined by investigator that could be detrimental to the participant, could compromise the study, or show evidence of other etiologies for dementia."
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Screening magnetic resonance imaging (MRI) which shows evidence of significant abnormality that would suggest another potential etiology for progressive dementia or a clinically significant finding that may impact the participant's ability to safely participate in the study.
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Have any contraindications for MRI or positron emission tomography (PET).
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Have had prior treatment with a passive anti-amyloid immunotherapy that is less than 5 half-lives prior to randomization.
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease, Have received active immunization against A in any other study.
NCT05463731,Phase 3,Alzheimer's Disease,Eli Lilly and Company,unknown,Alzheimer Disease," Have known allergies to remternetug related compounds, or any components of the formulation."
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Subject with a psychiatric evolutionary and/or badly checked.
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2," Subject with a grave, severe or unstable pathology (left to the judgement of the investigator) the nature of which can interfere with the variables of evaluation."
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Epileptic subjects
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Subject under guardianship or curatorship
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Subject presenting contraindications to the MRI
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Known or supposed history (less than  or = 5 years) of severe alcoholism or misuse of drugs
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2," Vascular, inflammatory or expansive, visible lesion in the MRI, which can interfere on the criteria of diagnosis."
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, No health insurance
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2," Women of childbearing potential: a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause."
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, History of auto-immune disease
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, History within the past 10 years of a primary or recurrent malignant disease
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2," Diagnosis or history of other possible etiology of dementia, including but not limited to other neurodegenerative disorders (FTD, LBD, VaD, HD, PD, PSP-CBD)."
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2," Renal dysfunction at inclusion, clearance less than 30 mL/min"
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Chronic hepatic diseases as indicated by liver function tests abnormalities
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Abnormal thyroid function
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2," Therapeutic trial within 1 year preceding the first study period, or participation in a trial with active or passive immunization against amyloid if patient was assigned to the active treatment arm."
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2," Clinically significant evidence of Active viral infection (CMV, EBV, HCV, HBV, TPHA-VDRL, HIV)"
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2," Current or medical history of severe cardiopathy,"
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, - Severe dysfunction in a vital organ
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Patients with White Blood Count (WBC) less than  4.000/mm3; platelets less than  100.000/mm3; hematocrit (HCT) less than  30%.
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Patients with serum bilirubin and creatinine outside normal range.
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Patients with organ allografts.
NCT05468073,Phase 2,Alzheimer Disease,Centre Hospitalier St Anne,unknown,Alzheimer Disease;Aldesleukin;Interleukin-2, Patients who are likely to require corticosteroids